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Abstract 
Human African Trypanosomiasis (HAT), caused by Trypanosoma brucei 
subspecies, is one of the most neglected diseases: available treatments are old, toxic, 
and difficult to administer; they are not efficacious against all parasite species or disease 
stages and drug resistance is an increasing problem.  
Protein kinases are well validated drug targets for a variety of human diseases 
with many inhibitors under development or in the clinic. The T. brucei kinome has been 
annotated and there is evidence of essentiality of some of the members of this family. 
This thesis aims at evaluating the essentiality of Glycogen Synthase Kinase 3 (TbGSK3 
short; Tb927.10.13780) and chemically validating it as a potential drug target in T. 
brucei. 
TbGSK3 recombinant protein was biochemically characterised and screened 
against a focussed kinase library using the KinaseGlo assay method. Further repurchase 
and synthesis of novel compounds yielded 10 validated chemical series against TbGSK3 
short. In particular two series showed anti-proliferative activity against the parasite. 
GSK3 07 series was further investigated by the Drug Discovery Unit with a phenotypic 
approach for its off-target effects, and GSK3 09 series was further validated to act “on 
target”.  The latter series showed a good correlation between biochemical potency and 
cellular efficacy. Using a combination of chemical and genetic approaches TbGSK3 
short was demonstrated to be specifically targeted by a GSK3 09 tool molecule in T. 
brucei lysates. Furthermore, the in vitro efficacy in trypanosomes could be reverted by 
target over-expression. Further validation of its activity “on target” was given by its 
ability to modulate the cell toxicity caused by TbGSK3 short over-expression.  
The genetic validation of TbGSK3 short by generation of conditional null 
mutants was not possible due to the tight regulation of the protein levels and the cell 
toxicity associated with protein over-expression.  
The validated TbGSK3 short chemical tool could be used to elucidate the 
functions of TbGSK3 short in T. brucei, identify its substrates and increase the chance 
to solve the crystal structure of this enzyme for the design of novel inhibitors with 
different mechanism of inhibition and/or increased selectivity. 
 1 
 
Chapter 1 Introduction 
 
 
Figure 1.1 Classification of the endemic countries for HAT according to the 
reported cases in 2009  
The dark line separates the Western endemic countries for T. b. gambiense from the 
Eastern endemic countries for T. b. rhodesiense (figure adapted from Simarro et al., 
2011). 
 
Figure 1.2 Comparison between reported number of cases of T. b. gambiense and 
screen of the population  
Number of cases are reported as green columns and the population screened as blue 
circles over the period 1939–2004 in Africa (Figure from Brun et al., 2010). 
 2 
 
1.1 Human African trypanosomiasis 
Human African trypanosomiasis (HAT, or also known as sleeping sickness) is 
one of the most neglected parasitic diseases. If untreated, this disease is invariably 
lethal. Endemic in Sub-Saharan Africa, it puts at risk the lives of approximately 70 
million of people distributed over a territory that covers 36 countries (Simarro et al., 
2010). It is caused by infection with the unicellular parasite Trypanosoma brucei (T. 
brucei or T.b.) and transmitted by the bite of tse-tse fly of the genus Glossina.  
There are three sub-species of T. brucei causing Trypanosomiasis in humans and 
animals: T. b. gambiense, which causes the human chronic form of the disease in West 
and Central Africa and represents 95% of the cases; T. b. rhodesiense, which is 
responsible for the human acute form in East Africa in the remaining 5% of the cases; 
and T. b. brucei, which infects primarily cattle causing the animal form of the disease, 
called Nagana (Brun et al., 2010) (Figure 1.1). 
1.1.1 Epidemiology and distribution 
Human African Trypanosomiasis reached an estimated 800,000 deaths between 
1896 and 1906; between 1920 and 1940 there was a second epidemic, but at that time 
the colonial control program almost achieved the elimination of the disease by active 
screening and treatment of the population. After independence from colonialism, the 
political instability associated with wars and the lack of surveillance under the local 
health-systems caused the spread of a new epidemic in 1990 (Brun et al., 2010). The 
correlation between active control of the disease and reduction of number of cases is 
well established, as well as the reappearance when the surveillance is reduced (Brun et 
al., 2010) (Figure 1.2). 
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Figure 1.3 Number of cases reported of T. b. gambiense and T. b. rhodesiense 
in the period 2000 – 2009 (Figure adapted from Simarro et al., 2010).  
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Figure 1.4 Drug treatments for the second stage of T. b. gambiense infection 
in the period 2001-2010 NECT-EML: introduction of the nifurtimox-
eflornithine combination therapy (NECT) in WHO list of the essential medicines 
(EML) (Figure adapted from Simarro et al., 2012)  
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In 1997 a resolution from the World Health Organization (WHO) advocated 
interventions for HAT, increased the funding and the control activities, including active 
screen of the population and access to treatment tools, which resulted in a reported 
number of cases below 10,000 in 2009 (Simarro et al., 2010) (Figure 1.3). Despite the 
efforts made to compile an atlas of HAT, which associates foci to number of cases, it is 
likely that at least two thirds of the cases are not reported. HAT is endemic in 36 
African countries, but in 2009, nineteen disease-endemic countries reported no cases 
(Simarro et al., 2010). The Central African Republic and the Democratic Republic of 
the Congo are the most affected countries, reporting more than 1,000 cases annually; 
Chad more than 500 cases; and Angola, Sudan and Uganda more than 100 cases. The 
remaining eleven countries have reported less than 100 cases (Simarro et al., 2010) 
(Figure 1.1). The number of cases reported annually is only a fraction of the real 
number of infected people and the WHO estimate of the number of cases in 2006 was 
between 50,000 -70,000 (WHO, 2010).  
HAT is considered a neglected disease because it affects poor people living in 
rural areas in Sub-Saharan Africa. Furthermore, the drugs available to cure it are toxic, 
difficult to administer in poor settings and inefficacious for all forms and stages of the 
disease. Also resistance in the field is becoming an increasing problem, making the 
already poor treatments available even less efficacious (Fairlamb, 2003). Yet, there is 
very little economic incentive in developing new drugs as the disease affects 
marginalised people with very little political voice. This creates a very vicious cycle 
between poverty and disease aggravated by the fact that the animal form of the disease 
limits the availability of meat and milk and reduces the income of these already poor 
households. The FAO (Food and Agriculture Organization) estimates the annual loss in 
income associated to HAT to be around US$ 1.5 billion (WHO, 2010). 
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Although the numbers of cases have reduced in the recent years due to the joint 
effort of the WHO, non-governmental organizations (NGOs) such as Médecins Sans 
Frontières (MSF) and local governments together with the introduction of a new 
combined therapy (NECT) as first line treatment included in the WHO list of Essential 
Medicines (Figure 1.4), this disease still threatens the economic and human 
development of a large part of the African continent (Simarro et al., 2012). Reducing 
the attention and focus now could cause as in the past an increase in number of cases; 
on the other hand the reduction in number of cases opens the opportunity for the 
elimination of the disease, considering also that two new molecules have recently 
reached clinical development (section 1.2.3). However, the path to the clinical use of 
new molecules is extremely hard and characterised by high rate of failure (Brown and 
Superti-Furga et al., 2003); therefore it will be a mistake at this time to stop the 
development of new drugs for HAT. 
1.1.2 Trypanosome cell cycle in vector and in human host 
Trypanosoma brucei belongs to the order of Kinetoplastida. Species of this order 
are unicellular flagellated protozoa, characterised by a single large mitochondrion, 
which contains compacted DNA called the “kinetoplast” (Stuart et al., 2008). 
Trypanosomes are transmitted by the bite of flies of the genus Glossina, where both 
male and female flies are obligate blood-feeders and can transmit the disease. Around 
33 species of tse tse flies exist that can be sub-divided in three groups (Morsitans, 
Palpalis and Fusca) according to the habitat in which they live (savannah, river and 
forest) (Gooding and Krafsur, 2005). Climate and demographic changes have caused a 
redistribution of the vectors with consequent shift of the foci of the disease from 
savannah to forest areas and in some cases foci have been found in populated urban 
centres (Malvy and Chappuis, 2011).  
 
 
 
Figure 1.5 Life cycle of African trypanosome in the vector and in the human host 
(Figure adapted from Vickerman, 1985 and Barrett et al., 2007; pictures from WHO 
website, www.who.int). 
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The two major changes between the mammalian and the insect developmental 
cycle of African trypanosomes are at the level of mitochondrion and the surface 
membrane (Figure 1.5). In mammals the trypanosomes rely on glycolysis for ATP 
production because of the availability of glucose in the host fluids and are coated with 
variant surface glycoproteins (VSG) that protect the parasite from the host immune 
system by antigenic variation (Vickerman, 1985; Pays, 2005; Horn and McCulloch, 
2010). Only one VSG gene is expressed at a time from among 10-20 telomeric 
expression sites, in addition to around 1000 silent VSGs and VSG pseudogenes in 
subtelomeric regions (Horn and McCulloch, 2010). This remarkable capacity for 
antigenic variation makes the development of a vaccine for HAT difficult, relying 
exclusively on control activities and chemotherapeutics for surveillance of the disease. 
During a blood meal the fly deposits infective metacyclic trypanosomes in the 
dermal connective tissue, where they divide to form a chancre, and then move to the 
lymph nodes and into the bloodstream. Parasites can then multiply by mitosis as slender 
trypomastigotes. The parasitemia fluctuates according to the host immune response 
directed against the VSG on the plasma membrane of trypanosome, with increases in 
IgG and IgM and reduction in parasite numbers till the antigenic variation makes the 
immune response inadequate (Vickerman, 1985, Paulnock and Freeman, 2010). As 
parasite numbers increase, a parasite-derived soluble factor, stumpy derived factor (SIF) 
promotes cell cycle arrest in G0/G1 and generation of stumpy forms (Fenn and 
Matthews, 2007). The non-dividing stumpy forms are taken-up by the flies during the 
blood meal and they continue their life cycle in the vector (Vickerman, 1985).  
In the midgut of the vector the stumpy transforms into an elongated parasite, the 
proliferative procyclic form (Vickerman, 1985). In vitro, the transition from stumpy to 
procyclic can be obtained by a reduction in temperature and exposure to citrate/cis-
aconitate, both compatible with a drop in temperature during the night when the fly 
 Figure 1.6 Trypanosome cell architecture 
(Figure from ILRI website (International Livestock Research Institute), 
www.ilri.org) 
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tends to feed and with the citrate concentration in the fly midgut (Fenn and Matthews, 
2007).  A family of transporters called PAD (proteins associated with differentiation), 
expressed on the surface of the stumpy form, is required to sense the citrate/cis-
aconitate signal (Dean et al., 2009). Once in the vector the insect form of the parasite 
exchanges the variable antigen coat for procyclins and relies upon proline metabolism 
and oxidative phosphorylation as principal sources of energy (Fenn and Matthews, 
2007; Vickerman, 1985). The differentiation of the insect form of the parasite into an 
infective form takes between 3 and 5 weeks, during which the parasites undergo 
complex steps of differentiation and migrate to the salivary glands. Once in the salivary 
glands the procyclics transform into epimastigotes, which are characterised by a 
prenuclear kinetoplast. Finally, epimastigotes develop into the infective metacyclic 
forms, which are injected in the host during the blood meal. The metacyclic forms 
regain some of the characteristics of the forms infecting humans with a reduction in size 
of the mitochondrion and the re-appeareance of variable antigen coat (Vickerman, 1985) 
(Figure 1.5). 
 
1.1.3 Trypanosome cell architecture 
The trypanosome cell has an elongated and polarized form (Figure 1.6) 
(Matthews, 2005). During the life cycle the morphology of the cells changes with 
respect to the position of the flagellum, nucleus and kinetoplast, size of mitochondrion, 
efficiency of endocytosis, and protein expression of the parasite coat. In the slender 
trypomastigote and stumpy form the kinetoplast is positioned at the posterior end of the 
parasite and is connected through the mitochondrial membrane to the basal body of the 
flagellum. At the posterior end is also located the flagellar pocket that is the only site of 
exo- and endocytosis. The antigenic variation, occurring in the mammalian form of the 
parasite, requires that the full VSG coat is renewed every 12 mins in order to assure 
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evasion of the immune response (Overath and Englster, 2004). In the bloodstream 
trypomastigote the mitochondrion is an elongated organelle positioned all long the cell 
body from the posterior to the anterior end. The absence of an active oxidative 
respiration in bloodstream forms explains the lack of internal cristae. The mobility of 
trypanosomes depends upon a single flagellum that is anchored to the basal body at the 
posterior end of the cell and is attached to the cell body along its length. The flagellum 
has a typical “9+2” microtubule axoneme, and is connected to the cell through the 
paraflagellar rod (PFR) and a set of four microtubules that constitute the flagellum 
attachment zone (FAZ) (Vaughan and Gull, 2003). During proliferation, the new 
flagellum is replicated beside the old one, starting from the duplication of the basal 
body and kinetoplast. Once the duplication of the new flagellum is completed the 
separation starts from the anterior tip. The process of duplication and separation 
requires coordination of the replication and regulation of positioning of single 
organelles (flagellar pocket, flagellum, mitochondrion, kinetoplast and nucleus). The 
major changes in the insect procyclic and epimastigote cells is the positioning of the 
kinetoplast to a more anterior position that results in a progressively longer anterior 
flagellum that might help attachment to the salivary gland; the replacement of the VSG 
coat with the procyclin coat;  the increase of mitochondrial activity and the reduction of 
the endocytic rate (Matthews, 2005). 
 
1.1.4 Symptoms and diagnosis 
After infection the disease evolves in two different stages. The initial 
haemolymphatic stage, when the parasite is present in the bloodstream and lymphatic 
system, is characterised by generic symptoms: fever, headache, lymphadenopathies, and 
oedema and in some cases splenomegaly or hepatomegaly (Malvy and Chappuis, 2011). 
The disease progresses to the late meningo-encephalitic stage when the parasites 
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penetrate the central nervous system (CNS). The late stage of the disease is 
characterised by far more severe symptoms: disturbed sleep patterns, confusion, tremor, 
general motor weakness, hemiparesis, abnormal movements and neuro-psychiatric 
disorders. In the terminal phase of the disease the patient is in an unconscious state and 
if untreated the disease usually results in death (Malvy and Chappuis, 2011). The 
progression of the disease caused by T. b. gambiense is chronic and takes on average 
three years. In contrast T. b. rhodesiense causes an acute form of the disease that 
progress rapidly to the late stage in weeks or months (Brun et al., 2010). The diagnostic 
test available for T. b. gambiense is the card agglutination test (CATT) (Magnus et al., 
1978), a serological test with 87-98% sensitivity and 93-95% specificity (Brun et al., 
2010). A positive test has to be corroborated by a parasitological confirmation of the 
presence of the trypanosomes in lymph node aspirate and blood. The CATT test is 
sensitive only against T. b. gambiense and there are no available serological tests for T. 
b. rhodesiense. Thus, the diagnosis relies on the clinical symptoms and on the 
parasitological confirmation, which is easier for T. b. rhodesiense because of the higher 
number of circulating parasites (Brun et al., 2010; Malvy and Chappuis, 2011). 
Because treatment differs between stages of disease, the staging of the disease is 
compulsory after parasitological confirmation. The staging is determined by detection 
of trypanosomes and white blood cells in the cerebrospinal fluid (CSF) (>5 per l) 
(Brun et al., 2010; Malvy and Chappuis, 2011).   
 
1.2 Chemotheraphy of sleeping sickness 
1.2.1 T. b. rhodesiense infection 
Suramin (introduced in the early 1920s), a polyanionic sulphonated 
naphthylamine, is used to treat first-stage T. b. rhodesiense infection. This molecule 
Table 1.1 Drugs used for the treatment of human African trypanosomiasis 
Causitive 
agent  
Disease 
stage  
Drug  
(date 
introduced)  
Chemical structure  
Treatment regimen  
      adult doses  
T. b. 
rhodesiense 
First  
stage 
Suramin  
(1920s)  
 
IV test dose  
4-5 mg/kg on day 1 
then 
20 mg/kg IV weekly 
for 5 weeks 
 Second 
stage 
Melarsoprol  
(1949)  
 
slow IV infusion  
2.2 mg/kg/day  
for 10 days 
     
T. b. 
gambiense  
 
First  
stage 
Pentamidine  
(1941)  
 
IM or slow IV infusion 
4 mg/kg/day  
for 7 days   
 Second 
stage 
Eflornithine  
(1990)  
  
IV infusion  
100 mg/kg  
every 6 hours for 14 days  
 
 Second 
stage 
Nifurtimox-
eflornithine 
combination 
therapy, NECT  
(2009)  
  
oral nifurtimox  
3x5 mg/kg/day  
for 10 days  
+  
IV infusion 
200 mg/kg  
every 12 h for 7 days 
 
IV intravenous; IM intramuscular. 
(Table adapted from Malvy and Chappuis, 2011) 
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does not penetrate the CNS, being highly charged, so it cannot be used for the second-
stage of the disease (Fairlamb, 2003). The recommended dose regimen consists of an 
initial test dose of 4-5 mg/kg intravenous injection (IV) for the first day, and, in the 
absence of an acute reaction, the drug can be administered at the dose of 20 mg/kg IV 
weekly for 5 weeks (Malvy and Chappuis, 2011) (Table 1.1). The side effects are 
nephrotoxicity, peripheral neuropathy and bone marrow toxicity; generally their severity 
is mild and they revert once the treatment is completed. The mechanism of action of this 
drug is not completely understood, but the fact that resistance in the field has been 
rarely reported despite being used for many decades suggests that this drug might 
inhibit multiple targets (Barrett et al., 2003; Fries and Fairlamb, 2003). It has also been 
suggested that suramin mode of action might involve inhibition of glycolytic enzymes 
(Fairlamb and Bowman, 1980) and the synergistic action with eflornithine (DFMO) 
might implicate a role in polyamine metabolism (Clarkson et al., 1984). It is known that 
suramin enters the trypanosomes by endocytosis through the flagellar pocket, this 
process is receptor-mediated due to the tight binding to low-density lipoprotein (LDL) 
(Voogd et al., 1993). Recently Alsford and colleagues (2012) have elucidated how 
suramin uptake is mediated by an invariant surface glycoprotein (ISG75) that is 
specifically expressed in bloodstream form. Then ISG75 trafficking delivers the drug to 
the lysosome where it is liberated by the action of lysosomal proteases and possibly 
delivered to the cytosol through a lysosomal transmembrane protein (major facilitator 
superfamily transporter).  They also linked spermidine and N-acetylglucosamine 
biosynthesis to the mode of action of suramin.   
Melarsoprol (introduced in 1949), a melaminophenyl-based organic arsenical, 
remains the only therapeutic option for the second-stage of T. b. rhodesiense infection 
despite the extreme toxicity. The dose regimen is 2.2 mg/kg/day IV for 10 days (Malvy 
and Chappuis, 2011) (Table 1.1). Five to 10% of patients develop reactive 
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encephalopathy, which causes the death of half of them. The active metabolite is 
melarsen oxide, which is rapidly converted in the blood (Keiser et al., 2000). Melarsen 
oxide forms with trypanothione (bis-glutathionyl-spermidine) a stable and reversible 
adduct called MelT, which depletes the intracellular pool of trypanothione and acts as 
competitive inhibitor of trypanothione reductase (Fairlamb et al., 1989), an enzyme 
essential in maintaining the correct thiol-redox balance of trypanosomes. However, it 
has been argued that arsenicals interact more tightly with other thiols, including lipoic 
acid (Fairlamb et al., 1992) and that when lysis occurs due to arsenicals only a small 
fraction of trypanothione is conjugated with the merlasen oxide, making unclear if 
trypanothione and the enzymes involved in its metabolism are the real targets for this 
drug (Denise and Barrett, 2001). 
Melarsen oxide is transported in the cells by the P2 aminopurine transporter 
(Carter and Fairlamb, 1993), and mechanisms of resistance both in vitro and in the field 
are associated to loss of the P2 transporter (Barrett et al., 2007). An ATP-binding 
cassette (ABC) transporter, MRPA (multidrug resistance protein A) is responsible for 
the efflux of MelT from the cells, and over-expression of this transporter increases 
resistance to melarsoprol (Shahi et al., 2002). Alsford and colleagues (2012) also found 
that aquaglyceroporins (AQPs) were responsible for the cross-resistance of melarsoprol 
and pentamidine. In particular TbAQP2 has been further characterised as a high affinity 
melarsoprol and pentamidine transporter, previously reported as high affinity 
pentamidine transporter (HAPT1), and as a major determinant of cross-resistance to 
these drugs (Baker et al., 2012, Munday et al., 2014).  
1.2.2 T. b. gambiense infection 
Pentamidine (introduced in 1941), an aromatic diamidine, has been used as 
first-line treatment for the haemolymphatic stage of T. b. gambiense infection for over 
60 years. Being positively charged at physiological pH this molecule has poor oral 
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availability and no CNS penetration (Fairlamb, 2003). The use of this drug is thus 
limited to the treatment of first stage of the disease, for which it is administered by 
intramuscular (IM) or IV injection with a schedule of 4 mg/kg/day per 7 days (Malvy 
and Chappuis, 2011) (Table 1.1). Toxicity includes pain at the injection site, 
nephrotoxicity, leucopenia and hypoglycaemia (Malvy and Chappuis, 2011).  
The mechanism of action of pentamidine is not fully understood. Being a 
dication, pentamidine binds negatively charged molecules, as DNA, including the 
mitochondrial kinetoplast. However, the disruption of the kinetoplast DNA cannot 
account for all action of the drug as parasites that have lost the kinetoplast (a condition 
called dyskinetoplastidy) retain viability (Fairlamb, 2003). Other hypothetical 
mechanisms include effects on trans-splicing and RNA editing in trypanosomes; in fact 
pentamidine has been reported to inhibit group I intron catalytic activity in Candida 
albicans and Pneumocystis carinii (Zhang et al., 2002; Liu et al., 1994), but this 
hypothesis has not been further investigated. Also the enzyme S-adenosylmethionine 
decarboxylase (AdoMetC) was proposed as a target, due to the enzyme inhibition in 
vitro, but no changes in the levels of putrescine and spermidine were observed in T. 
brucei exposed to pentamidine in vivo (Berger et al., 1993) and no changes in 
sensitivity to the drug were observed in null mutants and in cells overexpressing 
AdoMetC in Leishmania donovani (Roberts et al., 2002).   It is known that the drug is 
concentrated in the trypanosomes by the P2 amino-purine transporter and by two 
pentamidine transporters, a low-capacity high-affinity pentamidine transporter (HAPT1) 
and a high-capacity low-affinity pentamidine transporter (LAPT1) (Carter et al., 1995; 
de Koning, 2001). Pentamidine reaches millimolar concentrations in the cell (Carter et 
al., 1995), so that its toxicity could be caused by multiple cellular targets. Recently it 
has been found that plasma membrane H
+
-ATPases may also be required for the 
pentamidine uptake (Alsford et al., 2012, Baker et al., 2012) and the high-affinity 
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pentamidine transporter (HAPT1) has been genetically identified to be TbAQP2 and 
responsible for the cross-resistance of pentamidine and melarsoprol.   
Eflornithine (1990), or D,L-α-difluoromethylornithine (DFMO), is an analogue 
of the amino acid ornithine and acts as an irreversible inhibitor of ornithine 
decarboxylase (ODC), the first enzyme in the biosynthesis of polyamines (Barrett et al., 
2007). It was initially developed as anticancer agent, but it has never been registered for 
this indication. DFMO is equi-potent against the human and parasite enzyme, but the 
specificity is achieved by the slower turnover of the parasite enzyme (Ghoda et al., 
1990; Heby et al., 2003). Inhibition of the enzyme causes an accumulation of S-
adenosyl methionine (Yarlett and Bacchi, 1988) and depletion of polyamines and 
trypanothione (Fairlamb et al., 1987) with consequent inappropriate methylation and 
increase in oxidative stress. The trypanosomes stop growing and transform into a 
stumpy-like form that is incapable of antigenic variation. A fully functional host 
immune system is then required to clear the parasites (Bitonti et al., 1986). 
Unfortunately the T. b. rhodesiense ODC is naturally resistant to the drug, probably due 
to a faster turnover of the enzyme (Iten et al., 1997). The transport of the drug in the 
parasite is carrier-mediated and in the laboratory it has been demonstrated that 
resistance to eflornithine can develop by loss of the amino acid transporter TbAAT6 
(Vincent et al., 2010; Baker et al., 2011; Schumann Burkard et al., 2011). 
The drug is active against the T. b. gambiense infection, but the cost and 
complexity of the administration does not make its use feasible for the first-stage of the 
disease. The regimen for the single therapy with eflornithine consists of 100 mg/kg 
every 6 hours for 14 days by IV infusion with a total of 56 injections for a full treatment 
(Malvy and Chappuis, 2011) (Table 1.1). The main adverse reactions include fever, 
headache, hypertension, peripheral neuropathy, tremor and gastrointestinal problems, 
including diarrhea (Brun et al., 2011). The complexity of the treatment in terms of 
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logistics and costs (the kit for one treatment weighs 20 kg at a cost of €554 including 
the transport to the rural health centres (Simarro et al., 2012) prompted a search for 
alternative therapies.  
DNDi (Drug for Neglected Disease initiative, a not-for-profit product 
development partnership) and Médecins Sans Frontières’ efforts to shorten the 
eflornithine-based treatment have been successful with the inclusion of the nifurtimox-
eflornithine combination therapy (NECT) in 2009 in the WHO list of Essential 
Medicines (Figure 1.4). A multicenter clinical trial has demonstrated that NECT was 
not inferior compared with the standard eflornithine treatment (Priotto et al., 2009). 
NECT regimen schedule combines eflornithine by IV at 200 mg/kg every 12 h for 7 
days (for a total of 14 IV injections rather than the 56 of the single therapy) with 
nifurtimox being given orally at 5 mg/kg three times a day for 10 days (Table 1.1).  
Nifurtimox is a nitrofuran derivative, already in use for the treatment of acute Chagas 
disease, caused by Trypanosoma cruzi. Previously, nifurtimox was given on 
compassionate grounds to second-stage patients resistant to melarsoprol, but because of 
its limited efficacy (30-80%), it was never granted registration as a monotherapy for 
HAT. Nifurtimox acts as a pro-drug and requires the activation of a specific parasite 
nitroreductase (NTR) to produce an unsaturated open-chain nitrile that is equally 
cytotoxic towards mammalian and parasite cells (Hall et al., 2011).  Nifurtimox 
resistance can be quickly generated in the laboratory by loss of a single NTR allele 
either through selection of drug resistant clones or targeted gene deletion (Wilkinson et 
al., 2008; Sokolova et al., 2010, Alsford et al., 2012).  The only significant adverse 
events reported for NECT are a higher incidence of tremors, gastrointestinal nausea and 
anorexia (Priotto et al., 2009). 
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1.2.3 New drug candidates for HAT 
A major advancement towards a better cure for HAT is the current clinical 
development of two new molecules. 
Fexinidazole, a 2-substituted 5-nitroimidazole, was identified as a promising 
candidate for the treatment of HAT by DNDi through a compound mining approach 
aimed at the re-discovery of potential anti-trypanosomial drugs from the already well-
known bioactive class of nitroimidazoles (Torreele et al., 2010). The re-utilization of 
this forgotten molecule (Winkelmann and Raether, 1978; Jennings and Urquhart, 1983) 
has the potential to represent a major breakthrough in the treatment for HAT. 
Fexinidazole is the first drug to enter clinical trials for stage two HAT in the last 30 
years and it is currently in clinical phase II/III study aimed at assessing safety and 
efficacy compared to NECT in patients with late stage HAT (http://clinicaltrials.gov/). 
If successfully developed as an oral drug, it will have the invaluable advantage that it 
can be used in both stage I and stage II of the disease, simplifying both the case 
management and the diagnostic process, and abolishing the need for a lumbar puncture. 
Fexinidazole has many of the desirable attributes defined by the Target Product Profile 
(TPP) for HAT: it is effective against both stages of the disease caused by both T. b. 
gambiense and T. b. rhodesiense and a short course of oral treatment (<7 days) is 
curative in murine models of acute and chronic disease (Torreele et al., 2010). In 
addition fexinidazole has the potential to achieve cure in the acute model with a single 
high dose (Torreele et al., 2010). Fexinidazole is quickly metabolised into the sulfoxide 
and sulfone metabolites, both having similar trypanocidal activity (Sokolova et al., 
2010). It is probable that the sustained in vivo activity of this drug in mice, rats and dogs 
is due to the combined exposure of the three chemical species having different half-
lives: 1-3 h for fexinidazole, 2-7 h for the sulfoxide, and up to 24 h for the sulfone after 
oral administration (Torreele et al., 2010). The mechanism of action of this drug seems 
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to be similar to other nitrodrugs and is mediated by the activation by NTR to generate a 
cytotoxic species (Hall et al., 2011). Resistance to nitrodrugs can be easily generated in 
the laboratory (Sokolova et al., 2010): cell lines resistant to nifurtimox show increased 
resistance to fexinidazole, raising the risk that resistance to this drug could develop even 
before its approval for clinical use. In order to reduce the risk of resistance, it would be 
necessary to evaluate a combination therapy of fexinidazole with existing drugs or new 
drugs that might become available in the future (Kaiser et al., 2011). 
SCYX-7158, a benzoxaborole derivative, represents the latest hope to develop a 
new treatment for HAT. This molecule was discovered as part of collaborative Drug 
Discovery program funded by DNDi and performed in collaboration with Scynexis and 
Pace University. This chemical series was initially synthesised by Anacor 
Pharmaceuticals and its activity against T. brucei was determined by phenotypic 
screening performed at the Sandler Center. Scynexis further developed this series until 
the identification of SCYX-7158 (Nare et al., 2010; Jacobs et al., 2011). This 
compound is active in vitro against both T. b. gambiense and T. b. rhodesiense, it is also 
efficacious in both stage 1 and stage 2 murine HAT models. The in vivo 
pharmacokinetic studies have demonstrated high bioavailability after oral 
administration, long half-life (24 h), high brain exposure and quick distribution to CSF 
to achieve therapeutically relevant concentrations (Jacobs et al., 2011). Up to date the 
mechanism of action of the oxaborole compounds is not known, but the rapid 
trypanocidal effect (12 h above the minimum inhibitory concentration) suggests that 
oxaboroles are retained within the parasites or they exert irreversible effects on the 
potential target(s) during this limited time frame (Nare et al., 2010). 
 Based on its promising characteristics SCYX-7158 has been selected as a 
preclinical candidate and in 2012 has entered phase I clinical studies on healthy 
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volunteers from Sub-Sahara Africa to determine safety, tolerability, pharmacokinetics 
and pharmacodynamics. 
 
1.3 Target assessment and target product profile 
The lack of efficacious drugs for all subspecies and stages of the disease urges 
research for drugs with novel mechanisms of action. The clinical development of 
fexinidazole and SCYX-7158 gives hope for an oral treatment for both stages of the 
disease and both subspecies, and for the simplification of the diagnosis by elimination 
of the disease staging. Unfortunately, the attrition rate of the clinical development 
process is quite high, with only one in 10 molecules completing the clinical 
development process (Brown and Superti-Furga et al., 2003).  
New drugs can be developed either using a phenotypic approach or by target-
driven screening campaigns (Gilbert, 2013). Although the first approach selects 
molecules active in cells and overcomes problems related to drug import and efflux, the 
lack of knowledge of the mechanism of action requires target deconvolution and the 
chemical development of the active compounds cannot be guided by structural 
information. The second approach requires the identification of validated drug targets as 
starting point for a screening campaign. This approach has the advantage to be target-
directed and the availability of structural knowledge or preliminary chemical validation 
in other species can speed up the process of drug discovery, but poses the challenge to 
translate the biochemical potency into efficacy against cells. Futher, many compounds 
active in protein-based assays are inactive in whole cells owing to their physicochemical 
properties (Nwaka and Hudson, 2006; Renslo and McKerrow, 2006). 
The process of drug target identification and validation at the Drug Discovery 
Unit in Dundee (DDU) is based upon a traffic-light system. Target assessment is 
performed against a series of parameters, such as genetic and chemical validation, 
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druggability, assay feasibility, toxicity, structural information and resistance potential as 
illustrated in detail by Frearson and colleagues (2007). The target assessment process 
has to be linked to the target-product profile (TPP) that defines the therapeutic 
requirements for a pre-clinical candidate molecule (Frearson et al., 2007; Wyatt et al., 
2011). The biological and physico-chemical properties are linked to the specific disease 
setting and the need of the affected populations. In the case of sleeping sickness an oral 
or parenteral treatment for the late stage of both gambiense and rhodesiense infection is 
among the priorities.  
The sequencing of the genome of the Tritryps, Trypanosoma brucei (Berriman 
et al., 2005; Jackson et al., 2010), Leishmania major (Ivens et al., 2005) and 
Trypanosoma cruzi (El-sayed et al., 2005) has undiscovered a plethora of potential drug 
targets. In order to rationalize and prioritize these targets various initiatives have been 
developed aimed at collating all available information and ranking the targets using 
similar parameters as those used for the target assessment in the DDU (Agüero et al., 
2008).  
The DDU has a balanced pipeline, including drug targets unique to the parasite 
for which the biology is well understood, but with little knowledge about their 
druggability, such as trypanothione reductase (Patterson et al., 2011), trypanothione 
synthetase (Torrie et al., 2009), and Trypanosome brucei pteridine reductase 1 (Spinks 
et al., 2011); drug targets that have been well validated in other organisms both 
genetically and chemically are also included, but the presence of orthologues poses the 
problem of toxicity, which could be overcome by exploiting the structural differences 
between the mammalian and parasite target (examples of such targets are Trypanosoma 
brucei N-myristoyltransferase (Frearson et al., 2010) and T. brucei cdc2-related protein 
kinase CRK3 (Cleghorn et al., 2011)). In combination the DDU adopts a phenotypic 
strategy aimed at the identification of bioactive molecules against the whole organism, 
  
 
Figure 1.7 Structure of the conserved kinase catalytic domain.  
 
Figure 1.7 Generic structure of a protein kinase 
Protein kinases have a small N-lobe containing five β sheets and one α helix 
called αC-helix. The bigger C-lobe contains 6 α-helices. The ATP binds in the 
cleft between the two lobes. The glycine-rich loop and the autophosphorylation 
loop are indicated in yellow (Figure from Taylor and Kornev, 2011). 
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postponing to a later stage the identification of the molecular target (Smith et al., 2011, 
De Rycker et al., 2013). 
 
1.4 Protein kinases  
Eukaryotic protein kinases (ePKs) catalyse a chemical reaction that requires the 
binding of ATP (or GTP) as a complex with Mg
2+
 or Mn
2+
, the binding of the protein 
substrate and transfer of the-phosphate from the phosphate donor to the hydroxyl 
residue (serine, threonine or tyrosine) of the protein substrate (Hanks and Hunter, 1995). 
The catalytic domain of protein kinases consists of twelve subdomains conserved across 
the major groups and containing characteristic conserved residues (Figure 1.7). The 
twelve subdomains are organised in two lobes: a smaller amino-terminal lobe (N-lobe) 
composed of five β sheets and one α helix and a larger carboxy-terminal lobe (C-lobe) 
composed of six α-helical domains (Hans and Hunter, 1995; Huse and Kuriyan, 2002). 
The two lobes are connected by a hinge linker.  The amino-terminal lobe is involved in 
the binding of the ATP and the carboxy-terminal lobe in the binding of the peptide 
substrate and initiation of the chemical reaction, with the cleft between the two domains 
being responsible for the catalysis. ATP is bound in this cleft between the two lobes, in 
an area described by a conserved loop (P loop). The P loop is a highly flexible glycine-
rich area also containing an aromatic residue: the glycine residues allow the 
coordination of the phosphates of the ATP via backbone interactions and the aromatic 
residue participates in the phosphate transfer. The activation loop, generally 20-30 
amino acids in length, is centrally located and allows the binding of the peptide acceptor 
in proximity of the -phosphate. Phosphorylation of the activation loop allows the 
stabilization of the kinase in an active conformation. The position and number of 
phosphorylation sites varies among ePKs (Hans and Hunter, 1995; Huse and Kuriyan, 
2002, Taylor and Kornev, 2011) (Figure 1.7). 
Table 1.2 Classification of PKs by groups in human and in Trypanosoma 
brucei 
Protein 
kinase 
group  
Hs kinases T. brucei kinases 
Manning 
 et al., 2002 
Parsons 
 et al.,  2005 
Nett 
 et al., 2009a 
Urbaniak  
et al., 2012 
Jones et al., 
2014 
AGC  63 12 22 18 14 
CAMK 74 14 28 33 14 
CK1  12 5 5 5 5 
CMGC  61 42 47 47 42 
RGC  5 0 0 0 0 
Other 83 39 40 38 42 
STE 47 25 28 30 25 
TK 90 0 0 0 0 
TKL  43 0 0 0 0 
unique 0 19 0 0 28 
atypical 40 20 12 11 20 
Total 518 176 182 182 190 
 
Protein kinases classification as defined by Miranda-Saavedra and Burton (2007): AGC 
(including cyclic-nucleotide and calcium-phospholipid dependent kinases, ribosomial 
S6-phosphorylating kinases, G protein coupled kinases, and close relatives); CAMK 
(calcium/calmodulin-regulated kinases); CK1 (casein kinases I, and close relatives); 
CMGC (cyclin-dependent kinases, mitogen activated protein kinases, glycogen synthase 
3 kinases, casein kinases II, CDK-like kinases); RGC (receptor guanylate cyclases); 
Other (mixed collection of kinases that could not be classified easily into the previous 
families);  STE (protein kinases involved in MAP kinase cascades, homologs of yeast 
sterile kinases); TK (tyrosine kinases); and TKL (tyrosine-kinase like, which are, in 
fact, serine/threonine kinases); atypical kinases (including alpha, PIKK [phosphatidyl 
inositol 3' kinase-related kinases], PDHK [pyruvate dehydrogenase kinases], and RIO 
[right open reading frame kinases]).  
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Eukaryotic PKs have been classified into major groups (Hanks and Hunter, 
1995; Manning et al., 2002; Miranda-Saavedra and Barton, 2007) as described in more 
detail in Table 1.2. ePKs play an important role in eukaryotic organisms (such as 
Caenorhabditis elegans (Plowman et al., 1999), Drosophila melanogaster (Rubin et al., 
2000), and Homo sapiens (Manning et al., 2002) including cell cycle regulation, 
differentiation, apoptosis, cell shape and organization, transcription, and metabolism 
(Cohen, 2000). Although for years protein phosphorylation was believed to be a 
regulation mechanism present only in higher eukaryotes, several bacterial homologues 
have been identified in recent years (Kennelly, 2003). Mutation and deregulation of 
protein kinases are responsible for human diseases, such as cancer and auto-
inflammatory diseases. The development of new molecules targeting this family has 
demonstrated that ePKs have structural features that make them druggable (Hopkins and 
Groom, 2002), resulting in the introduction into the clinic of blockbusters such as 
Gleevec and Iressa (Druker et al., 1996; Barker et al., 2001). A total of 22 kinase 
inhibitors have been approved as drugs for the treatment of various cancers and more 
than 300 compounds are under current clinical development (http://clinicaltrials.gov/). 
The economic potential to exploit this family to develop drugs for “profitable” diseases 
such as cancer, inflammation, diabetes and Alzheimer’s disease, has resulted in an 
exponential increase in structural and chemical knowledge (Noble et al., 2004).  
 
1.4.1 The T. brucei kinome 
By comparative analysis of the kinome of the three trypanosomatids, 
Trypanosoma brucei, Trypanosoma cruzi, and Leishmania major, Parsons and 
colleagues (2005) have initially found that orthologues are conserved across the three 
species and their kinome consists of 176, 190 and 199 PKs, respectively. The T. brucei 
kinome is around one third of the human one (518 PKs) and it is approximately 2% of 
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the parasite genome (~7500 proteins in total), well above the number of PKs for other 
unicellular parasites, such as Plasmodium falciparum (Leroy and Doerig, 2008; Parsons 
et al., 2005) (Table 1.2). Further studies have refined the initial classification done by 
Parsons and colleagues and up to date the T. brucei kinome consists of a total of 190 
members: 170 ePKs (including 12 predicted pseudo-kinases) and 20 atypical PKs (Nett 
et al., 2009a; Urbaniak et al., 2012a; Jones et al., 2014) (Table 1.2). Parsons and 
colleagues (2005) also identified 19 unique PKs in Trypanosoma brucei, which are the 
least conserved among the trypanosomatids and their divergence might be a potential 
source of selective drug targets, although they have been reassigned to ePKs groups by 
other studies (Nett et al., 2009a; Urbaniak et al., 2012a). 
The most striking difference among the parasite and human kinome is the 
absence of kinases belonging to the receptor-linked TK and TKL groups. Nevertheless 
tyrosine phosphorylation in T. brucei has been reported and attributed to the action of 
atypical tyrosine kinases such as Wee1, and dual specificity kinases (DYRKs, CLKs, 
and STE7) (Parsons et al., 1991; Nett et al., 2009b; Urbaniak et al., 2013). Moreover 
certain groups and families of ePKs are over-represented, such as CMGC, STE and 
NEK kinases. Another unique feature is the relative scarcity of transmembrane domains, 
to date only few kinases have been reported to be associated to membranes; eukaryotic 
initiation factor 2 alpha kinase at the membrane of the flagellar pocket (Moraes et al., 
2007), LDK at the membrane of lipid droplets (Flaspohler et al., 2010) and recently 
RDK1 (Jones et al., 2014; see section 1.4.2). Finally approximately 8% of the ePKs 
were reported to be pseudokinases, catalytically inactive, lacking some of the conserved 
residues indispensable for the enzymatic activity (Parsons et al., 2005).  
Phosphorylation has to play a key role in the parasite biology if protein kinases 
represent such large proportion of the genome. This has been recently confirmed by a 
global SILAC phosphoproteomic analysis performed in both procyclic form (PCF) and 
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bloodstream form (BSF) of T. b. brucei that has identified just above 10,000 
phosphorylation sites on 2,551 proteins (Urbaniak et al., 2013). PKs not only represent 
2% of the entire genome, but also one third of the expressed proteins seem to be 
regulated by phosphorylation. This is particularly important considering that T. brucei 
lacks of transcription factors and regulation of gene expression is done though mRNA 
processing (Clayton and Shapira, 2007) and post-translational modification (Urbaniak et 
al., 2013). The fact that phosphorylation as well as protein expression is differential in 
the two life stages of the parasite just adds a further degree of complexity to the 
understanding of the role of protein phosphorylation in T. brucei and in the 
kinetoplastids. 
 
1.4.2 Protein kinases in T. brucei as drug targets 
Protein kinases were initially proposed as drug targets in trypanosomes and 
Leishmania (Naula et al., 2005), due to their relative abundance in the trypanomatids 
genome and the potential role played in important functions such as regulation of the 
cell cycle and cytokinesis (Naula et al., 2005; Hammarton et al., 2007a; Hammarton, 
2007b). Indeed multiple kinases have now been studied and found to play a role in cell 
cycle regulation; these studies have also elucidated the differences in cell cycle between 
the two life stages of the parasite (Li, 2012; Farr and Gull, 2012, Tu et al., 2005). As 
expected cyclins and the CDK-related kinases (CRKs) are among the key regulators of 
the cell cycle: CRK1/cyc2 regulates DNA replication and G1/S transition, whilst 
CRK3/cyc6 controls G2/M progression (Tu and Wang, 2004; Tu et al., 2005). AUK1 
together with TLK1 plays a role in mitosis and spindle assembly (Tu et al., 2006, Li et 
al., 2006; Li et al., 2007; Li et al., 2008b), whereas MAPK6, PLK, PK50 and PK53 
have been characterised as main regulators of cytokinesis (Wei and Li, 2014; 
Hammarton et al, 2007c; Li et al, 2010; Ma et al., 2008). Akiyoshi and Gull (2014) 
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have recently identified 19 unconventional kinetochore proteins in Trypanosoma brucei, 
four of them are protein kinases: CLK1, CLK2, PK6 and a protein previously annotated 
as putative protein kinase (named KK10, KK19, KKT3 and KKT2, respectively, after 
the discovery of their function). These proteins are all responsible for DNA segregation. 
Cell replication in T. brucei requires also a coordinated duplication of its 
organelles: CRK9 seems to play a role in kinetoplast segregation in both PCF and BSF 
(Gourguechon et al., 2009; Jones et al., 2014); PLK is required for bilobe duplication 
and Golgi biogenesis as well as basal body duplication and flagellum elongation (de 
Graffenried et al., 2008; Ikeda and de Graffenried, 2012); and Vps34, a lipid kinase, 
segregates the Golgi complex after duplication (Hall et al., 2006). Jones and colleagues 
(2014) have performed a kinome wide RNAi study looking for cell viability in BSF and 
confirmed previously published findings, but also further characterised the function of 
known essential kinases as GSK3 short and Casein kinase 1.2 (Ojo et al., 2008; 
Urbaniak, 2009), and identified 15 novel cell cycle regulators. 
Protein kinases in T. brucei also play important roles in cell differentiation: ZFK 
(Vassella et al., 2001), mTOR4 (Barquilla et al., 2012) and MAPK5 (Domenicali Pfister 
et al., 2006) have been characterized as negative regulators of the differentiation from 
the proliferative trypomastigote to the quiescient stumpy induced by SIF in the human 
host. More recently an RNAi study has identified positive regulators of the quorum 
signalling and not surprisingly found among others three protein kinases (FlaK, NEK, 
and YAK) responsible for the signal transduction pathway that induces the cell-cycle 
arrest in G0/G1 characteristic of stumpy forms (Mony et al., 2014). The aforementioned  
RNAi study from Jones and colleagues (2014) has also identified two new kinases 
acting as repressors of differentiation from bloodstream to procyclic form, the STE-11 
like RDK1, which works in concert with the tyrosine phosphatase PTP1 and localizes at 
the membrane, and the RDK2 belonging to the NEK family, which works 
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independently from other triggers. Finally MKK1, a MAP Kinase Kinase, is the first 
kinase associated with the transmission of the disease from insect to human (Morand et 
al., 2012). 
Protein kinases in T. brucei are also important for cell proliferation: TbTOR1 regulates 
protein synthesis and nucleolar structure (Barquilla et al., 2008); TbTOR2 controls cell 
polarization and endocytosis (Barquilla et al., 2009); eukaryotic initiation factor 2 alpha 
kinase is associated to the flagellar pocket and is involved in sensing and translational 
control (Moraes et al., 2007) and CRK12 plays a role in endocytosis (Monnerat et al., 
2013). Very few physiological substrates of protein kinases have been identified 
compared to the abundance of phosphorylated proteins and sites in both life stages. The 
T. brucei phosphoproteome is enriched in proteins involved in functions such as mRNA 
binding and flagellum motility for which very little is known of the role played by 
protein kinases (Urbaniak et al., 2013). In the phosphoproteomic study, it also emerged 
that the MAPK kinase pathway is activated in both life cycle stages (Urbaniak et al., 
2013). It is known that in promastigote Leishmania mexicana MPK9 regulates the 
flagellum biogenesis and maintenance (Bengs et al., 2005), thus more work is necessary 
to investigate whether MAPK kinases control the flagellum biogenesis and functions 
also in T. brucei (Rotureau et al., 2009).  
In addition to single gene studies, various RNAi studies have confirmed that protein 
kinases represent a source of drug targets in T. brucei. A small RNAi screen has 
attempted to genetically validate 30 uncharacterized protein kinases in T. brucei and 
identified MPK2 and CRK12 as important genes for cell proliferation (Mackey et al., 
2011). A target sequencing RNAi screen against the T. brucei genome has found that 
protein kinases are over-represented among genes responsible for loss-of-fitness in 
bloodstream form cells and differentiation (Alsford et al., 2011). The already mentioned 
RNAi study of the whole T. brucei kinome has identified a comprehensive list of 
Table 1.3 T. brucei protein kinases genetically and chemically investigated 
Gene Product 
 
Function 
Chemical validation 
Genetic 
validation 
References 
ZFK (Tb927.11.9270) Differentiation from BSF to stumpy form, but not 
essential for BSF growth 
gene knock-out Vassella et al., 2001 
 
Nuclear DBF-2-related (NDR) 
kinases PK50 and PK53 
(Tb927.10.4940 and 
Tb927.7.5770) 
PK50 and PK53 are essential regulators of cytokinesis. 
Chemical validation: HTS against molecular targets 
PK50 and PK53 resulted in potent inhibition in the 
biochemical assay but low activity in cellular assay. Only 
PK53 inhibitor could bind the protein target in lysate. 
 
RNAi Hammarton et al., 2005;  Ma et al., 2010; 
DDU project ; Urbaniak et al., 2012a 
 
 
PKAC1/PKAC2 
(Tb927.9.11100 and 
Tb927.9.11030) 
Growth defect in BSF, cytokinesis RNAi, 
gene knockout 
Kramer et al., 2004 
LDK 
(Tb927.11.8940) 
Mild growth defect in BSF, lipid droplets biogenesis  Flaspohler et al., 2010 
Casein Kinase 1.2 
(Tb927.5.800) 
Growth inhibition in BSF. Role in kinetoplast division and 
cytokinesis 
Chemical validation: purvalanol B and imidazopyridines 
bind native LmexCK1.2 and LmajCK1.2, respectively. 
Lapatinib, canertinib, AEEE788 bind CK1.2 in T. brucei 
lysate. 
RNAi,  
gene knock-out 
attempted 
Urbaniak et al.; 2009; Jones et al., 2014, 
Knockaert et al., 2000; Allocco et al., 
2006, Katiyar et al., 2013 
CRK1 
(Tb927.10.1070) 
Growth defect in BSF and PCF 
Interaction with cyc2, cyc4, cyc5 and cyc7. 
Role in DNA replication and in G1/S transition 
Chemical validation: Diaminopyrimidines 
RNAi Tu and Wang, 2004; Tu and Wang, 2005; 
Li et al., 2012; Mercer et al., 2011; Jones 
et al., 2014 
CRK3 
(Tb927.10.4990) 
Growth defect, interaction with cyc6,  block in G2/M 
Chemical validation: LmexCRK3/cyc6 nanomolar 
inhibitors were identified by HTS, but they did not 
translate in potent inhibitors in vitro against either T. 
brucei or Leishmania  
RNAi Tu and Wang, 2004; Cleghorn et al., 2011 
Gene Product 
 
Function 
Chemical validation 
Genetic 
validation 
References 
(Tb927.6.1780) 
 
in both BSF and PCF 
 
 
MAPK5 
(Tb927.6.4220) 
Role in differentiation from BSF to stumpy form 
 
gene knock-out in 
PCF 
Domenicali Pfister et al., 2006 
 
MAPK6  (MPK2) 
(Tb927.10.5140) 
 
 
Furrow ingression and cytokinesis completion in PCF. 
Rapid cell death, essential for cytokinesis initiation in 
BSF.  
Chemical validation: Diaminopyrimidines 
RNAi 
 
 
 
Wei and Li, 2014; Jones et al., 2014, 
Mercer et al., 2011, Mackey et al., 2011  
 
 
MAPK14 
(Tb927.3.690) 
Cell death; essential in cytokinesis in BSF. 
Chemical validation: Diaminopyrimidines 
RNAi 
 
Jones et al., 2014, Mercer et al., 2011 
 
MAPK9 
(Tb927.10.14800) 
Chemical validation: Diaminopyrimidines 
  
Mercer et al., 2011 
 
ECK1 
(Tb927.11.16790) 
Essential in both PCF and BSF. In procyclic C-terminal 
truncation phenotype: abnormal cell proliferation 
Expression of 
truncated 
TbECK1  
Ellis et al., 2004 
KKT2 
(Tb927.11.10520) 
 
Unconventional kinetochore protein: segregation of both 
megabase chromosomes and minichromosomes. 
 
RNAi 
 
 
Akiyoshi and Gull, 2014 
 
 
KKT3  
(Tb927.9.10920) 
 
Unconventional kinetochore protein: arrested cell growth 
in BSF, normal cell cycle. 
 
RNAi 
 
 
Akiyoshi and Gull, 2014; Jones et al., 
2014 
 
FlaK 
(Tb927.2.2720) 
Signal transduction component of the quorum signalling RNAi 
 
Mony et al., 2014 
Aurora Kinase I (AUK1) 
(Tb927.11.8220) 
 
Divergent function: chromosome segregation and 
cytokinesis initiation in PCF; cytokinesis in BSF without a 
control on mitosis or organelle duplication. 
Chemical validation: VX-680 and Hesperidin replicate 
AUK1 RNAi phenotype. Danusertib inhibits AUK1 and is 
efficacious in cells and animal model 
 
RNAi Tu et al., 2006 ; Li and Wang, 2006; Li et 
al., 2008a; Jetton et al., 2009; Li et al., 
2009; Hu et al., 2014; Ochiana et al., 
2013. 
Gene Product 
 
Function 
Chemical validation 
Genetic 
validation 
References 
CRK6 
(Tb927.11.1180) 
No defect 
Chemical validation: Diaminopyrimidines 
 
RNAi Tu and Wang, 2004; Mercer et al., 2011 
CRK9 
(Tb927.2.4510) 
Mitosis  and cytokinesis initiation in PF and BSF   
Role in kinetoplast segregation 
RNAi Gourguechon and Wang, 2009; Jones et 
al., 2014 
CRK12 
(Tb927.11.12310) 
CRK12:cyc9 complex in both PCF and BSF  
Growth inhibition in BSF, role in endocytosis, no effect 
on cell cycle 
 
RNAi, 
gene knock-out 
Mackey et al., 2011; Monnerat et al., 
2013; Jones et al., 2014; Merritt and 
Stuart, 2013 
CLK1 and CLK2 
(Tb927.11.12410 and  
Tb927.11.12420) 
Growth defect in BSF. Responsible for missegregation in 
anaphase cells 
Chemical validation: hypothemycin, a covalent inhibitor 
of CDXG kinase, targets native CLK1 
 
RNAi Akiyoshi and Gull, 2014; Nishino et al., 
2013; Jones et al., 2014 
DYRK/YAK 
(Tb927.10.15020) 
Signal transduction component of the quorum signalling RNAi Mony et al., 2014 
TbGSK3 short and TbGSK3 long 
(Tb927.10.13780 and 
Tb927.7.2420) 
TbGSK3 short RNAi causes growth defects in BSF and 
differentiation. TbGSK3 long RNAi causes gain of fitness 
in procyclic stage. 
Chemical validation: Non selective/non-specific 
inhibitors of HsGSK3 cause growth defects in T. brucei 
and Leishmania. HTS vs Merck and Pfizer GSK3 focused 
libraries. Target in cell of hypothemycin, canertinib, 
lapatinib, and DDD00085893 
 
RNAi Ojo et al., 2008; Oduor et al., 2011; 
Urbaniak et al., 2012a; Nishino et al., 
2013; Katiyar et al., 2013; Jones et al, 
2014. 
KFR1 
(Tb927.10.7780) 
Proliferation of BSF induced by interferon-γ   
  
Hua and Wang, 1997 
 
MAPK2 
(Tb927.10.16030) 
Role in differentiation from BSF to PCF 
 
gene knock-out 
 
Muller et al., 2002 
 
MAPK4 Confers resistance to temperature stress, but not essential gene knock-out Guttinger et al., 2007 
Gene Product 
 
Function 
Chemical validation 
Genetic 
validation 
References 
T. brucei Tousled like Kinase 1  
(TbTLK1) 
(Tb927.4.5180) 
TLK1 cooperates with Aurora in the regulation of the 
spindle assembly and chromosome segregation 
Chemical validation: lapatinib, canertinib, AEEE788 
 
RNAi Li et al., 2007; Li et al., 2008b; Katiyar et 
al., 2013, Jones et al., 2014 
Casein kinase 2 (TbCK2) Localized at the nucleolus, interacts with the nucleolar 
proteins Nopp44/46 and NOG1. Growth arrest in BSF. 
Role in cytokinesis 
RNAi Park et al., 2002; Jensen et al., 2006; 
Jones et al., 2014 
 
NEK12.1/ RDK2 
(Tb927.4.5310) 
Repressor of differentiation in BSF RNAi Jones et al., 2014 
NEK17 
(Tb927.10.5950) 
Signal transduction component of the quorum signalling RNAi Mony et al., 2014 
TbNRKC kinase 
(Tb927.10.460) 
 
Basal body and cytokinesis RNAi  and 
overexpression 
mutants 
Pradel et al., 2006 
Polo-like kinase (TbPLK) 
(Tb927.7.6310) 
Basal body replication and kinetoplast migration, 
cytokinesis initiation. Localized at the flagellum is 
responsible for flagellum attachment elongation. 
Chemical validation: GW843682X causes block of 
cytokinesis. Analogue-sensitive approach to specifically 
target PLK in cells. 
 
RNAi Graham et al., 1998;  Kumar and Wang, 
2006; Hammarton et al., 2007c, de 
Graffenried et al., 2008 ; Li et al., 2010; 
Sun and Wang, 2011; Yu et al., 2012; 
Ikeda et al., 2012; Lozano-Núñez et al., 
2013 
RDK1 
(Tb927.11.14070) 
 
Repressor of differentiation in BSF RNAi Jones et al., 2014 
TbTOR1 (T. brucei Target of 
Rapamycin) 
(Tb927.10.8420) 
Regulation of cell growth by regulating cell cycle, protein 
synthesis and nucleolus structure 
Chemical validation: NVP-BEZ235 is a nanomolar 
mTOR/PI3K inhibitor, with efficacy indication in an acute 
mouse infection model. 
  
RNAi Barquilla et al.,  2008, de Jesus et al., 
2010, Diaz-Gonazalez et al.,  2011. 
Gene Product 
 
Function 
Chemical validation 
Genetic 
validation 
References 
TbTOR2  
(Tb927.4.420) 
Cell polarization, endocytosis and cytokinesis 
Chemical validation: TOR complex 2 is sensitive to 
rapamycin 
RNAi Barquilla et al.,  2009 
TbTOR4  
(Tb927.1.1930) 
Negative  regulator of  differentiation RNAi Barquilla et al.,  2012 
TbVps34  
(Tb927.8.6210) 
Lipid kinase. Segregation of the Golgi complex RNAi Hall et al., 2006 
Eukaryotic initiation factor 2 
alpha kinase (elF2alpha kinase) 
(Tb927.4.2500) 
Associated to the membrane of the flagellar pocket, 
involved in sensing and translational control 
NA Moraes et al., 2007 
MKK1 Role in transmission from insect to human 
Not essential in BSF and in PCF 
Knock-out Morand et al., 2012; Jensen et al., 2011 
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essential protein kinases, cell cycle and differentiation regulators (Jones et al., 2014). 
These studies have a certain degree of agreement among them and the previous 
literature, but still the proposed essential targets will require further chemical and 
genetic validation (Jones et al., 2014, Frearson et al., 2007). 
In recent years more information has been collated regarding which protein 
kinase targets might be essential in T. brucei. The majority of the genetic studies are 
performed by RNAi and over-expression with tetracycline inducible systems as gene 
knock-outs remain generally labour intensive and tricky for proteins that are finely 
regulated (Merritt and Stuart, 2013). The divergences among RNAi studies derive from 
the differential levels of gene knock-down achieved using different strains and 
constructs and off-target effects (degradation of mRNA of genes that were not 
intentionally targeted), making gene validation by RNAi not always conclusive (Merritt 
and Stuart, 2013). 
In some cases chemical validation has been attempted using known human 
protein kinase inhibitors that are not selective or specific for T. brucei (Ojo et al., 2008; 
Jetton et al., 2009; Diaz-Gonazalez et al., 2011). High throughput screening campaigns 
have been performed only for a handful of protein kinases (TbGSK3 short, PK50, 
PK53, TbPLK), mainly due to the lack of active recombinant proteins (Ojo et al., 2008; 
Oduor et al., 2011; Urbaniak et al., 2012a; DDU unpublished data). 
Although a detailed description of all the T. brucei kinases is beyond the scope 
of this thesis, a list of the best characterized kinases, their function and whether have 
been validated by genetic or chemical means is reported in Table 1.3. 
Protein kinases are potential drug targets for parasitic diseases. On the one hand, 
they offer the comparative advantage of piggybacking on the extensive knowledge 
already existing on human protein kinase inhibitors. On the other hand targeting 
enzymes present in the human host poses the challenge to develop selective inhibitors 
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against the parasite ortholog. However, the fact that most of the parasite kinases share 
less than 60% identity in the catalytic domain with respect to the corresponding human 
kinases suggests that is possible to develop selective kinase inhibitors that specifically 
target the parasite enzyme (Naula et al., 2005). Furthermore the availability of structural 
information relative to the human kinases combined with computational modelling is a 
powerful tool for the design of selective inhibitors exploiting key differences in the 
amino acid sequences. 
This thesis assesses the short form of glycogen synthase kinase 3 (GSK3) as a 
drug target in Trypanosoma brucei using a combined chemical and genetic approach 
(see section1.7).  
 
1.5 Glycogen synthase kinase: role in diseases and inhibitor 
development 
In humans the two isoforms of glycogen synthase kinase 3 (GSK3) are called 
GSK3α and GSK3β, these two enzymes have molecular weight of 51 kDa and 47 kDa, 
respectively. They are very similar in their kinase domain (98% identity), but differ in 
their amino- and carboxyl-terminal and functional activity (Doble and Woodget, 2003). 
Yet they are not interchangeable as demonstrated by the inability of GSK3α to rescue 
the embryonic lethality of GSK3β knock-out (Hoeflich et al., 2000). There are two 
variants of HsGSK3β, the minor splice variant HsGSK3-2 has an insert of 13 amino 
acids within the kinase domain. The insertion seems to be responsible for a differential 
recognition of scaffold proteins and also a differential localization (Mukai et al., 2002).  
The crystal structure of HsGSK3β has been solved shedding light on the 
mechanisms of activation, substrate recognition and inhibition (Dajani et al., 2001). 
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GSK3 is constitutively active, and its regulation occurs either by inactivation by 
upstream signals or by changes in substrate recognition.  
The activation loop of GSK3 is phosphorylated at Tyrosine 216 and Tyrosine 
279 in GSK3 and GSK3 respectively. The tyrosine phosphorylation is not required 
for kinase activity, but facilitates the phosphorylation of the substrate and increases 
protein stability (Dajani et al., 2001; Cole et al., 2004). The activation loop 
phosphorylation has been shown to be an autophosphorylation event (Cole et al., 2004), 
which happens after translation requiring the involvement of a chaperone protein 
(Lochhead et al., 2006).  
GSK3 preferentially phosphorylates substrates that are pre-phosphorylated at the 
priming site at the C-terminus in its consensus sequence Ser/Thr-X-X-X-
(phospho)Ser/Thr. The priming site is believed to interact with a positively charged 
pocket (Arg96, Arg180 and Lys205) that positions the protein substrate in the right 
orientation for the subsequent phosphorylation. Un-primed substrates can also be 
recognised and phosphorylated by GSK3, as they often have a negatively charged 
residue that mimics the primed site (Doble and Woodget, 2003). 
GSK3 can be regulated by phosphorylation on regulatory Ser9 and Ser21 
residues, respectively in GSK3 and GSK3. The upstream kinases protein kinase B 
(also called AKT), MAPK-activated protein kinase 1 (also called p90RSK), p70 
ribosomal S6 kinase, cAMP-activated protein kinase and protein kinase C (PKC) are 
responsible for phosphorylation of Ser9/21 causing reduction in kinase activity and 
consequently reduction in phosphorylation of downstream substrates (Doble and 
Woodget, 2003, Cross et al., 1995; Cohen et al., 1997).  The phosphorylation on 
Ser9/21 mimics the primed substrate, by occupying the site for the substrate in a 
competitive manner. High concentrations of primed substrate can compete for this 
intermolecular inhibition (Doble and Woodget, 2003).  
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GSK3 can also be regulated by interaction with docking proteins that allow the 
substrate to make contacts with the priming kinase. Specific combinations of 
scaffolding proteins and substrates (e.g. axin is the docking protein for casein kinase 1 
and presenilin is the docking protein for protein kinase A) determine different functions 
of GSK3 in the cell (Meijer et al., 2004). 
Apart from glycogen synthase, GSK3 has a plethora of substrates in the cell in 
various compartments: metabolic proteins such as ATP citrate lyase, acetyl-CoA 
carboxylase, cyclin D1 and E, the eukaryotic initiation factor eIF2B, axin, hexokinase, 
and presenilin; structural proteins such us tau, neurofilaments, dynein, kinesin light 
chain, and microtubule associated proteins (MAPIB); and transcription factors such β-
catenin, CREB, Myc, NFB, HSF-1, Notch, p53, and HIF-1. This list is not exhaustive 
and the functions and phosphorylation effects on various substrates have been reviewed 
by Doble and Woodget (2003). Thus it is not surprising that GSK3 in mammalian cells 
is involved in a wide spectrum of cellular processes, including cell proliferation, 
differentiation, embryonic development, metabolism, transcription, translation, 
cytoskeletal regulation, intracellular vesicular transport, cell cycle progression, 
circadian rhythm regulation and apoptosis (Frame and Cohen, 2001). 
GSK3 plays an important role in two major pathways, the Wnt/-catenin 
pathway, essential during embryonic development, and the Hedgehog pathway, 
involved in cell fate determination and morphology (Double and Woodget, 2003). 
Protein stability seems to be one of the mechanisms through which GSK3 regulates 
cellular processes (Xu et al., 2009). The phosphorylation of target proteins by GSK3 
induces ubiquitination and proteolysis, in the case of cytoplasmic levels of β-catenin in 
the wnt pathway, or proteolytic cleavage of the substrate, in the case of transcription 
activator Ci (Cubitus interruptus) in the Hedgehog pathway. GSK3 also plays an 
inhibitory role in cell cycle progression and cell proliferation as phosphorylation of both 
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cyclin D1 and cyclin E induces their rapid degradation (Kang et al., 2008). GSK3 
activity is elevated in cells quiescent and in G1 phase, but is lowered when cells 
progress in S phase. GSK3 may also play a role in DNA repair after UV irradiation by 
inducing degradation of cdc25A, and allowing cells more time for DNA repair (Kang et 
al., 2008). Over-expression of GSK3 and the consequent increase in its activity induce 
apoptosis in cells undergoing cellular stress (Cross et al., 2001; Pap and Cooper, 1998). 
It looks like GSK3 is a master regulator, able to integrate both positive and negative cell 
stimuli through regulation of the stability and turnover of the protein targets. 
There are several diseases that could benefit from GSK3 inhibitors based upon 
its role in different cellular processes. Lithium is an inhibitor of GSK3 used for the 
treatment of bipolar disorder and mood stabilization despite the potency in cells is only 
in the the millimolar range. Lithium has a dual mechanism of inhibition: it inhibits 
GSK3 directly through competition with the Mg
2+
 coordinating the ATP and indirectly 
by increasing the phosphorylation of the inhibitory serine in the N-terminus (Jope, 
2003). GSK3 has also been linked to other disorders of the nervous system, such as 
Alzheimer’s disease caused by hyperphosphorylation of tau and formation of 
neurofibrillary tangles. Furthermore, elevated GSK-3 activity can cause overproduction 
of β-amyloid and the senile plaques observed in the Alzheimer patients (Martinez et al., 
2011). GSK3 inhibition has been also considered as therapeutic target for neuronal cell 
death, Parkinson’s disease, Huntington’s disease, transmissible spongiform 
encephalopathies and regulation of the circadian-clock (Meijer et al., 2004). As the 
inhibition of GSK3 by protein kinase B is insulin mediated and results in activation of 
glycogen synthase with consequent increase in glucose utilization, pharmacological 
inhibition of GSK3 has also been considered for the treatment of type 2 diabetes. The 
possible role of GSK3 inhibition in cancer treatment is unclear: on one hand inhibition 
of GSK3 can cause activation of wnt signalling and accumulation of β-catenin, 
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responsible for many colorectal cancers and stabilization of cyclin D1 and C and Myc-1 
all involved in tumorigenesis; on the other hand dual CDK-GSK3 inhibitors could 
synergistically induce apoptosis in prostate cancer through a mechanism that involves 
enhancement of TRAIL (TNF-related apoptosis-inducing ligand) apoptotic activity. It 
has also been reported that GSK3 plays a role in the mitotic spindle and GSK3 
inhibition is responsible for arrest in prometaphase (Meijer et al., 2004). The use of 
GSK3 in cancer therapy therefore requires the careful design of inhibitors that do not 
interact with the wnt pathway or are specifically directed towards certain cellular 
compartments (Meijer et al., 2004).  
Additional therapeutic areas for GSK3 have been identified in the treatment of 
osteoporosis and vascular calcification. These conditions could be treated by the 
activation and inhibition of the Wnt/β-catenin signalling pathway, respectively. 
Although activators of GSK3 could also play a role in the treatment of cardiac 
hypertrophy and cancer, no direct activators of GSK3 are under development 
(Takahashi-Yanaga et al., 2013) 
More than 30 GSK3 inhibitors have been reported (Meijer et al., 2004); some of 
them have been co-crystallized with GSK3β in the ATP pocket (Bertrand et al., 2003). 
The majority of GSK3 inhibitors are not selective and generally GSK3 inhibition is 
associated with CDK2 inhibition as well, as the two enzymes are very closely related in 
their kinase domain (Bain et al., 2007; Meijer et al., 2004).  
Tideglusib, belonging to the chemical family of the thiadiazolidindiones 
(TDZDs), is the only GSK3 inhibitor currently in clinical development. Initially it was 
erroneously characterized as a non-competitive ATP inhibitor, but it has been recently 
demonstrated that it is in reality an irreversible inhibitor of GSK3 (Martinez et al., 
2002a; Dominiguez et al., 2012). Disappointingly the results for the completed phase II 
clinical trial for the treatment of Alzheimer’s disease and progressive supranuclear palsy 
  
 
 
Figure 1.8 Amino acid sequence alignment of HsGSK3β, HsGSK3α, TbGSK3short, and TbGSK3long 
The background colour varies from the least conserved residues (white) to the most conserved residues (dark blue). 
 30 
have revealed that although well tolerated by the patients one year after administration, 
this molecule has failed to show any clinical efficacy (Tolosa et al., 2014).  
 
1.6 Glycogen synthase kinase as a drug target in kinetoplastida  
Glycogen synthase kinase 3 is a conserved protein kinase across eukaryotes and 
has been proposed as a drug target against Toxoplasma gondii (Qin et al., 1998), 
Plasmodium falciparum (Droucheau et al., 2004), Trypanosoma brucei (Ojo et al., 
2008), and Leishmania donovani (Xingi et al., 2009).  
In T. brucei there are two isoforms of glycogen synthase kinase 3, TbGSK3 
short (Tb927.10.13780) and long (Tb927.7.2420), respectively 40 kDa and 55 kDa. 
Both isoforms are more similar to HsGSK3β than HsGSK3α with an identity of 40.9% 
and 33.1% for TbGSK3 short and TbGSK3 long to HsGSK3β, respectively. The two 
parasite isoforms share an identity of 30.6% between them (Ojo et al., 2008). The 
identity is more over the kinase domain, while the amino-terminal and carboxyl-
terminal domains are not very well conserved (Figure 1.8). 
A phosphoproteomic study performed by Nett and colleagues (2009a) in 
bloodstream form cells has shown that TbGSK3 short is phosphorylated in the 
activation loop at Tyr187, suggesting that the mechanisms of activation might be 
conserved between mammals and parasites. It is unclear whether the identified 
phosphorylation on Ser2 might mimic the mechanism of inhibition of GSK3 performed 
by the phosphorylated Ser9 in the N-terminus of HsGSK3β. Recently Urbaniak and 
colleagues (2013), performing a global phosphoproteomic study in procyclic and 
bloodstream form, have added two additional phosphorylation sites for TbGSK3 short 
on T6 and S41 and determined a differential protein expression in the two life stages 
(higher in bloodstream than procyclic form). The phosphorylation on the activation loop 
was also identified in the procyclic form only for TbGSK3 long at Tyr277 (Nett et al., 
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2009b). Tyrosine phosphorylation on GSK3 activation loop has also been found by 
phosphoproteomic studies in Leishmania infantum (Hem et al., 2010) and Trypanosoma 
cruzi (Nakayasu et al., 2009; Marchini et al., 2011).  
The substrate recognition patterns (S/TXXXphosphoS/T) are conserved 
considering that recombinant TbGSK3 short (Ojo et al., 2008) and LdGSK3 short 
(Xingi et al., 2009) could trans-phosphorylate a known primed GSK3 substrate based 
upon the GSK3 phosphorylation sites of mammalian glycogen kinase (Meijer et al., 
2004). In epimastigote T. cruzi, around 7% of the identified phosphoproteins were 
compatible with the GSK3 consensus sequence (Nakayasu et al., 2009) confirming also 
in kinetoplastids the relevant role played by GSK3, as one of the kinases with most 
substrates in the cell (Linding et al., 2007). 
The role of TbGSK3 is unknown. TbGSK3 short RNAi has been associated with 
defects in growth in both bloodstream form T. brucei and in differentiation (Ojo et al., 
2008; Alsford et al., 2011). On the other hand TbGSK3 long RNAi did not show 
significant effect on growth in bloodstream form, but was responsible for a gain-of-
fitness in procyclic indicating a differential role for this isoform of the enzyme (Ojo et 
al., 2008; Alsford et al., 2011). Recently Jones and colleagues (2014) have shown that 
TbGSK3 short knockdown causes cell arrest with a delay in mitosis and/or defects in 
cytokinesis.  These findings are supported by a study performed on Leishmania 
donovani that has established that LdGSK3 short is involved in cell cycle control and 
apoptosis-like death. The same study has also determined that in promastigote (insect 
form) cells the enzyme is cytosolic during logarithmic growth, but localises to the 
nucleus and flagellum at the stationary-phase, whereas in axenic amastigotes (model 
system used to study the intracellular amastigotes infecting the human macrophages) the 
cytosolic localisation is more punctate (Xingi et al., 2009). In Plasmodium falciparum 
the expression of GSK3 (PfGSK3) is predominant in the trophozoite stage; here the 
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protein is rapidly exported to the erythrocyte cytoplasm where it associates with 
vescicle-like structures called Maurer’s clefts suggesting a function in protein 
trafficking (Droucheau et al., 2004). An interesting speculative role for this kinase in P. 
falciparum is the regulation of the parasite cycle that occurs in a circadian-dependent 
manner (always multiple of 24 hours) (Droucheau et al., 2004). 
Up to date no crystal structure of TbGSK3 short has been solved, but it has been 
possible to build homology models using the solved structures for HsGSK3β (Ojo et al., 
2008; Oduor et al., 2011; Woodland et al., 2013) and LmajGSK3 (Ojo et al., 2011). 
These computational studies have identified key differences in the parasite ATP binding 
site that could be exploited to develop selective inibitors.  
Non-specific inhibitors of HsCDK2 and HsGSK3 have shown cellular efficacy 
with some correlation with the potency in vitro against recombinant TbGSK3 providing 
a preliminary indication of chemical inhibition of this enzyme in cells (Ojo et al., 2008). 
Furthermore a focused screen of Pfizer proprietary compounds targeting  HsGSK3β has 
identified two compounds with 7-fold selectivity for TbGSK3 short over HsGSK3β and 
this achieved selectivity has been rationalised by a key difference in the gatekeeper 
residue of the active site (TbM101/HsL132) (Oduor et al., 2011). This selectivity is in 
agreement with the bioinformatics analysis performed by Osolodkin and colleagues 
(2011) that has proposed to target the gatekeeper residue in order to achieve selectivity 
for GSK3 protozoal kinases. The substitution of the gatekeeper residue (Leu132Met) 
affects the volume of the binding site, and is present not only in Trypanosoma, but also 
in Plasmodium, Leishmania and Toxoplasma (Osolodkin et al., 2011). The methionine 
gatekeeper is longer and more flexible than the leucine explaining the selectivity 
towards the human enzyme of the majority of known GSK3 inhibitors. On the one hand 
the longer lateral chain can obstruct inhibitor binding due to steric clash, but on the 
other hand smaller inhibitors may be able to make hydrogen bonds with the sulphur of 
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the methionine thereby preferentially inhibiting the protozoan kinases (Osolodkin et al., 
2011).  
Unfortunately the selective compounds identified by Oduor and colleagues 
(2011) are quite promiscuous inhibitors of mammalian kinases with associated cellular 
toxicity and are unlikely to specifically target TbGSK3 in cells. 
Interestingly two distinct chemoproteomic studies, aimed at identifying the 
cellular targets of lapatinib, a kinase tyrosine inhibitor, (Katiyar et al., 2013) and of 
hypothemycin, a covalent inhibitor of kinase containing a CDXG motif (Cys-Asp-Xaa-
Gly) (Nishino et al., 2013), have identified TbGSK3 short among their targets in vivo in 
T. brucei. Both lapatinib and hypothemycin kill T. b. brucei in proliferation assays with 
potency of 1.5 µM and 170 nM, respectively. As TbGSK3 is not the only target 
identified, the cellular activity cannot be completely attributed to this enzyme. 
Nonetheless, these studies provide further evidence that this protein kinase can be 
targeted in the cells.  
None of the compounds studied up to date are specific enough as inhibitors of 
TbGSK3 short to be used as chemical probes to interrogate the still unknown biological 
functions of this kinase in T. brucei or selective enough towards HsGSK3β to be 
considered as starting points for medicinal chemistry optimization as anti-trypanosomal 
drugs. 
 
 34 
 
1.7 Aims of the project 
 
The objective of this project is to evaluate with a combination of chemical and 
genetic approaches Glycogen Synthase Kinase 3 (TbGSK3) as potential drug target in 
Trypanosoma brucei.  
The specific goals of the project are to: 
(1) perform a biochemical characterization of the molecular target; 
(2) identify small molecule inhibitors from a medium throughput screening (MTS) 
campaign against the molecular target; 
(3) identify any correlations between inhibition of the enzymatic activity (IC50) with 
respect to inhibition of trypanosome proliferation (EC50);  
 (4) determine the mode of inhibition and binding kinetics of identified inhibitors 
(determination of IC50, Ki, Kd, kon and koff); 
(5) investigate potential off-target mode(s) of action and identify the molecular targets 
responsible for the efficacy in vitro;  
(6) establish whether or not the mode of action is on target against the whole parasite by 
over-expression or under-expression studies looking for shifts in inhibitor potency. 
(7) examine essentiality by gene knock-out. 
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Chapter 2 Materials and methods 
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2.1 Materials 
The kinase focused set was collated by the Computational Group at the 
University of Dundee (Brenk et al., 2008). Further synthesis and chemical 
characterisation of inhibitors of TbGSK3 short were performed by Dr Andrew 
Woodland and Dr Laura Cleghorn for series GSK3 07 (Woodland et al., 2013) and by 
Dr Robert Urich for series GSK3 09 (Urich et al., 2014). All the reagents were bought 
from Sigma Aldrich if not otherwise stated. All the solutions were prepared with milliQ 
water. All the reagents were bought at the highest grade of purity and stored according 
to the manufacturer’s recommendations. 
2.2 General molecular biology 
2.2.1 Isolation of genomic DNA from bloodstream form T. brucei 
Genomic DNA (gDNA) was isolated from bloodstream form (BSF) T. brucei 
brucei strain 427 Lister (S427) (~ 100 ml of 1-2 x 10
6
 cell ml
-1
). Cells were harvested 
by centrifugation (800 x g, 10 min at room temperature) and resuspended in 450 l of 
lysis buffer (10 mM Tris-HCl, pH 8.0; 25 mM EDTA; 100 mM NaCl; 0.5% (w/v) SDS, 
0.1 mg ml
-1 
proteinase K). The resuspended cells was incubated overnight at 56 ºC. 
DNA was extracted with Tris-buffered, pH 8.0 phenol/chloroform/isoamyl alcohol 
(PCI, 25:24:1). The organic phase was separated from the aqueous one containing the 
DNA by two repeated cycles of extraction and centrifugation at 16,000 x g for 1 min. A 
final extraction was done with chloroform/isoamyl alcohol (CI, 24:1). Finally the 
extracted DNA was precipitated with 70% ethanol and let to dry prior to resuspension in 
10 mM Tris-HCl, pH 8.5 and stored at 4 ºC. 
 
Table 2.1 Primers used for recombinant protein expression in E. coli  
Primer use 
 
Name 
 
Primer sequence (5’-3’) 
 
 
Restiction 
Endonucleases 
 
Cloning in expression vectors   
1 TbGSK3short _ORF_s gcgcctcgagATGTCGCTCAACCTTACCGATGC XhoI 
2 TbGSK3short _ORF_as gcgcggatccTTACTTCTTCAGCAGATACTC BamHI 
    
3 TbGSK3long _ORF_s gcgcctcgagATGAGTGAGCGGATTTTGCCGTCG XhoI 
4 TbGSK3long _ORF_as gcgcggatccTTATATCGCATTCTCCGGC BamHI 
    
5 TbGSK3short _K49A_s AAGCACGGGGTCACTAGTAGCAATTGCAAAGGTGATACAAGATCCG Mutation  of 
K49A 6 TbGSK3short _K49A_as CGGATCTTGTATCACCTTTGCAATTGCTACTAGTGACCCCGTGCTT 
    
7 TbGSK3short _K49M_s CGGGGTCACTAGTAGCAATTATGAAGGTGATACAAG Mutation  of 
K49M 8 TbGSK3short_K49M_as CTTGTATCACCTTCATAATTGCTACTAGTGACCCCG 
 
Upper case letters refer to nucleotides corresponding to gene sequences in T. brucei; lower case refers to additional sequences used in generating 
constructs. The restriction sites are underlined. Bold case letters correspond to the mutation sites. 
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2.2.2 DNA amplification 
DNA was amplified by the polymerase chain reaction (PCR) using Platinum 
PCR SuperMix High Fidelity (Invitrogen) with proofreading ability according to the 
manufacturer’s guidelines. A 50 l reaction contained approximately 100 pmol of gene-
specific forward and reverse primers (Table 2.1 and Table 2.2) and approximately 1-
200 ng of genomic DNA or plasmid template. All PCR reactions were carried out in 
200 l tubes (Thermo Scientific) in a Thermo-Hybaid MSB 0.2G thermal cycler. 
Generally the tubes were incubated at 94 ºC for 2 min to denature the template and 
activate the enzyme. PCR amplification was generally performed in 30 cycles of 
denaturation (94 ºC for 30 s), annealing (30 s 55-68 ºC depending on the melting 
temperature of the primers) and extension (1 min at 68 ºC per kb). A final step of 
extension for 10 min at 72 ºC was included. PCR reaction products were stored at 4 ºC. 
 
2.2.3  Agarose gel electrophoresis and extraction of DNA  
DNA size and purity were analysed by agarose gel electrophoresis. Gels were 
prepared by dissolving 0.8% (w/v) agarose in TAE buffer (40 mM Tris-acetate, pH 8.0, 
1 mM EDTA) containing 0.1 µg ml
-1
 ethidium bromide for DNA staining. Separation 
was performed in TAE buffer at 80 V. DNA was visualised using an UVP 
transilluminator. One Kb Plus DNA Ladder (Invitrogen) was used as standard for size 
determination of DNA bands. If required, the DNA band of interest was excised from 
the gel and purified with the QIAquick Gel Extraction Kit (Qiagen) as per 
manufacturer’s guidelines. 
 
Table 2.2 Primers used for generation of knock-outs and rescue constructs 
Primer use 
 
Name 
 
Primer sequence (5’-3’) 
 
 
Restiction 
Endonucleases 
 
Knock-outs    
9 TbGSK3short _5UTR_s ataagaatgcggccgcGAGTGAACAAACACCTCCAAG NotI 
10 TbGSK3short _5UTR_as gtttaaacttacggaccgtcaagcttGTAGTGAATAGTGCGATTTTG HindIII/PmeI 
11 TbGSK3short _3UTR_s gacggtccgtaagtttaaacggatcCATGGTCGTGTTTTAAGTTGTG PmeI/BamHI 
12 TbGSK3short _3UTR_as ataagtaagcggccgcCGTGCCACACCTACTTGCTTC NotI 
Silent Mutation of HindIII  site in TbGSK3 short    
13 TbGSK3short (T960C)_s GGGAGCCAACAACGAAGCTCCCCAGTGGTA Silent mutation  of 
HindIII 14 TbGSK3short (T960C)_as TACCACTGGGGAGCTTCGTTGTTGGCTCCC 
Ectopic copy    
15 TbGSK3short _ORF_s gcgcaagcttcATGTCGCTCAACCTTACCGATGC HindIII 
16 TbGSK3short _ORF_s gcgccatATGTCGCTCAACCTTACCGATGC NdeI 
17 TbGSK3short _ORF_as gcgcggatccTTTACTTCTTCAGCAGATACTC BamHI 
18 TbGSK3short _ORF_as gcgcttaattaaCTTCTTCAGCAGATACTC PacI 
Silent Mutation of HindIII  site in TbGSK3 long   
19 TbGSK3long (T501C)_s CCGTGCGTTGTGAAGCTCCTGGATCATTTCTTCGC Silent mutation  of 
HindIII 20 TbGSK3long (T501C)_as GCGAAGAAATGATCCAGGAGCTTCACAACGCACGG 
Ectopic copy    
21 TbGSK3long _ORF_s gcgcaagcttcATGAGTGAGCGGATTTTGCCGTCG HindIII 
22 TbGSK3long _ORF_as gcgcggatccTTATATCGCATTCTCCGGC BamHI 
23 TbGSK3long _ORF_as gcgcttaattaaTATCGCATTCTCCGGC PacI 
 
Upper case letters refer to nucleotides corresponding to gene sequences in T. brucei; lower case refers to additional sequences used in generating 
constructs. The restriction sites are underlined. Bold case letters correspond to the mutation sites. 
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2.2.4 Cloning of PCR products 
Following PCR (section 2.2.2.) and, when necessary, gel extraction (section 
2.2.3.), blunt-end PCR products were usually sub-cloned into pCR-BluntII-TOPO 
vector (Invitrogen). Ligations were carried out for 30 min on ice, following the 
manufacturer’s guidelines. Ligated TOPO vectors were immediately transformed into 
50 µl TOP10 chemically competent cells, as described in section 2.2.5. Alternatively 
when the PCR products were obtained by primers with overhanging regions they were 
digested with the restriction endonucleases corresponding to their cloning sites (Table 
2.1 and Table 2.2.) and ligated in the vector according to section 2.2.8. 
 
2.2.5 Transformation of competent E. coli cell lines 
Transformation of plasmids was achieved by heat shock of the following 
competent cells: Escherichia coli strains TOP10 (Invitrogen) were used for cloning and 
sequencing, JM109 (Stratagene) for DNA amplification, XL10-Gold Ultracompetent 
(Stratagene) for ligation of expression plasmids, BL21 Star (DE3) (Invitrogen) for 
protein expression of TbGSK3 short and long, and ArcticExpress (DE3) RIL 
(Stratagene) for expression of insoluble proteins at low temperature. Typically, 50 ng of 
plasmid DNA was added to 10 - 50 μl competent cells and incubated on ice for 10 min. 
Cells were then subjected to heat shock according to the manufacturer’s conditions in a 
water bath at 42 °C, followed by a further incubation on ice for 2 min. SOC medium 
(250 μl, containing 0.5% (w/v) yeast extract, 2% (w/v) tryptone, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgCl2, 20 mM MgSO4 and 20 mM glucose) was added and the resulting 
culture was incubated at 37 °C for 1 h. Cells were then plated out on Luria Bertiani (LB, 
0.5% (w/v) yeast extract, 1% (w/v) tryptone and 1% (w/v) NaCl, pH 7.5) agar plates 
supplemented with appropriate antibiotics. Plates were incubated at 37 °C overnight and 
colonies were picked and grown at 37 °C with agitation at 200 rpm in 10 ml LB 
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medium containing appropriate antibiotics. All the LB media and plates were prepared 
by the media kitchen of the University of Dundee. 
 
2.2.6 Purification and digestion of plasmid DNA  
Transformed cultures were incubated overnight at 37 °C with agitation at 200 
rpm. Cells were harvested by centrifugation (3,800 x g, 15 min, room temperature) and 
plasmid DNA was purified using a QIAprep kit (Qiagen) according to the 
manufacturer’s instructions. Plasmids were analysed by digestion with appropriate 
restriction enzymes. Typically, 10 units of each restriction enzyme (New England 
Biolabs, Promega or Fermentas) and 1 μl of the recommended 10-fold buffer were 
added to 200 ng plasmid DNA, with autoclaved milliQ water added to a final volume of 
10 μl. The total amount of restriction enzymes was kept below 10% for both single and 
double digests. Reactions were incubated at 37°C in a water bath for 2 h and then 
analysed by agarose-gel electrophoresis (section 2.2.3.). For preparative purposes, DNA 
was digested in a larger volume (up to 100 μl) maintaining the equivalent ratio between 
DNA, restriction enzymes and buffer, the reactions were incubated overnight at 37 °C. 
If digested DNA was used for ligation, the restriction enzymes were inactivated 
according to the manufacturer’s indications. Linearised plasmids were treated with 
Antarctic phosphatase (New England Biolabs) according to the manufacturer’s 
indication and phosphatase inactivated for 5 min at 65 °C. Both plasmids and inserts 
were purified by gel extraction (section 2.2.3.) prior to ligation. 
 
2.2.7 DNA sequencing 
DNA sequencing was performed by DNA Sequencing and Services at the 
University of Dundee (http://www.dnaseq.co.uk), using Applied Biosystems Big-Dye 
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Terminator chemistry version 3.1 on an Applied Biosystems 3730 automated capillary 
DNA sequencer. Plasmid DNA samples were submitted at concentrations of 16 – 20 ng 
µl
-1
.  
 
2.2.8 Ligation 
Ligation reactions were carried out with gel-purified restriction fragments 
(section 2.2.6). Purified target vector (~50 ng) and insert were typically combined in 
molar ratios of 1:1, 1:3 and 1:5, respectively, in a 10-µl reaction. To control for 
background vector self-ligation, 50 ng of vector was incubated in the absence of insert. 
Ligations were carried out in the presence of 1 U T4 DNA ligase (Promega or Roche) at 
RT for 5 h or at 4 °C overnight. Following incubation, the T4 DNA ligase was 
inactivated by heating at 65 °C for 10 min. The ligation reaction (1 µl) was transformed 
in 30 – 50 µl XL10-Gold Ultracompetent cells (Stratagene) as in section 2.2.5. Single 
colonies of the transformed cells were used for plasmid purification (section 2.2.6.), and 
the accuracy of the assembled constructs was verified by restriction digest and DNA 
sequencing as previously described (section 2.2.6. and 2.2.7.).  
 
2.2.9 Southern analysis of genomic DNA 
Genomic DNA isolated from wild-type and genetically modified T. brucei was 
analysed by Southern blot (Southern, 1975). DNA (~5 µg) was digested overnight at 37 
°C in the presence of the restriction enzymes (New England Biolabs). The digested 
DNA was resolved on a 0.8% (w/v) agarose gel (section 2.2.3.) and depurinated in 0.25 
M HCl for 10 min. Following equilibration in 0.4 M NaOH, DNA was transferred to a 
positively charged nylon membrane (GE Healthcare) by the downward capillary transfer 
method (Sambrook and Russell, 2001). When the transfer was complete, the membrane 
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was rinsed in 5 X SSC buffer (supplied as 20 X buffer by Invitrogen) for 25 min and 
DNA was cross-linked to the membrane by UV irradiation at 1200 µJ cm
-2
. The 
membrane was pre-hybridised at 42 °C for 2 h in DIG Easy Hyb (Roche) prior to 
overnight hybridisation at 42 °C with the denatured digoxigenin-dUTP-labelled DNA 
probe. Probes were prepared in advance from the open reading frame (ORF) of TbGSK3 
short or its 5’UTR, using PCR DIG Probe Synthesis Kit (Roche), following the 
manufacturer’s guidelines.  
Washing of the membrane post hybridisation, as well as the immunological 
detection of the probe, were performed with the DIG Wash and Block Buffer Set and 
the CSPD ready-to-use reagent (Roche), according to the manufacturer’s guidelines. 
The processed membrane was exposed to Amersham Hyperfilm ECL (GE Healthcare) 
for 2 min. To strip the membrane for subsequent hybridisations, the membrane was 
rinsed in autoclaved ultrapure MilliQ water for 1 min and washed twice for 15 min at 37 
°C with 0.2 M NaOH, 0.1% SDS. The stripped membrane was neutralised in 2 X SSC 
buffer and either stored at 4 °C or pre-hybridised and processed further, as described. 
 
2.3 Recombinant protein expression and purification 
2.3.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE was used to determine the size and the purity of recombinant 
proteins (Laemmli, 1970). Equal volume of 2 X Laemmli buffer (Bio-Rad) containing 
0.5% (v/v) β-mercaptoethanol (ME) was added to each sample and heated for 10 min 
at 70 ºC prior to analysis. Electrophoretic separation of the bands was carried out using 
NuPAGE Novex 4-12% Bis-Tris mini Gels (Invitrogen) and the XCell SureLock Mini-
cell apparatus at 200 V for approximately 50 min using MOPS SDS (Invitrogen) as 
 
Figure 2.1 pET-15b_TEV_BAP cloning/expression region 
Starting Methionine (M), linker (GSS), His6 tag (HHHHHH), TEV protease 
recognition motif (ENLYFQG, the cleavage occurs between the Q and G residues), 
Biotin Acceptor Peptide (BAP) (GGLNDIFEAQKIEWH) and cloning sites (XhoI and 
BamHI). 
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running buffer. Protein bands were stained with Coomassie Blue (0.25 % (w/v) 
coomassie Brilliant Blue R250, 40% (v/v) methanol and 10% (v/v) acetic acid) and 
destained with 20% (v/v) methanol and 10% (v/v) acetic acid. Precision Plus (All blue, 
Bio-Rad) protein standard was used to determine the relative molecular mass (Mr) of 
the resolved bands. 
 
2.3.2 Protein quantification 
Recombinant proteins and protein content from lysates were quantified using the 
Bio-Rad protein assay based on the Bradford method (Bradford, 1976) according to the 
manufacturer’s instructions using BSA as standard. Absorbance at nm was 
measured in a WPA Biowave II spectrophotometer. Recombinant proteins were also 
quantified using the calculated extinction coefficient (ProtParm) at 280 nm using the 
WPA Biowave II spectrophotometer. 
 
2.3.3 Recombinant protein expression 
The plasmid pET-15b-TEV-BAP was a modification of pET-15b (Novagen) 
where the sequence encoding the thrombin cleavage site was replaced with the Tobacco 
Etch Virus (TEV) protease recognition motif and the Biotin Acceptor Peptide sequence 
was also inserted (Figure 2.1). This plasmid was a generous gift of Ms Sharon 
Shepherd (University of Dundee). This expression plasmid allows the purification of the 
recombinant protein by metal-ion affinity chromatography using the Hexahistidine tag 
(His6), the cleavage by TEV protease that can be easily produced in house and the 
specific biotinylation at the N-terminus by the biotin-protein ligase BirA (Predonzani et 
al., 2008). Expression constructs were transformed into the expression strains of E. coli 
indicated in Table 2.3 as described in section 2.2.5. Single colonies were cultured as 
Table 2.3 Protein expression and purification conditions 
 
Protein No 
 
Expression conditions 
 
Nickel affinity chromatography binding 
buffer
a
 
Purification method
b
 
TbGSK3 short 1 BL21 Star (DE3) 
Auto-induction medium + Amp,  
22 ºC, 20 h 
 
20 mM Hepes, pH 7.4; 0.5 M NaCl; 1 mM 
TCEP; 0.05% (w/v) CHAPS; 5% (v/v) 
glycerol; 30 mM imidazole 
 
IMAC 
TEV cleavage 
IMAC 
SEC 
TbGSK3 long 2 BL21 Star (DE3) 
Auto-induction medium + Amp,  
22 ºC, 20 h 
 
20 mM Hepes, pH 7.4; 0.5 M NaCl; 1 mM 
TCEP; 0.05% CHAPS; 5% (v/v) glycerol; 
30 mM imidazole 
 
IMAC 
TEV cleavage 
IMAC 
TbGSK3(K49A) short 3 BL21 Star (DE3) 
Auto-induction medium + Amp,  
22 ºC, 20 h; 37ºC, 20 h 
 
20 mM Hepes, pH 7.4; 20-500 mM NaCl; 
1 mM TCEP; 0.05-0.5% CHAPS; 20-30 
mM imidazole 
 
IMAC: low level of 
expression 
TbGSK3(K49A) short 4 ArcticExpress (DE3) RIL 
Auto-induction medium + Amp,  
13 ºC, 48 h 
 
20 mM Hepes, pH 7.4; 0.5 M NaCl; 1 mM 
TCEP; 0.05% CHAPS; 30 mM imidazole 
 
IMAC 
IEX 
IMAC after ATP/MgCl2 
incubation 
TbGSK3(K49M) short 5 ArcticExpress (DE3) RIL 
Auto-induction medium + Amp,  
13 ºC, 48 h 
 
20 mM Hepes, pH 7.4; 0.5 M NaCl; 1 mM 
TCEP; 0.05% CHAPS; 30 mM imidazole 
 
IMAC 
IMAC with washes with 
ATP/MgCl2/denaturated 
protein from E. coli. 
 
a
Lysis buffers were obtained supplementing binding buffers with 500 M activated sodium-orthovanadate, 500 M sodium fluoride, 500 M sodium--
glycerophosphate, 500 M sodium-pyrophosphate; EDTA-free protease inhibitor tablet (Roche) and DNase I (Roche). 
b
 Metal-ion affinity chromatography (IMAC), size-exclusion chromatography (SEC), ion-exchange chromatography (IEX). 
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previously described (section 2.2.5.). Cultures were harvested by centrifugation (3800 x 
g, 15 min, RT) and resuspended in fresh LB containing 100 g ml-1 ampicillin. The 
cultures were then used to inoculate 1 L of pre-warmed auto-induction medium with 
ampicillin. BL21 Star (DE3) cells in auto-induction medium were incubated with 
agitation at 200 rpm for 3 h at 30 ºC, followed by 24 h incubation at the selected 
temperatures (Table 2.3). ArcticExpress (DE3) RIL cells in auto-induction medium 
were incubated with agitation at 200 rpm for 6 h at 30 ºC, followed by 48 h incubation 
at 13 ºC. Following incubation, cells were harvested by centrifugation (4,500 x g, 30 
min, 4 ºC). Cell pellets were resuspended in lysis buffer (Table 2.3), either processed or 
flash frozen in liquid nitrogen and stored at -80 ºC. 
 
2.3.4 Immobilised metal ion affinity chromatography  
Hexahistidine-tagged recombinant proteins were purified by immobilised metal 
ion affinity chromatography (IMAC). Cells were lysed using a Continuous One-Shot 
Cell Disruptor (Constant Systems) under a 30 kpsi pressure. Lysates were clarified by 
centrifugation (20,000 x g, 30 min, 4 °C) and supernatants were passed through a 0.22 
μm PES membrane filter (Helena Biosciences). A 5 ml HiTrap chelating HP column 
(GE Healthcare) was pre-equilibrated using a binding buffer identical to the 
composition of lysis buffer (10 X column volume) before the filtrate was passed 
through the column. The column was washed with 20 ml of binding buffer and 
connected to an AKTA
 
FPLC purifier. Bound proteins were eluted in 2 ml fractions 
from the column using a 0-100% gradient of 500 mM imidazole in the binding buffer at 
a flow rate of 5 ml min
-1
. Eluates were analysed by SDS-PAGE (section 2.3.1.). 
Fractions (2 ml) containing the highest concentrations of recombinant proteins were 
pooled together and dialysed (4 °C for 16 h) against binding buffer in absence of 
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imidazole in a 10-kDa molecular weight cut-off slide-A-lyzer cassette (Pierce 
Biotechnology) to remove imidazole. 
Purified TbGSK3 short and long were further cleaved of their hexahistidine tag 
(section 2.3.5). Further purification of contaminating proteins co-purifying with 
TbGSK3(K49A) and TbGSK3(K49M) short kinase dead mutants was attempted by 
anion exchange chromatography (section 2.3.6.) and further metal ion affinity 
chromatography after either incubation with the binding buffer supplemented with 1 
mM ATP, 1 mM MgCl2 or extensive washes with binding buffer containing 5 mM ATP, 
10 mM MgCl2 and 0.1 mg ml
-1
 denaturated proteins from E. coli (Rial et al., 2002).  
 
2.3.5 TEV cleavage of hexahistidine-tag 
Hexahistidine tags were removed from recombinant TbGSK3 short and long by 
TEV cleavage following nickel column affinity chromatography. Recombinant TbGSK3 
short and long were incubated with His6-tagged TEV protease (prepared by Mr Adam 
Roberts, University of Dundee), with a ratio of 10:1 (w/w) recombinant enzyme versus 
TEV protease at 4°C for 16 h, during dialysis in binding buffer in absence of imidazole. 
Following incubation, reactions were passed through a 1-ml HiTrap chelating HP 
column to remove free tags and the tagged proteins, which were bound to the column. 
The flowthrough containing the cleaved proteins was collected. TbGSK3 long was 
dialysed in the storage buffer (20 mM Hepes, pH 7.4; 150 mM NaCl; 1 mM DTT), 
concentrated by centrifugation (3,800 x g, 4°C) using vivaspin 20 concentrators 
(Sartorius Stedim Biotech) with 10 kDa MWCO and polyethersulfone membranes. 
Concentrated TbGSK3 long was quantified (section 2.3.2) and flash frozen in small 
aliquots following the addition of 10% (v/v) glycerol. The aliquots were stored at -80 
°C. TbGSK3 short was further purified by gel filtration chromatography (section 2.3.7).  
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2.3.6 Anion-exchange chromatography 
Prior to anion-exchange chromatography pooled fractions of cleaved 
recombinant protein were desalted using PD-10 columns (GE Healthcare) according to   
manufacturer’s guidelines and concentrated using a vivaspin 20 concentrator (Sartorius 
Stedim Biotech) (10 Kda MWCO).  A 5-ml HiTrap Q HP column (GE Healthcare) was 
pre-equilibrated with 10 X column volume of the appropriate binding buffer. Desalted 
proteins were loaded manually onto the column using a syringe. The column was 
washed with 20 ml binding buffer and connected to the AKTA FPLC purifier. Bound 
proteins were eluted in 2 ml fractions from the column using a 0-100% gradient of 0.5 
M NaCl in the binding buffer at a flow rate of 5 ml min
-1
. Eluates were analysed by 
SDS-PAGE and fractions containing the highest concentrations of pure recombinant 
proteins were pooled.  
 
2.3.7 Gel filtration chromatography 
Cleaved TbGSK3 short was dialysed overnight at 4 °C in the gel filtration buffer 
(20 mM Hepes, pH 7.4; 150 mM NaCl; 1 mM DTT; 10% (v/v) glycerol) and separation 
by gel filtration was performed using HiLoad 26/60 Superdex 200 prep grade column. 
Column equilibration, automated sample loading and protein separation were carried 
out according to the manufacturer’s guidelines. Fractions (2 ml) were collected and 
analysed by SDS-PAGE (section 2.3.1). Following each run, gel filtration standards 
(Bio-Rad) were applied to the column and resolved under the same conditions as the 
sample. To determine the molecular mass (Mr) of the resolved proteins, a calibration 
curve was prepared by plotting log Mr for each gel filtration standard as a function of its 
elution volume. TbGSK3 short was concentrated by centrifugation (3,800 x g, 4°C) 
using a vivaspin 20 concentrator (Sartorius Stedim Biotech) with 10 kDa MWCO. 
Table 2.4  Primary and secondary antibodies used for Western blotting analysis  
Primary antibody 
 
Immunogen 
 
Dilution Secondary antibody Dilution 
Mouse anti-phospho-
GSK3 (Tyr279/Tyr216) 
mAb,  
clone 5G-2F (Upstate, 
Millipore) 
 
c-KQLLHGEPNVS[pY]ICSRI 
203-219 from Drosophila 
GSK3/shaggy enzyme 
1:375 or 1:500 Goat anti-mouse IgG, 
HRP-conjugated (Bethyl)  
1:5,000 
 
     
Mouse anti-GSK3/ 
mAb, clone 4G-1E 
(Upstate, Millipore) 
 
c-KQLLHGEPNVSYICSRI 
203-219 Drosophila 
GSK3/shaggy enzyme 
1:375 or 1:500 Goat anti-mouse IgG, 
HRP-conjugated (Bethyl)  
1:5,000 
 
     
Rabbit anti-GSK3/ 
mAb 
(Upstate, Millipore) 
 
Recombinant full length human 
GSK3 
1:1000 Goat anti-rabbit IgG,  
HRP-conjugated (BioRAD) 
 
1:3,000 
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Concentrated TbGSK3 short was quantified (section 2.3.2.) and flash frozen in small 
aliquots. The aliquots were stored at -80 °C.  
 
2.3.8 Protein characterization by mass spectrometry 
Identification of proteins by mass fingerprinting analysis was performed by the 
FingerPrints Proteomics Facility at the University of Dundee. Samples were submitted 
to the facility resolved on a NuPAGE Novex 4-12% Bis-Tris gel and stained with 
Coomassie blue (section 2.3.1). Protein bands of interest were excised from the gel and 
trypsin-digested, prior to analysis by nano-LC coupled to electrospray ionisation tandem 
MS (ESI-MS-MS), using the 4000 QTRAP (Applied Biosystems) tandem MS system. 
 
2.3.9 Protein characterization by Western blotting 
Prior to analysis by Western blotting, unstained SDS-PAGE gels (section 2.3.1.) 
were equilibrated in Towbin transfer buffer (25 mM Tris, 192 mM glycine, 20% (v/v) 
methanol; Towbin et al., 1979). Proteins were transferred onto Protran nitrocellulose 
membrane (Whatman) using Trans-Blot SD semi-dry electrophoretic transfer cell (Bio-
Rad) at 25 V for 20 min. Membranes were incubated for at least 1 h with 5% (w/v) dry 
milk in PBS containing 0.5% (v/v) Tween 20 to block non-specific binding sites. 
Primary and secondary (horseradish peroxidise (HRP)-conjugated) antibodies (Table 
2.4) were sequentially incubated with the blot for 1 h each in PBS containing 1% (w/v) 
dry milk and 0.5% (v/v) Tween 20, with an intermediate washing step (3 x 10 min) in 
antibody dilution buffer. Finally, membranes were washed (3 x 10 min) in buffer 
without milk. Washed blots were incubated with Amersham ECL or ECL Plus
 
detection 
reagent (GE Healthcare) and exposed to Hyperfilm ECL (GE Healthcare), following the 
manufacturer’s protocol. 
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2.4 Enzymatic and kinetic studies 
2.4.1 TbGSK3 biochemical characterization 
TbGSK3 short was sub-cloned and fused to an N-terminal maltose binding 
protein which was subsequentially expressed and purified as previously reported in 
literature (Ojo et al., 2008). For biochemical characterization of TbGSK3 short, the 
kinase assay buffer (25 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 5 mM DTT, 0.02% (w/v) 
CHAPS, 2 U ml
-1
 Heparin) and mix of ATP/[γ-33P]-ATP and GSP2 substrate (Biotin-
C6-YRRAAVPPSPSLSAHSSPHQ[pS]EDEEE) (Pepceuticals) were used in a 
radiometric P-81 cellulose filterplate assay (Whatman).  
 
2.4.2 Determination of the TbGSK3 short Km for the substrates 
The Michaelis-Menten constants (Km) for the ATP and the peptide substrate 
GSP2 were determined by varying the concentrations of both substrates in a matrix 
experiment. To determine bireactant kinetic parameters, the equation:  
 [A][B][B][A]
[A][B]max


abba KKKK
V
v

   (equation 1) 
 
was used, where v represents the measured velocity, Vmax is the maximum velocity, [A] 
and [B] and Ka and Kb are the concentrations and Michaelis Menten constants, 
respectively, of substrates A and B, and  is the co-operativity factor between the two 
substrates (Segel, 1993). The  parameter was fitted either as free or fixed to 1 and the 
best fit was assessed using the Akaike information criterion (Burnham and Anderson, 
2002). Graphs and analysis were performed using SigmaPlot 10.0.  
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2.4.3 Determination of mechanism of inhibition 
To establish mode of inhibition, rates were determined at 10 inhibitor 
concentrations with 4 varied concentrations of one substrate with a saturating 
concentration of the other. Each data set was individually fitted to the Michaelis-Menten 
equation, and the resulting Lineweaver-Burk plots were examined for diagnostic 
patterns for competitive (equation 2), mixed (equation 3), or non-competitive inhibition 
(equation 4).  
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Mixed inhibition   
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Non-competitive inhibition   
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  (equation 4) 
 
Where v represents the measured velocity, Vmax is the maximum velocity, [S] is the 
concentration of substrate S and Km is the Michaelis-Menten constant, and Ki and Ki’are 
the constants of inhibition (Segel, 1993). Graphs and analysis were done using Grafit 
6.0. 
 
2.4.4 Surface Plasmon Resonance 
Amine-coupling reagents (N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide [EDC], N-
hydroxy-succinimide [NHS], and ethanolamine HCl) were purchased from Biacore AB.  
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The Running Buffer used in all SPR experiments was 25 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 10 mM MgCl
2 
and 5 mM DTT plus 1% DMSO, and degassed and sterile-
filtered through 20 μm filters by vacuum filtration apparatus (Millipore).  
Interaction analyses were performed using Biacore T100 optical biosensor equipped 
with research-grade CM5 sensor chips (Biacore AB). Biacore instrument was primed 
with HBS-N buffer (Biacore) after removing maintenance chip and docking CM5 
sensor chip. To prepare the sensor chip for interaction analysis, the dextran layer 
coating the CM5 chip surface was preconditioned with two consecutive injections for 
each of 100 mM HCl, 50 mM NaOH, and 0.5 % SDS. Aliquots of these preconditioning 
solutions were injected over all four flow cells for 6 s at a flow rate of 100 μL min-1. 
Data were always collected at the highest collection rate.  
Coupling conditions were first optimised by preparing 1 μL of TbGSK3 short in 50 μL 
of Immobilisation Buffer (Biacore) at two different pHs (5.5 and 4.5). The ligand 
solutions were injected over sensor chip surface using a contact time of 2 min at a flow 
rate of 10 μL min-1. Subsequently, a short pulse of 50 mM NaOH was injected over the 
surface at flow rate 100 μL min-1 to remove last traces of the electrostatically bound 
ligand.  
Using a flow rate of 10 μL min-1, the sensor chip’s four flow cells were activated 
at 25 °C with a 7 min injection of a 1:1 mixture of EDC and NHS. For amine coupling, 
1 μL of GSK-3 (concentration = 0.6 mg mL-1) along with 2 μL of 10 mM ATP and 100 
μL acetate (pH 5.5) was injected at a flow rate of 10 μL min-1 for 7 min. Finally, 1M 
ethanolamine was injected for 7 min to deactivate the surface. To test for analyte (ATP) 
binding, a threefold dilution series of six concentrations with a starting concentration of 
500 μM was prepared and injected at flow rate of 10 μL min-1 at 20 °C. One flow cell 
was used as a reference to substract nonspecific binding, drift and bulk refractive index. 
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2.4.5 Isothermal Titration calorimetry 
Both TbGSK3 short and TbGSK3 long were extensively dialyzed against buffer 
containing 25 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 1 mM DTT, 0.02% CHAPS and 
1% DMSO. Experiments were carried out at 20 °C with a VP-ITC titration calorimeter 
(MicroCal Inc.) with 1 μM protein in the cell and 30 μM DDD00085893 in the syringe. 
Each titration experiment consisted of a 5 μl injection followed by 29 injections of 
10 μl. Data were fitted to a single binding site model using Origin (version 7.0 
MicroCal). 
 
2.5 Screening 
2.5.1 Compound library 
The kinase focused set library was collated from commercial sources. At the 
time of screening, the library included 4110 compounds, with purity confirmed to be 
higher than 90%. The criteria used for the library selection were previously described in 
literature (Brenk et al., 2008). Briefly, the selection was based upon literature and patent 
searches of already known kinase scaffolds, which were then used to assemble the 
collection of commercially available inhibitors. The virtual set was filtered in order to 
eliminate non drug-like compounds, reactive or toxic groups. The final library contained 
113 scaffolds that were represented with a minimum of 1 compound and a maximum of 
50 examples per scaffold.  
 
2.5.2 Screening workflow 
The kinase library was screened in a single point assay at 25 M in a KinaseGlo 
format (Promega).  Compounds showing a percentage of inhibition higher than 3-times 
the standard deviation (SD) of the high controls were cherry picked and re-tested in 
 
 
Figure 2.2 KinaseGlo assay principle  
(A) KinaseGlo is a luminescent-based assay that detects the amount of ATP left 
un-reacted at the end of the kinase reaction. The emission of light is due to the 
oxidation of the substrate luciferin to oxyluciferin by the addition of Luciferase 
enzyme in the presence of Mg
2+
.
 
(B) Linear regression of the titration curve of the 
ATP from to 10 M up to 170 nM, linear regression and regression coefficient are 
shown.  
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double point at 25 M. The reconfirmed hits were tested in 10-data points curves from 
30 M to 1 nM in two independent determinations in a Flashplate assay (PerkinElmer). 
The material from the top concentration of the curve was analysed by LC-MS in order 
to confirm structure and purity of the hits. Where possible, validated hits were 
repurchased or re-synthesised in house for the final validation. Only fully validated hits 
were further investigated. Data from the screening campaign were analysed in 
collaboration with a medicinal chemist and a computational chemist in the DDU (Dr 
Andrew Woodland and Dr Torsten Luksch, respectively) 
 
2.5.3 Primary screening assay – KinaseGlo format 
For the primary screening of the focussed kinase inhibitor library a 384-well 
KinaseGlo (Promega) luminescence-based assay previously described was used (Ojo et 
al., 2008). The luminescence is inversely related to kinase activity. Unreacted ATP is 
used as substrate by Ultra-Glo Luciferase when Kinase-Glo Reagent is added to stop the 
kinase reaction, products of the reactions are the mono-oxygenation of luciferin and the 
generation of light (Figure 2.2 A). The ATP titration curve done in TbGSK3 kinase 
buffer confirmed that the light emission was linear up to 10 M ATP (Figure 2.2 B). 
Luminescence is generally less prone to interference from library compounds than 
fluorescence-based assays, and in this particular assay format inhibitors of the 
Luciferase enzyme are not detected as false positives.  
 The reactions contained 7.5 nM TbGSK3 short, 3.2 μM GSP2 substrate peptide 
(Biotin-C6-YRRAAVPPSPSLSAHSSPHQ[pS]EDEEE) (Pepceuticals), 1 μM ATP and 
25 μM test inhibitor compound in optimised kinase assay buffer in a final volume of 30 
l. DMSO and an 8-point titration of GW8510 (Sigma) from 1 μM to 50 pM were 
included as controls. Reactions were incubated at room temperature for 1 h and stopped 
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by the addition of 30 l KinaseGlo reagent. Plates were then sealed and the signal was 
left to stabilize for 1 h in the dark before luminescence was determined using a 
TopCount NXT HTS counter (PerkinElmer).  
 
2.5.4 Potency screening assay – Flashplate assay 
For hit validation and all subsequent compound potency determinations, a 
radiometric 96-well Flashplate assay (PerkinElmer) was adopted, with a final volume of 
50 l per reaction. Compounds were solubilised in DMSO at a top concentration of 3 
mM and serially diluted to achieve 10-point titration of final assay concentrations from 
30 μM to 0.3 nM with a final DMSO concentration of 1% (v/v). The reaction mixtures 
contained 1 μM biotinylated GSP2 substrate (Biotin-C6-
YRRAAVPPSPSLSAHSSPHQ[pS]EDEEE), 1 μM ATP, 3.7 KBq/well [γ-33P]-ATP 
and 2.5 nM TbGSK3 short in the TbGSK3 kinase assay buffer (25 mM Tris-HCl, pH 
7.5, 10 mM MgCl2, 5 mM DTT, 0.02% (w/v) CHAPS, 2 U ml
-1
 Heparin). Inhibitors 
were screened for selectivity assessment also against HsGSK3  and HsCDK2/Cyclin 
A.  
For HsGSK3  assay the reaction mixes contained 1 μM biotinylated GSP2 
substrate, 2 μM ATP, 7.4 KBq/well [γ-33P]-ATP and 15 nM HsGSK3  in the TbGSK3 
kinase assay buffer. For HsCDK2/cyclin A assay the reaction mixtures contained 1 mM 
CDK5 biotinylated peptide substrate (Biotin-C6-PKTPKKAKKL), 1 μM ATP, 7.4 
KBq/well [γ-33P]-ATP and 2 nM HsCDK2/cycine A in the kinase assay buffer (50 mM 
Tris-HCl, pH 7.5, 10 mM MgCl2, 2 mM DTT, 100 mM NaCl, 0.2 mM EGTA, 0.02% 
(v/v) Brij35).  
Reactions were incubated for a further 60 min at room temperature on a shaker 
before being terminated by the addition of 25 mM EDTA. Reaction mixtures were 
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transferred to 96-well streptavidin-coated Flashplates (PerkinElmer) and incubated for 
60 min at room temperature on an orbital shaker. Plates were washed twice with PBS, 
0.1% (v/v) Tween 20 using a microplate washer (Wellwash AC Thermo Labsystems), 
sealed and read using a TopCount NXT HTS counter (PerkinElmer).  
 
2.5.5 Screening batch – pass criteria 
During screening quality control (QC) plates were added as follows: 2 QC plates 
for every 6 assay plates for the primary screen and re-test screen; 2 QC plates for every 
12 assay plates for the potency screen. Each assay plate had also internal QC 
represented by high (un-inhibited reaction) and low controls (no enzyme) and a standard 
inhibitor curve. Analysis of the QC data enabled the acceptance of a batch of plates 
based upon three main parameters: standard inhibitor IC50 in a range of acceptance, Z'-
factor ( 'Z ) value ≥ 0.6 (equation 5), coefficient of variation (CV) ≤ 10%. 
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
    (equation 5) 
Where 'Z  represents the Z'-factor, High  and Low  are the standard deviations of the 
high and log controls respectively, and High  and Low  are the average of the high and 
log controls respectively (Zhang et al., 1999).  
 
2.5.6 Mammalian kinase profiling 
Selected compounds were screened against a panel of mammalian kinases 
routinely run by the Division of Signal Transduction Therapy (DSTT) at the University 
of Dundee in duplicate point at 10 M. Enzymes included in the panel and assay 
conditions are reported in literature (Bain et al., 2007). All biochemical assays are run 
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below the Km for the ATP for each enzyme allowing comparison of inhibition across the 
panel.  
 
2.5.7 Data analysis 
IC50 values were determined using a 4-parameter equation in XLFit 4.2 model 
205 (equation 6):  
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The inhibition was background corrected and normalized for the un-inhibited 
reaction, bottom and top values were left free to float, but could be fixed at 0 and 100% 
inhibition respectively, if needed. In equation 6, y is the percentage of inhibition at 
inhibitor concentration [I].  IC50 is defined as the concentration of inhibitor for which 
the activity of the enzyme is inhibited of 50% and Hill slope is a measure of the 
stoichiometry of the reaction. For 1:1 interaction between inhibitor and ligand a Hill 
slope factor of 1 is expected (Copeland, 2005). 
 
2.5.8 Proliferation assay of MRC5 and BSF T. brucei cells 
The routine screen of hits identified against BSF T. brucei and MRC5 (human 
lung fibroblast) was performed by the Drug Discovery Unit, and in particular Mr Iain 
Collie, Ms Bhavya Rao and Ms Irene Hallyburton. Mr Daniel James assisted with the 
data management and analysis. Measurement of inhibition of the proliferation of MRC5 
cells was performed using a modification of cell viability assay previously described 
(Raz et al., 1997). Compounds (50 μM to 0.5 nM, 0.5% DMSO final concentration) 
were incubated with 2 x 10
3
 cells per well in a final volume of 200 l in the appropriate 
culture medium (MEM with 10% foetal bovine serum) in clear 96 well plates (Greiner). 
 55 
Plates were incubated at 37 °C in the presence of 5% CO2 for 69 h. Rezasurin was then 
added to a final concentration of 50 μM, and plates were incubated as above for a 
further 4 h before being read on a BioTek flx800 fluorescent plate reader. Measurement 
of inhibition of the proliferation of BSF T. brucei brucei strain 427 lister and analysis of 
the data was done accordingly to section 2.6.6.  
 
2.6 T. brucei cell culture and genetic manipulation 
2.6.1 Bloodstream form T. brucei cell culture 
BSF T. b. brucei strain Lister 427 (S427), previously genetically modified to 
express T7 RNA polymerase (T7RNAP) and the tetracycline repressor protein (TetR) 
(Wirtz et al., 1999) was used as the parental cell line referred hereafter as wild-type 
(WT). This cell line is under G418-neomicin (NEO) selection and allows inducible 
expression of ectopic genes under the control of the T7 promoter and tetracycline 
operator. Wild-type and genetically modified T. brucei cell lines generated during this 
study were routinely diluted every time they reached a concentration of approximately 2 
x 10
6
 cells ml
-1 
in fresh modified HMI9-T medium (HMI-9 containing 56 mM 
thioglycerol in place of 200 mM 2-mercaptoethanol) supplemented with 2.5 g ml-1 of 
G418 to sustain the drug selection and the required drugs for the genetic modified cell 
lines. Cells were routinely cultured at 37 ºC with 5% CO2. HMI-9T medium was 
routinely prepared by the Drug Discovery Unit, University of Dundee.  
 
2.6.2 Cell density  
BSF T. brucei cells were counted manually using a Neubauer hemocytometer 
chamber under a light microscope (Zeiss). Alternatively, cells were counted using a 
CASY cell counter Model TT (Sharfe) according to the manufacturer’s guidelines. 
 
 
Figure 2.3 Schematic representing cloning steps in the construction of knock-out 
cassettes 
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2.6.3 Generation of TbGSK3 short single knock-out cell lines 
Single knock-outs (SKO) of TbGSK3 short (Tb927.10.13780) were generated by 
homologous recombination (Figure 2.3 and section 4.1.2). The replacement cassettes 
were generated by designing primers for the 3' and 5' untranslated regions (UTR) 
immediately before and after the open reading frame (ORF). Using the Tritryps.org 
genome browser application, the 5'-UTR region upstream and 3'-UTR region 
downstream of the codifying region of TbGSK3 short were selected with a size of 359 
bp and 301 bp, respectively. The 5'-UTR and 3'-UTR were PCR amplified from T. 
brucei S427 genomic DNA (section 2.2.1.) using TbGSK3short_5UTR_s and 
TbGSK3short_5UTR_as, TbGSK3short_3UTR_s and TbGSK3short_3UTR_as coupled 
primers, respectively (Table 2.2). The 5'-3'UTR region was subsequently knitted by 
overlap extension PCR (Roper et al., 2002) of the two UTRs using the 
TbGSK3short_5UTR_s and TbGSK3short _3UTR_as primers and introduction of the 
linking region HindIII, PmeI and BamHI. The resulting PCR product was inserted using 
the cloning NotI sites in a pGEM-5Zf (+) vector (Promega). Either the resistance genes 
hygromycin phosphotransferase (HYG) or puromycin acetyltransferase (PAC) were 
subsequently inserted into the cloning sites HindIII and BamHI. DNA sequencing 
confirmed the accuracy of the final transfection constructs. Genetically modified cell 
lines were named accordingly the nomenclature defined by Clayton and colleagues 
(1998) (Table 2.5). 
 
2.6.4 Generation of transgenic T. brucei cell lines 
Wild-type BSF T. brucei cells were transfected using the Amaxa Nucleofector 
system (Lonza), according to Burkard (2007). Briefly, plasmid DNA was linearised by 
 Table 2.5 Lists of mutant cell lines generated in BSF T. brucei 
Genotype
a
 Restriction sites
b
 Markers Abbreviations
c
 
    
TetR NEO GSK3short /GSK3short  NEO WT 
pGEM-5Zf(+): knock-outs    
Δgsk3short::PAC/GSK3short HindIII/BamHI NEO, PAC SKO (PAC) 
Δgsk3short::HYG/GSK3short HindIII/BamHI NEO, HYG SKO (HYG) 
pLew82: leaky over-expression    
GSK3short
Ti
 HindIII/BamHI NEO, BLE WT
OE
 GSK3short
Ti
  
GSK3short
Ti
 Δgsk3short::PAC/GSK3short HindIII/BamHI NEO, PAC, BLE SKOOE GSK3shortTi 
pLew100v5: conditional over-expression    
GSK3short
Ti
 HindIII/BamHI NEO, BLE cWT
OE
 GSK3short
Ti
  
GSK3short
Ti
 Δgsk3short::PAC/GSK3short HindIII/BamHI NEO, PAC, BLE cSKOOE GSK3shortTi 
GSK3short
Ti
 Δgsk3short::HYG/GSK3short HindIII/BamHI NEO, HYG, BLE cSKOOE GSK3shortTi 
GSK3short
Ti
 Δgsk3short::PAC/Δgsk3short::HYG HindIII/BamHI NEO, PAC, BLE, HYG cDKOOE GSK3shortTi 
GSK3(K49A)short
Ti
 HindIII/BamHI NEO, BLE cWT
OE
 GSK3(K49A)short
 Ti
 
GSK3(K49A)short
Ti Δgsk3short::PAC/GSK3short HindIII/BamHI NEO, PAC, BLE cSKOOE GSK3(K49A)shortTi  
TbGSK3long
Ti
 HindIII/BamHI NEO, BLE cWT
OE
 GSK3long
 Ti
 
pLew100: conditional expression    
GSK3short
Ti
 NdeI/BamHI NEO, BSD cWT GSK3short
Ti
 
GSK3short
Ti
 Δgsk3short::PAC/GSK3short NdeI/BamHI NEO, BSD, PAC cSKO GSK3shortTi 
GSK3short
Ti
 Δgsk3short::HYG/GSK3short NdeI/BamHI NEO, BSD, HYG cSKO GSK3shortTi 
GSK3short
Ti
 Δgsk3short::PAC/Δgsk3short::HYG NdeI/BamHI NEO, BSD, PAC, HYG cDKO GSK3shortTi 
a
 Genotype is defined according Clayton and colleagues (1998) rules for genetic nomenclature for Trypanosoma and Leishmania. 
b 
The restriction sites refer to the cloning sites for the plasmid of interest. All constructs were linearised by NotI. 
c 
The abbreviations are defined upon the degree of gene over-expression and control of tetracycline induction. 
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NotI digestion, purified by precipitation in 70% ethanol (v/v) containing 80 mM sodium 
acetate, and resuspended in autoclaved MilliQ water to a final concentration of 1 g l-
1
. For a single transfection 10 g of DNA was mixed with 4 x 107 cells (logarithmic 
phase of growth) and 100 l of Amaxa Nucleofactor system (Lonza). The 
electroporation was performed using the program X-001 of the Nucleofector II 
electroporator and cells were subsequently incubated in pre-warmed medium overnight 
(section 2.6.1). Approximately 16 h later, the selection drugs were added (5g ml-1 
puromycin (PAC), hygromycin (HYG), phleomycin (BLE), or blasticidin (BSD)) and 
cultures were diluted 25- and 625-times and incubated in 24-well plate for 4-5 days. 
Transfected cells with tetracycline inducible expression vectors were cultured in 
medium supplemented with 1g ml-1 tetracycline added daily in order to induce the 
exogenous protein expression. Table 2.5 reports the genotype, the cloning sites, the 
markers used for selection and the abbreviated name of all generated BSF T. brucei cell 
lines. 
 
2.6.5 Cloning of genetic modified T. brucei lines 
All mutant T. brucei cell lines were cloned by limiting dilution. After drug 
selection and two passages in fresh medium, parental cell lines were diluted to 1.5 cells 
ml
-1
 and plated in 96-well plate (200 l per well) in order to obtain ⅓ parasite per well 
in a medium supplemented with the relevant drug for selection and tetracycline was 
added daily where required. After 1 week, dividing cells were present generally in 30% 
of the wells, between 5 to 10 clones were selected for further analysis. Clonal cell lines 
were also stabilated at a density of 1 x 10
6
 cell ml
-1
 in HMI9-T medium containing 10 % 
(v/v) glycerol in liquid nitrogen.  
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2.6.6 Growth inhibition studies of T. brucei 
The in vitro sensitivity of inhibitors to BSF T. brucei was measured at an 
effective compound concentration which inhibits cell growth by 50% (EC50). One 
hundred and ninety-nine l of a cell suspension (2.5-5 [x 103] cells per ml based upon 
cell growth regeneration time) were plated in 96-well plates. Inhibitors were diluted in 
100% DMSO in a 10-point dilution curve (1:2 dilutions) and 1l inhibitor was added to 
each well by a manual multichannel pipette. Each plate had 8 wells with high controls 
(DMSO only) and 8 wells with low controls (only medium). Generally pentamidine or 
melarsoprol were added as a standard control. After incubation for 69 h at 37 ºC, 50 M 
resazurin was added and the plates were incubated at 37 ºC for additional 4 h. 
Fluorescence due to the formation of resorufin was measured at excitation of 528 nm and  
emission of 590 nm by a BioTek flx800 fluorescent plate reader.  
Background corrected data and normalized with respect to the un-inhibited 
growth were analysed with a four- parameter non-linear regression using GraFit 6.0:  
ottom
I
range
y
Hillslope
b
EC
][
1
50








   (equation 7) 
In equation 7 y is the percentage of inhibition at the corresponding inhibitor 
concentration [I], range is the difference between the high and low controls, bottom is 
the background and EC50 is the effective dose of inhibitor required to inhibit the cell 
growth by 50%. Data are reported as the weighted mean ± SD of three independent 
determinations done in triplicate. 
The weighted mean EC50 and Hill slope coefficient were subsequently used to 
calculate the EC99 (concentration of inhibitor required to kill 99% of cells): 
EC99 = EC50 x 99 
1/Hill slope
   (equation 8) 
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2.6.7 Cell lysis for Western blotting 
Cells were pellet at 800 g at room temperature for 10 min. The cell lysate was 
prepared as reported by Nett and colleagues (2009b). Briefly, cells were washed three 
times in ice-cold PBS prior to lysis with ice-cold RIPA (10 mM Tris-HCL, pH7.5; 1 
mM Sodium--glycerophosphate, 1 mM sodium pyrophosphate; 1 mM sodium fluoride, 
5 mM EDTA, 0.5% NP40, 0.2% sodium deoxycholate, 0.2% SDS, EDTA-free protease 
inhibitor tablet (Roche), 100 M activated sodium-orthovanadate) at a ratio of 1 x 109 
cells per 1 ml of buffer. The lysate was sonicated in ice three times for 15 s at 80% 
power (Jencons) and centrifugated at 14,000 rpm for 20 min at 4 °C. The protein 
concentration of the supernatant was measured using the Bradford protein assay kit 
(Bio-Rad). Equal amount of protein lysate (~10 g) or cells number (~1 x 107) were 
loaded per lane. 
2.7 Chemical-proteomics 
2.7.1 Kinobeads method 
This method relies on the use of kinobeads immobilizing a mixture of seven 
protein kinase inhibitors that interact with a very broad spectrum of kinases and purine-
binding proteins (Bantscheff et al., 2007). The incubation of cell lysate with increasing 
concentration of an unmodified inhibitor results in competition between the inhibitor 
target and the kinobeads. This competition will decrease the iTRAQ (isobaric Tags for 
Relative and Absolute Quantitation) ion sensitivity for peptides derived from the target 
protein. The advantage of this method is that the inhibitor treatment of the cell lysate is 
done before the incubation with the kinobeads, so that is possible by competition to 
identify the inhibitor’s targets and to estimate their IC50 values (White, 2007). More 
details regarding the methods are reported by Urbaniak and colleagues (2012). The 
chemical-proteomic validation was performed in collaboration with Cellzome using hit 
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compounds identified by the target-based screening campaigns I performed for TbGSK3 
short, PK50 and PK53. 
 
2.8 Molecular modelling 
The homology modelling of TbGSK3 short and the generation of binding modes 
of GSK3 07 and GSK3 09 compounds were performed by Dr Torsten Luksch and Dr 
Robert Urich, University of Dundee. 
 
2.8.1 Homology modelling 
The homology model for TbGSK3 short (Tb927.10.1378) was built using the 
human GSK3 beta crystal structures as templates (Protein Data Bank accession no. 
1R0E). HsGSK3 provided a template for 91% of the TbGSK3 sequence (amino acids 
20-348). ClustalW was used to generate the sequence alignments which were 
subsequently used for building the homology models with Modeller9-2 (Sali and 
Blundell, 1993).  
2.8.2 Generation of binding modes 
An energy-minimised conformation of DDD00065658 was built using Sybyl 
(Tripos Inc., Sybyl, St. Louis, MO (USA) 2004). This conformation was manually 
placed in the binding pocket of the TbGSK3 short homology model with Moloc (Gerber 
and Müller, 1995) and subsequently minimised with the Moloc MAB force field. 
During the minimisation process the ligand was considered as fully flexible whereas all 
protein amino acids were kept rigid.  
The putative binding modes of DDD00085893 and DDD00101234 were built in 
the same manner as described for DDD00065658. 
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Chapter 3 Results 
  
Figure 3.1 Determination of the kinetic parameters for TbGSK3 short 
The Km for the ATP and the substrate (GSP2) were determined in a matrix 
experiment where the initial velocities (v) were determined as nM of product 
formed per minute. The grid represents the predicted velocities fitted with a 
Random Mechanism with alpha equal to 1. 
 
Table 3.1 Determination of Km for ATP and GSP2  
 MBP-TbGSK3 short  His6-TbGSK3 short 
Substrate 
Km  
(µM) 
 
Published  Km
app
  
(µM) 
(Ojo et al., 2008)
a
 
 
 
Published  Km 
  (µM) 
(Ojo et al., 2011)
b
 
GSP2 8.4 ± 1.3
c
 2.4  6.6 ± 3.6 
ATP 11.0 ± 1.8
c
 4.5  9.4 ± 2.0 
 
a
The Km
app
 values for ATP and GSP2 were measured with a filterplate assay, it is not 
reported if the kinetic parameters were measured at saturating concentration of both 
substrates. 
b
The Km values for ATP and GSP2 were measured with a filterplate assay by varying the 
concentrations of both substrates. 
c
The standard deviation reported is the error associated to the fitting by multi-regression 
analysis. The results reported are representative of one experiment, but the kinetic 
parameters were confirmed by multiple experiments. 
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3.1 Identification of small molecule inhibitors 
3.1.1 Biochemical characterization of TbGSK3 
The short form of the recombinant T. brucei Glycogen Synthase kinase 3 
(TbGSK3 short, Tb927.10.1378) was provided by the University of Washington as part 
of a collaboration with the Drug Discovery Unit (DDU) with the aim of discovering 
novel inhibitors. The recombinant enzyme was tagged at the N-terminus with a maltose 
binding protein (MBP), which simplified the purification procedure and enhanced the 
solubility of the protein. This enzyme had been previously used to screen a small set of 
HsGSK3 inhibitors revealing some preliminary indication of correlation between 
enzyme potency and inhibition of T. brucei growth (Ojo et al., 2008). 
The substrate specificity of TbGSK3 short shows similarity to the human 
isoform, HsGSK3, as it can phosphorylate primed substrates and recognises the same 
consensus sequence as the human enzyme: S/TXXXphoshoS/T (Dajani et al., 2001). 
The substrate used for the biochemical assay was the peptide substrate GSP2 (biotin-C6-
YRRAAVPPSPSLSAHSSPHQ[phosphoS]EDEEE). I determined the Km values for the 
ATP and the peptide substrate in a matrix experiment by varying the concentrations of 
both substrates while measuring the rate of the reaction as nmole of product formed per 
minute. This experimental design permits the determination of the kinetic parameters, 
and also tests for co-operativity between substrates (Figure 3.1). The Km for ATP and 
GSP2 were 8.4 ± 1.3 M and 11.0 ± 1.8 M respectively, with no evidence of co-
operativity. These values are of the same order of magnitude as those previously 
published for the same recombinant MBP-TbGSK3 short used here and a His6-tagged 
TbGSK3 short (Ojo et al., 2008; Ojo et al., 2011) (Table 3.1). The lack of co-
operativity between the two substrates indicates that the concentration of one substrate 
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does not affect the Km of the other one, allowing more flexibility in the set up of 
biochemical assays suitable for hit identification (Copeland, 2003; Yang et al., 2009).  
 
3.1.2 Primary Screen of TbGSK3 short   
A focused kinase library of 4,110 compounds was assembled at the DDU based 
upon literature and patent review that had identified 113 scaffolds able to bind into the 
ATP pocket of kinases; for each scaffold up to 50 examples were purchased that 
fulfilled the criteria of lead-like properties and did not have unwanted functional groups 
(Brenk et al., 2008). This set is biased towards the identification of ATP-competitive 
inhibitors, as it had been collated using already commercial available kinase inhibitor 
scaffolds (Brenk et al., 2008). The primary screening assay I set-up was aimed to 
increase the sensitivity towards ATP-competitive inhibitors, i.e. the ATP concentration 
in the assay was fixed at 1 M, 10-fold below the Km for the ATP of 11 M (Copeland, 
2003).  
KinaseGlo is a luminescent-based assay that detects the amount of ATP left un-
reacted at the end of the kinase reaction. The detection is attributed to the emission of 
light from oxidation of the substrate luciferin to oxyluciferin by the addition of 
Luciferase enzyme in the presence of Mg
2+ 
(Figure 2.1 A). This assay format has many 
advantages: first, it does not require radiolabeled ATP or modified substrates, and, 
second, it is a homogeneous assay that does not require separation steps, hence it can be 
easily automated in microplate assays to increase the assay throughput. One 
disadvantage of this format is its reliance on the measurement of the concentration of 
the unreacted substrate, hence in order to obtain a reasonable signal to noise ratio (SN) 
it is necessary to ensure that the consumption of substrate is higher than 10%. This has 
implications for the accuracy of the potency of the identified hits, in particular with 
  
Figure 3.2 GW8510 standard inhibitor IC50 determination  
(A) GW8510 structure. (B) GW8510 prototypical inhibition curve (data are IC50 
± SD, Hill slope ± SD, of 27 independent determinations). GW8510 was used as 
positive control in all assay plates and its potency used as measure of the assay 
reproducibility.  
 
 
Table 3.2 TbGSK3 short assay conditions and screening statistics  
 KinaseGlo assay  Flashplate assay  
TbGSK3 short  7.5 nM  2.5 nM  
GSP2  3.2 M  1 M  
ATP  1 M (<Km)  1 M (<Km) 
Z'
a  0.61 ± 0.02  
(n = 15)
b
 
0.80 ± 0.01 
(n = 34) 
GW8510 IC
50
  10 ± 0.05 nM  
(n = 15) 
6.0 ± 0.7 nM  
(n = 34) 
a
Z' is a measure of the robustness of the assay  (Zhang et al., 1999). 
b
Values are reported as mean ± SEM and number of independent determinations (n). 
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respect to the weaker inhibitors that could be missed as a consequence of deviation of 
enzyme linearity (Copeland, 2005).  
In the primary screen, known inhibitor GW8510 (Ojo et al., 2008) was included 
as a standard control and used as an indicator of the reproducibility of the assay 
conditions across all plates (Figure 3.2 A and B). I screened the focused kinase set in 
384-well assay format as a single point at 25 μM generating a robust set of data  with a 
Z’ parameter above 0.6 (Zhang et al., 1999) (Table 3.2). 
From this primary screen, 567 compounds with percentage of inhibition higher 
than 30% were subsequently re-tested in a duplicate point screen, which gave 517 
reconfirmed compounds with inhibition values higher than 30%, representing a hit rate 
of 12.8% (Figure 3.3 A and B). The high hit rate was due to the fact that the library was 
biased towards kinase inhibitors and that the sensitivity of the assay was enhanced 
towards ATP-competitive inhibitors by the concentration of ATP in the assay set below 
its Km.  
 
3.1.3 Potency Screen of TbGSK3 short 
For hit validation and all subsequent compound potency determinations, I 
developed a radiometric 96-well Flashplate assay (PerkinElmer). Although the 
KinaseGlo format brings many advantages for screening of chemical libraries, its 
reliance upon ATP consumption means it requires a level of substrate consumption 
higher than 10% to achieve an acceptable signal window and hence it is not a suitable 
assay for accurate IC50 determinations. The alternative Flashplate assay measures the 
product formation relying on the transfer of 
33
P-labeled phosphate from ATP to the 
biotinylated substrate. The substrate is selectively bound to the streptavidinated plates, 
the unreacted [γ-33P]-ATP removed by a series of washes and the emission of beta 
radiation is detected by addition of scintillation liquid. 
  
Figure 3.3 Primary screen 
(A) Distribution of the percentage of inhibition of focussed kinase set. Hits (highlighted in blue) were selected using as threshold 3 
standard deviation units from the average of high controls (≥ 30% inhibition). (B) Correlation plot of the 567 selected hits re-tested in 
duplicate.  
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The assay was performed at a concentration below the Km for ATP of the 
enzyme, so that the Ki
app
 for ATP-competitive inhibitors approximates the measured 
IC50 value, aiding the assessment of selectivity (Cheng and Prusoff, 1973). I carried out 
potency evaluations (10-point curves) in duplicate for the 100 most potent compounds. 
As in the primary screen, the potency assay format yielded highly robust data (Z’ = 0.80 
± 0.08, Table 3.2). The compounds exhibited a range of potencies for TbGSK3 short 
(Table 3.3), which were highly reproducible (Figure 3.4), with 15 compounds having 
IC50 values <1 μM. The structure and purities of the hits taken into potency assessment 
were subsequently confirmed by LCMS. 
 
3.2 Hit validation 
3.2.1 TbGSK3 short series classification 
The confirmed hits were classified by Dr Andrew Woodland into series based 
upon structure similarity and the most potent compound of each series was considered 
as its representative. From the screening of the recombinant TbGSK3 short eight 
compound series were identified (GSK3 01-08), and additional examples of two 
inhibitors series, GSK3 09 and GSK3 10 were synthesised by Dr Robert Urich based on 
a combination of in-house expertise and literature data (Wyatt et al., 2008). Both GSK3 
09 and GSK3 10 series had highly potent inhibitors against TbGSK3 short (Figure 3.5).  
Where possible the hit compounds were repurchased and re-tested. In addition a 
programme of hit expansion, via purchasing of analogues or investigation of the 
presence of similar scaffolds in the DDU large diversity set (Brenk et al., 2008) was 
conducted to expand on the preliminary structure-activity relationship (SAR). All the 
GSK3 series were assessed for chemical properties, evidence of an initial SAR in the 
biochemical assay, correlation of the activity against TbGSK3 short versus the T. b. 
  
Figure 3.4 Potency screen 
The 100 most potent hits were tested in 10-data point curve in 2 independent 
determinations, the correlation plot between the LogIC50 of the replicates is 
reported.  
 
 
 
 Table 3.3 Ranking of the kinase set compound potencies 
 
IC50 (µM) Number of Compounds 
<1 15 
1-10 75 
10-20 10 
20-30 - 
 
  
Figure 3.5 Compound series identified from focused screening and testing of 
literature compounds  
Most active examples identified from the screen are shown with the core scaffold 
highlighted in red.  
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brucei proliferation assay, toxicity against MRC5 proliferation assay, and selectivity 
against a panel of mammalian recombinant kinases. In particular, two series, GSK3 07 
and GSK3 09, were subjected to further studies (Woodland et al., 2013, Urich et al., 
2014).  
 
3.2.2 GSK3 07 series: correlation, specificity and selectivity 
GSK3 07 is a series of 2,4-diaminothiazol-5-carbaldehydes (Figure 3.5) for 
which only two examples were present in the initial DDU focused kinase set. The most 
potent compound, DDD00065658 had an IC50 value of 0.38 M. This compound 
showed a high ligand efficiency of 0.52 kcal mol
−1 a
 and hence was deemed to be an 
interesting starting point for hit validation (Hopkins et al., 2004). Using a combination 
of diversity and docking studies (section 3.2.7) 21 compounds were selected for testing 
from the DDU general screening and commercial sources. The IC50 values were 
determined for TbGSK3 short, HsGSK3  and HsCDK2/cyclin A as well as EC50 values 
for bloodstream form (BSF) T. b. brucei and MRC5 cell lines. The data for some key 
examples of GSK3 07 are summarised in Table 3.4. The hit expansion was successful 
with compound DDD00086390 (IC50 value of 0.03 M) which was over 10-fold more 
active than the initial hit DDD00065658 (IC50 value of 0.38 M). DDD00086390 
showed also a greater activity for HsGSK3 (IC50 value of <10 nM) than for TbGSK3 
short which seemed to be a general trend for the GSK3 inhibitors from this series. 
GSK3 07 compounds generally showed good levels of selectivity for T. b. brucei versus 
MRC5 cells, giving preliminary indication that inhibition of HsGSK3 could be tolerated 
                                                 
 
 
a
 Ligand efficiency is a measure of the affinity related to the MW: Ligand efficiency = [-RT Ln 
(IC50)] / Nnon-hydrogen atoms 
 Table 3.4 GSK3 07 Selection of early hits with activities against TbGSK3 
short, HsGSK3β, HsCDK2, BSF T. b. brucei and MRC5 cells 
 
R1 R2 
TbGSK3 
short 
IC50 
(µM) 
HsGSK3β 
IC50 
(µM) 
HsCDK2 
IC50 
(µM) 
BSF  
T. b. brucei 
EC50 
(µM) 
MRC5 
EC50 
(µM) 
        
DDD00065658  
 
0.38 <0.010 
 
0.15 
 
2.6 >15 
DDD00066736 Me 
 
>30 ND ND 38 >50 
DDD00066742 Me 
 
>30 ND ND 29 >50 
DDD00063206 
 
Me 1.1 ND ND 13 26 
DDD00086390 
  
0.03 <0.010 0.27 0.16 13 
DDD00086393 
  
0.04 <0.010 0.045 0.13 >50 
DDD00086398 
  
0.1 <0.010 0.72 0.7 4 
The number of determinations was two or higher. ND: not determined. 
  
 
Figure 3.6 Correlation plot for GSK3 07 compounds 
Correlation plot between inhibition of TbGSK3 short and inhibition of 
bloodstream form T. b. brucei cell growth for the initial set of compounds (solid 
lane) and for the later set (dashed lane). 
 Table 3.5 GSK3 07 Selection of late hits with activities against TbGSK3 short, 
HsGSK3β, HsCDK2/cyclin A, BSF T. b. brucei and MRC5 cells 
 
R1 R2 
TbGSK3 
short 
 IC50 
(µM) 
HsGSK3β 
IC50 (µM) 
HsCDK2/ 
cyclin A 
%I 
At 1 µM 
BSF  
T. b. 
brucei 
EC50 
(µM) 
MRC5 
EC50 
(µM) 
DDD00086390 
  
0.03 0.007 91% 0.2 13 
DDD00088340 
  
0.02 <0.01 97% 0.12 1.6 
DDD00088327 
 
 
 
0.4 2.5 31% 0.4 20 
DDD00088328 
  
0.1 <0.01 90% 0.2 >50 
DDD00088331 
 
 
0.2 0.13 17% 9 35 
DDD00088337 
 
 
0.06 <0.01 84% 0.18 38 
DDD00088338 
  
0.19 <0.01 91% 0.13 11 
DDD00088336 
  
0.7 <0.01 30% 0.4 41 
DDD00088334 
  
0.5 <0.01 65% 5.7 38 
DDD00088342 
 
 
3.4 0.5 21% 0.04 20 
DDD00090123 
  
12 ND ND 0.30 >50 
The number of determinations was two or higher. ND: not determined. 
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to some extent by these cells. It was also observed that it was possible to achieve 
selectivity over HsCDK2, a desirable feature considering the similarity between these 
enzymes and potential toxicity issues related to inhibition of HsCDK2 (Meijer et al., 
2004) (Table 3.4). 
For the early compounds investigated from this series cell efficacy (BSF T. 
brucei LogEC50) correlated with the enzyme potency (TbGSK3 LogIC50) (correlation 
coefficient equal to 0.90) with a 5-fold drop off between the TbGSK3 short and T. 
brucei activities (Figure 3.6). For ATP-competitive inhibitors a drop-off of activity is 
expected between the IC50 values measured in a biochemical assay, where the 
concentration of ATP is below its Km, and the EC50 values measured in the cellular 
assay, where the physiological concentration of ATP is in the millimolar range (Cheng 
and Prusoff, 1973; Knight and Shokat, 2005). Considering that in the case of TbGSK3 
short the Km for ATP determined is 11 μM, the expected drop-off between biochemical 
and cellular assay should be around 100 fold (Knight and Shokat, 2005). Indeed, other 
factors such as protein binding or the requirement for a high level of inhibition of the 
enzyme to achieve a phenotypic effect, could actually result in a drop off greater than 
100-fold. The 5-fold difference between potency against the enzyme and the cell 
activity for this series was inconsistent with an exclusive ATP-competitive mechanism 
of inhibition of TbGSK3 short as the direct cause of the cell activity. 
Further optimisation within this series was designed to improve inhibitor 
potency. The newly synthesised compounds were also tested against TbGSK3 short, 
HsGSK3, HsCDK2/cyclin A, BSF T. b. brucei and MRC5 cells (Table 3.5). Compound 
DDD00088327 showed 6-fold selectivity towards TbGSK3 short (IC50 0.4 M) with 
respect to HsGSK3  (IC50 2.5 M), giving an indication that it was possible to obtain 
compounds more potent towards the parasite isoform of the enzyme. The most 
significant development was the diverging correlation between TbGSK3 potency and T. 
   
 
Table 3.6 Mammalian kinase selectivity panel for series GSK3 07 
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MKK1 0 74 84 94 68 96 94 AMPK 41 74 78 85 96 67 101
ERK1 59 91 66 127 20 72 73 MARK3 34 93 59 89 100 25 112
ERK2 26 58 58 59 16 68 95 BRSK2 42 79 53 62 93 55 95
JNK1 36 67 54 103 60 75 98 MELK 34 57 79 42 70 47 89
JNK2 48 65 69 88 39 81 90 CK1 14 37 91 91 82 13 74
p38 MAPK 14 16 48 47 24 8 102 CK2 107 108 99 102 114 111 118
P38 MAPK 47 55 44 74 22 12 82 DYRK1A 12 14 60 71 25 10 88
p38g  MAPK 53 75 81 47 71 77 89 DYRK2 25 26 60 67 39 79 90
p38s MAPK 56 87 63 65 67 62 102 DYRK3 51 69 81 89 57 83 96
ERK8 9 24 19 36 18 14 43 NEK2a 68 88 79 89 93 92 93
RSK1 24 50 48 63 67 29 89 NEK6 60 87 91 102 113 97 100
RSK2 47 82 78 104 85 38 104 IKKb 55 64 67 116 70 82 99
PDK1 64 96 82 94 106 65 108 PIM1 71 80 74 81 94 79 90
PKB 89 95 85 94 85 84 90 PIM2 80 88 76 88 94 91 109
PKB 70 88 88 86 73 85 83 PIM3 32 69 68 48 69 69 82
SGK1 80 85 89 100 81 98 91 SRPK1 26 46 51 45 93 6 92
S6K1 53 55 39 91 78 57 86 MST2 42 94 64 92 97 40 104
PKA 77 86 75 73 97 90 106 EF2K 84 79 83 93 89 95 111
ROCK 2 42 72 56 97 97 55 107 HIPK2 3 35 31 37 64 16 79
PRK2 33 75 62 90 98 57 95 PAK4 32 66 73 61 88 47 88
PKC 70 85 73 84 101 64 100 PAK5 38 80 72 75 103 66 110
PKC zeta 33 68 50 85 83 83 104 PAK6 52 82 94 91 93 87 98
PKD1 29 40 23 53 35 46 85 SRC 42 91 63 85 99 47 99
MSK1 73 82 74 99 122 87 102 LCK 53 86 87 93 86 49 85
MNK1 71 75 70 102 105 110 105 CSK 57 87 84 79 95 90 98
MNK2 70 82 87 99 94 99 96 FGF-R1 39 62 59 99 97 64 87
MAPKAP-K2 98 100 99 104 96 99 102 IRR 16 22 22 32 25 24 93
PRAK 72 74 88 82 96 63 103 EPH A2 77 99 82 106 110 71 106
CAMKKb 15 52 35 98 63 12 83 MST4 65 90 69 79 76 57 90
CAMK1 34 58 62 52 86 55 109 SYK 45 84 81 86 91 37 111
SmMLCK 22 47 51 59 44 29 74 YES1 25 63 31 76 114 26 109
PHK 74 90 92 105 105 88 112 IKKe 35 81 48 85 88 84 108
CHK1 24 91 75 110 96 86 80 TBK1 53 98 80 91 88 92 95
CHK2 27 75 49 90 61 30 53 IGF-1R 41 90 144 78 80 80 118
GSK3 0 12 2 3 1 4 15 VEG-FR 30 77 55 86 57 17 82
CDK2-Cyclin A 2 34 17 48 5 2 13 BTK 60 86 86 98 75 68 79
PLK1 65 84 87 120 82 86 93 IR-HIS 63 85 88 103 75 88 93
Aurora B 59 91 76 72 75 24 107 EPH-B3 78 95 92 105 88 59 94  
 
Compounds were tested in duplicate at 10 M. Data shown as percentage of 
uninhibited activity. The ranking of inhibition is shown as a heat map: red below 
30% residual activity; orange 31-50% residual activity; yellow 51-70% residual 
activity; white above 70% residual activity. The kinase profiling was performed 
by the Division of Signal Transduction Therapy (DSTT) at the University of 
Dundee.  
  
 
 
Figure 3.7 Mechanism of inhibition was determined for (A) DDD00088338 
and (B) DDD00088340  
Rates (cpm in 20 min) were determined at the reported inhibitor concentrations in 
M with 4 varied concentrations of ATP at saturating concentration of the other 
substrate. The resulting Lineweaver-Burke plots were examined for diagnostic 
patterns for competitive inhibition and globally fitted to the equation for 
competitive inhibition. 
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brucei anti-proliferative activity, as it is shown by the lack of correlation for these latter 
compounds (Figure 3.6). The unrelated SAR between enzyme activity and cell efficacy 
in vitro is particularly evident for compounds DDD00088342 and DDD00090123, 
which have greater potency against T. brucei cells (EC50 values of 40 nM and 300 nM 
respectively) than against TbGSK3 short (IC50 values of 3.4 M and 12 M 
respectively).  
Finally, the potential toxicity of these compounds was also assessed by testing a 
select group against a panel of mammalian kinases performed by DSTT at the 
University of Dundee (Bain et al., 2003; Bain et al., 2007). Initial compounds 
(DDD00086390, DDD00086405, DDD00086406 and DDD00089411) and late 
compounds (DDD00088338, DDD0008340 and DDD0009213) were profiled at 10 M 
in duplicate (Table 3.6). The profiling results illustrate that these compounds were 
potent inhibitors of the human HsGSK3 (percentage of inhibition of at least 85%) and 
also consistently hit HsCDK2/cyclin A, but selectivity against HsCDK2/cyclin A could 
be achieved. The compounds had a diverse ranking of toxicity against MRC5 cells, with 
the less promiscuous compounds generally being inactive against this cell model.  
 
3.2.3 GSK3 07 series: mode of inhibition and Ki characterization 
I performed studies of the mechanism of inhibition of DDD00088338 and 
DDD00088340, selected compounds from GSK3 07 series, which confirmed that they 
are ATP-competitive inhibitors of TbGSK3 short (Figure 3.7). The resulting Ki values 
(0.25 ± 0.03 µM and 0.05 ± 0.01 for DDD00088338 and DDD00088340, respectively) 
correlated well with the determined IC50 values in the biochemical assay (Table 3.6). 
This was expected, considering that the concentration of ATP in the assay is below the 
Km for the ATP, the IC50 values are a good approximation of Ki. These compounds had 
  
 
Table 3.7 GSK3 09 Selection of R1 substituted aminopyrazoles with activities 
against TbGSK3 short, HsGSK3β, HsCDK2/cyclin A, BSF T. b. brucei and 
MRC5 cells 
 
R1 
TbGSK3 
short 
IC50 
(µM)  
HsGSK3β 
IC50 (µM)
  
HsCDK2/
cyclin A 
IC50 (µM)
  
BSF 
T. b. 
brucei 
EC50  
(µM)  
MRC5 
EC50 
(µM)  
DDD00085893 
 
0.002 < 0.005 0.019 0.52 31 
DDD00085905 
 
0.007 < 0.005 0.010 0.32 0.13 
DDD00085896 
 
0.016 < 0.005 0.269 1.09 2.5 
DDD00085887 
 
0.024 < 0.005 0.038 1.31 0.76 
The number of determinations was two or higher.  
  
Table 3.8 Mammalian kinase selectivity panel for series GSK3 09  
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MKK1 54 83 17 76 MARK3 84 93 83 74
ERK1 75 100 33 93 BRSK2 55 77 60 83
ERK2 18 51 2 92 MELK 32 100 13 96
JNK1 31 77 8 71 CK1 55 88 25 89
JNK2 51 82 15 63 CK2 74 100 21 81
P38α MAPK 81 80 71 81 DYRK1A 6 84 1 79
P38β MAPK 74 95 91 90 DYRK2 3 63 1 28
P38γ MAPK 60 72 24 95 DYRK3 24 100 2 80
P38σ MAPK 57 85 38 72 NEK2a 100 99 69 95
ERK8 14 27 7 47 NEK6 100 84 70 82
RSK1 74 70 54 77 IKKb 54 100 36 86
RSK2 92 82 93 78 PIM1 46 100 13 92
PDK1 87 87 86 94 PIM2 90 97 82 85
PKBα 96 85 86 95 PIM3 19 94 1 96
PKBb 45 98 84 80 SRPK1 90 78 72 83
SGK1 89 92 81 95 MST2 72 81 69 84
S6K1 100 100 58 94 EF2K 99 85 92 79
PKA 81 74 76 91 HIPK2 14 100 4 93
ROCK2 81 74 72 88 PAK4 68 74 27 39
PRK2 95 83 65 77 PAK5 68 75 47 51
PKCα 49 90 48 91 PAK6 97 90 71 77
PKC zeta 57 83 60 96 Src 98 94 85 91
PKD1 46 59 59 72 Lck 76 90 67 87
MSK1 80 86 66 91 CSK 85 77 73 91
MNK1 76 81 82 103 FGF-R1 99 95 72 116
MNK2 100 63 77 97 IRR 39 87 26 75
MAPKAP-K2 92 33 90 13 EPH A2 100 100 100 99
PRAK 52 92 65 84 MST4 46 49 30 80
CAMKKb 34 50 27 41 SYK 78 100 70 84
CAMK1 36 76 46 87 YES1 100 79 45 103
SmMLCK 25 65 23 55 IKKe 62 85 46 87
PHK 89 63 45 77 TBK1 63 96 73 91
CHK1 100 84 94 83 IGF-1R 96 100 15 79
CHK2 100 75 51 59 VEG-FR 52 90 29 93
GSK3β 33 0 0 10 BTK 100 100 100 91
CDK2 1 9 1 38 IR-HIS 84 99 50 81
PLK1 100 96 99 95 EPH-B3 60 100 72 88
Aurora B 46 87 47 91 IKK 68 90 71 ND
AMPK 46 88 49 104 MINK1 ND ND ND 18  
 
Compounds were tested in duplicate at 10 M and data shown as percentage of 
uninhibited activity. The ranking of inhibition is shown as a heat map: red below 
30% residual activity; orange 31-50% residual activity; yellow 51-70% residual 
activity; white above 70% residual activity. The kinase profiling was performed 
by the Division of Signal Transduction Therapy (DSTT) at the University of 
Dundee.  
ND: not determined. 
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a different ratio between efficacy in cells and biochemical potency (the ratio T. brucei 
EC50 /Ki varied from 0.4 for DDD00088338 to 4.3 for DDD00088340) which was 
unexpected for inhibitors with the same mechanism of inhibition. The divergent ratios 
of cellular and enzymatic activities, despite the ATP-competitive mechanism of 
inhibition towards the molecular target TbGSK3 short, give additional hints that these 
compounds have a common pharmacophore shared with other unknown targets in T. 
brucei. 
 
3.2.4 GSK3 09 series: correlation, specificity and selectivity 
GSK3 09 is a series of 4-amino-1H-pyrazole-5-carboxamide (Figure 3.5). These 
compounds were synthesised based on the literature, by varying residues to explore the 
relationship between TbGSK3 short, HsCDK2 and HsGSK3 activity (Wyatt et al., 
2008). Initially 19 examples were tested and some of them were found to be nanomolar 
inhibitors of TbGSK3 short, such as compounds DDD00085893, DDD00085905, 
DDD00085896 and DDD00085887 with IC50 values ranging from 2 to 24 nM (Table 
3.7).  Interestingly, the most potent compound DDD00085893 was active against T. b. 
brucei cells (EC50 of 0.52 M), and it was not toxic against MRC5 cells (EC50 of 30 
M). This compound was profiled against the mammalian panel of kinases at 10 M; 
only HsGSK3 and HsCDK2/cyclin A were inhibited more than 90% (Table 3.8) with 
IC50 values of 1 nM and 19 nM, respectively, indicating that in MRC5 cells HsGSK3 
inhibition did not cause cell toxicity.  All the compounds from this series obtained by 
replacement of R1 were not selective against HsGSK3, but selectivity could be 
achieved against HsCDK2/cyclin A.  
The other two compounds (DDD00085887 and DDD00085905) profiled against 
the mammalian kinase panel were more promiscuous and this was reflected by a higher 
   
 
Figure 3.8 Correlation plot between inhibition of TbGSK3 short and 
inhibition of T. brucei cell growth for GSK3 09 series 
The compounds substituted in position R1 are indicated with close circles and the 
compounds substituted in position R2 are indicated with open circles. 
 
 
 Table 3.9 GSK3 09 Selection of R2 substituted aminopyrazoles with activities 
against TbGSK3 short, HsGSK3β, HsCDK2/cyclin A, BSF T. b. brucei and 
MRC5 cells 
  
R2 
TbGSK3 
short 
IC50 (µM)
  
HsGSK3β 
IC50 (µM)
  
HsCDK2/ 
cyclin A 
IC50 (µM)
  
BSF 
T. b. 
brucei 
EC50  
(µM)  
MRC5 
EC50 
(µM)  
DDD00101238 
 
0.001 0.02 2.04 4.51 42.08 
DDD00101236 
 
0.001 ND > 10 6.59 > 50 
DDD00101223  0.008 0.08 2.4 11.64 > 50 
DDD00101234 
 
0.001 0.33 > 10 5.92 50 
DDD00101250 
 
0.002 0.07 1.56 6.42 33.68 
DDD00101247 
 
0.004 0.12 1.31 8.15 > 50 
DDD00101237 
 
< 0.001 ND > 4.76 6.69 45.28 
DDD00101224 
 
0.006 0.07 4.3 11.50 > 50 
DDD00101246  0.001 0.1 4.8 7.29 > 50 
DDD00101242 
 
0.006 0.14 4.67 12.22 > 50 
   
R2 
TbGSK3 
short 
IC50 (µM)
  
HsGSK3β 
IC50 (µM)
  
HsCDK2/ 
cyclin A 
IC50 (µM)
  
BSF 
T. b. 
brucei 
EC50  
(µM)  
MRC5 
EC50 
(µM)  
DDD00101248 
 
0.001 0.05 1.16 4.09 35.43 
DDD00101235 
 
0.008 0.08 > 10 8.90 37.82 
DDD00101220 
 
0.018 ND > 10 15.58 > 50 
DDD00101240 
 
0.015 0.32 > 10 20.22 > 50 
DDD00101228  0.012 0.22 > 10 18.84 > 50 
DDD00101229 
 
0.081 0.45 > 10 50 > 50 
DDD00101239  0.034 0.30 > 10 42.75 > 50 
DDD00101221 
 
0.316 0.66 > 10 > 50 > 50 
DDD00101230 
 
0.318 0.94 > 10 > 50 > 50 
DDD00101232 
 
0.142 0.87 > 10 > 50 > 50 
DDD00101241 
 
0.332 0.47 > 10 > 50 > 50 
DDD00101243 
 
0.054 0.63 > 10 > 50 > 50 
   
R2 
TbGSK3 
short 
IC50 (µM)
  
HsGSK3β 
IC50 (µM)
  
HsCDK2/ 
cyclin A 
IC50 (µM)
  
BSF 
T. b. 
brucei 
EC50  
(µM)  
MRC5 
EC50 
(µM)  
DDD00107470 
 
0.001 ND ND 7.66 >50 
The number of determinations was two or higher. ND: not determined. 
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toxicity against MRC5 cells with EC50 values of 0.76 M and 0.13 M, respectively 
(Table 3.7 and Table 3.8). GSK3 09 series overall had a very good correlation between 
inhibition of the recombinant TbGSK3 short and efficacy in vitro versus BSF T. b. 
brucei cells (correlation coefficient of 0.80) giving an indication that  this series could 
exert its action “on target” against TbGSK3 short (Figure 3.8). Moreover, the drop-off 
between enzyme inhibition and cellular efficacy was ~ 100-fold. This was consistent 
with the expected ATP-competitive mode of inhibition (as discussed in section 3.2.2). 
Further optimization within the series was aimed at exploring whether it was 
possible to obtain selectivity towards HsGSK3β retaining potency against TbGSK3 
short. As DDD00085893 was the most promising inhibitor (potent against TbGSK3 
short in the biochemical assay, blocking proliferation of BSF T. b. brucei in culture, and 
not toxic against MRC5 cells) the 2,6-dimethoxybenzamide group was retained in 
position R1 and an array of substituents was made in position R2 (Table 3.9). The 
majority of variations on this position retained the activity against TbGSK3 short in the 
nanomolar range. The R2-substituted compounds were tested in proliferation assay 
against BSF T. b. brucei and MRC5 cells. As for the R1-substituted analogues, also for 
the R2-substitutes there was a good correlation (correlation coefficient of 0.94) between 
the enzymatic inhibition of TbGSK3 short and cell efficacy in BSF T. b. brucei culture 
with a 1000-fold drop in potency between the biochemical and the cellular assay 
(Figure 3.8).  
Interestingly, compared to the variations in position R1, a majority of R2 
analogues showed selectivity over both HsCDK2/cyclin A and HsGSK3β up to reaching 
more than 10,000-fold selectivity towards HsCDK2 and more than 300-fold selectivity 
towards HsGSK3β. Compound DDD00101234, substituted with a benzyl in position R2 
is the most selective TbGSK3 short inhibitor known so far (Table 3.9) (Ojo et al., 2008; 
Oduor et al., 2011). This compound not only is a potent TbGSK3 inhibitor selective 
  
 
 
Figure 3.9 Mechanism of inhibition of DDD00085893 towards ATP 
 Rates (cpm in 20 min) were determined at the reported inhibitor concentrations 
(M) with 4 varied concentrations of ATP at the Km
app
 concentration of the other 
substrate (8.4 µM) and 2.5 nM of TbGSK3 short. The direct plot (A) and the 
derived Lineweaver-Burke plot (B) were examined for diagnostic patterns before 
globally fitting the data to the equation for competitive inhibition. The Ki value of 
DDD00085893 is 5.7 ± 0.1 nM. 
  
Figure 3.10 Mechanism of inhibition of DDD00085893 towards GSP2 
substrate 
Rates (cpm in 20 min) were determined at the reported inhibitor concentrations 
(M) with 4 varied concentrations of GSP2 substrate at the Km
app
 concentration of 
the ATP (11 M) and 2.5 nM of TbGSK3 short. The direct plot (A) and the 
derived Lineweaver-Burke plot (B) were examined for diagnostic patterns before 
globally fitting the data to the equation for mixed inhibition. The calculated Ki  
and Ki’ value of DDD00085893 are 7.5 ± 3.1 nM and 35.9 ± 11.9 nM, 
respectively. 
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towards the human isoform, but also retains efficacy against the BSF T. b.  brucei in 
culture (EC50 of 5.9 µM) and is not toxic for MRC5 cells (EC50 of 50 µM) (Table 3.9). 
DDD00101234 was also profiled against a panel of mammalian kinases. This 
compound inhibited the activity of only three PKs more than 80%: GSK3β, MAPKAP-
K2 and MINK1, confirming that is a selective kinase inhibitor (Table 3.8). 
 
3.2.5 GSK3 09 series: Mode of inhibition and Ki determination 
I determined the Ki of DDD00085893 proving that this compound acts through 
competitive inhibition with respect to ATP (Figure 3.9) and mixed inhibition towards 
the peptide substrate GSP2 (Figure 3.10). Increasing the concentration of 
DDD00085893 resulted in an increase in the Km
app
 for ATP, but the Vmax remained 
unchanged. On the other hand, varying the concentration of inhibitor caused changes in 
both Vmax and Km
app
 for the peptide substrate GSP2. The calculated Ki of DDD00085893 
(5.7 ± 0.1 nM) correlates as expected with the IC50 in the biochemical assay, taking into 
consideration that the IC50 value was determined at an ATP concentration below its Km. 
 
3.2.6 Mode of binding of series GSK3 07 and GSK3 09 
The homology model for TbGSK3 short was built by Dr Torsten Luksch using 
as template the solved crystal structure of HsGSK3 (pdb code 1R0E). These two 
proteins shared a high degree of identity (52%) in their kinase domains, but a closer 
look at their binding pocket revealed that inhibitor selectivity could be achieved 
exploiting the difference in nine residues in the binding site (Figure 3.11 and Table 
3.10). TbGSK3 short is also very similar to HsCDK2, although in this case there are 
differences in some key residues in the kinase domain that could be exploited to achieve 
selectivity (Table 3.10). These findings were in agreement with the independent 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Superposition of the HsGSK3 crystal structure 1R0E with the 
homology model of TbGSK3 short 
The HsGSK3β structure is in pink, the TbGSK3 short homology model in blue. 
Both structures are shown in cartoon representation. Amino acids that are 
different in the binding pocket of TbGSK3 short in comparison to HsGSK3β are 
represented as sticks. Residue numbers are for HsGSK3. The homology 
modelling was performed by Dr Torsten Luksch (figure from Woodland et al., 
2013). 
 
 
 
 
 Table 3.10 Differences in the ATP binding pockets of TbGSK3, HsGSK3β 
and HsCDK2  
TbGSK3 HsGSK3β HsCDK2 
V25 V61 K9 
 A26 I62 I10 
G27 G63 G11 
Q28 N64 E12 
G29 G65 G13 
T30 S66 T14 
F31 F67 Y15 
V34 V70 V18 
L36 Q72 K20 
A47 A83 A31 
K49 K85 K33 
E61 E97 I52 
M65 M101 L55 
V77 V110 V64 
M101 L132 F80 
E102 D133 E81 
F103 Y134 F82 
104 V135 L83 
P105 P136 H84 
E106 E137 Q85 
T107 T138 D86 
H109 Y140 K88 
R110 R141 K89 
K154 K183 K129 
H156 Q185 Q131 
N157 N186 N132 
L159 L188 L134 
C170 C199 A144 
D171 D200 D145 
 
Amino acids of HsGSK3β or HsCDK2 which differ in TbGSK3 short are shown 
in bold (table from Urich et al., 2014). 
  
  
 C
 
 
Figure 3.12 Proposed binding modes for (A) DDD00065658, (B) DDD00085893, and (C) DDD00101234 in the homology model of 
TbGSK3 short 
Both, ligands and protein are represented in sticks and colour coded by atom types. Ligand carbon atoms are shown in pink and protein carbon 
atoms in light blue. Hydrogen bonds are shown as yellow dotted lines. The binding modes were generated by Dr Torsten Luksch and Dr Robert 
Urich (figures adapted from Woodland et al., 2013 and Urich et al., 2014).  
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observations of Ojo and co-workers (2008; 2011). This homology model was used for 
the docking of the identified inhibitors from both series GSK3 07 and GSK3 09 which 
were predicted to bind in the ATP pocket (Figure 3.12 A, B and C).  
In the binding mode of the GSK3 07 initial hit, DDD00065658, the 2, 4-
diaminothiazole group has a kinase hinge binding recognition motif allowing hydrogen 
bonds to the backbone of Glu102, Phe103, and Val104 (Figure 3.12 A). All the other 
residues DDD00065658 is interacting with are conserved between HsGSK3β and 
TbGSK3 short, so it is not surprising that all the compounds tested from this series in 
the kinase panel (Table 3.6) are not selective towards HsGSK3β (Woodland et al., 
2014). 
A potential binding mode was generated also for DDD00085893 and protein-
ligand interactions were analysed by Dr Robert Urich (Figure 3.12 B). Also the 4-
amido-5-carboxamide-pyrazole group bears a kinase hinge binding motif and makes 
hydrogen bonds to the backbone of Glu102, Phe103, and Val104. Notably, the 
gatekeeper residue differs between TbGSK3 short, HsGSK3β, and HsCDK2 (Table 
3.10). While HsGSK3β and TbGSK3 short enzymes have Leu132 or Met101, 
respectively, in this position, in HsCDK2 a Phe80 is present. The gatekeeper region of 
HsCDK2 is more constrained and less accessible by bulky R
1
-substituents such as the 
2,6-dimethoxybenzamide group of DDD00085893. This main difference could explain 
the selectivity of this compound towards HsCDK2.  
The achieved selectivity towards HsGSK3β of the compounds substituted in R2 
could be rationalised again docking the compounds in the homology model for TbGSK3 
short. The docking of DDD00101234 suggests that the source of the selectivity is the 
replacement of Phe103 in a hydrophobic pocket of TbGSK3 short with Tyr134 in 
HsGSK3β. The phenyl of the N-benzylamide moiety of DDD00101234 can interact 
with the aromatic side chain of Phe103 in TbGSK3 short, but it is electrostatically 
  
Figure 3.13 DDD00085893 inhibition of TbGSK3 short activity and rate of 
killing of BSF T. b. brucei cell proliferation 
(A) The inhibition of the recombinant TbGSK3 short was measured using a 
filterplate assay (open circles), whereas cell proliferation inhibition of 
bloodstream trypanosomes was measured with resazurin assay (close circles) (as 
reported in Materials and Methods). Fifty percent and 90% of inhibition are 
represented respectively with a blue and red line. Data points are average of 
triplicate determinations ± SD. (B) BSF T. b. brucei cells were cultured in 
presence of different concentrations of DDD00085893 as reported in the legend. 
Cell densities were determined daily by manual counting with a haemocytometer. 
Each data point is average of two determinations.  
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repulsed by the polar lateral chain of Tyr134 in HsGSK3β (Urich et al., 2014). This 
moiety also has hydrophobic interactions with Leu36 and Ala26 in TbGSK3 short. 
Leu36 is replaced by polar amino acids in HsGSK3β and HsCDK2 (Gln72 and Lys20, 
respectively), further diminishing hydrophobic interactions and increasing the 
selectivity of DDDD001010234 over HsGSK3β and HsCDK2 (Figure 3.12 C). 
 
3.2.7 DDD00085893 is a cidal inhibitor of T. brucei 
DDD00085893 is a potent ATP-competitive inhibitor of the recombinant 
TbGSK3 short with an IC50 of 3 nM and Ki
 
of 5.4 nM. In my assays, this compound also 
demonstrated a detrimental effect on BSF T. brucei proliferation with an EC50 of 3.9 
Ma. The shift in potency is in agreement with the ATP-competitive mechanism of 
inhibition and the differential concentration of ATP in T. brucei (mM range) and in the 
biochemical assay (1 M) (as discussed in section 3.2.2 and 3.2.4) (Figure 3.13 A).  
In order to verify whether DDD00085893 had a cidal or a static effect on BSF T. 
brucei, cells were incubated for 72 h with inhibitor concentration ranging from 0 to 50 
M (Figure 3.13 B). Cells were counted daily and subcultured in fresh medium after 
removal of the inhibitor. As expected, 50% of growth inhibition was obtained at 5 µM, 
a concentration equivalent to the EC50 value determined with the resazurin assay. After 
incubation for 24 h in presence of 50 µM of DDD00085893, no cells were detectable, 
but cells washed free of the inhibitor could recover after 8 days. In contrast after 
                                                 
 
 
a
 This value was 10-times higher with respect to the one determined by the DDU routine 
screening, the discrepancy could be explained by the fact that: (i) a new batch of inhibitor was 
synthesised and (ii) in the meantime some medium components were re-placed resulting with faster 
growth of the BSF T. brucei. Both factors could have impacted in the change of potency of 
DDD00085893, which remained thereafter constant throughout my study. 
 Table 3.11 Determination of DDD00085893 IC50, for TbGSK3 short and EC50, 
EC90, EC99 and EC99.9 for BSF T. brucei  
 
DDD00085893 TbGSK3 short (nM) (n=4) 
Hill slope IC50    
     
0.9 ± 0.1 3 ± 1     
     
DDD00085893 BSF T. brucei (M) (n=4) 
Hill slope EC50 EC90 EC99 EC99.9 
     
2.5 ± 0.2 3.9 ± 0.6 9.5 ± 2.1 25.3 ± 7.1 25.4 ± 7.1 
     
Where n is the number of 4 independent experiments.  
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incubation for 48 h with 50 µM the trypanosomes did not recover, even after washing 
off of the inhibitor. Thus, DDD00085893 is a cidal inhibitor of Trypanosoma brucei 
after 48 h incubation at the concentration of 50 µM. Overall these findings are 
consistent with the EC99 (or minimum inhibitory concentration, MIC) of this inhibitor 
which is greater than 25 M (Table 3.11).  
 
3.3 Target identification by chemical proteomic approach 
3.3.1 Kinobeads approach 
From the screening of TbGSK3 short, two chemical series were identified with 
an effect on the proliferation of BSF T. brucei. Intriguingly, series GSK3 07 had a very 
limited drop-off between cellular and enzyme potency, with some examples clearly 
having off-target effects displaying higher potency against the cells rather than the 
enzyme. In contrast, series GSK3 09 had a tighter correlation between cell and enzyme 
activity in agreement with an ATP-competitive mechanism of inhibition. Consequently 
this was considered a promising series for the chemical validation of TbGSK3 short as a 
drug target in T. brucei. Although the biochemical assay of the recombinant TbGSK3 
short seemed to be a good model for the prediction of the efficacy of the compounds in 
the cells, the biological complexity in cells is far higher than in a biochemical assay, 
therefore it is important to prove that the cellular effect is due to the action of the 
inhibitor on the target enzyme (Patricelli et al., 2011). To achieve this, we decided to 
investigate the targets of these compound series in T. brucei lysate in collaboration with 
Cellzome AG (Heidelrberg, Germany). 
A chemical proteomic approach was undertaken for the direct identification of 
kinase inhibitor targets in cell lysates (Bantscheff et al., 2007) utilising kinobeads and 
iTRAQ technology (section 2.7.1).  Bantscheff and colleagues (2007) tested their 
  
Figure 3.14 Proteomic profiling of DDD00085893 in BSF T. b. brucei and 
MRC5 lysates by kinobeads competition assay  
Competition binding curves calculated by iTRAQ reporter signals (measured as 
percentage of residual binding). DDD00085893 was dosed in 5 concentrations 
ranging from 39 nM to 10 M in T. brucei (A) and in MRC5 cell lysates (B). The 
curves are the non-linear fits using the 2- and 4-parameter IC50 equation with 
GraFit.  
This work was done in collaboration with Cellzome (Heidelberg) (Urbaniak et al., 
2012a).
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technology against numerous human and rodent cell lines proving that a broad spectrum 
of protein kinases interacted with the kinobeads. Kinobeads not only capture protein 
kinases, but also other ATP- and purine-binding proteins such as chaperones, helicases, 
ATPases, motor proteins, transporters and metabolic enzymes (Bantscheff et al., 2007). 
Similarly this technology could be used to identify directly in T. brucei lysate the native 
targets of inhibitors and also to verify potential toxicity directly in MRC5 lysate.  
The kinobeads could bind T. brucei kinases with a coverage of 57 kinases 
belonging to AGC (5 examples), CAMK (10), CK1 (1), CMGC (22), other (3), STE (6), 
NEK (9), and atypical (1) families (Urbaniak et al., 2012a).  
Compound DDD00085893 is a potent inhibitor of TbGSK3 short in vitro, with a 
good efficacy against cultured T. brucei and good selectivity against mammalian cells 
(Table 3.7). The kinobead profiling of DDD00085893 against T. b. brucei cell lysates 
confirmed the TbGSK3 short was specifically targeted by this compound. In the 
chemical proteomic experiment a total of 171 proteins, 49 of them protein kinases, were 
detected by affinity enrichment with the kinobeads (Urbaniak et al., 2012a). When 
incubated with DDD00085893 ranging from 10 M to 39 nM only five proteins were 
no longer bound, four of which were protein kinases (Figure 3.14 A). The top binder of 
this inhibitor was TbGSK3 short with 17% of residual binding at 39 nM (an IC50 value 
could not be extrapolated). The protein kinase hits belonged to the same family of 
CMGC kinases and in the rank order of affinity were MAPK kinase (Tb427.10.3230) 
with an IC50 of 2.6 M, RCK kinase (Tb427.10.14800) with IC50 of 3.2 M,  CDK-like 
kinase ECK1 (Tb11.01.8550) with IC50 of 6.6 M, and finally a hypothetical protein 
(Tb927.4.4060) with an IC50 of 12.9 M.  
These results confirm that TbGSK3 short is the main target of DDD00085893 in 
T. b. brucei cells and that this compound has an affinity in the low nM range for the 
endogenous protein as well as the recombinant one. The coverage of the T. b. brucei 
 Table 3.12 Kinobeads competition assay for the BSF T. b. brucei and MRC5 
targets of DDD00085893 
 
BSF T. b. brucei targets 
 
GeneDB accession 
number 
IC50 ± SD (M) 
or percentage of inhibition 
   
CMGC/GSK Tb427.10.13780 17% at 39 nM 
CMGC/MAPK Tb427.10.3230 2.62 ± 0.85 
CMGC/RCK Tb427.10.14800 3.23 ± 1.6 
CMGC/ECK1 Tb427.01.8550 6.61 ± 2.9 
hypothetical protein Tb427.04.4060 12.9 ± 6.4 
   
MRC5 targets 
IPI accession 
number 
 
IC50 ± SD (M) 
 
   
HsGSK3 IPI00216190.1 0.087 ± 0.03 
HsGSK3 IPI00292228.1 0.076 ± 0.16 
CDK9 IPI00552413.2 0.45 ± 0.02 
Cyclin T1 IPI00030247.1 0.61 ± 0.08 
   
These data have been published by Urbaniak et al., 2012a 
  
Figure 3.15 ClustalW alignment of TbGSK3 short and TbGSK3 long  
Blue coloured residues are identical. Sequences highlighted in gray are the 
peptides identified in the competition experiment. LCDFGSAK peptide is shared 
by TbGSK3 short and TbGSK3 long.  
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kinome by the kinobeads in this experiment was 27% (considering a total of 182 PKs) 
and DDD00085893 was not a promiscuous inhibitor of these kinases.  
A similar competition experiment was conducted with MRC5 lysates in order to 
evaluate the selectivity of this compound against the parasite kinome and potential toxic 
effects against the host kinome. In MRC5 lysates the kinobeads could bind 238 proteins, 
125 of which were annotated as protein kinases. Only four were actually displaced by 
incubation of DDD00085893 ranging from 10 M to 39 nM. The top binders were 
HsGSK3 with an IC50 of 87 nM, other binders were HsGSK3 with an IC50 of 76 nM, 
CDK9 with an IC50 of 0.45 M and its binding partner cyclin T1 with a comparable 
affinity (Figure 3.14 B and Table 3.12). These results indicate that the compound 
DDD00085893 is a specific inhibitor of TbGSK3 short, but not completely selective for 
T. brucei. 
T. brucei has two isoforms annotated in GeneDB, TbGSK3 long 
(Tb927.07.2420) and TbGSK3 short (Tb927.10.1378), which are 40% identical at the 
amino acid level. In the competition experiment all the identified peptides were unique 
to TbGSK3 short with only one peptide sequence in common (LCDFGSAK) between 
the two isoforms (Figure 3.15). The results from the kinobeads experiment prove that 
DDD00085893 binds the native TbGSK3 short, although binding to the long isoform 
cannot be definitely ruled out. To date TbGSK3 long protein has never been identified 
in any global proteomic and phosphoproteomic study in bloodstream form T. b. brucei 
(Urbaniak et al., 2012b; Urbaniak et al., 2013). 
 
  
 
Figure 3.16 Expression and purification of recombinant TbGSK3 short 
tagged at the N-terminus with His6-BAP tag 
Protein sample were run on 4-12% SDS-PAGE gel and stained with Coomassie 
Blue. (A) Purification by Ni-affinity column: (M) marker; (1) insoluble fraction; 
(2) clarified lysate by centrifugation; (3) flowthrough; (4-8) fractions at higher 
absorbance of the eluate of the Ni-affinity column. (B) TEV protease cleavage and 
purification by Ni-affinity chromatography: (1) pooled fractions from first Ni-
affinity column; (2) over-night reaction with TEV protease; (3) flowthrough by 
the second Ni-affinity chromatography collecting the cleaved BAP-TbGSK3 short 
protein.
  
 
Figure 3.17 Size-exclusion purification of recombinant TbGSK3 short tagged at the N-terminus with BAP tag 
Protein samples were run on 4-12% SDS-PAGE gel and stained with Coomassie Blue. (A) Size exclusion chromatogram and (B) corresponding SDS-
PAGE of analysed fractions: (1) His6-cleaved BAP-TbGSK3 short pooled fractions; (2-10) labeled fractions in the chromatogram (A) with higher 
absorbance values. (C) Determination of native mass of TbGSK3 short indicated with a gray square on the calibration curve obtained using as 
standards thyroglobulin (670 kDa), bovine gamma-globulin (158 kDa), chicken ovalbumin (44 kDa), equine myoglobin (17kDa).  
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3.4 Protein expression and purification 
3.4.1 Protein expression and characterization of BAP-tagged TbGSK3 
short  
In order to support further studies of inhibitor characterization and chemical-
genetic validation, I expressed recombinant TbGSK3 short protein in house. The protein 
used for the hit identification (kindly provided by the University of Washington) had at 
the N-terminus a large MBP tag (45.1 kDa) (Ojo et al.,2008). The attempts I made to 
determine the binding kinetics of GSK3 07 and 09 compounds using this construct by 
Surface Plasmon Resonance (SPR) were unsuccessful, due to the fact that the 
recombinant TbGSK3 tagged with MBP was inactive after immobilization onto the 
CM5 chip by amino-coupling. This procedure includes a step at pH 5.5 that can cause 
loss of activity. Furthermore, proteins with bulky tags are not ideal for immobilization 
for SPR because they decrease the assay sensitivity due to the increased distance 
between the binding interaction and chip surface.  
The Biotin Acceptor Peptide (BAP) tag, which can be site-specifically 
biotinylated by the biotin-protein ligase BirA (Predonzani et al., 2008), improves the 
rate of success of SPR analysis by specific biotinylation in a known position that does 
not interfere with the activity of the protein and the immobilization at the chip surface 
can happen through the extremely strong interaction of biotin with streptavidin (Kd = 10
-
15 
M) (Predonzani et al., 2008). 
The TbGSK3 short encoding region was cloned into the modified pET-15b-
TEV-BAP vector and the expressed protein was purified by metal ion-affinity 
chromatography (Figure 3.16 A). The N-terminal His6-tag was subsequently cleaved by 
TEV protease and the cleaved protein purified by a second nickel column (Figure 3.16 
B). The cleaved protein was further purified by size-exclusion chromatography (Figure 
3.17 A and B). The protein had the expected Mr of 43.1 kDa by SDS-PAGE analysis, 
  
 
 
Figure 3.18 Characterization of recombinant TbGSK3 short tagged at the N-
terminus with BAP peptide  
(A) Protein sample after TEV cleavage and size exclusion purification. Protein sample 
was run on 4-12% SDS-PAGE gel and stained with Coomassie Blue. (B) Identity 
confirmation by Mass-fingerprint analysis of the His6-BAP tagged TbGSK3 short 
performed by the Mass Proteomics Facility at the University of Dundee (Mr Douglas 
Lamont). (C) Plot of the distribution of sedimentation coefficients generated by 
analytical ultracentrifugation (AUC) of TbGSK3 short at 0.15 mg/ml in buffer 20 mM 
Hepes pH 7.4, 1 mM DTT, 150 mM NaCl, 10% glycerol (Dr Mark Agacan).  
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but the elution of TbGSK3 short from the gel filtration column indicated a tetrameric 
status (Figure 3.17 C). The protein identity was confirmed by mass-fingerprint analysis 
(Figure 3.18 A and B), and ultracentrifugation revealed that the protein was primarily 
monomeric, but aggregates were also present in solution (Figure 3.18 C). The detergent 
present in the purification buffer might be responsible for the increased tendency of the 
protein to aggregate.  
The protein yield for the His6-tagged protein was higher than 20 mg per litre of 
culture, but the cleavage of the His6-tag and the following steps of purification gave a 
final yield of 5 mg per litre.  
The BAP-tagged TbGSK3 short was active with a specific activity of 8.7 nM 
min
-1
 nM
-1
 at room temperature (201.4 nM min
-1 
mg
-1
, MW 43,129.6 Da) that was ~2-
times higher than the MBP-tagged TbGSK3 preparation received from University of 
Washington that had an activity of 4 nM min
-1
 nM
-1
 (46.8 nM min
-1 
mg
-1
, MW 85,391.6 
Da).  
Due to time constraints and limited access to instrumentation this TbGSK3 short 
construct was not used for the biophysical characterization of the GSK3 inhibitors by 
Surface Plasmon Resonance, but it represents a useful reagent for further studies and 
potentially for undertaking fragment screening in the search for novel inhibitors with 
potential alternative mechanism of binding and inhibition. 
 
3.4.2 Protein expression and characterization of TbGSK3 long 
TbGSK3 long protein has never been found expressed in bloodstream form 
trypanosomes in previous proteomic and phosphoproteomic studies (Urbaniak et al., 
2012b; Urbaniak et al., 2013), whereas the peptide corresponding to the 
autophosphorylation loop of TbGSK3 long has been identified by a phosphoproteomic 
analysis conducted in procyclic cells (NVPposphoYIFSR) (Nett et al., 2009b), meaning 
  
 
 
 
Figure 3.19 Expression and purification of recombinant TbGSK3 long tagged at 
the N-terminus with His6-BAP tag 
Protein sample were run on 4-12% SDS-PAGE gel and stained with Coomassie Blue. 
(A) Purification by Ni-affinity column. (M) marker; (1) insoluble fraction; (2) 
clarified lysate by centrifugation; (3-4) flowthrough; (5-11) fractions at higher 
absorbance of the eluate of the Ni-affinity column. (B) TEV protease cleavage and 
purification by Ni-affinity chromatography: (1) pooled fractions from first Ni-affinity 
column; (2) over-night reaction with TEV protease; (3) flowthrough by the second Ni-
affinity chromatography collecting the cleaved BAP-TbGSK3 long protein. 
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that the protein is expressed in the insect life stage most likely in an active form. 
Moreover, RNAi studies have shown that this protein kinase is not essential in 
bloodstream form cells or for differentiation to procyclic form, and its knock-down is 
beneficial for the proliferation of procyclic cells (Alsford et al., 2011; Jones et al., 
2014). This suggests that TbGSK3 short and TbGSK3 long have different expression 
and functions in the different life stages and they cannot compensate for each other.  
In order to address the question whether DDD00085893 could bind TbGSK3 
long in vitro and in cultured cells I expressed recombinant protein in E. coli and 
overexpressed this gene in BSF T. b. brucei (see section 4.1.8). 
 The open reading frame (ORF) region of the long form of TbGSK3 was cloned 
from the genomic DNA of strain 427 (S427) using as reference the coding region 
reported in the genome for the strain 927 (S927) in GeneDB. The consensus sequence 
of three independent PCR reactions was compared to the DNA sequence reported in the 
reference S927 genome and 11 single nucleotide polymorphisms (SNPs) were identified 
between S427 and S927, four of these SNPs translated in four different amino acids 
(D15N, A51V, V201L and T322S).
a
  
The ORF of the long isoform of TbGSK3 was cloned in the same modified pET-
15b-TEV-BAP plasmid used for the protein expression of TbGSK3 short. The His-
tagged form of the recombinant protein was expressed in E. coli and purified in a 
soluble form by metal-affinity chromatography; subsequently the protein was untagged 
by TEV cleavage and purified by a second nickel ion-affinity column (Figure 3.19 A 
and B). The protein had the expected Mr of 58.1 kDa by SDS-PAGE analysis (Figure 
                                                 
 
 
a
 These differences were in agreement with the genome sequence subsequently reported in 
Trytripsdb.org for T. brucei  Lister strain 427. 
  
 
Figure 3.20 Expression and purification of recombinant TbGSK3 long tagged at 
the N-terminus with BAP peptide in E. coli 
A) Protein sample after TEV cleavage and second nickel ion affinity column. Protein 
sample was run on 4-12% SDS-PAGE gel and stained with Coomassie Blue. B) 
Identity confirmation by Mass-fingerprint analysis performed by the Mass Proteomics 
Facility at the University of Dundee (Mr Douglas Lamont). C) Plot of the distribution 
of sedimentation coefficients generated by analytical ultracentrifugation (AUC) of 
TbGSK3 long at 0.75 mg/ml in buffer 20 mM Hepes pH 7.4, 2 mM DTT, 150 mM 
NaCl (Dr Mark Agacan).  
  
Figure 3.21 Isothermal titration calorimetry of DDD00085893 with TbGSK3 
short and TbGSK3 long  
Isothermal titration calorimetry data for a solution of A) 3 µM of TbGSK3 short and 
B) 3 µM of TbGSK3 long titrated with 30 µM DDD00085893. The two panels show 
the raw data. 
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3.20 A), the identity was confirmed by mass-fingerprint and verified to be primarily a 
monomer by ultracentrifugation (Figure 3.20 B and C).  
The protein yield for the His6-tagged TbGSK3 long was of 5 mg per litre of 
culture, but after the cleavage of the His6-tag the final yield was of 1.6 mg per litre.  
Using the same peptide substrate previously used for the biochemical assay, I 
compared the enzymatic activity of TbGSK3 long BAP-tagged at the N-terminus to the 
activity of TbGSK3 short, BAP-tagged as well at the N-terminus. TbGSK3 long was 
~380-fold less active than TbGSK3 short with a specific activity of 0.023 nM min
-1
 nM
-
1
 (0.4 nM min
-1 
mg
-1
, MW 58,126.3 Da). Neither enzyme was capable of 
autophosphorylation in the absence of substrate, but considering that both proteins 
cross-reacted with an antibody directed against the phosphorylated tyrosine of the 
activation loop (see following section), it is plausible that the proteins were already 
fully phosphorylated on this residue during protein production and no further 
autophosphorylation could happen. This is in agreement with what has been reported in 
literature that the autophosphorylation on the activation loop is an intramolecular 
reaction happening immediately after translation, during the protein folding and assisted 
by chaperone proteins, such as Hsp90 (Lochhead et al., 2006).  
Because of the extremely low enzymatic activity it was not possible to address 
the question whether DDD00085893 could inhibit TbGSK3 long in vitro with an 
activity assay, but isothermal titration calorimetry (ITC), which does not require 
enzymatic activity, gave a preliminary indication that DDD00085893 does not bind 
TbGSK3 long in solution (Figure 3.21 A). On the other hand TbGSK3 short did bind 
DDD00085893, but due to buffer mismatch it was not possible to integrate the results 
and obtain a Kd value (Figure 3.21 B). Further experiments are also required to fully 
characterise the kinetics of binding of DDD00085893 to TbGSK3 short. 
 
 kDa kDa
 
Figure 3.22 Western blot analysis of recombinant BAP-TbGSK3 short and long 
Western blot analysis showed that only the p-Tyr-GSK3 antibody directed against the 
activation loop (C-KQLLHGEPNVS[pY]ICSRY), cross-reacted with the long form of 
TbGSK3 protein expressed in E. coli (Figure 3.20 A). In contrast, the anti-GSK3 
directed versus the same un-phosphorylated peptide did cross-react with the short 
isoform but not cross-react with the long isoform (Figure 3.20 B). 
Serial dilutions (1:2 from 0.2 μg to 0.05 μg) of recombinant TbGSK3 short and long 
probed with anti-phosphoTyr-GSK3 (A) and anti-GSK3 antibodies (B). (C) ClustalW 
alignment of the activation loop of HsGSK3 and TbGSK3 enzymes. The arrows 
indicate Tyr216 in HsGSK3β and the conserved Tyr across species and isoforms. 
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3.4.3 Western blot analysis of recombinant TbGSK3 short and TbGSK3 long 
Commercially available antibodies (Millipore) raised against both the 
phosphorylated and un-phosphorylated form of a synthetic peptide 
(KQLLHGEPNVS[phosphoY]ICSRY) corresponding to the autophosphorylation loop 
of the Drosophila GSK3/shaggy enzyme were tested for cross-reactivity against 
recombinant TbGSK3 short and long. Considering that this region is highly conserved 
in all species, the antibodies were also expected to recognise the T. brucei isoforms of 
the enzyme. 
Western blot analysis conducted on the recombinant proteins showed that the 
phospho-Tyr-GSK3 antibody directed against the activation loop (C-
KQLLHGEPNVS[pY]ICSRY), cross-reacted with both the short and long isoforms of 
TbGSK3 expressed in E. coli (Figure 3.22 A). In contrast, the GSK3 antibody directed 
against the same un-phosphorylated peptide cross-reacted only with the short isoform 
(Figure 3.22 B). The insertion of six amino acids in the antibody recognition sequence 
of TbGSK3 long might account for the lack of cross-reactivity with the antibody 
directed against the unphosphorylated substrate (Figure 3.22 C). 
Together with the activity data these results indicate that the TbGSK3 long gene 
encodes for a protein that can be expressed in E. coli in a soluble form, that can 
autophosphorylate in the activation loop and trans-phosphorylate a primed substrate, 
although with an extremely low specific activity with respect to the short isoform. 
Interestingly TbGSK3 long has in its sequence an Arg residue instead of a catalytically 
important Lys residue (K86 in HsGSK3β, R88 in TbGSK3 long). Usually this mutation 
is used to make kinase dead mutants and this might explain why the enzyme activity is 
so low and lack of significant catalytic activity might also explain why this isoform is 
not essential and not expressed or expressed at undetectable levels in T. brucei. It might 
also be the case that the protein is also less stable and easily degraded because of this 
  
 
 
Figure 3.23 Expression and purification of HIS6-BAP-TbGSK3(K49A) in E. coli 
and western blot analysis  
(A) TbGSK3(K49A) expression and partial purification from BL21(DE3)* cells 
cultured in auto-induction media at 22 ºC for 24 hours before lysis. Coomassie bleu 
staining of SDS-PAGE: (1) insoluble fraction; (2) clarified bacterial cell lysate by 
centrifugation (19,000 rpm for 30 min at 4 ºC); (3) flowthrough; (4) pooled fractions 
purified by Ni-affinity chromatography. The same samples were transferred into two 
nitrocellulose blots and probed with antibodies directed against anti-phospho-
tyrosine-GSK3 (pTyr-GSK3) (B) and anti-GSK3 (GSK3) (C). Proteins at the 
expected size of TbGSK3 short (40.3 kDa) are marked by arrows. The HIS6-BAP-
tagged TbGSK3(K49A) has a molecular weight of 45.3 kDa. 
  
Figure 3.24 Purification of recombinant HIS6-BAP-TbGSK3(K49A) in E. coli 
(A) TbGSK3(K49A) expression and partial purification from ArcticExpress (DE3) RIL cells cultured in auto-induction media at 13 ºC for 48 h 
before lysis. Coomassie blue stained SDS-PAGE: (M) marker; (1) insoluble fraction; (2) clarified lysate by centrifugation (19,000 rpm for 30 
min at 4 ºC) (dil 1/10); (3) flowthrough from the Ni-affinity column; (4) washes with binding buffer; (5-11) fractions at higher absorbance of the 
eluate of the Ni-affinity column. (B) Second Ni-affinity column after incubation at 4 ºC for 1 h in Buffer A supplemented with 1 mM ATP, 1 
mM MgCl2. Coomassie blue stained SDS-PAGE: (M) marker; (1) pooled fractions after the first Ni-affinity and following purification by ion 
exchange chromatography; (2) flowthrough from the second Ni-affinity column; (3) washes; (4-11) fractions at higher absorbance of the eluate 
from the second Ni-affinity column. In both panels the arrows indicate the expected Mr for HIS6-BAP-tagged TbGSK3(K49A) (45.3 kDa) and 
for Oleispira antartica Cpn60 (60 kDa). 
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mutation, the reason for this could be that usually autophosphorylation contributes to 
the stability of the protein, but, given that the protein is almost inactive, a lack of 
autophosphorylation might cause instability and degradation. 
3.4.4 Protein expression and purification of TbGSK3 short inactive 
mutant  
In order to address the question whether DDD00085893 could bind the inactive 
form of TbGSK3 short in vitro and in cultured cells, kinase dead mutants of TbGSK3 
short were expressed in E. coli and overexpressed in T. b. brucei cultured cells (see 
section 4.1.7). 
Based on the homology model of mammalian GSK3β the catalytic Lys85 
corresponding to Lys49 in TbGSK3 short was mutated to Ala (K49A) or Arg (K49R) to 
obtain kinase-dead mutants (He et al., 1995; Eldar-Finkelman et al., 1996).  
The mutated TbGSK3(K49A) short was cloned into the pET-15b-TEV-BAP 
plasmid (Figure 2.1). The plasmid was transformed in BL21(DE3)* cells for protein 
expression in auto-induction medium at 22ºC for 20 h (Studier, 2005) using similar 
conditions previously reported for the expression of the N-terminus His6-tagged 
TbGSK3 short (Ojo et al., 2011). The mutant protein was poorly expressed in these 
conditions and primarily insoluble (Figure 3.23 lane 1) as demonstrated also by 
Western analysis (Figure 3.23 B and C). An increase in protein expression and 
solubility was obtained using ArcticExpress (DE3) cells due to the co-expression of 
chaperonins Cpn60 and Cnp10 from Oleispira antarctica (Ferrer et al., 2003; Ferrer et 
al., 2004). Indeed, TbGSK3(K49A) short was co-purified with a contaminant protein at 
higher molecular weight (~60 kDa), which mass-fingerprint analysis confirmed to be 
the OaCpn60. The attempts to separate this co-purified contaminant by anion exchange 
chromatography (data not shown) and by incubation with the binding buffer 
supplemented with 1 mM ATP, 1 mM MgCl2 were unsuccessful (Figure 3.24 A and B).  
  
Figure 3.25 Purification of recombinant HIS6-BAP-TbGSK3(K49M) in E. coli 
(A) TbGSK3(K49M) expression and partial purification from ArcticExpress (DE3) RIL cells cultured in autoinduction media at 13 ºC for 48 h. 
Coomassie blue stained SDS-PAGE: (M) marker; (1) insoluble fraction; (2) clarified lysate by centrifugation (19,000 rpm for 30 min at 4 ºC); 
(3) flowthrough from the Ni-affinity column; (4) washes with binding buffer supplemented with 10 mM MgCl2 and 1 mM ATP; (5-14) fractions 
at higher absorbance of the eluate of the Ni-affinity column. (B) Second Ni-affinity column after extensive washes with binding buffer 
containing 5 mM ATP, 10 mM MgCl2 and 0.1 mg/ml denaturated proteins from E. coli. Coomassie blue stained SDS-PAGE: (M) marker; (1) 
pooled fractions from the first Ni-affinity column dialysed overnight in buffer A without imidazole; (2) flowthrough; (3) washes with 5 mM 
ATP, 10 mM MgCl2 and 0.1 mg/ml denaturated proteins from E. coli; (4-11) fractions at higher absorbance of the eluate from the Ni-ion affinity 
column. In both panels the arrows indicate the expected Mr for HIS6-BAP-tagged TbGSK3(K49M) (45.3 kDa) and for Oleispira antartica 
Cpn60 ( ~60 kDa). 
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Similar results were also obtained when an alternative kinase dead mutant was 
generated by replacement of Lysine49 with a Methionine, obtaining the kinase dead 
mutant called TbGSK3(K49M) short. This mutant protein also co-purified with 
OaCpn60 when expressed from ArcticExpress (DE3) cells at 13 ºC for 48 h (Figure 
3.25 A). Also, in this case attempts to separate the contaminating protein after extensive 
washes with binding buffer containing 5 mM ATP, 10 mM MgCl2 and 0.1 mg ml
-1
 
denaturated proteins from E. coli were unsuccessful (Rial et al., 2002) (Figure 3.25 B).  
In conclusion, the expression of the kinase dead mutants TbGSK3(K49A) and 
TbGSK3(K49M) from ArcticExpress(DE3) cells resulted in partially soluble proteins 
tightly associated with a chaperonin. It is likely that also in cultured BSF T. b. brucei 
these mutants are unstable when over-expressed (see section 4.1.6). Indeed, it is 
reported that autophosphorylation in the activation loop increases the stability of 
HsGSK3β (Cole et al., 2004) and it is an intramolecular chaperone-dependent event that 
occurs after translation (Lochhead et al., 2006). This might also explain why the 
inactive mutant protein would be so tightly bound to the chaperonin protein and failed 
to progress from this transitional intermediate to the fully active protein.   
Due to protein instability it is not possible to confirm whether DDD00085893 is 
able to bind the kinase dead mutants TbGSK3(K49A) and TbGSK3(K49M).  
Interestingly a band at the expected molecular weight for TbGSK3(K49A) short 
was observed in the Western analysis also with the anti-phoshoTyr antibody directed 
against the activation loop (Figure 3.23 B), this is surprising considering that this is an 
intramolecular autophosphorylation, meaning that this expressed protein although 
unstable is not completely inactive. Further work would be required to test the activity 
of these preparations using an in gel kinase assay. 
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Chapter 4 Chemical-genetic validation of 
TbGSK3 short 
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4.1 Chemical validation using genetic approach 
 
4.1.1 Rationale of the chemical-genetic approach 
TbGSK3 short was initially proposed as a drug target for human African 
trypanosomiasis  by Ojo and colleagues (2008). Phosphoproteomic studies conducted in 
T. brucei revealed that this protein is expressed in both bloodstream (Nett et al., 2009a) 
and in procyclic trypanosomes (Nett et al., 2009b). In both the parasite life stages the 
activation loop of TbGSK3 short was found to be phosphorylated, an indication that this 
kinase should be enzymatically active considering that in other species this is an auto-
phosphorylation event (Eldar-Finkelman et al., 1996; Cole et al., 2004). 
RNA interference (RNAi) studies demonstrated that knock-down of TbGSK3 
short causes a growth defect in BSF T. brucei, while the knock-down of the long 
isoform has no effect on cell growth (Ojo et al., 2008). Subsequently Alsford and 
colleagues (2011) conducted a genome-wide RNA interference target sequencing study 
directed against both bloodstream and procyclic T. b. brucei. Their findings confirmed 
that RNAi of TbGSK3 short resulted in inhibition of proliferation and differentiation in 
bloodstream form only. Recently another RNAi study has confirmed that TbGSK3 short 
knock-down in bloodstream form trypanosomes causes arrest of growth and plays a role 
in mitosis and/or cytokinesis (Jones et al., 2014).   
To date this potential drug target has never been genetically validated by 
generation of knock-outs and the chemical compounds used by others for chemical 
validation of TbGSK3 short were not sufficiently specific to clearly attribute their 
cellular effects to exclusive “on target” activity (Ojo et al., 2008; Oduor et al., 2011; 
Ojo et al., 2011). The chemical proteomic approach we performed in collaboration with 
  
 
 
Figure 4.1 Generation of TbGSK3 single knock-out (SKO) cell lines  
(A) Schematic representation of the generation of the TbGSK3 single knock-out 
(SKO) cell lines. The replacement of an endogenous allele by incorporation of the 
puromycin-resistance gene (PAC) produced Tbgsk3::PAC/TbGSK3 cell line 
(SKO(PAC), top) and the replacement with the hygromycin-resistance gene (HYG), 
produced Tbgsk3::HYG/TbGSK3 cell line (SKO(HYG), bottom). (B) Analysis of 
restriction sites for BamHI/PstI for TbGSK3/TbGSK3 (WT), Tbgsk3::PAC/TbGSK3 
(SKO(PAC)) and Tbgsk3::HYG/TbGSK3 (SKO(HYG)) loci and expected fragment 
sizes when probed with TbGSK3 5’-UTR. (C) Southern analysis of ~5 µg of DNA 
digested with BamHI and PstI from WT, SKO(PAC)
 
and SKO(HYG)
 
and probed with 
TbGSK3 5'-UTR. 
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Cellzome demonstrated that DDD00085893 binds to the TbGSK3 short native protein 
with high affinity (IC50 below 40 nM) and is also a specific GSK3 inhibitor for both T. 
brucei and human MRC5 cells (see section 3.3 and Urbaniak et al., 2012a). Next I 
wanted to assess whether this compound could specifically act “on target” in living 
cells. 
To date the role of TbGSK3 short has not yet been elucidated, and its 
physiological substrates in T. brucei are unknown; hence it was not possible to validate 
DDD00085893 directly by inhibiting the phosphorylation of TbGSK3 short downstream 
targets. An alternative strategy to demonstrate that DDD00085893 specifically inhibits 
TbGSK3 short in cultured trypanosomes is by modulating its protein expression in 
mutant cell lines. An inhibitor that acts “on target” is more potent against mutant cell 
lines under-expressing the molecular target and becomes less potent when the target 
protein is overexpressed (Wyllie et al., 2009), or in other words the potency to a small 
molecule inhibitor acting “on target” can be modulated by changing the level of protein 
expression of its molecular target. 
 
4.1.2 Null mutants of TbGSK3 short have a lethal phenotype  
It was previously demonstrated that TbGSK3 short gene is present as a single 
copy per haploid genome by Southern analysis (Ojo et al., 2008).  
Single knock-out cell lines (SKO) were obtained by replacement of one TbGSK3 
allele with the puromycin N-acetyl transferase resistance gene (PAC) flanked with the 
5'- and 3'- untranslated regions (5'-UTR and 3'-UTR) of TbGSK3 short generating the 
Tbgsk3::PAC/TbGSK3 cell line. Likewise it was possible to incorporate the 
hygromicin phosphotransferase resistance gene (HYG) generating the 
Tbgsk3::HYG/TbGSK3 cell line. (Figure 4.1 A and B). The replacement of a single 
  
 
Figure 4.2 Strategy for inducible expression of an ectopic copy  
(A) The WT cell line constitutively expresses T7 RNA polymerase and the 
tetracycline repressor protein (TetR) under G418-neomicin (NEO) selection. (B) 
Inducible expression vectors designed for integration in the ribosomal locus.  Figure 
adapted from Wirtz et al., 1999 and Professor George Cross’ website 
(http://tryps.rockefeller.edu/trypsru2_plasmids.html). 
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allele with the resistance gene cassettes in the TbGSK3 locus was confirmed by 
Southern analysis (Figure 4.1 C). Repeated attempts to obtain a null mutant replacing 
the second allele by homologous recombination with either PAC or HYG were 
unsuccessful. Similarly also for other essential genes studied up to date in T. brucei, in 
which there is not a metabolic by-pass or compensation of function by other isoforms 
and/or enzymes, it has not been possible to generate null mutants (Roper et al., 2002; 
Sienkiewicz et al., 2008; Urbaniak, 2009; Wyllie et al., 2009). This negative result 
suggests that TbGSK3 short is an essential gene in T. brucei, although it cannot be 
considered a definitive proof of its essentiality (Frearson et al., 2007).  
 
4.1.3 Generation of conditional cell lines and tuning of the ectopic 
expression 
When it is not possible generate a null mutant directly by replacement of both 
alleles, an established procedure is to insert an ectopic copy of the gene in an alternative 
locus under tetracycline-inducible regulation (Wirtz et al., 1999). This strategy requires 
a background cell line, referred as wild-type (WT), which constitutively expresses T7 
RNA polymerase (T7RNAP) and the tetracycline repressor protein (TetR) under G418-
neomicin (NEO) selection (Figure 4.2 A) (Wirtz et al., 1999). The ectopic copy is 
generally inserted in the ribosomal locus, its expression being regulated by a 
tetracycline-inducible promoter. Selection is possible by the presence of a resistance 
cassette regulated by a constitutive T7 promoter. Different vectors can induce different 
level of expression of the ectopic protein based upon their “leaky” nature or tighter 
regulation, so that the ectopic protein expression can be finely tuned, in particular for 
toxic genes (Wirtz et al., 1999).  
For the generation of TbGSK3 short over-expressing cell lines, the pLew82 
over-expressor vector was initially used as it gives the highest level of expression at the 
  
 
Figure 4.3 Genotypic analyses of conditional cell lines  
(A) Agarose gel of PCR reactions performed with 100 ng genomic DNA from conditional cell 
lines cWT
OE
 GSK3short
Ti 
(BLE, pLew100v5) (lane 1-3), cSKO(PAC)
OE
 GSK3short
Ti
 (BLE, 
pLew100v5)(lane 4a-4b), WT
OE
 GSK3short
Ti 
(BLE, pLew82) (lane 5-8), and SKO(PAC)
OE
 
GSK3short
Ti
 (BLE, pLew82) (lane 9a-10b) to confirm incorporation of resistance genes, PAC 
(600bp) and BLE (424 bp). M, marker. (B) Southern blot analysis of DraI and PstI digested 
genomic DNA (~5 µg) from WT (lane 1), TbGSK3short SKO (HYG) (lane 2), TbGSK3short 
SKO (PAC) (lane 3), cWT
OE
 GSK3short
Ti 
(BLE, pLew100v5) (lane 4-6), cSKO(PAC)
OE
 
GSK3short
Ti
 (BLE, pLew100v5)(lane 7), WT
OE
 GSK3short
Ti 
(BLE, pLew82) (lane 8-11), and 
SKO(PAC)
OE
 GSK3short
Ti
 (BLE, pLew82) (lane 12-13). Southern blot probed with TbGSK3 
short ORF. WT shows the expected size of 1.5 kbp (completed digested DNA) and 1.8 kbp 
(partial digested DNA). The membrane had previously been probed with the 5’-UTR probe 
and stripped. The expected extra band at 0.7 kbp for the introduction of  HYG in the 
TbGSK3short SKO (HYG) cell line is still visible in the blot (lane 2). (C) Map of the 
restriction sites for DraI and PstI in WT cell lines, TbGSK3short SKO (HYG)  and 
TbGSK3short SKO (PAC). 
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expense of a poor regulation since it is controlled by a leaky tetracycline-inducible T7 
promoter. This vector has a single T7 promoter that drives transcription of both the 
ectopic gene and the drug resistance gene, whereas transcription is terminated 
downstream by tandem T7 terminators (Figure 4.2 B). The unregulated over-expression 
of TbGSK3 short by the pLew82 vector caused either cell toxicity or deletion of the 
ectopic copy by gene rearrangement, although the gene conferring resistance was 
maintained (lane 5, 9a and 10a in Figure 4.3 A and lane 12 and 13 in Figure 4.3 B). 
These results suggested that the level of TbGSK3 short protein in T. brucei is tightly 
regulated and expression above the physiological levels is as lethal as gene deletion. 
These finding were in agreement with the fact that over-expression of HsGSK3 was 
able to induce apoptosis in a variety of cell lines (Pap et al., 1998; Beurel and Jope, 
2006). 
The pLew100 vector is tightly regulated by a PARP (procyclic acidic repetitive 
protein) promoter with two Tet operators, thus the level of conditional expression of the 
ectopic copy under induction is comparable to the WT level (Figure 4.2 B). Therefore, 
it is generally used as a rescue construct for generation of conditional null mutants, but 
it is not suitable for protein over-expression above physiological levels (Wirtz et al., 
1999). A modified version of the pLew100 vector, called pLew100v5
a
 combines 
expression above physiological levels with a tighter regulation that can be finely tuned 
by tetracycline concentration. This vector has a back-to-back dual promoter, a 
constitutive T7 promoter which drives the drug resistance and a regulated rRNA 
polymerase (rRNAP) that drives the expression of the ectopic gene (Figure 4.2 B). 
Using pLew100v5 it was possible to introduce an ectopic copy of TbGSK3 short both 
                                                 
 
 
a
 http://tryps.rockefeller.edu/trypsru2_plasmids.html 
  
Figure 4.4 Cumulative growth analyses of wild-type and genetically modified 
TbGSK3 short cell lines 
(A) WT growth was compared to the growth of SKO (PAC) and SKO (HYG) clonal 
cell lines. (B) WT growth in the absence (closed symbols) and in the presence (open 
symbols) of 1 g ml-1 of tetracycline (tet) was compared to the cumulative growth of 
a conditional over-expressing clone (cWT
OE
) and a TbGSK3 conditional single 
knock-out clone (cSKO
OE
).  
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into WT and SKO background cell lines generating conditional over-expressing 
(cWT
OE
) and conditional single knock-out (cSKO
OE
) cell lines. PCR and southern blot 
analysis of genomic DNA from these cell lines confirmed that the ectopic copy under 
phleomycin (BLE) selection was introduced and retained (lane 1 to 4a in Figure 4.3 A 
and lane 4 to 7 in Figure 4.3 B).
a
 
 
4.1.4 Over-expression of TbGSK3 short is toxic for cell viability 
The growth of the mutant cell lines generated using pLew100v5 as conditional 
over-expressor was compared to the growth of WT cell lines. SKO clones (both SKO 
(PAC) and SKO (HYG)) showed comparable growth to the WT (Figure 4.4 A). The 
growth of the conditional over-expressing cell lines in the presence and absence of 
tetracycline (tet) compared to WT trypanosomes showed growth defects when induced 
by tetracycline around day 2-3 and an erratic growth profile (Figure 4.4 B). The defect 
in growth observed under tetracycline induction supports the indication that TbGSK3 
short over-expression is toxic for the cells. 
 
4.1.5 Expression of TbGSK3 short and long in BSF T. b. brucei 
Bloodstream form T. b. brucei lysates were probed with the same anti-phospho-
tyrosine GSK3 antibody that cross-reacted with recombinant TbGSK3 short and 
                                                 
 
 
a
 The restriction enzymes used in the Southern analysis (DraI and PstI) gave two bands for the 
WT  when probed with the TbGSK3 short probe due to the presence of two DraI restriction sites in the 
5’-UTR region of TbGSK3 short and partial digestion (see Figure 4.3 B and C). The partial digestion of 
the DNA does not compromise the validity of the information obtained regarding the incorporation of the 
ectopic copy and therefore the blot is shown as evidence of ectopic copy incorporation.  To avoid this 
problem in further Southern analysis a new pair of restriction enzymes was chosen (BamHI and PstI, see 
Figure 4.1B).  
  
 
Figure 4.5 Western blot analysis of BSF T. b. brucei 
Immunoblots of whole cell extracts (5, 10 and 20 µg) from BSF T. b. brucei were 
probed with (A) anti-phospho-GSK3 (α-pTyr-GSK3) and (B) anti-GSK3 (α-GSK3) 
antibodies in two independent blots. In both panels the arrows indicate the expected 
Mr for TbGSK3 short (40.3 kDa) and for TbGSK3 long (55.3 kDa). 
 
  
Figure 4.6 Targeting of TbGSK3 short by DDD00085893 in bloodstream form T. 
b. brucei 
(A) EC50 values determination against WT (closed circles), SKO (HYG) (open 
squares) and SKO (PAC) (open diamonds). (B) EC50 determination against TbGSK3 
short-overexpressing (cWT
OE
) and conditional SKO (cSKO
OE
) cells non-induced 
(close upward triangles and close downward triangles, respectively). Tetracycline-
induced cWT
OE
 (open upward triangles) and cSKO
OE
 (open downward triangles) 
showed cell toxicity that could be rescued by increasing concentration of 
DDD00085893. EC50 values are indicated in the graph by the red dotted lines. Data 
are shown as mean ± SD of triplicate measurements.  
 Table 4.1 Sensitivity to DDD00085893 of WT, SKO, TbGSK3 conditional over-expressing (cWT
OE
) and conditional SKO (cSKO
OE
) cell 
lines 
 
Cell line EC50, M Ratio EC50 Ratio EC50 Hill slope Ratio Hill slope 
 minus Tet plus Tet plus Tet / minus Tet plus Tet / WT minus Tet plus Tet plus Tet / minus Tet 
WT 3.9 ± 0.1 3.8 ± 0.1 1.0 1.0 2.5 ± 0.3 1.9 ± 0.6 
 
0.8 
 
SKO (PAC) 2.1 ± 0.1 2.3 ± 0.1 1.1 **0.5 2.1 ± 0.1 2.0 ± 0.1 
 
1.0 
 
SKO (HYG) 2.2 ± 0.2 2.3 ± 0.2 1.0 *0.6 1.5 ± 0.1 1.8 ± 0.5 
 
1.2 
 
cWT
OE
 3.5 ± 0.1 9.3 ± 0.8 *2.7 *2.4 2.6 ± 0.1 3.9 ± 0.1 
 
*1.5 
 
cSKO
OE
 1.9 ± 0.3 11.4 ± 0.9 **6.0 *2.9 2.2 ± 0.2 4.0 ± 0.2 
 
*1.8 
 
EC50 values are weighted means and standard errors (SEM) of at least two independent determinations done in triplicate. 
pLew100v5 was used as rescue construct for the conditional over-expression of the ectopic copy under tetracycline control. 
The two-tailed P values were calculated using an unpaired t-test performed using the weighted mean, the SEM and number of independent 
determinations. P values below 0.05 (95%) were considered statistically significant (*), P values below 0.01 (99%) were considered highly 
statistically significant (**). 
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TbGSK3 long, and the anti-GSK3 antibody that recognised only the recombinant 
TbGSK3 short (see section 3.4.3, Figure 3.22 A and B). Bands at the expected 
molecular mass of ~40 kDa for TbGSK3 short and ~55 kDa for TbGSK3 long were 
visible on both blots, in addition to an intense non-specifc band at 100 kDa for the  
immunoblot probed with the anti-phospho-tyrosine GSK3 antibody  (Figure 4.5 A and 
B). Two distinct bands were visible at the predicted molecular mass for TbGSK3 short 
in the blot probed with the anti-GSK3 antibody, presumably the phosphorylated and 
unphosphorylated form of the enzyme, and a single band for the blot probed with the 
anti-phosho-tyrosine GSK3. These results seem to indicate that these antibodies are able 
to cross-react with not only the recombinant TbGSK3 short but also the protein in the 
cell lysate. Considering that the anti-GSK3 antibody could not recognise the 
recombinant TbGSK3 long, it is unclear if the band observed at ~50 kDa in both blots is 
TbGSK3 long or an aspecific cross-reacting protein.   
 
4.1.6 Chemical validation of TbGSK3 short as drug target 
To assess whether TbGSK3 short was specifically targeted by DDD00085893 in 
trypanosomes, TbGSK3 short SKO cell lines and over-expressing cell lines (cWT
OE
 and 
cSKO
OE
), obtained using pLew100v5 as conditional over-expressor, were compared 
with the WT for their relative sensitivity to this inhibitor. 
The increase in sensitivity of the SKO cell lines to DDD00085893 correlated 
well with an expected reduction of the 50% in protein expression due to deletion of one 
allele. Indeed, after 72 h incubation DDD00085893 EC50 values were 2.2 ± 0.2 and 2.1 
± 0.1 M for SKO cell lines (SKO(HYG) and SKO(PAC), respectively) compared to an 
EC50 value of 3.9 ± 0.1 M for the WT (Figure 4.6 A, Table 4.1). Western analysis 
demonstrated that TbGSK3 short protein levels were higher in tetracycline-induced 
  
 
Figure 4.7 Western blot analysis of mutant cell lines for TbGSK3 short 
Cells were grown for 72 hours in presence (+) or absence (-) of tetracycline (tet) prior to analysis. (A) Ponceau staining of the blot is used as 
loading control. In each lane were loaded ~10 g of protein at the exception of tetracycline-induced cSKO for which not enough cells survived 
to the induction. (B) The blot was probed with anti-pTyr-GSK3. A 100 kDa non-specific band was also detected, which was used as an internal 
loading control. (C) The same blot was stripped and blot with anti-GSK3.  
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cWT
OE
 and cSKO
OE
 cell lines than in WT cells (Figure 4.7 A, B and C). The non-
induced cWT
OE
 and cSKO
OE
 cells had EC50 values of 3.5 ± 0.1 and 1.9 ± 0.3 M, 
respectively, comparable to the values of their respective parental cell lines (Figure 4.6 
B, Table 4.1). Conditional over-expression of TbGSK3 short affected cell growth 
causing cell toxicity that could be rescued by increasing concentrations of 
DDD00085893 up to 3 M, but higher concentrations of compound resulted in 
inhibition of growth in itself. The induced cell lines reached maximum growth at 3 M, 
and this growth level was used to normalize the inhibitor effect of DDD00085893; the 
derived inhibition profile had an unusual U shape depicting rescue of growth inhibition 
below 3 M and the inhibitory effect above this concentration. The inhibition shifted 
with respect to the parental cell lines, and in particular tetracycline-induced cWT
OE
 and 
cSKO
OE
 had EC50 value of 9.3 ± 0.8 and 11.4 ± 0.9 M, respectively, displaying a 
decrease in sensitivity. These tetracycline-induced cell lines also gave an increase in 
their Hill-slope values, which increased 1.5 and 1.8 fold, respectively, compared to the 
parental cell lines (Figure 4.6 B and Table 4.1). A steeper Hill-slope can be attributed 
to off-target effects or to a reduction of the percentage of enzyme inhibition necessary to 
achieve a cellular effect (Czock and Keller, 2007; Sampah et al., 2011). 
In conclusion, an increase in TbGSK3 short protein expression and/or activity is 
detrimental to cell proliferation in bloodstream form T. b. brucei and the associated 
toxicity can be chemically modulated by DDD00085893. Taken together these results 
provide evidence that DDD00085893 targets TbGSK3 short in cultured trypanosomes 
and chemically validates TbGSK3 short as drug target in BSF T. brucei. 
 
  
Figure 4.8 Genotypic analysis of conditional over-expressing TbGSK3(K49A) 
kinase dead cell lines 
Southern blot analysis of conditional over-expressing kinase dead TbGSK3 short cell 
lines obtained using pLew100v5 plasmid. Genomic DNA from the T. b. brucei 427 wild-
type (WT), from TbGSK3(K49A) over-expressing
 
cell line (cWT
K49A
) and from 
TbGSK3K49A
Ti
 ΔTbgsk3::PAC/TbGSK3 cell line (cSKOK49A) was digested with BamHI 
and PstI and probed with the TbGSK3 ORF probe. The blot shows the incorporation of 
the ectopic copy. 
 
 
 
Figure 4.9 Cumulative growth of T. brucei WT and conditional over-expressing 
TbGSK3(K49A) kinase dead cell lines 
Wild-type (WT) (closed circles); non-induced and tetracycline-induced 
TbGSK3(K49A) kinase conditional over-expressing cell lines (cWT
K49A
) (closed and 
open squares, respectively); non-induced and tetracycline-induced TbGSK3(K49A) 
kinase dead conditional single knock-out (cSKO
K49A
) (close and open triangles, 
respectively). 
  
 
 
 
Figure 4.10 DDD00085893 sensitivity towards conditional over-expressing 
TbGSK3(K49A) kinase dead cell lines 
 Non-induced and tetracycline-induced cWT
K49A
 EC50 values of 4.4 ± 0.2 and 4.6 ± 
0.2 μM were determined (closed and open circles, respectively). Non-induced and 
tetracycline-induced cSKO
K49A
 EC50 values of 2.1 ± 0.1 and 2.3 ± 0.2 μM were 
determined (open and closed squares, respectively). WT (closed triangle) and SKO 
(close diamond) inhibition profiles were added as comparison to cWT
K49A
 and 
cSKO
K49A
 cell lines. EC50 values are indicated in the graph by the red dotted lines. 
Data are shown as mean ± SD of triplicate measurements.  
 Table 4.2 Sensitivity of DDD00085893 towards cell lines conditional over-expressing TbGSK3(K49A) kinase dead mutant 
 
DDD00085893 EC50 ± SD, M Ratio EC50 Ratio EC50 Hill slope ± SD Ratio Hill slope 
Cell line minus Tet plus Tet plus Tet / minus Tet plus Tet / WT
a
 minus Tet plus Tet plus Tet / minus Tet 
WT
a 
3.9 ± 0.1 3.8 ± 0.1 1.0 1.0 2.5 ± 0.3 1.9 ± 0.6 
 
0.8 
 
cWT
K49A 
4.4 ± 0.2 4.6 ± 0.2 1.1 1.2** 2.7 ± 0.2 3.1 ± 0.2 
 
1.1 
 
SKO
a 
2.1 ± 0.1 2.3 ± 0.1 1.1 0.5** 2.1 ± 0.1 2.0 ± 0.1 
 
1.0 
 
cSKO
K49A 
2.1 ± 0.1 2.3 ± 0.2 1.1 0.6* 2.9 ± 0.2 3.3 ± 0.2 
 
1.1 
 
a 
EC50 value for WT and SKO as reported in Table 4.1.  
EC50 values are means and standard errors of triplicate measurements. 
The two-tailed P values were calculated using an unpaired t test calculated using the weighted mean, the SD and number of replicates. P values 
<0.05 (95%) were considered statistically significant (*), P values <0.01 (99%) were considered highly statistically significant (**). 
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4.1.7 Over-expression of inactive TbGSK3 short in bloodstream form  
Having shown that DDD00085893 is an “on target” inhibitor of TbGSK3 short, I 
wanted to address the question as to whether this compound targeted both the active and 
inactive forms of the enzyme, as well as whether the toxic effects associated with 
TbGSK3 over-expression were due to an increase in enzyme activity or an increase in 
cellular protein concentration. In HsGSK3 there is a conserved lysine (Lys) at position 
85 that plays an important role in the catalytic activity of the enzyme (Cole et al., 2004). 
Mutation of this residue to alanine (Ala) results in a catalytically inactive form of the 
enzyme. This residue is conserved in all orthologues of GSK3 including the 
kinetoplastids (Figure 1.8).  
Using this information I generated a kinase dead mutant of TbGSK3 short by 
site-direct mutagenesis in which Lys49 was mutated to Ala, namely hereafter 
TbGSK3(K49A) short. Conditional over-expressing cell lines were obtained by 
transfection of an ectopic copy of this mutant using pLew100v5 vector into both wild-
type and single knock-out background cell lines.  The incorporation of the ectopic copy 
in selected clones was confirmed by Southern analysis (Figure 4.8). The growth of 
cWT
K49A
 and cSKO
K49A
 cells was compared to the growth of their parental cell lines 
and were found to be slightly slower (Figure 4.9). The sensitivity of DDD00085893 to 
the tetracycline induced and un-induced cWT
K49A
 and cSKO
K49A
 cells was tested after 
72 h exposure and found unchanged with respect to the sensitivity to WT and SKO cell 
lines. The tetracycline induction had no effect on the sensitivity of DDD00085893 
against cWT
K49A
 clonal cell lines with EC50 values of 4.4 ± 0.2 and 4.6 ± 0.2 μM for 
non-induced and tetracycline-induced, respectively. Similarly also cSKO
K49A
 cell lines 
had EC50 values of 2.1 ± 0.1 and 2.3 ± 0.2 μM for non-induced and tetracycline-
induced, respectively (Figure 4.10 and Table 4.2).  
  
 
 
 
Figure 4.11 Western Blot analysis of T. brucei conditional over-expressing 
TbGSK3(K49A) kinase dead mutant cell lines 
Cells were induced with tetracycline (tet) for 72 h prior to analysis. Blots were probed 
with antibody directed against phospho-tyrosine-GSK3 (pTyr-GSK3) (A) and anti-
GSK3 (GSK3) (B), the corresponding Ponceau staining of the blots is also shown 
as loading control (C and D). Ten g of total protein was loaded for each lane. 
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Previously it had been reported that the phosphorylation of HsGSK3 in the 
activation loop is an autophosphorylation event (Cole et al., 2004), thus it is assumed 
that the kinase-dead enzyme could not be phosphorylated in the activation loop. 
Western blot analysis of tetracycline-induced cWT
K49A
 and cSKO
K49A
 did indeed show 
no increase in the amount of the phosphorylated form of the enzyme, but also total 
protein levels did not appear to be increased either (Figure 4.11). The fact that total 
protein was not elevated after tetracycline induction suggests that the kinase-dead either 
is not over-expressed or this form of the enzyme is unstable and quickly targeted for 
degradation considering that the wild-type protein was over-expressed despite being 
toxic (Figure 4.7). This hypothesis would be in agreement with Cole and colleagues’ 
(2004) observation that the phosphorylation in the activation loop is not required for 
protein activity but rather for stability. Further evidence that the kinase dead might be 
unstable in T. b. brucei cells comes from the inability to obtain soluble recombinant 
protein in E. coli not interacting with folding proteins (see section 3.4.4, Figure 3.24 
and Figure 3.25). Thus, the failure to demonstrate over-expression of the kinase dead 
mutant leaves unanswered the question whether the cellular toxicity is caused by the 
increase in enzyme activity or protein level of TbGSK3 short. 
 
4.1.8 Over-expression of TbGSK3 long in bloodstream form T. brucei 
The chemical proteomic approach clearly identified TbGSK3 short as target of 
DDD00085893 in T. brucei lysate. All the peptides attributed to TbGSK3 were unique 
to this isoform at the exclusion of one peptide (LCDFGSAK) that was shared between 
the short and the long form (Tb427.07.2420) (section 3.3.1, Figure 3.13). The low 
number of observations for this peptide and the fact that no unique peptides for the long 
isoform were observed makes it unlikely that the long isoform of TbGSK3 was among 
the binders of DDD00085893 in the chemical-proteomic experiment. 
  
 
 
Figure 4.12 DDD00085893 sensitivity towards conditional over-expressing 
TbGSK3 long cell line 
 EC50 values of 4.5 ± 0.7 and 5.4 ± 1.0 μM were determined for a non-induced and 
tetracycline-induced clonal cell line over-expressing the long form of TbGSK3. EC50 
values are indicated by the red dotted lines. Data are shown as mean ± SD of triplicate 
measurements.  
 
  
 
Figure 4.13 Western Blot analysis of T. brucei conditional over-expressing 
TbGSK3 long cell lines  
Cells were induced with tetracycline (tet) for 72 h prior of the study. Blots were 
probed with antibody directed against phospho-tyrosine-GSK3 (pTyr-GSK3) (A) 
and anti-GSK3 (GSK3) (B), the corresponding Ponceau staining of the blots is also 
shown as loading control (C and D). Arrows indicate the expected size for TbGSK3 
short and TbGSK3 long. An unspecific band at 100 kDa is reported as internal loading 
control. Ten g of total protein was loaded per each lane. 
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In previous studies, the knock-down of TbGSK3 long did not affect the growth 
of BSF T. brucei (Ojo et al., 2008, Alsford et al., 2011) and was associated to a gain-of-
fitness in procyclic form (Alsford et al., 2011). The phosphoproteomic studies 
conducted by Nett and colleagues (2009a; 2009b) identified no phosphorylated peptides 
belonging to the long isoform in the BSF, but in procyclic a unique phosphorylated 
peptide was identified corresponding to its activation loop (NVPpYIFSR). These data 
suggest that TbGSK3 long is expressed in the procyclic stage, probably in an active 
form, but there is no evidence to date of the expression of this protein in BSF in an 
active form. Thus, I sought to investigate whether this protein could be over-expressed 
in BSF T. brucei and could be inhibited by DDD00085893.  
I cloned the TbGSK3 long ORF (see section 3.4.2) into the pLew100v5 plasmid 
for ectopic over-expression in T. brucei. The growth of two distinct clonal cell lines 
resistant to phleomycin (BLE) were examined and found comparable to wild-type cells 
(data not shown). These cell lines had also unaltered sensitivity to DDD00085893 even 
when induced by tetracycline (Figure 4.12). Although a p-Tyr-GSK3 antibody can 
recognise the recombinant TbGSK3 long (see section 3.4.4), the protein was not 
detected in BSF lysates even when the expression was induced with tetracycline 
(Figure 4.13). A lack of expression or reduced stability in BSF would explain why 
TbGSK3 long does not play a role in the clinically relevant form of T. brucei, and 
therefore DDD00085893 presumably targets only TbGSK3 short. Not only Lys85, but 
also the conserved residue Lys86 plays a role in the kinase activity of GSK3 across 
species. Interestingly in TbGSK3 long this residue is mutated to Arg88, making 
TbGSK3 long more similar to a kinase dead mutant than an active protein. This might 
explain the extremely low activity of the recombinant protein (see section 3.4.2) and the 
associated instability might account for the low level of expression or rapid protein 
turnover. 
  
 
Figure 4.14 Southern blot analysis of conditional double knock-out cell lines 
obtained using the conditional over-expressor pLew100v5 plasmid 
Genomic DNA from the wild-type (WT) T. brucei S427, from ΔTbgsk3::PAC/TbGSK3 
cell line (SKO), from TbGSK3
Ti
 ΔTbTbgsk3::PAC/TbGSK3 cell line (cSKOOE) and 
TbGSK3
Ti
 ΔTbgsk3::PAC/ΔTbgsk3::HYG cell line (cDKOOE) was digested with BamHI 
and PstI and probed with the TbGSK3 ORF probe. The arrows show the expected size for 
TbGSK3 endogenous copy and for the ectopic TbGSK3Ti. Five g of digested DNA was 
loaded per lane. 
  
 
Figure 4.15 Cumulative growth of T. brucei WT and conditional null mutant cell 
line 
Wild-type (WT, closed circles) was compared to the growth of non-induced and 
tetracycline-induced conditional null mutant cell line (cDKO
OE
, closed and open 
squares, respectively). 
 
 
  
 
Figure 4.16 DDD00085893 sensitivity towards conditional null mutant (cDKO) 
cell line  
EC50 values of 3.6 ± 0.3 and 4.2 ± 0.3 μM were determined for non-induced and 
tetracycline-induced TbGSK3 cDKO
OE
 cell lines (close and open squares 
respectively). WT (closed circle) inhibition profile was added as comparison to 
cDKO
OE
 cell line. EC50 values are indicated by the red dotted lines. Data are shown as 
mean ± SD of triplicate measurements.  
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4.2 Genetic validation of TbGSK3 short 
4.2.1 Generation of conditional double knock-out using pLew100v5 
As reported in section 4.1.2 the failure to knock-out both alleles of TbGSK3 
gene suggests a lethal phenotype. Thus, generation of a conditional null mutant was 
attempted by insertion of an ectopic copy. When pLew100v5 was used as rescue 
construct, after several attempts it was possible to select a clonal cell line that was 
resistant to both PAC and HYG, suggesting that both alleles of the WT gene were 
replaced. The removal of both copies was confirmed by Southern analysis (Figure 
4.14). The growth of this conditional null mutant was compared to wild type cells and 
found to be equivalent both in presence and absence of tetracycline (Figure 4.15). The 
sensitivity to DDD00085893 of the cDKO
OE
 cell line was unaltered with EC50 values of 
3.6 M and 4.2 M when un-induced and tetracycline-induced, these values were not 
significantly different from the EC50 value of 3.9 M for the WT cell line (Figure 4.16). 
The unaltered sensitivity to DDD00085893 indicated that the level of protein expression 
was unchanged, even when tetracycline was withdrawn from the culture medium. It is 
known that conditional null mutants can escape from the tetracycline regulatory 
machinery in particular when the protein is essential for the parasite survival. Previously  
it has been reported that reverting cell lines had undergone genetic rearrangement and 
deleted the TETR gene thereby losing the tetracycline control (Roper et al., 2002). Other 
mechanisms could also be responsible for the lack of tetracycline control and the 
constitutively expression of TbGSK3 short, as such as mutations in the TetR gene or 
expression of a non-functional TetR protein (Sienkiewicz et al., 2008). The cause of 
reversion was not deemed to be part of the remit of the study and was therefore not 
further investigated.  
  
 
Figure 4.17 Southern blot analysis of pLew100 conditional WT (cWT) and 
conditional single knock-out (cSKO) cell lines 
Five µg of genomic DNA from four different clones of TbGSK3 conditional WT 
(lanes 1 to 4) and conditional single knock-out cell lines (lanes 5 to 8) were digested 
with BamHI and PstI and probed with the ORF of TbGSK3 short. Expected size for 
the endogenous TbGSK3 and ectopic TbGSK3
Ti
 are reported on the right hand-side. 
  
Figure 4.18 Cumulative growth of T. brucei WT, conditional WT and conditional 
single knock-out cell lines obtained using pLew100 as rescue vector 
Wild-type (WT) growth in the absence of tetracycline (tet) was compared to the 
growth of non-induced and tetracycline-induced pLew100 conditional WT (cWT) and 
conditional single knock-out (cSKO) cell lines.  
  
 
 
Figure 4.19 DDD00085893 sensitivity towards pLew100 conditional WT and 
conditional single knock-out cell lines  
 EC50 values of 2.5 ± 0.2 and 2.7 ± 0.1 μM were determined for non-induced and 
tetracycline-induced TbGSK3 cSKO cell lines (close and open inverted triangles 
respectively). EC50 values of 3.2 ± 0.1 and 3.8. ± 0.1 μM were determined for non-
induced and tetracycline-induced TbGSK3 cWT cell lines (closed and open squares 
respectively). WT (closed circle) and SKO (close triangle) inhibition profiles were 
added as comparison. EC50 values are indicated by the red dotted lines. Data are 
shown as mean ± SD of triplicate measurements.  
 
 Table 4.3 Sensitivity of DDD00085893 towards conditional WT (cWT) and conditional SKO (cSKO) cell lines 
DDD00085893 EC50, M Ratio EC50 Ratio EC50 Hill slope Ratio Hill slope 
Cell line minus Tet plus Tet plus Tet / minus Tet plus Tet / WT minus Tet plus Tet plus Tet / minus Tet 
WT
a
 3.9 ± 0.1 3.8 ± 0.1 1.0            1.0 2.5 ± 0.3 1.9 ± 0.6 0.8 
SKO
 a
 2.1 ± 0.1 2.3 ± 0.1 1.1   0.5** 2.1 ± 0.1 2.0 ± 0.1 1.0 
pLew100v5        
cWT
OEa
 3.5 ± 0.1 9.3 ± 0.8   2.7* 2.4* 2.6 ± 0.1 3.9 ± 0.1  1.5* 
cSKO
OE a
 1.9 ± 0.3 11.4 ± 0.9     6.0** 2.9* 2.2 ± 0.2 4.0 ± 0.2  1.8* 
pLew100        
cWT
b
 3.2 ± 0.1 3.8 ± 0.1     1.2** 1.0 2.7 ± 0.1 2.9 ± 0.2 1.1 
cSKO
 b
 2.5 ± 0.2 2.7 ± 0.1 1.1      0.7*** 3.0 ± 0.1 3.5 ± 0.1 1.2** 
a
EC50 values are weighted means and standard errors (SEM) of at least two independent experiments done in triplicate. 
b
EC50 values are means and standard deviations (SD) of triplicate measurements. 
The two-tailed P values were calculated using an unpaired t test calculated using the weighted mean, the SD or SEM and number of replicates. P 
values <0.05 (95%) were considered statistically significant (*), P values <0.01 (99%) were considered highly statistically significant (**), P 
values ≤0.001 (99.9%) were considered extremely statistically significant (***). 
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As previously reported (section 4.1.4) over-expression above physiological 
levels of TbGSK3 was toxic for the cells, but they seemed to be able to adjust to the 
increased protein expression after one week of continuously culturing in presence of 
tetracycline (Figure 4.4). The loss of tetracycline control may have occurred at the level 
of the cSKO
OE
 cell lines when continuously induced with tetracycline for one week 
prior to the final transfection to obtain the cDKO
OE
. Incidentally, when cSKO
OE
 cells 
were cultured in the presence of tetracycline for a shorter period of time (3 days) before 
the final transfection event, no cells were recovered after drug selection.  
 
4.2.2 Generation of conditional double knock-out using pLew100 
An alternative strategy was used to generate a potential cDKO by the use of 
pLew100, an expression vector that could achieve lower protein expression more 
comparable to the physiological levels. Using pLew100 as rescue construct it was 
possible to insert an ectopic copy of TbGSK3 short into WT and 
ΔTbgsk3::PAC/TbGSK3 (SKO) cells obtaining, respectively, TbGSK3Ti (cWT) and 
TbGSK3
Ti
 ΔTbGSK3::PAC/TbGSK3 (cSKO) cell lines, as confirmed by Southern 
analysis of clonal lines (Figure 4.17). The growth of the TbGSK3
Ti
 (cWT) and 
TbGSK3
Ti
 ΔTbgsk3::PAC/TbGSK3 (cSKO) clonal cell lines was comparable to the 
background cell lines WT and SKO respectively (Figure 4.18), without any toxic side 
effects due to tetracycline induction. Moreover, there was no shift in sensitivity towards 
DDD00085893 (Figure 4.19 and Table 4.3), suggesting that the level of protein was 
not elevated above physiological levels.  
The transfection of HYG flanked with the UTR’s regions of TbGSK3 short into a 
cSKO background (GSK3short
Ti
 Δgsk3short::PAC/GSK3short) generated cell lines that 
were resistant to both selectable markers and were selected in clonal cell lines by 
limiting dilution. Unfortunately, southern analysis showed that these clones had not 
  
 
Figure 4.20 Southern blot analysis of cDKO cell lines obtained using pLew100 as 
rescue vector  
Genomic DNA from the wild-type (WT) T. brucei 427, ΔTbgsk3::PAC/TbGSK3 cell 
line (SKO), from TbGSK3
Ti
 ΔTbTbgsk3::PAC/TbGSK3 cell line (cSKO) and TbGSK3Ti 
ΔTbgsk3::PAC/ΔTbgsk3::HYG cell line (cDKO) was digested with BamHI and PstI and 
probed with the TbGSK3 short ORF probe (A) and TbGSK3 short 5'UTR probe (B). 
Panel A depicts the incorporation of the ectopic copy in the cSKO and cDKO cell lines, 
the removal of the endogenous copies and the insertion of an additional copy of TbGSK3 
gene in an alternative locus (band indicated by an arrow at ~4,500 bp). Panel B shows the 
incorporation of puromycin-resistance gene (PAC) in the SKO and cSKO cell lines and 
the further incorporation of hygromycin-resistance gene (HYG) at the expected bp size in 
the cDKO. Also this blot shows the extra band at ~ 4,500 bp. Same amounts of digested 
DNA (5 µg) were loaded into two different gels and transferred into two distinct blots. 
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only replaced both allelic copies of TbGSK3 short, but had also undergone gene 
rearrangement and that the endogenous copy of TbGSK3 had shifted to an alternative 
locus (Figure 4.20). The observation that the second allelic copy of the gene had 
translocated to another locus probably indicates that the level of expression of the 
ectopic copy under pLew100 control did not reach levels that could maintain the 
parasites’ viability once the second allelic copy of the gene was removed.  
These data suggest that the gene knock-outs can be particularly difficult to 
obtain for proteins that have tightly regulated levels of expression or are toxic at 
concentrations above physiological levels. Under these circumstances alternative 
methods of gene validation are required. Taken together, these experiments indicate that 
TbGSK3 short is an essential druggable gene in BSF T. brucei due to the following: (i) 
knock-outs could not be obtained even using different rescue constructs and (ii) its 
activity can be modulated by small molecule inhibitors directly in cells.  
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Chapter 5 Discussion 
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5.1 Key findings 
At the beginning of this project TbGSK3 short had been just proposed as a drug 
target for Human African trypanosomiasis. Its genetic validation was based upon a mild 
growth defect by RNAi and chemically validated by using compounds that were not 
selective or specific for TbGSK3 short (Ojo et al., 2008). In the previous studies the 
correlation existing between biochemical and cellular activity was quite loose and the 
cellular activity could not be completely attributed to TbGSK3 short, considering the 
promiscuity of the compounds. Finally, the highest selectivity that could be achieved 
towards HsGSK3 was only seven fold (Oduor et al., 2011). 
Despite the very limited genetic and chemical validation available for TbGSK3 
short as potential drug target, what made it attractive from a drug discovery point of 
view was 1) the availability of recombinant active enzyme and biochemical assays for 
medium throughput screening (Ojo et al., 2008), 2) the pre-existing chemical 
knowledge on protein kinase inhibitors together with the availability of an in-house 
focused kinase library of chemical starting points (Wyatt et al., 2008; Brenk et al., 
2007),  and 3) the availability of crystal structures for HsGSK3 and HsCDK2, the most 
closely related kinases to TbGSK3 short in humans.  
In addition to the main question whether TbGSK3 short was a good drug target 
or not, there were other unanswered questions about 1) the level of enzyme inhibition 
required to obtain cell efficacy and in particular if TbGSK3 short inhibition would be 
cytocidal or cytostatic; 2) whether it would be possible to achieve higher selectivity 
between the human and parasite kinases; and 3) what the function(s) of TbGSK3 short 
might be in T. brucei or other kinetoplastids. The presence of another isoform in the T. 
brucei genome, TbGSK3 long, also posed the question whether this enzyme which has 
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been characterised as not essential by RNAi (Ojo et al., 2008; Alsford et al., 2011), 
would have been able to compensate for the inhibition of TbGSK3 short.  
This project has contributed greatly to the chemical and genetic validation of 
TbGSK3 short as drug target determining that: 
1) TbGSK3 short is a druggable target; 
2) TbGSK3 short is most likely to be an essential gene; 
3) selectivity can be achieved towards both HsGSK3 and greatly towards 
HsCDK2; 
4)  a high enzyme inhibition (~99%) is required for cell efficacy, due to the 
millimolar concentrations of ATP in the trypanosomes, indicating that 
alternative mechanisms of inhibition other than competitive with respect to 
ATP would be required to achieve nanomolar cell efficacy by specific 
inhibition of TbGSK3 short;  
5) TbGSK3 long is most likely to be an inactive enzyme, poorly expressed in 
BSF T. brucei if at all, therefore unable to compensate for TbGSK3 short 
functions; 
6) a specific chemical tool for TbGSK3 short has been developed and 
characterised to reveal the function(s) of this protein kinase in T. brucei.  
 
5.2 TbGSK3 short is a druggable target in African trypanosomes 
The druggability of a target is a measure of the likelihood of identifying drug-
like molecules that can modulate its activity in cells, in animal models and ultimately in 
human with both adequate efficacy and safety (Frearson et al., 2007). 
The biochemical screening carried out with the recombinant MBP-tagged 
TbGSK3 short has led to the identification of a few series of small molecule inhibitors 
(GSK3 01-08) able to inhibit the enzyme in the nanomolar range (Woodland et al., 
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2013). The previous knowledge about HsCDK2 inhibitors had contributed to the 
synthesis of two additional series (GSK3 09-10) that were extremely active against 
TbGSK3 short (Wyatt et al., 2008, Urich et al., 2014). 
The identification of small molecule inhibitors against a recombinant enzyme is 
not per se an indication that a protein is druggable as the biochemical assay could be a 
model system unable to replicate the physiological conditions in which the native 
protein functions in the cell (Copeland et al., 2005, Patricelli et al., 2011). The 
establishment of a correlation between biochemical inhibition and cellular efficacy is a 
first step in the chemical validation of a drug target, although correlation does not 
necessarily mean causation (Hardy and Peet, 2004).  
In the case of compounds from GSK3 09 series their nanomolar potency in the 
enzymatic assay translated into micromolar efficacy in BSF T. b. brucei, with high 
correlation among all the members of the series substituted in different positions. The 
shift in potency between the biochemical assay and the cellular assay could be 
explained by the ATP-competitive mechanism of inhibition and the differential ATP 
concentration in the cells with respect to the biochemical assay (Cheng and Prusoff, 
1973; Hofer et al., 1998). In contrast, although compounds from series GSK3 07 were 
very potent and had a very promising ligand efficacy, they had a minimal drop in cell 
efficacy that could not be explained by either the biochemical inhibition of TbGSK3 
short or their ATP-competitive mechanism of inhibition. Therefore this series was not 
considered to act on target anymore and was subsequently pursued phenotypically. This 
project, which was initially set-up as target-based approach, has evolved into a new 
project aimed at identifying phenotypically active compounds. These have been 
subsequently developed into potent leads for both HAT, Nagana and Leishmaniasis 
(DDU, unpublished work). Currently compounds developed from this series are facing 
preclinical development selection for the treatment of Leishmaniasis and identification 
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of their target(s) is ongoing. Preliminary results indicate that the cellular targets are 
other protein kinases. 
Some of the GSK3 09 inhibitors were specific TbGSK3 short inhibitors and 
selectivity towards both HsCDK2 and HsGSK3 could be achieved, up to 10,000 and 
330 fold, respectively, with the most selective TbGSK3 short compound being 
DDD00101234 so far. This compound has also moderate efficacy in trypanosomes and 
no toxicity in human MRC5 cells. 
 The chemical proteomic approach defined TbGSK3 short as the main target for 
DD00085893 among the protein kinases that could be bound by this compound. Using 
kinobeads it was possible to screen a third of the T. brucei kinome, the biggest panel of 
T. b. brucei kinases available to date with the advantage of testing endogenous proteins 
rather than recombinant ones. The binding of an inhibitor to a target protein in the T. b. 
brucei lysate does not confirm that this binding is responsible for the efficacy in cells, 
particularly considering that the cellular ATP is removed from the lysate to reduce 
competition.  
The definitive proof that a compound is acting on target is the modulation of the 
inhibitor potency directly in cells expressing different levels of protein (Hardy and Peet, 
2004). The deletion of a TbGSK3 short copy by gene knock-out increased the 
sensitivity to DDD00085893 by about 2-fold, whereas the over-expression of an ectopic 
copy of TbGSK3 short decreased the sensitivity to DDD00085893 of ~3-fold (Figure 
4.6 A and B). Further evidence that DDD00085893 acts on target comes from the 
ability of this inhibitor to revert the toxicity associated with over-expression and(or) 
hyper-activity of this protein. This small molecule inhibitor is able to work as a 
chemical switch, modulating the activity in the cells to a level that is no longer toxic for 
cell proliferation. Taken together, all these data provide the best chemical validation of 
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TbGSK3 short as druggable target and provide a validated chemical tool for 
investigating the role of this kinase in T. brucei. 
Other chemical proteomic approaches have recently identified two bioactive 
compounds, lapatinib and hypothemycin, which target TbGSK3 short among other 
protein kinases in T. b. brucei cells (Katiyar et al., 2013, Nishino et al., 2013). These 
two molecules are not specific inhibitors of TbGSK3 short as they act on multiple 
targets, so they cannot be used as tool compounds for interrogating TbGSK3 short 
biology. Interestingly these compounds target a combination of proven essential 
kinases. Together with TbGSK3 short, hypothemycin targets mainly TbCLK1, an 
essential kinase recently characterised to be an unconventional kinetochore protein 
(Akiyoshi and Gull, 2014). Lapatinib targets other three additional protein kinases, two 
of which have been characterised to be essential: TbTLK1 (Li et al., 2007; Li et al., 
2008b) and CK1.2 (Urbaniak et al., 2009). While hypothemycin is quite a promiscuous 
inhibitor of human kinases targeting a total of 45 kinases with unsurprising associated 
toxicity (Schirmer et al., 2006), lapatinib is an extremely specific inhibitor of epidermal 
growth factor receptor (EGFR) (Karaman et al., 2008) already approved for clinical 
use
a
. These recent findings add further evidence to the druggability of  TbGSK3 short in 
T. brucei. 
                                                 
 
 
a
 New derivatives of lapatinib have been developed specifically to increase 
trypanocidal activity and have shown efficacy in animal model (Patel et al., 2013). The 
phenotype of the lead compound 23 is similar to the phenotype for the knockdown of 
CK1.2 described by Jones and colleagues (2014). 
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Proof that TbGSK3 short can be specifically targeted with small molecule 
inhibitors in cells (in vitro) is only the first step in its validation as drug target for HAT. 
It still remains to demonstrate the selective toxicity, efficacy and safety of the inhibition 
of this target with drug-like molecules in animal models (in vivo) and ultimately in 
human (clinical trials).  
 
5.3 TbGSK3 short is an essential gene 
TbGSK3 short is a druggable target in African trypanosomes, but is it an 
essential target? The fact that genetic knock-outs were not obtained even in presence of 
inducible expression of an ectopic copy supports the idea that this is an essential target 
and that there are no alternative pathways for the cell to compensate for the loss of this 
gene. Attempts to obtain genetic knock-outs of GSK3 have failed not only in T. brucei, 
but also in Plasmodium falciparum (Tewari et al., 2010). Unfortunately the tendency 
not to publish negative results makes it difficult to review all of the genes for which 
genetic validation has been attempted and has failed. 
All the RNAi studies performed in T. b. brucei are in agreement that TbGSK3 
short plays a role in BSF trypanosomes (Ojo et al., 2008; Alsford et al., 2011; Jones et 
al., 2014). It has been also reported that protein down regulation causes cell arrest rather 
than cell death (Jones et al., 2014), but irreversible cell death can be obtained dosing 
DDD0085893 at concentration equal to the EC99 (Figure 3.13 B). This result indicates 
that almost complete enzymatic inhibition is required to get a cidal effect, and also 
alerts us that the outcomes of RNAi studies might reflect the level of protein 
knockdown rather than the real static/cidal nature of the target. The use of a target-
specific inhibitor for determining the rate of killing and the recovery after wash-off 
gives a far better indication of the static or cidal nature of a target compared to RNAi 
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studies, but it requires well validated and specific tool molecules (Jacobs et al., 2011; de 
Rycker et al., 2012). 
 
5.4 Alternative strategies of inhibition to obtain selectivity and 
efficacy 
The extremely high enzyme inhibition required to obtain cellular efficacy poses 
two problems for the development of drug inhibitors of this protein kinase. First, for 
ATP-competitive inhibitors picomolar potencies are required to reach nanomolar 
efficacy in cells, and second, although we have demonstrated that selectivity can be 
obtained towards HsGSK3β, lack of selectivity and potential toxicity could be still a 
problem for extremely potent compounds (Cohen and Goedert, 2004; Martinez et al., 
2002b). Furthermore it would be advantageous to have only a moderate inhibition of 
HsGSK3β considering the toxicity concerns associated with the inhibition of the human 
enzyme (hypoglycaemia, cardiotoxicity, neuronal deregulation, nephrotoxicity and 
potential tumorigenesis) (Eldar-Finkelman and Martinez, 2011). 
The development of inhibitors with alternative mechanisms of inhibition could 
address both the selectivity and efficacy issues. At present, alternative strategies of 
inhibition have been already considered for HsGSK3β: allosteric inhibitors (Palomo et 
al., 2011); irreversible inhibitors (Castro et al., 2008; Perez et al., 2011; Dominguez et 
al., 2012); substrate competitive inhibitors (Avrahami et al., 2013; Licht-Murava and 
Eldar-Finkelman, 2011; Eldar-Finkelman et al., 2010); and activators (Takahashi-
Yanaga et al., 2003; Takahashi-Yanaga et al., 2006). Moreover, small molecules that 
regulate cell localization, interaction with scaffolding proteins or inhibitors of the 
priming kinases could provide alternative mechanisms of inhibition for HsGSK3 
(Meijer et al., 2004). 
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5.4.1 Allosteric inhibitors   
Allosteric inhibitors generally act by inducing conformational changes without 
binding in the ATP pocket. Allosteric modulators should be more selective with less 
off-target side effects as they bind in sites that are more unique to a specific kinase 
rather than the well conserved ATP binding site. However, drug resistance could be 
developed more easily, as mutations that are not directly responsible for the kinase 
activity are better tolerated than changes in the catalytic residues that tend to be 
conserved (Johnson, 2009).  
Palomo and colleagues (2011) have performed a computational study on 
HsGSK3β and found that there are 7 targetable cavities which are present in the 
majority of GSK3-ligand crystal structures analysed. Of these seven cavities, only three 
are known binding sites of GSK3: 1) the ATP binding pocket, 2) the substrate binding 
site and 3) the axin/fratide binding pocket (Palomo et al., 2011). 
The ATP noncompetive inhibitor manzamine A binds to the enzyme in the 
substrate binding site constituted by three basic residues, Arg96, Arg180, and Lys205, 
near the activation loop which is responsible for the binding of the primed substrate. 
The binding of this inhibitor in the substrate pocket was postulated by computational 
studies and experimentally confirmed by competition studies with a synthetic primed 
substrate (Palomo et al., 2011). A similar site seems to be occupied by L803, a peptide 
reported to bind in the cavity near loop 85-95 (Avrahami et al., 2013). Lastly the 
quinoline derivative VP0.7 is  a reversible allosteric inhibitor of HsGSK3β (IC50 ~3 
µM), non-competitive towards both ATP and a synthetic primed substrate, which has 
been docked to bind preferentially in cavity 7 with a resulting conformational change 
that will impede substrate binding (Palomo et al., 2011). Other “allosteric” cavities have 
never been explored by small molecule inhibitors, but could be potential targeted by 
rational design to achieve both efficacy and selectivity. Further computational studies 
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are required to evaluate if similar cavities are present in TbGSK3 short and whether key 
differences could be exploited to achieve selectivity towards the human enzyme. 
An alternative “allosteric” inhibition could be achieved by targeting  the inactive 
conformation. This approach has some pharmacological advantages compared to the 
targeting of the active conformation: the inactive configuration is more unique than the 
active conformation shared among all protein kinases, and more importantly the inactive 
kinase has a lower affinity for the ATP and an inhibitor specifically targeting this 
conformation will be less susceptible to the competition of the intracellular ATP 
(Johnson, 2009; Knight and Shokat, 2005).  
Lapatinib, targeting TbGSK3 short in T. b. brucei cells (see section 5.2) (Katiyar 
et al., 2013), is a tyrosine kinase inhibitor known to specifically target the inactive 
conformation of the Epidermal Growth Factor Receptor (EGFR) (Wood et al., 2004). 
Another interesting property of lapatinib is its slow off-rate (half-life 300 min) 
compared to other inhibitors that target the active conformation of EGFR, such as 
gefitinib and erlotinib, with off-rates of approximately 30 min (Johnson, 2009; Wood et 
al., 2004). The inhibitor dissociation from the inactive conformation is probably slow as 
requires conformational changes or alternatively because of the very tight binding. The 
combination of a slow off-rate and specificity towards the inactive conformation are 
desirable characteristics for inhibitors of TbGSK3 short. Lapatinib targets TbGSK3 
short, thus this suggests that it is possible to target the inactive conformation of this 
protein kinase. 
HsGSK3β is a constitutively active protein. The tyrosine phosphorylation of the 
activation loop (Tyr216 in HsGSK3β) is an intramolecular chaperone-dependent event 
happening immediately after translation (Lochhead et al., 2006). The tyrosine 
phosphorylation increases the protein stability (Cole et al., 2004) and locks the protein 
in an active conformation. Once activated, HsGSK3β is an intermolecular Ser/Thr 
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kinase that is no longer dependent on chaperone activity (Lochhead et al., 2006). Some 
inhibitors are able to target specifically the activation process (i.e. geldanamycin, 
radicicol, LiCl, SB216763) and their effect could be monitored using the rabbit 
reticulocyte lysate translation system (Lochhead et al., 2006). Biochemical assay 
formats using the constitutionally active recombinant protein would miss inhibitors of 
the auto-activation of GSK3, so novel assays able to monitor the transient post-
translational activation should be developed to find inhibitors with this alternative 
mechanism of inhibition.  
 
5.4.2 Irreversible inhibition 
Irreversibile inhibitors are an attractive alternative to ATP-competitive 
inhibitors: high inhibitor concentration is not required for efficacy in cells as the 
inhibitor cannot dissociate from its target. Thus to restore activity requires protein re-
synthesis; irreversible inhibition can prevent the development of resistance; with 
irreversible inhibitors it is possible to obtain an efficacy far higher than the one obtained 
using reversible inhibitors without prolonged exposure, and rational design can help the 
development of molecules that specifically target the protein kinase of interest (Rastelli 
et al., 2008; Liu et al., 2013). Irreversible inhibitors are also powerful tools as mutants 
of the reactive cysteine can rescue the inhibition phenotype providing in-cell evidence 
of the mode of action and specificity of inhibition (Liu et al., 2013). 
Usually an irreversible inhibitor is specifically targeted to a binding site where it 
can initially have reversible interactions, then the proximity between a cysteine (or other 
amino acid side chain) and the reactive moiety of the molecule allows the establishment 
of the irreversible interaction. In the case of irreversible inhibitors, the potency cannot 
be monitored by measurement of IC50 or Ki values, as the time of incubation plays a 
relevant role. Both the Ki of the non-covalent initial binding and the rate of inhibition of 
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the covalent binding should be taken in consideration for the development of 
irreversible inhibitors (Liu et al., 2013). The turnover of the protein is another important 
factor to take in consideration, as the protein function is recovered when new protein is 
synthesised (Liu et al., 2013). 
HsGSK3 is among the human protein kinases that have a reactive cysteine 
immediately before of the DFG motif that could be targeted by irreversible inhibitors. 
Indeed this binding site has been exploited for the development of two inhibitors of 
HsGSK3β: Tideglusib (Castro et al., 2008; Dominguez et al., 2012) and compound 40, 
a maleimide-based molecule substituted with a reactive halomethylketo (HMK) moiety 
(Perez et al., 2011).  
Tideglusib is a thiadiazolidinone based compound currently in clinical 
development for both Alzheimer’s disease and progressive supranuclear palsy. It was 
initially erroneously classified as non-ATP competitive inhibitor (Castro et al., 2008) as 
irreversible inhibitors often display same pattern of inhibition as non-ATP competitive 
inhibitors in reciprocal plots, based on the assumption that the binding of the inhibitor to 
its target is rapid and reversible. Recently it has been characterised to be an irreversible 
inhibitor by a more in-depth mode of inhibition study (Dominguez et al., 2012). The 
fact that its mechanism of inhibition was misinterpreted underlines the importance in 
drug discovery of undertaking rigorous studies of the mode of inhibition rather than 
relying exclusively on IC50 and Ki determination, but also determining reversibility of 
inhibition, time dependency and study of the kinetics of binding. Compound 40, a 
maleimide derivative substituted with a reactive halomethylketo (HMK) moiety (Perez 
et al., 2011), was rationally designed with the aim to transform ATP-competitive 
reversible inhibitors in irreversible inhibitors, by covalently binding the reactive Cys199 
with the HMK moiety. This compound was confirmed to bind covalently by Maldi-TOF 
analysis and its efficacy was demonstrated in cells by the decrease of Tau 
 110 
phosphorylation. Irreversible inhibitors of GSK3 targeting Cys199 are specific towards 
CDK kinases as this residue is not conserved. 
Hypothemycin is a polyketide natural product that binds irreversibly to 45 
human protein kinases containing a specific CDXG motif (Schirmer et al., 2006). In this 
motif the reactive Cys is close to the conserved Asp residue responsible for the binding 
to the Mg
2+
 complexed with the ATP (Rastrelli et al., 2008). TbGSK3 short contains 
this motif and it is among the protein kinases targeted by this compound in T. brucei 
lysates (Nishino et al., 2013). The cell efficacy of this inhibitor was mainly attributed to 
TbCLK1 by virtue of the higher inhibition of both the recombinant enzyme and stronger 
binding of the native protein immunoprecipated after incubation with hypothemycin. 
Nonetheless this demonstrates that irreversible inhibition can be achieved for TbGSK3 
short.  
 
5.4.3 Substrate inhibitors 
Protein kinases have different specificities for protein substrates and are more 
likely to bind and trans-phosphorylate specific consensus sequences. Competitive 
inhibitors for the substrate have generally weak interactions and protein-protein 
interaction inhibitors have been generally disregarded as difficult to develop. 
Although both the binding site for the primed substrate and the auto-inhibition 
performed by the pseudo-substrate (phosphorylated Ser9 at the N-terminus) are well 
understood from a structural point of view (Dajani et al., 2001; Ilouz et al., 2008; 
Palomo et al., 2011; Eldar-Finkelman et al., 2010), very few substrate inhibitors have 
been reported for HsGSK3β. GSK3 has an unique substrate recognition motif 
(S/TXXXphoshoS/T). The substrate binds between the two lobes, in a site delimited by 
the P-loop and the short loop from Gln89 to Asn95 (Licht-Murava et al., 2011). It 
establishes interactions with Gln89, Asn95 and Phe93. The 89-95 loop is well 
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conserved in kinetoplastids, with the exception of TbGSK3 long where none of the 
residues essential for substrate recognition are conserved (see Figure 1.8). Thus, it is 
not surprising that the ability to trans-phosphorylate the synthetic primed substrate 
GSP2 is considerably lower compared to TbGSK3 short (see section 4.1.8). This loop is 
involved in substrate recognition, but it does not affect the ability of GSK3 to auto-
phosphorylate the Tyr216 in the activation loop (Licht-Murava et al., 2011). 
In addition, the phosphorylated priming site interacts with a positively charged 
pocket constituted by Arg96, Arg180 and Lys205. GSK3 preference for primed 
substrates has led to the identification of L803-mts: a peptide mimetic inhibitor based 
upon the recognition sequence of heat shock-factor 1 (HSF-1) (Eldar-Finkelman et al., 
2010). This peptide has a weak IC50 of 40 µM, but has shown in vivo efficacy in 
diabetes and CNS models of neuroprotection, antidepressive activity and axon 
morphogenesis (Eldar-Finkelman et al., 2010; Eldar-Finkelman and Martinez, 2011). 
Modifications of this peptide inhibitor aimed to increase the hydrophobic interactions 
with Phe93 have brought to the development of the more potent inhibitors L803F and 
PQ9P (Eldar-Finkelman and Martinez, 2011). In conclusion, although substrate 
competitive inhibition can be obtained for HsGSK3β, this is associated with moderate 
efficacy, but greater selectivity, both characteristics that are considered positive 
attributes for the therapeutic uses of HsGSK3β inhibitors.  It would be interesting to 
investigate whether it would be possible to develop selective substrate competitive 
inhibitors of TbGSK3 short, although both parasite and human kinases are very similar 
in their substrate recognition sites (the only difference is the substitution of one residue 
in the 85-95 loop). 
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5.4.4 Alternative screening strategies 
The development of TbGSK3 short inhibitors with an alternative mechanism of 
inhibition rather than ATP-competitive would require different assays and screening 
strategies. The TbGSK3 short screening campaigns, conducted here in Dundee and 
elsewhere, were biased towards the identification of ATP-competitive inhibitors 
because the ATP concentration was set below the Km for the ATP  and because of the 
nature of compounds tested (kinase focussed library and known HsGSK3 inhibitors) 
(Ojo et al., 2008, Oduor et al., 2011). Allosteric inhibitors could be identified by the 
screening of fragment libraries in assay platforms not biased towards ATP competitors. 
The identified binders with higher ligand efficiency could be rationally improved using 
the available homology models built for TbGSK3 short to expand them towards 
allosteric cavities (Hopkins et al., 2004; Ciulli and Abell, 2007). By adopting 
biophysical assays, it would possible to obtain indications on the kinetic properties of 
the binders (slow binders, longer residence time); properties that could direct in the 
selection of the best compound for development, rather than rely exclusively on potency 
(IC50 or Kd) (Copeland et al., 2006). The available recombinant BAP-tagged TbGSK3 
short protein, suitable for biotinylation, could be used to develop biophysical assays for 
both surface plasmon resonance and biolayer-interfometry-based platforms. 
Unfortunately TbGSK3 short has not been crystallized to date, but the new potent 
ligands from series GS309 could be used for co-crystallization studies. The availability 
of the enzyme crystal structure could be of great help in the development of fragment 
derived compounds, as it would give confirmation of their mode of binding and direct 
their chemical development. 
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5.5 Generation of a chemical tool to dissect new biology 
DDD00085893 has all the wanted characteristics of the chemical probe:  it is 
specific enough to correlate the in vitro potency to its cellular efficacy, its mechanism of 
inhibition has been studied and is coherent with its efficacy in cells, and its efficacy has 
been tested in target over-expressing cell lines (Hardy and Peet, 2004; Cohen, 2010; 
Frye, 2010; Workman and Collins, 2010). The combined use of both chemical and 
genetic approaches provides an orthogonal validation and the establishment of causal 
relationship between the inhibition of the target and in cell effect. As a validated  
chemical probe for TbGSK3 short DDD00085893 can be used for interrogating its 
role(s) and function(s) in T. brucei and for the identification of its physiological 
substrates. 
The functions of TbGSK3 short in T. brucei are unknown, but on the basis of 
HsGSK3β roles and what is known on other species, it can be postulated a role in cell 
cycle control (Gladden and Diehl, 2005); in protein synthesis (Wang et al., 2001); 
regulation of flagellar assembly and intraflagellar transport (Wilson and Lefebvre, 2004, 
Nett et al., 2009b; Absalon et al., 2008a; Absalon et al., 2008b); and pro-apoptotic 
action (Beurel and Jope, 2006; Xingi et al., 2009) among others. TbGSK3 could also 
play a role in protein degradation and targeting for ubiquitination, determining protein 
stability and turnover (Xu et al., 2009).  
Preliminary SILAC experiments have been performed by Dr Michael Urbaniak 
using DDD00085893 (unpublished data) to identify the substrates of TbGSK3 short in 
BSF trypanosomes; although protein levels are not affected by sub-lethal doses, 
multiple sites have both significantly increased and decreased levels of phosphorylation. 
Target proteins with higher levels of change in phosphorylation, combined with the 
knowledge of the pathways in which HsGSK3β is involved, could be prioritized for 
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substrate validation in conjunction with pharmacological studies of the phenotype of 
cells treated with DDD00085893. 
 
5.6 Conclusions  
This kinase target-based project had two main outcomes. First, the genetic-
chemical validation of TbGSK3 short as drug target using compounds from the GSK3 
09 series that were synthesized based upon previous literature knowledge (Wyatt et al., 
2008). Second, and the identification of a phenotypically active series (GSK3 07) that 
acts off-target with efficacy in animal models for both HAT and leishmaniasis. 
The limited cell efficacy of specific and potent TbGSK3 short inhibitors in 
trypanosomes and the narrow window of selectivity towards the HsGSK3β caused the 
de-prioritization of TbGSK3 short as drug target in the DDU pipeline, even though this 
protein target can be now regarded as fully chemically validated in vitro for HAT. 
However, some important lessons from this project can be learned, in particular 
considering more protein kinase target-based projects are entering the DDU pipeline as 
potential drug targets for HAT and leishmaniasis. 
Protein kinases as drug targets should be selected according to their essentiality 
proven in animal models and/or by RNAi. The target proteins that require lower degree 
of enzymatic inhibition or protein knock-down for a cidal effect in cells should be 
prioritised for screening (Jones et al., 2014). Furthermore, the screening cascades 
should not be limited to the identification of ATP-competitive inhibitors and where 
possible an array of assay platforms and conditions should be tested in order to identify 
compounds with alternative mechanisms of inhibition or favourable kinetics.  
Although specificity is a vital characteristic for a chemical probe, it is not a 
requirement for a lead molecule. Promiscuous inhibitors towards a pool of essential 
parasitic protein kinases, but selective towards the human isoforms would be the best 
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candidates for further chemical development. Until now the limiting step in the 
execution of protein kinase target-based projects has been the availability of active 
recombinant protein, and, even when available, recombinant enzymes have not always 
been able to predict cell efficacy (Urbaniak et al., 2012a). Recently global approaches 
have informed us about essentiality of protein kinases (Alsford et al., 2011; Jones et al., 
2014), level of protein expression and phosphorylation in T. brucei (Urbaniak et al., 
2012b and Urbaniak et al., 2013). We need now to automate medium throughput 
systems integrated with proteomics that allow the characterization of phenotypically 
active compounds directly on cell lysates (Bantscheff et al., 2007; Patricelli et al.,2011), 
in order to identify potent binders to multiple essential native protein kinases. The 
development of these platforms will inform whether it is possible to identify potent 
kinase inhibitors with favourable network pharmacology for the treatment of HAT 
(Hopkins et al., 2008). 
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ABSTRACT: The protozoan parasite Trypanosoma brucei is the
causative agent of African sleeping sickness, and there is an urgent
unmet need for improved treatments. Parasite protein kinases are
attractive drug targets, provided that the host and parasite kinomes
are suﬃciently divergent to allow speciﬁc inhibition to be achieved.
Current drug discovery eﬀorts are hampered by the fact that
comprehensive assay panels for parasite targets have not yet been
developed. Here, we employ a kinase-focused chemoproteomics
strategy that enables the simultaneous proﬁling of kinase inhibitor
potencies against more than 50 endogenously expressed T. brucei
kinases in parasite cell extracts. The data reveal that T. brucei
kinases are sensitive to typical kinase inhibitors with nanomolar potency and demonstrate the potential for the development of
species-speciﬁc inhibitors.
The protozoan parasite Trypanosoma brucei is transmittedby the bite of an infected Tsetse ﬂy and causes African
sleeping sickness, which is also known as Human African
Trypanosomasis (HAT). The disease is invariably fatal if left
untreated and results in upward of 10,000 deaths each year in
sub-Saharan Africa.1 T. brucei has a complex digenetic lifecycle
between the insect vector and mammalian host, and the ability
to adapt to these environments is essential to its survival and
virulence. During early stages of infection the clinically relevant
bloodstream form of the parasite proliferates in the blood and
lymph of the human host and then in the second stage enters
the cerebrospinal ﬂuid and brain, resulting in coma and death.
Current treatments are expensive, toxic, and diﬃcult to
administer, leaving an urgent unmet need for improved
therapeutic agents.2
Protein kinases play key roles in the control of growth and
cell signaling and are a major target of the pharmaceutical
industry. Parasite protein kinases have been proposed as
attractive targets for drug discovery as such eﬀorts can “piggy-
back” on the extensive knowledge of the development of
inhibitors against human protein kinases.3 In the case of T.
brucei, bioinformatic analysis of the genome has identiﬁed 176−
182 putative protein kinases on the basis of sequence similarity,
the majority of which can be placed within well-recognized
kinase groups (Supplementary Table S1).4,5 Eﬀorts to
determine the detailed biological role of T. brucei protein
kinases are ongoing, although knock-down by RNA interfer-
ence has provided evidence of the essential nature of a
signiﬁcant number of protein kinases.6 However, the rationale
to develop drugs to target the T. brucei kinome poses a
conundrum: if mammalian and parasite protein kinases are
suﬃciently similar to be identiﬁed and classiﬁed on the basis of
sequence similarity and are inhibited by typical inhibitors, will
parasite kinase inhibitors lack host−parasite speciﬁcity?
Conversely, if the kinases are suﬃciently diﬀerent that host−
parasite speciﬁcity can be readily obtained, will they be
inhibited by typical inhibitors of mammalian kinases? In
other words, we need to consider the similarity of the chemical
space that parasite and mammalian protein kinase inhibitors
occupy, rather than the similarity in protein kinase sequence.
One way to probe the inhibitor chemical space is to proﬁle
inhibitor activity against both the mammalian and parasite
kinomes. Such proﬁling is often achieved using in vitro activity
assays against a panel of recombinant protein kinases,7 but
there is no such panel available for the T. brucei kinome; indeed
only a handful of active T. brucei kinases have been
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Figure 1. Chemical proteomics approach to proﬁling the targets of kinase inhibitors. T. brucei cell lysates are incubated in the presence or absence of
the test inhibitor prior to the addition of mixed kinase-inhibitor beads (kinobeads) to enrich kinases and related proteins. The presence of the test
kinase inhibitor prevents the binding of its target(s) to the kinobeads. Analysis of the kinobead-bound subproteome by quantitative tandem mass
spectrometry using isobaric tags allows inhibition curves to be calculated for each protein observed.
Figure 2. Proﬁling the kinome expressed in bloodstream form T. brucei using complementary mass spectrometry-based observations. (a) Venn
diagram summarizing overlapping protein kinase observations. (b) Details of protein kinases observed (black square), divided by kinase group
classiﬁcation according to the similarity of their catalytic domains. Proteome: detection at natural abundance. Phosphorylated: enrichment of
phosphorylated peptides.5 Kinobeads: enriched by immobilized mixed kinase-inhibitors.
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recombinantly expressed as active enzymes.8−10 A recent
advance in kinase inhibitor proﬁling uses a chemical proteomic
methodology that captures a substantial portion of the
expressed kinome (and related proteins) contained in cell
lysates on a mixed kinase-inhibitor matrix known as
kinobeads.11,12 Addition of a kinase inhibitor to the cell lysates
enables it to bind to its speciﬁc target(s), occupying the binding
sites and preventing binding to the kinobeads, whereas the
binding of nontargeted kinases and other proteins are
unaﬀected. Incubation of the lysate with varying concentrations
of the inhibitor and subsequent analysis of the kinobead-bound
subproteome by quantitative mass spectrometry allows
inhibition curves to be generated for each protein observed
(Figure 1). We reasoned that this methodology should be
species independent, provided that the kinobeads are
suﬃciently promiscuous to capture a sizable portion of the
parasite kinome.
Here, we present the results of our eﬀorts to establish
kinobead chemoproteomics proﬁling in T. brucei and estimate
the coverage of the parasite kinome. Our strategy enabled us to
access more than 50 parasite kinases for inhibitor proﬁling,
which by far exceeds any currently available enzyme panels. We
report the proﬁle of the mammalian kinase inhibitors
staurosporine and BMS-387032 and several early hit com-
pounds identiﬁed as parasite protein kinase inhibitors by the
Drug Discovery Unit at the University of Dundee.
■ RESULTS AND DISCUSSION
Coverage of the T. brucei Kinome. Kinobeads consist of
immobilized analogues of a variety of ATP competitive kinase
inhibitors that show relatively promiscuous binding to the
mammalian kinases, but their ability to bind kinases from more
divergent organisms has not been examined. To establish to
what extent T. brucei protein kinases were able to bind to the
kinobeads, we examined the subproteome enriched from cell
Figure 3. Chemical proteomics proﬁling of Staurosporine and BMS-387032 against the trypanosome and human kinome. Horizontal bars represent
IC50 value calculated from the isobaric reporter signals, gray bars indicate where binding was not quantiﬁed. Lysates were incubated with varying
concentrations of compounds prior to incubation with kinobeads, and the bound fraction was quantiﬁed by tandem mass spectrometry. Data for TK,
TKL, atypical, and lipid kinase are not shown for clarity; the full data for the trypanosome proﬁle can be found in Supplementary Table S5, and the
CLL cell data has been reported previously.17
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lysates of the clinically relevant bloodstream form of T. brucei.
Initially, we compared four versions of kinobeads that diﬀer in
the identity of the immobilized inhibitors (see Methods). In
these experiments, we observed the enrichment of a total of a
57 protein kinases (Supplementary Table S2). The enrichment
of a signiﬁcant number of trypanosome protein kinases by these
promiscuous mammalian kinase inhibitors suggests that the
ATP binding pocket architecture is broadly conserved between
the two species.
Estimating the portion of the trypanosome kinome captured
is not straightforward, as the bloodstream form represents just
one of the multiple lifecycle stages of T. brucei and may not
express every kinase encoded by the genome. Before we could
determine the proportion of the bloodstream form kinome that
was captured by kinobeads, we needed to estimate how many
protein kinases were present in the cell lysates. To achieve this,
we took advantage of the diﬀering bias of two orthogonal
proteomic techniques. By analyzing the total proteome
contained in the non-enriched cell lysate we identiﬁed the
most abundant 3248 proteins, which included 90 protein
kinases (Supplementary Table S3). This data shows good
overlap with a recent comparative SILAC proteomic study of
the bloodstream and procyclic form T. brucei, which identiﬁed
65 protein kinases,13 including 18 not seen in this study. A
separate phosphoproteomic study by Nett et al.,5 which used
strong cation exchange and TiO2 chromatography to enrich for
phosphopeptides, identiﬁed 43 phosphorylated protein kinases
in bloodstream form T. brucei. Comparison of the protein
kinases identiﬁed by these three orthogonal proteomics
techniques revealed overlapping and complementary coverage
of the bloodstream form kinome (Figure 2 and Supplementary
Table S4), providing experimental observation of a total of 124
protein kinases out of the predicted 182 (68%). The kinases
that bind to kinobeads are not signiﬁcantly biased toward
abundant (Supplementary Figure S1) or phosphorylated
protein kinases or any particular kinase group. Mapping the
kinases that bind to kinobeads onto the phylogeny of the T.
brucei kinome shows that kinobead enrichment appears to be
independent of the degree of sequence homology (Figure 2).
While it is likely that the coverage of this observable
bloodstream form kinome is not complete, it is in reasonable
agreement with transcriptome studies that suggest 25% of the
genome is diﬀerentially expressed between bloodstream and
procyclic form T. brucei cells.14 The kinobead-enriched
subproteome contains 46% of the observed bloodstream form
kinome (31% of the predicted genome), comparable to the
coverage obtained from analysis of human cell lysates (52% of
the predicted genome).
Proﬁling of Known Kinase Inhibitors. Kinobead-based
proﬁling enables access to a sizable fraction of the expressed
trypanosome kinome, which can be used to determine the
potency and selectivity of kinase inhibitors in cell extracts by
means of a multiplexed competition binding assay. The
kinobeads version producing the best coverage of the T. brucei
kinome was used to determine the kinase inhibition proﬁle of
two well-studied kinase inhibitors: Staurosporine and BMS-
387032. The binding of these inhibitors to their cellular targets
was quantiﬁed by mass spectrometry using isobaric tags for
relative and absolute quantiﬁcation (iTRAQ)15,16 for 51 protein
kinases and 67 other kinobead-binding proteins (Figure 3 and
Supplementary Table S5). Staurosporine, a natural product, is a
prototypical ATP-competitive pan-kinase inhibitor that binds to
many protein kinases with high aﬃnity and little selectivity.11 In
a previous study we reported kinobead proﬁling of
staurosporine in primary chronic lymphocytic leukemia cells17
and demonstrated that more than a third of the observed
human kinome (41/112) displayed submicromolar IC50 values
(Figure 3). This pan-kinase activity was retained against the T.
brucei kinome, with more than a third of the observed
trypanosome kinome (18/44) displaying IC50 values <1 μM,
including 10 with IC50 values below 100 nM (Figure 3).
The second kinase inhibitor to be proﬁled, BMS-387032, an
established pan-cyclin-dependent kinase (CDK) inhibitor, was
selected because T. brucei have a relatively expanded CMGC
group including many putative CDK or CDK-like (CDKL)
family members.4,5 Kinobead proﬁling of BMS-387032 against
primary chronic lymphocytic leukemia cells showed that all of
the seven observed CDKs were inhibited, with CDK2, CDK9,
CRK7, and PCSTAIRE2 displaying submicromolar IC50 values
(Figure 3).17 BMS-387032 retained the ability to inhibit the
majority of the observed trypanosome CDKs, including
targeting the CDK2-related kinases CRK2 and CRK3 with
submicromolar potency (IC50 of 148 and 57 nM, respectively),
although no inhibition of CRK1 was observed (Figure 3). In
addition, the compound selectivity was slightly broader than
just the CDKs, with two additional kinases (CMGC and
CAMK) also inhibited with IC50 values below 500 nM, which
may reﬂect the divergence of the trypanosome kinome. These
data provide the ﬁrst molecular evidence that the trypanosome
kinome is sensitive to typical mammalian kinases inhibitors
with nanomolar potencies and suggest that other standard
kinase inhibitor scaﬀolds may retain substantial activity.
Proﬁling Trypanosome Kinase Inhibitors. The Drug
Discovery Unit at the University of Dundee has conducted a
number of screening campaigns to help identify preclinical
candidates for the treatment of African sleeping sickness,
including target-based screens against the T. brucei protein
kinases Glycogen Synthase Kinase 3 (GSK3, Tb427.10.13780)
and the Nuclear DBF-2-related (NDR) kinases PK50
(Tb427.10.4940) and PK53 (Tb427.07.5770).8 Details of the
compound screening and optimization will be reported
elsewhere. To further probe the chemical space that
mammalian and trypanosome kinase inhibitors occupy and
demonstrate the utility of chemical proteomics in antiparasitic
drug discovery, we proﬁled hits selected from these screens
(Supplementary Tables S6 and S7). The compounds selected
all show nanomolar potency against their respective molecular
target in vitro and variable eﬃcacy against cultured trypanosome
and human hepatocyte (MRC5) cells (Table 1).
Table 1. Trypanosome Kinase Inhibitors
GSK3 PK50 PK53
compound ID DDD85893 DDD34425 DDD88213
T. brucei enzyme IC50
(μM)a
<0.002 0.013 ± 0.006 0.73 ± 0.14
T. brucei kinobead IC50
(μM)b
<0.039 not observed 5.7
T. brucei EC50 (μM)
c 1.3 ± 1.2 0.86 ± 0.52 45 ± 4
H. sapiens MRC5 EC50
(μM)c
28 ± 9.7 >50 >50
H. sapiens kinobead IC50
(μM)b
<0.06 not observed not observed
aEnzyme IC50 values were determined using a plate-based radiometric
assay. bKinobead IC50 is described in Methods.
cCell EC50 values were
determined using an Alamar blue assay.34
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The compound DDD85893 was identiﬁed as a potent
inhibitor of T. brucei GSK3 (TbGSK3) in vitro, with good
eﬃcacy against cultured T. brucei and good selectivity against
cultured human cells. The kinobead proﬁling of DDD85893
against T. brucei cell lysates conﬁrmed that TbGSK3 was
inhibited with nanomolar potency, with three other CMGC
kinases inhibited at micromolar level (Figure 4). The
compound also showed a very clean proﬁle against human
MRC5 cell lysates, with only human GSK3α, GSK3β, and
CDK9 inhibited with nanomolar potency. These data show that
the compound DDD85893 has excellent selectivity for GSK3
and limited other CMGC members but does not display any
species speciﬁcity.
The second compound to be proﬁled (DDD34425) was
identiﬁed as a potent inhibitor of T. brucei PK50 in vitro, with
good eﬃcacy against cultured T. brucei and good selectivity
against cultured human cells. Unfortunately, the expected target
PK50 was not among the kinases that bound to the kinobeads,
Figure 4. Chemical proteomics proﬁling of trypanosome kinase inhibitors against the kinome of bloodstream form T. brucei. Horizontal bars
represent IC50 value calculated from the isobaric reporter signals; gray bars indicate where binding was not quantiﬁed. Lysates were incubated with
varying concentrations of compounds prior to incubation with kinobeads, and the bound fraction was quantiﬁed by tandem mass spectrometry. Data
for TK, TKL, atypical, and lipid kinase are not shown for clarity; the full data can be found in Supplementary Tables S6 and S7.
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suggesting that the ATP binding site contains features that are
not recognized by the set of standard ligands immobilized on
the beads. Indeed, none of the four human NDR kinases
(NDR1, NDR2, LATS1, LATS2) were among the kinases in
MRC5 lysates that bound to the kinobeads. However, the
kinobead proﬁle of DDD34425 against T. brucei cell lysates
revealed that MAPK10 and MAPK5 were inhibited with
nanomolar potency, with three other kinases inhibited at
micromolar level (Figure 4). As T. brucei bloodstream form
MAPK5 null mutants grow normally in vitro18 and little is
known about MAPK10,19 it is unclear what eﬀect, if any, their
inhibition may contribute to the observed trypanocidal eﬀect of
DDD34425. The kinobead proﬁle against MRC5 cell lysates
showed a broader speciﬁcity, with the MAPK NKL and TKLs
RIPK2 and ALK2 inhibited with nanomolar potency. Six
additional kinases from four diﬀerent groups were inhibited at
the micromolar level. These data revealed that the compound
DDD34425 lacks speciﬁcity against the observable trypano-
some kinome and signiﬁcant poly pharmacology against the
observable human kinome, including a number of tyrosine-
speciﬁc kinases that are absent from T. brucei.
The compound DDD88213 was identiﬁed as a submicro-
molar inhibitor of T. brucei PK53 in vitro but lacked eﬃcacy
against both cultured T. brucei and human cells. The kinobeads
proﬁle of DDD88213 against T. brucei cell lysates revealed that
PK53 was inhibited with an IC50 of 5.7 μM, with CK2α2 also
inhibited with similar potency (Figure 4). The 10-fold drop in
potency between the enzyme IC50 and the kinobeads binding
assay is not signiﬁcantly diﬀerent from that seen with other
inhibitors and may reﬂect diﬀerences between puriﬁed proteins
and cell extracts. Moreover, the potency determined with
kinobeads is in line with the weak activity of the compound in
the Alamar blue assay. The kinobead proﬁle against MRC5 cell
lysates showed that none of the observable human kinome was
signiﬁcantly inhibited by DDD88213. These data show that
while this compound does appear to be speciﬁcally targeting
the desired trypanosome kinase and appears to have little eﬀect
on the human kinome, it lacks suﬃcient potency to achieve the
desired trypanocidal eﬀect and would require further
optimization.
The ﬁnal compound to be proﬁled was recently identiﬁed as
a potent inhibitor of the Leishmania major cyclin dependent
kinase 2-related kinase 3 (LmCRK3) (compound 33, Cleghorn
et al.20) but lacked eﬃcacy against cultured L. major or the
related parasite T. brucei.20 As active recombinant T. brucei
CRK3 (TbCRK3) is not available for in vitro screening, we
attempted to use kinobead proﬁling to investigate whether the
lack of cellular potency against T. brucei was due to lack of
potency against TbCRK3. The kinobead proﬁle of the
compound revealed that none of the observed T. brucei kinases
were signiﬁcantly inhibited, including TbCRK3, and neither
were any mammalian kinase (Supplementary Tables S6 and
S7). The complete lack of inhibition suggests that the native
state of parasite CRK3s is distinct from the recombinant form
used for in vitro screening. While these diﬀerences may be due
to the absence of the associated cyclin, a recent screen against
LmCRK3-cyclin 6 also resulted in compounds that lacked
eﬃcacy against cultured L. major.21
Summary and Conclusions. We set out to examine the
similarity of the chemical space that parasite and mammalian
protein kinase inhibitors occupy using a recently developed
chemical proteomics approach to proﬁle kinase inhibitors. The
data presented here represent the ﬁrst molecular evidence that
typical ATP-competitive inhibitors can retain low nanomolar
potency against T. brucei protein kinases. The inhibition proﬁle
of the compounds does not seem to map directly between the
two species, suggesting that it may be possible to exploit these
diﬀerences to obtain host/parasite speciﬁcity. It is also possible
that the diﬀerences observed are an artifact due to the limited
coverage of the kinome achieved by kinobead enrichment.
However, the lack of bias in the enriched kinome suggested that
this is unlikely.
Our data suggest that phenotypic screening of known kinase
inhibitors against T. brucei is likely to identify potent
compounds but also show that it is inappropriate to infer the
molecular target on the basis of the inhibition proﬁle
established in mammalian systems. The chemoproteomics
approach presented to proﬁle potential kinase inhibitors
simultaneously covers as much as half the observed blood-
stream form kinome, representing a 10-fold increase in the
selection of active parasite kinases currently available for drug
discovery. Development of kinobeads tailored to the
trypanosome kinome, for instance, by immobilizing novel
inhibitors identiﬁed through phenotypic screening, is an
attractive approach to extend the coverage of the parasite
kinome. Importantly, the approach presented here is species-
independent and can be applied to any clinically relevant
pathogen for which a genome sequence is available.
■ METHODS
Reagents and Drugs. All reagents were purchased from Sigma
unless otherwise noted. Staurosporine was purchased from IRIS
Biotech, and BMS-387032 was custom synthesized by Park Place
Research.
Preparation of Bloodstream Form T. brucei Cell Lysates.
Bloodstream form T. brucei brucei variant 117 (MITat1.4) was puriﬁed
from infected rodent blood over DE52 cellulose as described
previously.22 The cells were centrifuged at 800 × g for 10 min at 4
°C and resuspended at 1 × 109 cells/mL in ice-cold buﬀer 1 containing
protease and phosphatase inhibitors (0.1 mM TLCK, 1 μg/mL
Leupeptin, 1 μg/mL aprotinin, 1 mM PMSF, 1 mM benzamidine,
Phosphatase Inhibitor Cocktail II (Roche)), and hypotonic lysis was
allowed to proceed for 10 min on ice. An equal volume of ice-cold
buﬀer 2 (100 mM Tris pH 7.5, 10% glycerol, 300 mM NaCl, 50 mM
NaF, 3 mM MgCl2, 0.2 mM Na3VO4, 1.6% Igepal-CA630, 2 mM
DTT, 0.1 mM TLCK) was added, and the lysate was centrifuged at
145,000 × g for 1 h at 4 °C. The BCA assay (Pierce) was used to
determine the total protein content in the supernatant, and the
concentration was adjusted to 5 mg/mL. Aliquots were frozen in liquid
nitrogen and stored at −80 °C prior to use.
Preparation of H. sapiens MRC5 Cell Lysates.MRC5 cells were
grown at 37 °C, 5% CO2 in MEM supplemented with 10% FCS. Cell
lysates were prepared washing the cells brieﬂy in PBS, incubating with
an equal volume of buﬀers 1 and 2 for 15 min, and then processing the
crude lysate as described above.
Proteomic Analysis. The total proteome was determined in
duplicate by fractionating 25 μg of the bloodstream form T. brucei cell
lysate by SDS-PAGE and pixilation into 24 bands, followed by in-gel
reductive alkylation and tryptic digest. Samples were analyzed by liquid
chromatography − tandem mass spectrometry on a Eksigent 1D+
HPLC system coupled to a LTQ-Orbitrap mass spectrometer
(Thermo scientiﬁc). MS spectra were searched using Mascot (Matrix
Science) against a nonredundant, in-house compiled database of
Trypanosoma brucei 927 and 427 strains obtained from TriTrypDB 3.0
23 with additional protein sequences from SwissProt and RefSeq
databases, as well as known contaminant sequences such as keratins
and trypsin. To assess the false discovery rate (FDR) “decoy” proteins
(reverse of the protein sequence) were added to the database. Protein
identiﬁcations were accepted as follows: (i) For single spectrum to
sequence assignments, we required the assignment to be the best
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match and a minimum Mascot score of 37 and a 10× diﬀerence of the
assignment over the next best assignment. On the basis of these
criteria, the decoy search results indicated <1% false discovery rate
(FDR). (ii) For multiple spectrum to sequence assignments and using
the same parameters, the decoy search results indicate <0.1% FDR. To
make our data accessible to the scientiﬁc community, we have
uploaded the results of this study to TriTrypDB (http://www.
tritrypdb.org).23
Kinobead Proﬁling. Procedures are essentially as described
previously.11,17,24 Kinobeads were prepared by immobilization of
ATP-mimetics on sepharose beads, with the four versions diﬀering in
the identity of the immobilized kinase ligands, as described in
Supplementary Table S8.
For kinobead proﬁling, compounds were dissolved in DMSO,
added at various concentrations (0, 0.039, 0.156, 0.625, 2.5, and 10
μM) to 1-mL cell lysate samples, and incubated for 45 min at 4 °C.
Subsequently, kinobeads were added to each sample and incubated for
a further 60 min at 4 °C. The kinobeads were collected by
centrifugation and washed with lysis buﬀer containing 0.2% Igepal-
CA630, and bead-bound proteins were eluted with NuPAGE LDS
buﬀer (Invitrogen) containing 50 mM DTT for 30 min at 50 °C
followed by alkylation with 20 mg/mL iodoacetamide for 30 min.
Samples were puriﬁed on 4−12% NuPAGE gels, stained with colloidal
Coomassie blue, digested with trypsin, and subsequently labeled with
TMT isobaric tagging reagents (ThermoFisher Scientiﬁc).15 Tryptic
peptides were separated over 4 h using nanoﬂow reversed-phase
chromatography online coupled to an Orbitrap mass spectrometer.
Peptide fragmentation was performed using PQD, and peptides were
identiﬁed with Mascot and quantiﬁed as described.25
Identiﬁcation of the T. brucei 427 Strain Kinome. The
annotated proteins from T. brucei brucei 427 strain was obtained from
TriTrypDB 3.023 and scanned through a highly sensitive and speciﬁc
multilevel HMM library of the protein kinase superfamily,26 followed
by expert curation. Assignment of putative protein kinases to the main
ePK and aPK groups was done by using the E-value cutoﬀs speciﬁc for
each group as described previously.26,27 This procedure identiﬁed and
assigned 187 protein kinases (Supplementary Table S1).
Phylogenetic Analysis. The phylogeny of the kinase groups
identiﬁed in T. brucei 427 strain was determined using the Phylogeny.fr
platform28 and comprised the following steps: Sequences were aligned
with T-Coﬀee (v6.85) using pairwise alignment methods,29 and
ambiguous regions (i.e., containing gaps and/or poorly aligned) were
removed with Gblocks (v0.91b)30 with low stringency (Min. seq. for
ﬂank pos.: 55%, Max. contig. nonconserved pos.: 8, Min. block length:
5, Gaps in ﬁnal blocks: half). The phylogenetic tree was reconstructed
using the maximum likelihood method implemented in the PhyML
program (v3.0 aLRT)31 with reliability for internal branch assessed
using the aLRT test (minimum of SH-like and Chi2-based
parametric).32 Graphical representation and editing of the phyloge-
netic tree was performed with TreeDyn (v198.3).33
■ ASSOCIATED CONTENT
*S Supporting Information
This material is free via the Internet at http://pubs.acs.org.
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: m.d.urbaniak@dundee.ac.uk; gerard.c.drewes@gsk.
com.
Notes
The authors declare the following competing ﬁnancial
interest(s): The authors T.M., D.E., M.B., and G.D. are
employees of Cellzome AG, which contributed to the funding
of this work by payment-in-kind.
■ ACKNOWLEDGMENTS
This work was funded by the Welcome Trust (Grants 085622
and 077705, and Strategic award 083481). We thank F.
Simeons, L. Stojanovski, and K. Read of the University of
Dundee Drug Discovery Unit for assistance in the culture of T.
brucei in rodents and M. Boesche (Cellzome) for performing
mass spectrometry.
■ REFERENCES
(1) Simarro, P., Diarra, A., Ruiz Postigo, J., Franco, J., and Jannin, J.
(2011) The Human African Trypanosomiasis control and Surveillance
Programme of the WHO 2000−2009: The Way Forward. PLoS Negl.
Trop. Dis. 5, e1007.
(2) Frearson, J. A., Wyatt, P. G., Gilbert, I. H., and Fairlamb, A. H.
(2007) Target assessment for antiparasitic drug discovery. Trends
Parasitol. 23, 589−595.
(3) Naula, C., Parsons, M., and Mottram, J. C. (2005) Protein kinases
as drug targets in Trypanosomes and Leishmania. Biochem. Biophys. Acta
1754, 151−159.
(4) Parsons, M., Worthey, E. A., Ward, P. N., and Mottram, J. C.
(2005) Comparative analysis of the kinomes of three pathogenic
trypanosomatids: Leishmania major, Trypanosoma brucei and Trypano-
soma cruzi. BMC Genomics 6, 127−146.
(5) Nett, I. R. E., Martin, D. M. A., Miranda-Saavedra, D., Lamont,
D., Barber, J. D., Mehlert, A., and Ferguson, M. A. J. (2009) The
phopshoproteome of bloodstream form Trypanosoma brucei, causative
agent of African sleeping sickness. Mol. Cell. Proteomics 8, 1527−1538.
(6) Alsford, S., Turner, D. J., Obado, S. O., Sanchez-Flores, A.,
Glover, L., Berriman, M., Hertz-Fowler, C., and Horn, D. (2011)
High-Throughput phenotyping using parallel sequencing of RNA
interference targets in the African Trypanosome. Genome Res. 21,
915−924.
(7) Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000)
Specificity and mechanism of action of some commonly used protein
kinase inhibitors. Biochem. J. 351, 95−105.
(8) Ma, J., Benz, C., Grimaldi, R., Stockdale, C., Wyatt, P., Frearson,
J., and Hammarton, T. C. (2010) Nuclear DBF-2-related kinases are
essential regulators of cytokinesis in bloodstream stage Trypanosoma
brucei. J. Biol. Chem. 285, 15356−15368.
(9) Urbaniak, M. D. (2009) Casein kinase 1 isoform 2 is essential for
bloodstream form Trypanosoma brucei. Mol. Biochem. Parasitol. 166,
183−185.
(10) Ojo, K. K., Gillespie, J. R., Reichers, A. J., Napuli, A. J., Verlinde,
C. L., Buckner, F. S., Gelb, M. H., Domostoj, M. M., Wells, S. J.,
Scheer, A., Wells, T. N., and Van Voorhis, W. C. (2008) Glycogen
synthase kinase 3 is a potential drug target for African trypanosomiasis
therapy. Antimicrob. Agents Chemother. 52, 3710−3717.
(11) Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche,
M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., Reader,
V., Sweetman, G., Bauer, A., Bouwmeester, T., Hopf, C., Kruse, U.,
Neubauer, G., Ramsden, N., Rick, J., Kuster, B., and Drewes, G. (2007)
Quantitative chemical proteomics reveals mechanisms of action of
clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035−1044.
(12) Bantscheff, M., and Drewes, G. (2012) Chemoproteomic
approaches to drug target identification and drug profiling. Bioorg.
Med. Chem. 20, 1973−1978.
(13) Urbaniak, M. D., Guther, M. L. S., and Ferguson, M. A. J.
(2012) Comparative SILAC proteomic analysis of Trypanosoma brucei
bloodstream and procyclic lifecycle stages. PLoS One 7, e36619.
(14) Jensen, B. C., Sivam, D., Kifer, C. T., Myler, P. J., and Parsons,
M. (2009) Widespread variation in transcript abundance within and
across developmental stages of Trypanosoma brucei. BMC Genomics 10,
482.
(15) Thomson, A., Schafer, J., Kuhn, K., Kienle, S., Schwarz, J.,
Schmidt, G., Naeumann, T., Johnstone, R., Mohammed, A. K., and
Hamon, C. (2003) Tandem mass tags: a novel quantification stratergy
for comparative analysis of complex protein mixtures by MS/MS. Anal.
Chem. 75, 1895−1904.
ACS Chemical Biology Articles
dx.doi.org/10.1021/cb300326z | ACS Chem. Biol. 2012, 7, 1858−18651864
(16) Ross, P., Huang, Y., Marchese, J., Williamson, B., Parker, K.,
Hattan, S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., Purkayastha,
S., Junhasz, P., Martin, S., Bartlet-Jones, M., He, F., Jacobson, A., and
Pappin, D. (2004) Multiplexed protein quantitation in Saccharomyces
cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell.
Proteomics 3, 1154−1169.
(17) Kruse, U., Pallasch, C. P., Bantscheff, M., Eberhard, D., Frenzel,
L., Ghidelli, S., Maier, S. K., Werner, T., and Wendtner, C. M. (2011)
Chemoproteomics-based kinome profling and target deconvolution of
clinical multi-kinase inhibitors in primary lymphocytic leukemia cells.
Leukemia 25, 89−100.
(18) Pfister, D. D., Burklard, G., Morand, S., Renggli, C. K., Roditi, I.,
and Vassella, E. (2006) A mitogen-activated protein kinase controls
differentiation of bloodstream forms of Trypanosoma brucei. Eukaryotic
Cell 5, 1126−1135.
(19) Rotureau, B., Morales, M. A., Bastin, P., and Spath, G. F. (2009)
The flagellum-mitogen-activated protein kinase connection in
Trypanosomatids: a key sensory role in parasite signalling and
development? Cell. Microbiol. 11, 710−718.
(20) Cleghorn, L. A., Woodland, A., Collie, I. T., Torrie, L. S.,
Norcross, N., Luksch, T., Mpamhanga, C., Walker, R. G., Mottram, J.
C., Brenk, R., Frearson, J. A., Gilbert, I. H., and Wyatt, P. G. (2011)
Identification of inhibitors of the Leishmania cdc2-related protein
kinase CRK3. ChemMedChem 6, 2214−2224.
(21) Walker, R. G., Thomson, G., Malone, K., Nowicki, M. W.,
Brown, E., Blake, D. G., Turner, N. J., Walkinshaw, M. D., Grant, K.
M., and Mottram, J. C. (2011) High throughput screening yield small
molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependant
kinase. PLoS Negl. Trop. Dis. 5, e1033.
(22) Cross, G. A. M. (1984) Release and purification of Trypanosoma
brucei variant surface glycoprotein. J. Cell. Biochem. 24, 79−90.
(23) Aslett, M., Aurrecoechea, C., Berriman, M., Brestelli, J., Brunk,
B. P., Carrington, M., Depledge, D. P., Fischer, S., Gajria, B., Gao, X.,
Gardner, M. J., Gingle, A., Grant, G., Harb, O. S., Heiges, M., Hertz-
Fowler, C., Houston, R., Innamorato, F., Iodice, J., Kissinger, J. C.,
Kraemer, E., Li, W., Logan, F. J., Miller, J. A., Mitra, S., Myler, P. J.,
Nayak, V., Pennington, C., Phan, I., Pinney, D. F., Ramasamy, G.,
Rogers, M. B., Roos, D. S., Ross, C., Sivam, D., Smith, D. F.,
Srinivasamoorthy, G., Stoeckert, C. J., Jr., Subramanian, S., Thibodeau,
R., Tivey, A., Treatman, C., Velarde, G., and Wang, H. (2010)
TriTrypDB: a functional genomic resource for the Trypanosomatidae.
Nucleic Acid Res. 38, D457−D462.
(24) Bergamini, G., Bell, K., Shimamura, S., Werner, T., Cansfield, A.,
Mueller, K., Perrin, J., Rau, C., Ellard, K., Hopf, C., Doce, C., Leggate,
D., Mangano, R., Mathieson, T., O’Mahony, A., Plavec, I., Rharbaoui,
F., Reinhard, F., Savitski, M. M., Ramsden, N., Hirsch, E., Drewes, G.,
Rausch, O., Bantscheff, M., and Neubauer, G. (2012) A selective
inhibitor reveals PI3Kγ dependence of TH17 cell differentiation. Nat.
Chem. Biol. 8, 576−582.
(25) Bantscheff, M., Boesche, M., Eberhard, D., Matthieson, T.,
Sweetman, G., and B., K. (2008) Robust and sensitive iTRAQ
quantification on an LTQ Orbitrap mass spectrometer. Mol. Cell.
Proteomics 7, 1702−1713.
(26) Miranda-Saavedra, D., and Barton, G. J. (2007) Classification
and functional annotation of eukaryotic protein kinases. Proteins 68,
893−914.
(27) Martin, D. M., Miranda-Saavedra, D., and Barton, G. J. (2009)
Kinomer v.1.0: a database of systematically classified eukaryotic
protein kinases. Nucleic Acid Res. 37, D244−250.
(28) Dereeper, A., Guignon, V., Blanc, G., Audic, S., Buffet, S.,
Chevenet, F., Dufayard, J. F., Guindon, S., Lefort, V., Lescot, M.,
Claverie, J. M., and Gascuel, O. (2008) Phylogeny.fr: robust
phylogentic analysis for the non-specialist. Nucleic Acid Res. 36, 36.
(29) Notredame, C., Higgins, D., and Heringa, J. (2000) T-Coffee: A
novel method for multiple sequence alignment. J. Mol. Biol. 302, 205−
217.
(30) Castresana, J. (2000) Selection of conserved blocks from
multiple alignments for their use in phylogenetic analysis. Mol. Biol.
Evol. 17, 540−552.
(31) Guindon, S., and Gascuel, O. (2003) A simple, fast, and accurate
algorithm to estimate large phylogenies by maximum likelihood. Syst.
Biol. 52, 696−704.
(32) Anisimova, M., and Gascuel, O. (2006) Approximate likelihood
ration test for branches: a fast, accurate and powerful alternative. Syst.
Biol. 55, 539−552.
(33) Chevenet, F., Brun, C., Banuls, A. L., Jacq, B., and Chisten, R.
(2006) TreeDyn: towards dynamic graphic and annotation analyses of
trees. BMC Bioinfomatics 7, 439.
(34) Durrant, J. D., Urbaniak, M. D., Ferguson, M. A. J., and
McCammon, J. A. (2010) Computer-aided identification of
Trypanosoma brucei uridine diphosphatase galactose 4′-epimerase
inhibitors: towards the development of novel therapies for African
sleeping sickness. J. Med. Chem. 53, 5025−5032.
ACS Chemical Biology Articles
dx.doi.org/10.1021/cb300326z | ACS Chem. Biol. 2012, 7, 1858−18651865
The Design and Synthesis of Potent and Selective Inhibitors of
Trypanosoma brucei Glycogen Synthase Kinase 3 for the Treatment
of Human African Trypanosomiasis
Robert Urich,† Raﬀaella Grimaldi,† Torsten Luksch,† Julie A. Frearson,† Ruth Brenk,*,‡,§
and Paul G. Wyatt*,†
†Drug Discovery Unit, College of Life Sciences, University of Dundee, Sir James Black Centre, Dow Street, Dundee DD1 5EH, U.K.
‡Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Sir James Black Centre,
Dundee DD1 5EH, U.K.
*S Supporting Information
ABSTRACT: Glycogen synthase kinase 3 (GSK3) is a
genetically validated drug target for human African trypanoso-
miasis (HAT), also called African sleeping sickness. We report
the synthesis and biological evaluation of aminopyrazole
derivatives as Trypanosoma brucei GSK3 short inhibitors. Low
nanomolar inhibitors, which had high selectivity over the oﬀ-
target human CDK2 and good selectivity over human GSK3β
enzyme, have been prepared. These potent kinase inhibitors
demonstrated low micromolar levels of inhibition of the
Trypanosoma brucei brucei parasite grown in culture.
■ INTRODUCTION
Human African trypanosomiasis (HAT) or African sleeping
sickness is a serious life threatening disease.1 Around 60 million
people in 36 African countries are currently in constant threat
of infection. Although the reported number of cases has
dropped over recent years, the actual number of unreported
cases is estimated to be around 70000−80000.2 HAT is caused
by infection with Trypanosoma brucei, a vector-borne parasite,
which is transmitted by the bite of tsetse ﬂies. The symptoms of
the disease occur in two main stages. In the ﬁrst stage, known
as the hemolymphatic phase, the parasites multiply in blood,
subcutaneous tissues, and lymph, causing headaches, fever,
itching, joint pains, and swelling of lymph nodes. In the second
stage, or neurological phase, the trypanosomes cross the
blood−brain barrier and invade the central nervous system.
This phase entails confusion, change of behavior, reduced
coordination, sensory disturbances, disturbance of sleep cycle,
and ﬁnally death. Most available drugs for HAT display severe
toxic side eﬀects, require long periods of administration, and/or
are expensive due to the logistics to reach rural African areas.3
Further, resistance to all in use drugs has been observed in the
laboratory and/or in the ﬁeld,4 resulting in an urgent
requirement for better, safer, and inexpensive therapeutic
alternatives to the current treatments.
Genetic knockdown studies have identiﬁed several proteins
that are essential for the survival of the parasite, including
members of the protein kinase (PK) family.5−8 In Trypanosoma
brucei PKs are essential in many fundamental cellular processes,
e.g., proliferation, diﬀerentiation, and cell cycle control, and can
therefore be considered as potential drug targets for the
treatment of HAT.7,9−12
In the T. brucei genome there are two kinases that are highly
homologous to human glycogen synthase kinase 3 (HsGSK3):
TbGSK3 short and TbGSK3 long.13 RNA interference (RNAi)
knockdown of TbGSK3 has shown that TbGSK3 short is
critical for cell growth, with a role in the control of mitosis and/
or cytokinesis.7,13
The ability to selectively inhibit TbGSK3 over the oﬀ-target
HsGSK3 is highly desirable because mouse knockout studies
revealed that the disruption of the murine GSK3β gene causes
embryonic lethality; consequently, nonselective inhibitors are
not applicable for use in infants and women of child bearing
age.14,15
From a homology perspective, TbGSK3 is not only very
closely related to HsGSK3β but also to other human PKs such
as cyclin dependent kinase 1 (HsCDK1) and cyclin dependent
kinase 2 (HsCDK2).16 HsCDK2 and HsCDK1 are essential for
G1/G2 progression and S/M-phase entry of the cell cycle. Oﬀ-
target inhibition of these human kinases will therefore result in
cell cycle arrest and reduction of cellular proliferation and as
such potentially lead to severe side eﬀects.
Over the past decade, various groups and pharmaceutical
companies have identiﬁed multiple series of HsGSK3β
inhibitors.16,17 Recently, Astex Therapeutics and researchers
at the University of Osaka have developed a series of
aminopyrazoles that are potent inhibitors of HsGSK3β.18−20
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Co-crystal structures of this series with HsGSK3β are not
available to date; however, complex structures with the closely
related HsCDK2 have been determined.19 In all structures, the
pyrazole scaﬀold forms two hydrogen bonds to the hinge
region of HsCDK2 (Figure 1). Further, the NH group of the 3-
position amide forms an additional hydrogen-bond interaction
to the backbone of Leu83. A water-mediated hydrogen bond
from the amide carbonyl oxygen atom to the backbone NH of
Asp145 is also observed. The R1 residues (Figure 2) access the
gatekeeper region between the gatekeeper residue Phe80 and
the catalytic Asp145 (Figure 1). The R2 substituents occupy the
hydrophobic pocket II, formed by the backbone of the linker
region, Leu83, Phe82, and side chains of Ile10, Asp86, and
Leu134. Finally, an intramolecular hydrogen bond between the
R1-NH and R2-carbonyl group is present. The similarity of
HsCDK2, HsGSK3β, and TbGSK3 indicates that amino-
pyrazoles will also bind into the ATP-binding site of the latter
enzyme.13,16
Herein, we describe the design, synthesis, and biological
evaluation of aminopyrazole inhibitors which bind to TbGSK3
short. The inhibitors were also tested against the closely related
oﬀ-targets HsGSK3β and HsCDK2 and evaluated against a
panel of mammalian protein kinases. The most potent
compound has nanomolar aﬃnity for TbGSK3 short, is
selective over HsGSK3β and HsCDK2, and clean in the kinase
panel. By using computer-aided molecular modeling, we were
able to rationalize the observed selectivity proﬁle. Enzyme
aﬃnity correlated with inhibition of T. b. brucei proliferation,
albeit a 100-fold oﬀset in potency, was found. In light of these
results, we discuss the value of TbGSK3 short as a drug target
for HAT.
■ RESULTS
Starting Point. The aminopyrazole derivatives developed
by Astex Therapeutics and Yumiko Uno et al. for inhibition of
HsCDK2 and HsGSK3β enzymes were chosen as a starting
point for the investigation of TbGSK3 short inhibitors.18−20
Aminopyrazoles analogues were generated by substituting at
either R1 or R2 position (Figure 2) using two synthetic routes
(Scheme 1A,B).19
Diﬀerences in the ATP Binding Pockets of TbGSK3,
HsGSK3β, and HsCDK2. A structural model of TbGSK3 was
built to assess the diﬀerences in the binding sites of TbGSK3
short, HsGSK3β, and HsCDK2 and to guide ligand design. An
overlay of 42 HsGSK3 crystal structures showed that there is
low ﬂexibility in the ATP binding site. Only the regions
including Phe67 and Arg141 showed some mobility. Phe67
either points toward or away from the hinge region. Arg141
also spans a number of distinct conformations, including
examples where it occupies space in the binding site (1J1B,
1J1C, 1O9U, 2O5K) and therefore could inﬂuence docking
results. However, to allow for ligands of a signiﬁcant size, we
have used examples with Arg141 pointing out of the binding
site. Therefore, two homology models for TbGSK3 were
generated representing both states of Phe67. As we were mainly
interested in aminopyrazoles with less extended R1 groups, the
crystal structure with Phe67 pointing toward the hinge (with
structure 1r0e as a representative) was more suited as model
system. The selection of 1r0e instead of other members of this
group (with Phe67 pointing toward the hinge) was arbitrary.
For this analysis, all residues that are located within 6 Å of the
ligand bound to the template structure (1r0e) were considered.
The binding pockets of TbGSK3 and HsGSK3β diﬀer by
nine amino acid residues (Table 1, Figure 3A). Of the amino
acid side chains that point toward the ligand, the most
signiﬁcant diﬀerences are the replacement of Tyr134 in
HsGSK3β with Phe103, Leu132 with Met101, Gln72 with
Leu36, and Tyr140 with His109. The binding pockets of
TbGSK3 and HsCDK2 are more diverse. Here, in total 16 out
of 26 amino acids were found to be diﬀerent (Table 1, Figure
3B), the most important of these diﬀerences being the
replacement of Lys20 in CDK2 with Leu36, Phe80 with
Met101, His84 with Pro105, Lys89 with Arg110, and Ala144
with Cys170. Interestingly, most of the amino acid diﬀerences
occurred in the hydrophobic pocket II and the gatekeeper
region. Therefore, we decided to direct the optimization of the
lead scaﬀold toward suitable interactions with amino acids
which are located in these subpockets of the ATP binding site.
Chemistry. The synthesis of R1 and R2 substituted
aminopyrazole derivatives started from 4-nitro-pyrazole-3-
carboxylic acid 1 and is described by two diﬀerent routes
Figure 1. Co-crystal structure (2vu3) of AT751919 (carbon atoms in
gray) bound to CDK2. The binding pocket of CDK2 is shown in light-
blue surface representation. Key: red sphere, water molecule; black
dashed lines, protein−ligand and water−ligand hydrogen bonds;
yellow stick, hydrogen atom..
Figure 2. Generic binding mode of the R1 and R2 substituted
aminopyrazole scaﬀold (carbon atoms in gray).
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(Scheme 1) based on previous work from Wyatt et al.19 In
route A, 1 was coupled with trans-4-methoxycyclohexylamine
using EDC as the activating agent. Reduction of the subsequent
intermediate 2 by hydrogenation in the presence of palladium
on carbon generated amino pyrazole 3. The conversion to
compounds 4a−z was accomplished by coupling of 3 with a
suitable selection of carboxylic acids. In route B, after
esteriﬁcation of the carboxyl group of 1, the nitro group of
intermediate 5 was reduced to aﬀord amine 6. Treatment of 6
with 2,6-dimethoxybenzoyl chloride under standard conditions,
followed by base hydrolysis of the ester, provided acid 8. In the
ﬁnal step, 8 was coupled with appropriate amines in a
microwave reaction using polystyrene-bound carbodiimide to
yield ﬁnal compounds 9a−x.
Activity and Selectivity of R1 Substituted Compounds.
Twenty-six R1 substituted aminopyrazole analogues (Table 2)
were made according to the synthetic route shown in Scheme
1A. A range of R1 groups varying in size and polarity was
chosen to probe whether the diﬀerences in the gate keeper
region between TbGSK3, HsGSK3, and HsCDK2 could be
exploited to derive selective and potent TbGSK3 inhibitors
(Figure 3).
Enzyme Activity. All compounds showed good potency
against TbGSK3 (<1 μM). An unsubstituted phenyl ring (4f)
provided on average a 20-fold improvement of inhibition
potency relative to saturated six-membered ring systems (4a
and 4b) and benzyl groups (4c, 4d, and 4e). In general, a
variety of diﬀerent aryl and heteroaryl rings (4g−4y compared
to 4a and 4b) in the R1 position led to signiﬁcantly improved
potency against TbGSK3. Additionally, a wide variety of
substituents were tolerated on the phenyl ring. In general,
ortho-substituted phenyl rings gave the best improvement in
activity compared to the unsubstituted phenyl group (4j, 4k,
4m, and 4n). The methoxyphenyl moieties in 4j, 4m, and 4n,
which had TbGSK3 IC50 values of 4, 2, and 3 nM, respectively,
were the most favorable substituents. These derivatives were
approximately 10-fold more potent than the unsubstituted
phenyl compound 4f. Only the 2,4,6-trimethoxyl derivative 4n
showed >10-fold selectivity over HsGSK3. Interestingly, this
was also the most selective compound for HsCDK2 (>1000-
fold).
To rationalize the observed selectivity, all analogues were
docked into the binding sites of TbGSK3, HsGSK3β, and
HsCDK2 and their poses were visually analyzed. For most
compounds, a binding mode similar to that observed for
AT751919 in HsCDK2 (Figure 1) was predicted in TbGSK3,
HsGSK3β, and HsCDK2. One important diﬀerence between
HsCDK2, TbGSK3, and HsGSK3β is the gatekeeper residue
(Table 1, Figure 3A,B). While HsGSK3 and TbGSK3 enzymes
have Leu or Met, respectively, in this position, in HsCDK2 Phe
is present. As a consequence, the gatekeeper region of HsCDK2
(located between Phe80 and Asp145) is more restricted
compared to the other two enzymes. This resulted in a higher
energy, out of plane conformation of the amide group of 4f
when binding into this pocket (Figure 4), while a low energy
conformation was found when binding into T. brucei and
human GSK3 (not shown). Further, without induced ﬁt
adaptations, the bulky R1-substituents such as the 2,6-
dimethoxybenzamide group of 4m, the 2,4,6-trimethoxybenza-
mide groups 4n, and the phenylaminobenzamide groups of 4k
Scheme 1. Synthetic Routes for 50 R1 and R2 Substituted Aminopyrazoles (4a−z and 9a−x)a
aReagents and conditions used in routes A and B: (a) trans-4-methoxycyclohexylamine, EDC, HOBt, DMF, rt; (b) 10% Pd/C, H2, DMF, rt; (c)
R1COOH, EDC, HOBt, DIPEA, rt; (d) SOCl2, MeOH, 0°C, rt; (e) 10% Pd/C, H2, EtOH, rt; (f) 2,6-dimethoxybenzoylchloride, Et3N, dioxane, rt;
(g) NaOH, dioxane, H2O, rt; (h) R2NH2, polystyrene-bound carbodiimide, HOBt, acetonitrile, MW, 100 °C.
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and 4l can only be accommodated by the gatekeeper region of
TbGSK3 and HsGSK3β but not the narrower HsCDK2
gatekeeper region. These observations might explain the
reduced binding aﬃnity of 4f for HsCDK2 compared to
HsGSK3. Of note, this explanation is further supported by the
report by Wyatt et al.,19 which found that the aryl groups which
are located in the same position need to twist in order to
provide potent CDK2 activity.
Antiparasitic Activity. All R1 substituted compounds were
tested for their ability to inhibit the proliferation of bloodstream
form (BSF) T. b. brucei in culture. As an initial indication of
potential toxicity, compounds 4a−4z were additionally tested
against proliferating human fetal lung ﬁbroblast cells (MRC5
cell line). Four compounds (4g, 4j, 4m, and 4y) had EC50
values <1 μM and a further 11 compounds had EC50 values <3
μM against BSF T. b. brucei (Table 2). The EC50 values
correlated well with enzyme activity (R2 = 0.73, Figure 5).
However, a 100-fold drop from enzyme to cellular activity was
observed. Selectivity over the MRC5 cells was achieved with
compounds 4m (60-fold), 4s (>19-fold), 4x (12-fold), and 4n
(>9-fold), however, the majority of compounds showed a poor
selectivity over MRC5 cells.
Activity and Selectivity of R2 Substituted Compounds.
As 4m was the most potent inhibitor of TbGSK3 and
proliferation of T. b. brucei cells, we retained the 2,6-
dimethoxybenzamide group at position R1 for optimization of
the R2 substituent. R2 substituted aminopyrazole analogues
(9a−9x) were made according to the synthetic route shown in
Scheme 1B to explore the structural requirements for
improvement of antiparasitic activity and selectivity over the
closely related human kinases.
Enzyme Activity. The majority of variations led to potent
TbGSK3 inhibitors, indicating that chemical diversity at this
position was well tolerated (Table 3). One of the SAR trends
observed was that six-membered saturated rings (9c) and
seven-membered saturated rings (9d) were favored over their
three- and four-membered equivalents (9a and 9b). Further, it
Table 1. Diﬀerences in the Binding Pockets of TbGSK3,
HsGSK3β, and HsCDK2a
TbGSK3 HsGSK3β HsCDK2
V25 V61 K9
A26 I62 I10
G27 G63 G11
Q28 N64 E12
G29 G65 G13
T30 S66 T14
F31 F67 Y15
V34 V70 V18
L36 Q72 K20
A47 A83 A31
K49 K85 K33
E61 E97 I52
M65 M101 L55
V77 V110 V64
M101 L132 F80
E102 D133 E81
F103 Y134 F82
104 V135 L83
P105 P136 H84
E106 E137 Q85
T107 T138 D86
H109 Y140 K88
R110 R141 K89
K154 K183 K129
H156 Q185 Q131
N157 N186 N132
L159 L188 L134
C170 C199 A144
D171 D200 D145
aAmino acids of hGSK3β or HsCDK2 which diﬀer in TbGSK3 short
are shown in boldface.
Figure 3. Superposition of the binding sites of the homology model of TbGSK3 short (blue carbon atoms) with (A) the HsGSK3β crystal structure
(PDB code 1r0e) and (B) the HsCDK2 crystal structure (PDB code 2vu3). The solvent accessible surface of TbGSK3 short is shown in light blue.
Only residues that diﬀer between the binding pockets are shown. For orientation, the ligands bound to crystal structures are also displayed. Amino
acid residue labels are for TbGSK3.
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was noted that the replacement of the cyclohexane of 9c with a
phenyl ring or 4-pyridine, to give 9k or 9l, gave a 6-fold
decrease in potency against TbGSK3. The 2-pyridine analogue
(9m), on the other hand, was much less active (50-fold) against
TbGSK3. Homologation of aromatic (9g) and saturated six-
membered (9j) rings by one carbon atom produced inhibitors
with 1 nM activity for TbGSK3. For aliphatic side chain
derivatives 9r−9w, the pentanyl and 1-isopropoxypropanyl
analogues had IC50 values of 1 nM. The impact of replacing the
amide group (3-position) with carboxylic acid and ester groups
was investigated with compounds 8 and 7. Compound 8
containing a carboxylate group in the 4-position showed a
dramatic loss in activity (IC50 >50 μM). The ester group of
compound 7 on the other hand was better tolerated (IC50 0.5
μM). Interestingly, compared with 4a−4z, a majority of R2
substituted analogues (9a−9x) showed selectivity over
Table 2. Kinase Inhibitory Activity and Antiproliferative Eﬃcacy of R1 Substituted Aminopyrazoles
IC50 (μM) IC50 (μM) IC50 (μM) EC50 (μM)
compd TbGSK3a HsGSK3βa ratio HsGSK3β/TbGSK3 HsCDK2a ratio HsCDK2/TbGSK3 T. b. bruceib MRC5c
4a 0.50 0.008 0.16 1.0 2 16 >50
4b 0.69 0.008 0.0012 0.38 0.55 32 >50
4c 0.39 0.14 0.35 0.82 2.1 23 >50
4d 0.50 0.21 0.42 0.85 1.7 22 40
4e 0.23 0.2 0.87 0.29 1.3 7.3 3.1
4f 0.024 <0.005 >0.21 0.038 <1.6 1.3 0.8
4g 0.020 <0.005 0.25 0.014 <0.7 0.4 1.0
4h 0.018 <0.013 <0.72 0.1 5.6 2.3 3.3
4i 0.053 0.02 0.38 0.07 1.3 2.8 3.4
4j 0.004 <0.013 <3.3 0.1 25 0.9 1.5
4k 0.011 0.02 1.8 >10 >910 4.4 35
4l 0.066 0.03 0.45 >10 >150 5.8 16
4m 0.002 <0.005 <2.5 0.19 95 0.5 31
4n 0.003 0.09 30 3.1 1000 5.9 >50
4o 0.053 <0.005 <0.09 0.22 4.2 3.8 11
4p 0.024 <0.005 <0.21 0.083 3.5 2.6 0.6
4q 0.057 <0.005 <0.08 0.63 11 9.6 13
4r 0.016 <0.005 <0.31 0.27 17 1.1 2.5
4s 0.019 <0.005 <0.26 0.13 6.8 2.7 >50
4t 0.070 <0.005 <0.071 1.0 14 2.0 20
4u 0.013 <0.005 <0.38 nd nd 1.2 0.8
4v 0.063 <0.005 <0.080 0.042 0.67 1.9 1.0
4w 0.094 <0.005 <0.053 0.15 1.6 2.6 5.9
4x 0.10 0.042 0.42 2.2 22 2.9 34
4y 0.007 <0.005 <0.72 0.01 1.4 0.3 0.1
4z 0.92 0.005 0.0058 22 24 >50 28
aData represents the average of two or more experiments. bConcentration required to inhibit the growth of T. b. brucei in culture by 50% over 72 h.
cConcentration required to inhibit the growth of MRC5 cells in culture by 50% over 72 h.
Figure 4. Predicted binding mode of 4f in HsCDK2. Putative
hydrogen bonds are shown as black dotted lines. Docking results
suggested that the phenyl ring of compound 4f needs to be
signiﬁcantly twisted out of plane by approximately 60° compared to
the amide in order to ﬁt into the gatekeeper region.. Figure 5. Correlation between the inhibition of recombinant TbGSK3
and bloodstream form T. b. brucei proliferation by R1 substituted
aminopyrazole derivatives (4a−z).
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HsCDK2 and HsGSK3β. These are the most selective TbGSK3
inhibitors described to date.
The predicted binding mode of 9g in TbGSK3 oﬀers an
explanation for the observed selectivity (Figure 6). In the
highest scoring docking pose, the core scaﬀold adopts a similar
binding mode as observed for AT7519 in HsCDK2 (Figure
1).19 In addition, the docking results suggested that the
hydrophobic pocket II of TbGSK3 was occupied by the N-
benzylamide group of 9g in such a way that its phenyl moiety
formed T-shaped edge-to-face interactions with the side chain
of Phe103 and hydrophobic interactions with Leu36 and Ala26.
In hGSK3β, Phe103 is replaced with a Tyr (Table 1, Figure
3A), resulting in steric clash and electrostatic repulsion toward
the benzyl moiety of 9g. Further, Leu36 is substituted with
Gln72 in hGSK3β and Lys20 in HsCDK2, diminishing
hydrophobic interactions between the benzyl moiety of 9g
and these residues. Overall, these changes together with
diﬀerences in the gatekeeper region of HsCDK2 (see above)
are likely to be responsible for the high selectivity of 9g for
TbGSK3 over hGSK3 and HsCDK2. Similar observations
regarding the R2 group placement and selectivity were also
made for compound 9h supporting this model.
Antiparasitic Activity. The R2 substituted compounds were
tested against BSF T. b. brucei and MRC5 cells. As for the R1-
substituted analogues, a good correlation between the EC50 and
IC50 values and a 100-fold drop in activity between the
biochemical and cell assay was observed (Figure 7). Compound
9c had an EC50 for T. b. brucei of 4 μM (Table 3). Limited
selectivity (>7-fold) over MRC5 cells was achieved with
compounds 9c, 9d, 9g, 9s, and 9t. It was found that the
compounds showed selective inhibition of TbGSK3 over
HsGSK3 (>20-fold) and HsCDK2 (>1200-fold).
Human Kinase Selectivity Proﬁle. PK inhibitors
frequently inhibit multiple kinases, often leading to oﬀ-target
toxic eﬀects. To assess the selectivity of the aminopyrazole
inhibitors, remaining activity at 10 μM concentration was
measured for compounds 4f, 4m, and 4y against a panel of 80
human PKs and for compound 9g against 124 human PKs.
Compounds 4m and 9g were found to be highly speciﬁc (Table
4). Compound 4m inhibited only two PKs, namely GSK3β and
CDK2, at more than 80%. 9g showed activity against three PKs:
GSK3β, MAPKAP-K2, and MINK1 at more than 80%.
Compound 4f was found to inhibit seven PKs and compound
4y 15 PKs by greater than 80% at 10 μM.
■ DISCUSSION
In this work, we exploited the knowledge of the previously
described aminopyrazoles inhibitors of HsCDK2 and
HsGSK3β20 to identify selective inhibitors of the TbGSK3
short isoform. This kinase has been shown using genetic
manipulation studies to be essential for the survival of the T. b.
brucei parasite.13 However, we wanted to conﬁrm if antiparasitic
activity could be gained using selective, small molecule
inhibitors of TbGSK3. The ability to selectively inhibit
TbGSK3 over HsGSK3 and HsCDK2 is essential to avoid
potential side eﬀects. Therefore, more than 50 aminopyrazole
derivatives were synthesized and screened against TbGSK3,
HsGSK3β, HsCDK2, and proliferating T. b. brucei and human
cells in culture.
Table 3. Kinase Inhibitory Activity and Antiproliferative Eﬃcacy of R2 Substituted Aminopyrazoles
IC50 (μM) IC50 (μM) IC50 (μM) EC50 (μM)
compd TbGSK3a HsGSK3βa ratio HsGSK3β/TbGSK3 HsCDK2a ratio HsCDK2/TbGSK3 T. b. bruceib MRC5c
9a 0.012 0.22 18 >10 >830 19 >50
9b 0.008 0.08 10 2.4 300 12 >50
9c 0.001 0.05 50 1.2 1200 4.1 35
9d 0.001 0.02 20 2.0 2000 4.5 42
9e 0.018 nd nd >10 560 16 >50
9f 0.081 0.45 5.6 >10 120 50 >50
9g 0.001 0.33 330 >10 10000 5.9 50
9h 0.015 0.32 21 >10 670 20 >50
9i 0.14 0.87 6.2 >10 71 >50 >50
9j 0.001 nd nd nd nd 7.7 >50
9k 0.006 0.07 12 4.3 720 11.5 >50
9l 0.004 0.12 30 1.3 330 8.2 >50
9m 0.32 0.94 2.9 >10 31 >50 >50
9n 0.002 0.07 35 1.6 800 6.4 34
9o 0.001 nd nd >4.8 4800 6.7 45
9p 0.006 0.14 23 4.7 780 12 >50
9q 0.008 0.08 10 >10 1300 8.9 38
9r 0.034 0.3 8.8 >10 290 43 >50
9s 0.001 0.1 100 4.8 4800 7.3 >50
9t 0.001 nd nd >10 10000 6.6 >50
9u 0.33 0.47 1.4 >10 30 >50 >50
9v 0.32 0.66 2.1 >10 31 >50 >50
9w 0.054 0.63 12 >10 190 >50 >50
9x 0.002 <0.005 <2.5 0.19 95 0.5 31
8 >50 >10 >10 >50 >50
7 0.52 4.5 8.7 >10 19 >50 >50
aData represents the average of two or more experiments. bConcentration required to inhibit the growth of T. b. brucei in culture by 50% over 72 h.
cConcentration required to inhibit the growth of MRC5 cells in culture by 50% over 72 h.
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The results (Table 2 and Table 3) showed that almost all
compounds were highly potent TbGSK3 inhibitors. The activity
could be rationalized using the homology models and
subsequent molecular docking studies (Figure 4 and Figure
6). The aminopyrazole derivatives make three H-bond
interactions with the kinase hinge region, driving much of the
potency of the compounds against the three kinases studied.
Selectivity could be derived from substitution at both R1 and R2
positions.
From a homology perspective, HsCDK2 is the most closely
related kinase to HsGSK3β.16 Although, the enzymes only share
approximately 33% amino acid identity, their ATP binding
pockets are highly conserved,16 resulting in the majority of
known HsCDK2 inhibitors also potently inhibiting HsGSK3β.
The results demonstrated that the required proﬁle could be
achieved, with several compounds with high aﬃnity (<18 nM)
for TbGSK3 showing high selectivity (>500-fold) over
HsCDK2. Docking studies provided a number of important
insights into the binding modes and the selectivity proﬁle of
aminopyrazole derivatives. First, the docking results suggested
that if the phenyl ring of compound 4f is planar with the amide
group at R1 position it cannot bind into the truncated gate
keeper region of HsCDK2, deﬁned by Phe80 in HsCDK2,
compared to Met101 in TbGSK3. To ﬁt into this region of
HsCDK2, the phenyl ring needs to signiﬁcantly twist out of
plane of the amide, with a torsion angle of approximately 60°,
resulting in reduced binding aﬃnity (Figure 4). To stabilize this
twist, di-ortho-substituents on the R1 phenyl group are required
to cause a steric/electronic clash with the carbonyl of the amide
bond. However, this region of the pocket in HsCDK2 is narrow
(in a plane perpendicular to the hinge backbone and the
pyrazole core), only allowing small ortho-substituents (such as
in compound 9g) on the phenyl group. In contrast, the wider
gatekeeper regions of hGSK3 and TbGSK3 can tolerate large
substituents such as the ortho-dimethoxy groups of compound
4m or 4n and the ortho-phenylaminobenzamide groups of 4k
or 4l. Second, the highest increase in selectivity (>10000-fold)
over HsCDK2 was achieved by accessing the hydrophobic
pocket II. Exploitation of hydrophobic interactions in these two
pockets not only reliably increased ligand-binding aﬃnity but
also impacted on the selectivity proﬁle of these compounds. On
the basis of the biological results of compound 9g and
structural modeling studies, we have shown that selectivity over
Figure 6. Proposed binding mode of 9g in the homology model of
TbGSK3 (blue carbon atoms) overlaid on the HsGSK3β crystal
structure (pink carbon atoms). Both ligand and protein are
represented as sticks and color coded by atom types. Ligand carbon
atoms are shown in gray, protein carbon atoms of TbGSK3 are shown
in blue, and HsGSK3β carbon atoms in salmon. Amino acid residue
labels are for TbGSK3. Hydrogen bonds and hydrophobic interactions
are shown as black dotted lines, with interaction distances in
angstroms. TbGSK3 amino acids which are involved in hydrophobic
interactions with the benzyl group are marked in bold. The gold
sphere represents the center of the phenyl ring..
Figure 7. Correlation between the inhibition of recombinant TbGSK3
and bloodstream from T. b. brucei proliferation using R2 substituted
aminopyrazole derivatives (9a−x).
Table 4. Kinase Proﬁling against a Panel of Mammalian
Kinasesa
PKs 4f 4m 4y 9g
MKK1 54 83 17 76
ERK2 18 51 2 92
JNK1 31 77 8 71
JNK2 51 82 15 63
ERK8 14 27 7 47
MAPKAP-K2 92 33 90 13
GSK3b 33 0 0 10
CDK2 1 9 1 38
MELK 32 100 13 96
DYRK1A 6 84 1 79
DYRK2 3 63 1 28
DYRK3 24 100 2 80
PIM1 46 100 13 92
PIM3 19 94 1 96
HIPK2 14 100 4 93
IGF-1R 96 100 15 79
MINK1 nd nd nd 18
aNumbers represent average percentage of activity compared to the
control at 10 μM. In this table, only kinases with activity values <20%
are shown (for full table see Supporting Information). PK activity
values <20% are marked in bold.
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HsGSK3 can be achieved by exploiting the Phe103Tyr,
Leu36Gln, and Ala26Ile active site diﬀerences in the hydro-
phobic pocket II of TbGSK3 enzyme (Figure 6). Taken
together, the region between the gate keeper residue and the
catalytic aspartate of the DFG loop, together with the
hydrophobic pocket II, are the key areas to exploit to achieve
high selectivity over HsCDK2.
The TbGSK3 short enzyme IC50 values correlated well with
the T. b. brucei antiproliferative EC50 activities of the described
substituted aminopyrazole inhibitors (Figures 5 and 7),
indicating that the compounds act on target. However, a 100-
fold drop in cell activity was observed, compared to that in the
TbGSK3 assay (1 μM). The calculated physical properties
(MW < 473; log P −0.4−3.6; PSA < 130 Å) of the series of
compounds suggest this loss of activity was not driven by lack
of cellular penetration. In addition, the compound series was
observed to be highly chemically stable under the range of
synthetic conditions used during the chemistry campaign,
suggesting that chemical degradation was not responsible for
the loss of activity in the proliferation assay. Although
metabolism by the parasite cannot be ruled out, the high
degree of correlation between enzyme inhibition and
antiparasitic activity suggests this is not the case, as it would
be not expected that all compounds be metabolized to a
constant extent. Therefore, the drop of activity was probably
due to the high ATP concentration (millimolar range) in the
cell compared to the kinase assay conditions.21 Furthermore,
chemical proteomic proﬁling conducted in parasite cell extracts
conﬁrmed that compound 4m binds the endogenous TbGSK3
short with nanomolar aﬃnity and very few other kinase targets
with much lower aﬃnity in the micromolar range.22
■ CONCLUSION
In this study, we have developed a series of substituted
aminopyrazole amides as TbGSK3 short inhibitors starting
from a compound series initially designed by Astex
Therapeutics to inhibit HsCDK2 and HsGSK3β. SAR
investigation and optimization successfully provided 18 low
nanomolar (IC50 <10 nM) inhibitors of TbGSK3 with high
selectivity (>10000-fold) over HsCDK2. With compound 9g,
we have shown that good (330-fold) selectivity over HsGSK3
can be achieved by targeting the hydrophobic pocket II.
Compound 9g is the most selective TbGSK3 inhibitor
described to date.13,23−25 In addition, 9g proved to be highly
selective against a panel of 124 human PKs, showing >90%
inhibition at 10 μM against only one PK, HsGSK3β. Molecular
modeling has also shown that despite overall conservation in
sequence and conformation between the three PKs (HsGSK3β,
HsCDK2, and TbGSK3), the binding pockets have distinct
features that determine their speciﬁcity for particular
compounds. Further, we have shown that enzymatic inhibition
correlates well with cell eﬃcacy over a wide range of
concentrations and a representative member of this series
binds the endogenous TbGSK3 with nanomolar potency,
indicating that compounds deﬁnitely act on target.22 However,
a general 100-fold drop in activity between target and cellular
activities resulted at best in compounds with low micromolar
antiparasitic activity. Taken together, this data suggests that
speciﬁc ATP competitive hinge binders of TbGSK3 short
require low picomolar potency to obtain nanomolar anti-
proliferative activity against T. brucei. This leads us to the
conclusion that alternative strategies are required. First, non-
ATP competitive approaches to inhibition of TbGSK3, through
irreversible hinge binders or allosteric inhibitors, could be
pursued. However, these approaches have potential downsides,
through the introduction of a reactive functionality or an
increased chance of resistance causing mutations, respectively.
Second, a polypharmacology approach through the inhibition
of a number of essential T. brucei kinases in addition to
TbGSK3 could be investigated, although obtaining selectivity
over human kinases would be more problematical. However,
the aminopyrazole compounds (4a−4z and 9a−9x) reported
here represent an excellent start for chemistry optimization of
selective TbGSK3 short inhibitors and an outstanding probe for
studying the physiological functions of TbGSK3 short in T.
brucei parasites.
■ EXPERIMENTAL SECTION
Molecular Modeling. Homology Modeling. Sequence alignments
between T. brucei and HsGSK3β were generated using ClustalW.26
Subsequently, Modeler 9.227 was used to build homology models of
TbGSK3 short, whereas the HsGSK3β crystal structure (PDB code
1r0e) served as template. Modeler was run with default settings, and
only the highest-scoring structure was used for further analysis and
modeling.
Ligand Docking. FlexX 2.0.1 (BioSolveIT GmbH) was used to
dock ligands ﬂexible into protein binding sites.28 The active sites were
deﬁned as the areas within 7 Å of the co-crystallized ligands of
HsCDK2 (PDB code 2vu3)19 and HsGSK3β (PDB code 1r0e)29 or
the equivalent residues in the homology model of TbGSK3. In all three
structures, protonation states of amino acids and the orientations of
the protons of hydroxyl and amine groups of active-site residues were
manually assigned using the FlexX GUI. A highly conserved water
molecule (H2O 82 in 1r0e or H2O 2134 in 2vu3) was kept in all three
protein structures used for docking. Docking was carried out using
default settings, and only the highest scoring binding modes were
visually analyzed.
All ﬁgures of protein binding sites were prepared using PyMol.30
Potency Screen Assays. For compound potency determinations,
a radiometric 96-well Flashplate assay (PerkinElmer) was adopted.
Compounds were solubilized in DMSO at a top concentration of 3
mM and serially diluted to achieve 10-point titration of ﬁnal assay
concentrations from 30 μM to 0.3 nM with a ﬁnal DMSO
concentration of 1% (v/v). The reaction mixtures contained 1 μM
biotinylated GSP2 substrate, 1 μM ATP, 3.7 KBq/well [γ-33P]-ATP
and 2.5 nM TbGSK3 in the TbGSK3 kinase assay buﬀer. GSK3
inhibitors were screened for selectivity assessment also against
HsGSK3β. For HsGSK3 assay, the reaction mixes contained 1 μM
biotinylated GSP2 substrate, 2 μM ATP, 7.4 KBq/well [γ-33P]-ATP
and 15 nM HsGSK3β in the TbGSK3 kinase assay buﬀer (25 mM
Tris-HCl, pH 7.5, 10 mM MgCl2, 5 mM DTT, 0.02% CHAPS, 2 U/
mL heparin). For HsCDK2/cyclin A assay, the reaction mixtures
contained 1 mM CDK5 biotinylated peptide substrate (Biotin-C6-
PKTPKKAKKL), 1 μM ATP, 7.4 KBq/well [γ-33P]-ATP and 2 nM
HsCDK2/cyclin A in the kinase assay buﬀer (50 mM Tris-HCl, pH
7.5, 10 mM MgCl2, 2 mM DTT, 100 mM NaCl, 0.2 mM EGTA,
0.02% (v/v) Brij35).
Statistical Evaluation of Assay Reproducibility. The statistical
signiﬁcance of the compound potency (IC50) was based on the
performance of standard molecules which have been tested to a high
replication. In the case of TbGSK3 short assay, the standard
compound GW8510 was tested 93 times across 9 independent runs.
The average pIC50 value was 8.26 with a SD (standard deviation) of
0.23. The minimum signiﬁcant ratio (MSR) of 0.4 was evaluated
considering the following formula:
= × NMSR 2.3 SD/
where SD is the standard deviation and N the number of replicate
values routinely used for the assay (2 in our case).31 This implies that a
diﬀerence of >0.4 in pIC50 can be considered statistically signiﬁcant for
this assay.
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In the case of HsGSK3 assay, the standard compound GW8510 was
tested 47 times across 5 independent runs, with an average pIC50 value
of 8.10 and a SD of 0.21. This implies that a diﬀerence of >0.3 in pIC50
can be considered statistically signiﬁcant for this assay.
For the HsCDK2 assay, the analysis was performed using two
diﬀerent standards (GW8510 and staurosporine) tested respectively
ﬁve times in a single run and 19 times in 2 independent runs. This
implies that a diﬀerence of >0.3 in pIC50 can be considered statistically
signiﬁcant for this assay.
Mammalian Kinase Proﬁling. Selected compounds were
screened against a panel of mammalian kinases routinely run by the
Division of Signal Transduction Therapy (DSTT) at the University of
Dundee in duplicate at 10 μM.32 Enzymes included in the panel and
assay conditions are reported in the literature. All biochemical assays
are run below the Km
app for the ATP for each enzyme, allowing
comparison of inhibition across the panel.
Trypanosome and MRC5 Proliferation Assay. Measurement of
inhibition of the proliferation of MRC5 (human lung ﬁbroblast) cells
and T. b. brucei bloodstream stage cells was performed using a
modiﬁcation of the cell viability assay previously described.33
Compounds (50 μM to 0.5 nM) were incubated with 2 × 103 cells/
well in 0.2 mL of the appropriate culture medium (MEM with 10%
fetal bovine serum for MRC5 cells) in clear 96-well plates. Plates were
incubated at 37 °C in the presence of 5% CO2 for 69 h. Resazurin was
then added to a ﬁnal concentration of 50 μM, and plates were
incubated as above for a further 4 h before being read on a BioTek
ﬂx800 ﬂuorescent plate reader.
Chemistry. General Experimental Details. 1H and 13C NMR
spectra were recorded on either a Bruker Avance DPX 300 or 500
MHz spectrometer. Chemical shifts (δ) are expressed in parts per
million (ppm) and coupling constants (J) are in hertz (Hz). Signal
splitting patterns are described as singlet (s), broad singlet (br s),
doublet (d), triplet (t), quartet (q), quintuplet (quin), sextuplet (sex),
septet (sept), multiplet (m), or combinations thereof. LCMS (liquid
chromatography mass spectrometry) analyses were performed with
either an Agilent HPLC 1100 series connected to a Bruker Daltonics
MicrOTOF or an Agilent Technologies 1200 series HPLC connected
to an Agilent Technologies 6130 quadrupole LCMS, and both
instruments were connected to an Agilent diode array detector. LCMS
chromatographic separations were conducted with a Phenomenex
Gemini C18 column, 50 mm × 3.0 mm, 5 μm particle size; mobile
phase/acetonitrile +0.1% HCOOH 80:20 to 5:95 over 3.5 min, and
then held for 1.5 min; ﬂow rate 0.5 mL min−1. High resolution
electrospray measurements (HRMS) were performed with a Bruker
Daltonics MicrOTOF mass spectrometer. Thin layer chromatography
(TLC) was carried out on Merck silica gel 60 F254 plates using UV
light and/or KMnO4 for visualization. Column chromatography was
performed using RediSep 4 or 12 g silica prepacked columns. When
applicable, all glassware was oven-dried overnight and all reactions
were carried out under dry and inert conditions (Argon atmosphere).
All in this work synthesized compounds had a measured purity of
greater than 95% (measured on analytical HPLC-MS system). M+ data
are given below to substantiate the purity and integrity of the
compounds. 1H NMR, 13C NMR, and HRMS experiments were also
used to conﬁrm compound identity and purity.
N-((1r,4r)-4-Methoxycyclohexyl)-4-nitro-1H-pyrazole-3-carboxa-
mide (2). A mixture of 4-nitro-3-pyrazolecarboxylic acid (1) (2.33 g,
14.8 mmol), trans-4-methoxy-cyclohexylamine (2.39 g, 18.5 mmol),
EDC (3.55 g, 18.5 mmol), and HOBt (2.50 g, 18.5 mmol) in DMF
(75 mL) was stirred at ambient temperature for 16 h. The mixture was
reduced in vacuo and partitioned between saturated aqueous sodium
bicarbonate and EtOAc. The organic layer was washed (water, brine),
dried (MgSO4), and reduced in vacuo to give a yellow oil, which was
puriﬁed by column chromatography, eluting 0−100% EtOAc in
petroleum ether to give 2. Yield: 3.12 g (solid), 62%. 1H NMR
(DMSO-d6 DMSO-d6) δ (ppm) 14.02 (s, 1H), 8.73 (s, 1H), 8.57 (d, J
= 7.81 Hz, 1H), 3.74 (m, 1H), 3.24 (s, 3H), 3.11 (m, 1H), 1.95 (dd, J
= 55.8, 10.9 Hz, 4H), 1.27 (m, 4H). 13C NMR (DMSO-d6) δ (ppm)
159.04, 141.49, 132.17, 131.44, 77.40, 55.01, 47.58, 29.67, 29.30.
LRMS (ES+): m/z 269 [M + H]+.
4-Amino-N-(4-methoxycyclohexyl)-1H-pyrazole-3-carboxamide
(3). A solution of 2 (1.13 g, 4.2 mmol) in DMF (100 mL) was treated
with 10% palladium on carbon then shaken under hydrogen at room
temperature and atmospheric pressure for 5 h. The reaction mixture
was diluted with EtOAc, ﬁltered through Celite, washing with further
EtOAc, and the ﬁltrate reduced in vacuo to give crude 3 as brown oil.
Yield: 982 mg, 98%. 1H NMR (CD3OD) δ (ppm) 7.23 (s, 1H), 3.84
(m, 1H), 3.37 (s, 3H), 3.23 (m, 1H), 2.07 (dd, J = 45.8, 11.2 Hz, 4H),
1.38 (m, 4H). 13C NMR (MeOD-d4) δ (ppm) 165.58, 134.15, 133.13,
118.22, 79.72, 56.15, 48.58, 31.37. LRMS (ES+): m/z 239 [M + H]+.
General Method for Variation of Substituent R1: Example 4-
Benzamido-N-(4-methoxycyclohexyl)-1H-pyrazole-3-carboxamide
(4f). A mixture of benzoic acid (0.051 g, 0.42 mmol), 3 (0.1 g, 0.42
mmol), EDC (0.096 g, 0.5 mmol), and HOBt (0.068 g, 0.5 mmol) in
DMF (10 mL) was stirred at ambient temperature for 16 h. The
mixture was reduced in vacuo and partitioned between saturated
aqueous sodium bicarbonate and EtOAc. The organic layer was
washed (water, brine), dried (MgSO4), and reduced in vacuo to give a
creamy solid 4f, which was puriﬁed by column chromatography.
Evaporation of the appropriate fraction yielded the desired compound
as an amorphous solid. Yield: 39 mg, 27%. 1H NMR (CDCl3) δ (ppm)
10.65 (s, 1H), 8.52 (s, 1H), 8.01 (d, J = 7.2 Hz, 2H), 7.57 (t, J = 7.2
Hz, 1H), 7.51 (m, 2H), 6.86 (d, J = 8.3 Hz, 1H), 4.01 (m, 1H), 3.39
(s, 3H), 3.22 (m, 1H), 2.16 (m, 4H), 1.42 (m, 4H). 13C NMR
(CDCl3) δ (ppm) 164.36, 163.21, 133.54, 133.28, 132.03, 128.83,
127.24, 123.74, 120.82, 78.13, 55.91, 47.48, 30.69, 30.11. LRMS (ES+):
m/z 343 [M + H]+. HRMS (ES+): calcd for C18H23N4O3 [M + H]
+
343.1765, found 343.1751.
4-(4,4-Diﬂuorocyclohexanecarboxamido)-N-(4-methoxycyclo-
hexyl)-1H-pyrazole-3-carboxamide (4a). Yield: 90 mg (solid) 56%.
1H NMR (CDCl3) δ (ppm) 9.86 (s, 1H), 8.35 (s, 1H), 6.83 (d, J = 8.3
Hz, 1H), 3.95 (m, 1H), 3.39 (s, 3H), 3.21 (m, 1H), 2.44 (m, 1H), 2.22
(m, 2H), 2.11 (m, 6H), 1.94 (m, 2H), 1.81 (m, 2H), 1.40 (m, 4H).
13C NMR (CDCl3) δ (ppm) 171.61, 163.21, 133.28, 123.22, 122.55 (t,
J = 239.4 Hz), 120.71, 78.07, 55.91, 47.50, 42.74, 32.85 (t, J = 23.5
Hz), 30.35, 25.73. LRMS (ES+): m/z 385 [M + H]+. HRMS (ES+):
calcd for C18H27F2N4O3 [M + H]
+ 385.2046, found 385.2036.
N-(4-Methoxycyclohexyl)-4-(tetrahydro-2H-pyran-4-carboxami-
do)-1H-pyrazole-3-carboxamide (4b). Yield: 94 mg (solid), 64%. 1H
NMR (CDCl3) δ (ppm) 9.86 (s, 1H), 8.34 (s, 1H), 6.81 (d, J = 8.1
Hz, 1H), 4.07 (m, 2H), 3.95 (m, 1H), 3.47 (m, 2H), 3.39 (s, 3H), 3.20
(m, 1H), 2.59 (m, 1H), 2.13 (d, J = 11.0 Hz, 4H), 1.91 (m, 4H), 1.40
(m, 4H). 13C NMR (CDCl3) δ (ppm) 171.97, 163.30, 133.22, 123.23,
120.71, 78.12, 67.26, 55.92, 47.50, 42.20, 30.64, 30.12, 29.10. LRMS
(ES+): m/z 351 [M + H]+. HRMS (ES+): calcd for C17H27N4O4 [M +
H]+ 351.2027, found 351.2011.
4-(2-(2-Fluorophenyl)acetamido)-N-(4-methoxycyclohexyl)-1H-
pyrazole-3-carboxamide (4c). Yield: 56 mg (solid), 71%. 1H NMR
(CD3OD) δ (ppm) 8.20 (s, 1H), 7.38 (t, 7.7 Hz, 1H), 7.34−7.26 (m,
1H), 7.18−7.05 (m, 2H), 3.83 (m, 1H), 3.80 (s, 2H), 3.33 (s, 3H),
3.16 (m, 1H), 2.06 (br d, J = 11.5 Hz, 2H), 1.97 (br d, J = 12.0 Hz,
2H), 1.34 (m, 4H). 13C NMR (CD3OD) δ (ppm) 169.57, 164.14 (d, J
= 159.5 Hz), 134.23, 132.98, 130.64 (d, J = 10.9 Hz), 125.75, 123.77,
123.20 (d, J = 18.2 Hz), 121.96, 116.48 (d, J = 21.7 Hz), 79.69, 56.14,
48.68, 37.61, 31.41, 31.27. LRMS (ES+): m/z 375 [M + H]+. HRMS
(ES+): calcd for C19H24FN4O3 [M + H]
+ 375.1827, found 375.1817.
N-(4-Methoxycyclohexyl)-4-(2-(2-methoxyphenyl)acetamido)-
1H-pyrazole-3-carboxamide (4d). Yield: 43 mg (solid), 53%. 1H
NMR (DMSO-d6) δ (ppm) 13.13 (s, 1H), 9.76 (s, 1H), 8.15 (s, 1H),
8.00 (d, J = 8.3 Hz, 1H), 7.31−7.23 (m, 2H), 7.02 (d, J = 8.0 Hz, 1H),
6.93 (t, J = 7.4 Hz, 1H), 3.82 (s, 3H), 3.79−3.70 (m, 1H), 3.24 (s,
3H), 3.07 (m, 1H), 2.01 (d, J = 11.4 Hz, 2H), 1.79 (d, J = 11.4 Hz,
2H), 1.45 (m, 2H), 1.21 (m, 2H). 13C NMR (DMSO-d6) δ (ppm)
167.30, 162.43, 157.02, 132.38, 130.90, 128.59, 123.21, 122.30, 120.44,
119.70, 110.88, 77.70, 55.41, 55.04, 46.70, 38.17, 30.26, 29.73.
LRMS(ES+): m/z 387 [M + H]+. HRMS (ES+): calcd for C20H27N4O4
[M + H]+ 387.2027, found 387.2028.
4-(2-(2,6-Dichlorophenyl)acetamido)-N-(4-methoxycyclohexyl)-
1H-pyrazole-3-carboxamide (4e). Yield: 63 mg (solid), 81%. 1H
NMR (DMSO-d6) δ (ppm) 13.18 (br s, 1H), 9.86 (s, 1H), 8.14 (s,
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1H), 8.05 (d, J = 7.9 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.36 (t, J = 8.2
Hz, 1H), 4.10 (s, 2H), 3.76 (m, 1H), 3.24 (s, 3H), 3.08 (s, 1H), 2.01
(m, 2H), 1.81 (m, 2H), 1.45 (m, 2H), 1.19 (m, 2H). 13C NMR
(DMSO-d6) δ (ppm) 170.16, 162.31, 135.49, 131.62, 129.68, 128.30,
128.10, 122.23, 122.09, 77.68, 55.04, 46.77, 38.23, 30.25, 29.74. LRMS
(ES+): m/z 425 [M + H]+. HRMS (ES+): calcd for C19H23Cl2N4O3
[M + H]+ 425.1142, found 425.1147.
4-(2-Fluorobenzamido)-N-(4-methoxycyclohexyl)-1H-pyrazole-3-
carboxamide (4g). Yield: 97 mg (solid), 64%. 1H NMR (CDCl3) δ
(ppm) 10.89 (d, J = 12.2 Hz, 1H), 8.45 (s, 1H), 8.07 (m, 1H), 7.44
(m, 1H), 7.22 (m, 1H), 7.13 (m, 1H), 6.73 (d, J = 8.3 Hz, 1H), 3.96
(m, 1H), 3.29 (s, 3H), 3.11 (m, 1H), 2.05 (m, 4H), 1.31 (m, 4H). 13C
NMR (CDCl3) δ (ppm) 162.80, 160.84 (d, J = 246.9 Hz), 160.53,
133.81 (d, J = 10.9 Hz), 131.77, 124.79, 123.19, 121.42, 120.65 (d, J =
10.7 Hz), 116.46 (d, J = 21.8 Hz), 78.19, 55.88, 47.27, 30.75, 30.14.
LRMS (ES+): m/z 361 [M + H]+. HRMS (ES+): calcd for
C18H22FN4O3 [M + H]
+ 361.1670, found 361.1645.
N-(4-Methoxycyclohexyl)-4-(2-(triﬂuoromethyl)benzamido)-1H-
pyrazole-3-carboxamide (4h). Yield: 67 mg (solid), 78%. 1H NMR
(DMSO-d6) δ (ppm) 13.40 (s, 1H), 10.22 (s, 1H), 8.32 (s, 1H), 8.29
(d, J = 8.6 Hz, 1H), 7.90−7.88 (m, 1H), 7.84−7.81 (m, 1H), 7.78−
7.75 (m, 2H), 3.72 (m, 1H), 3.23 (s, 3H), 3.06 (m, 1H), 2.00 (br d, J =
12.5 Hz, 2H), 1.76 (br d, J = 12.5 Hz, 2H), 1.45 (m, 2H), 1.14 (m,
2H). 13C NMR (DMSO-d6) δ (ppm) 163.34, 162.73, 135.06, 133.01,
132.78, 130.73, 128.39, 126.63 (d, J = 5.2 Hz) 126.04 (d, J = 29.1 Hz),
123.57 (d, J = 276.3 Hz), 122.06, 120.30, 77.66, 55.06, 46.97, 30.28,
29.67. LRMS (ES+): m/z 411 [M + H]+. HRMS (ES+): calcd for
C19H22F3N4O3 [M + H]
+ 411.1639, found 411.1621.
4-(2-Ethylbenzamido)-N-(4-methoxycyclohexyl)-1H-pyrazole-3-
carboxamide (4i). Yield: 63 mg (solid), 81%. 1H NMR (CDCl3) δ
(ppm) 10.04 (s, 1H), 8.39 (s, 1H), 7.53 (d, J = 7.6 Hz, 1H), 7.39 (t, J
= 7.6 Hz, 1H), 7.30 (d, 7.7 Hz, 1H), 7.25 (t, J = 7.5 Hz, 1H), 6.87 (d, J
= 8.3 Hz, 1H), 3.92 (m, 1H), 3.36 (s, 3H), 3.16 (m, 1H), 2.90 (q, J =
7.6 Hz, 2H), 2.08 (br d, J = 10.0 Hz, 4H), 1.35 (m, 4H), 1.26 (t, J =
7.6 Hz, 3H). 13C NMR (CDCl3) δ (ppm) 167.60, 163.29, 142.86,
134.89, 133.19, 130.65, 129.69, 127.15, 126.11, 123.25, 120.94, 78.18,
55.86, 74.45, 30.58, 30.12, 26.44, 15.84. LRMS (ES+): m/z 371 [M +
H]+. HRMS (ES+): calcd for C20H27N4O3 [M + H]
+ 371.2078, found
371.2078.
4-(2-Methoxybenzamido)-N-(4-methoxycyclohexyl)-1H-pyrazole-
3-carboxamide (4j). Yield: 35 mg (solid), 45%. 1H NMR: (DMSO-
d6) δ (ppm) 13.25 (s, 1H), 11.77 (s, 1H), 8.44 (s, 1H), 8.15 (s, 1H),
8.04 (s, 1H), 7.63 (s, 1H), 7.29 (s, 1H), 7.18 (s, 1H), 4.15 (s, 3H),
3.88 (m, 1H), 3.30 (s, 3H), 3.16 (m, 1H), 2.08 (m, 2H), 1.91 (m, 2H),
1.55 (m, 2H), 1.29 (m, 2H). 13C NMR (DMSO-d6) δ (ppm) 162.43,
160.94, 157.47, 133.49, 131.33, 122.29, 120.83, 120.59, 120.28, 112.32,
77.73, 56.05, 55.05, 46.72, 30.28, 29.83. LRMS (ES+): m/z 373 [M +
H]+. HRMS (ES+): calcd for C19H25N4O4 [M + H]
+ 373.1870, found
373.1873.
N-(4-Methoxycyclohexyl)-4-(2-(phenylamino)benzamido)-1H-
pyrazole-3-carboxamide (4k). Yield: 41 mg (solid), 45%. 1H NMR
(DMSO-d6) δ (ppm) 13.32 (br s, 1H), 10.93 (s, 1H), 9.53 (s, 1H),
8.31 (s, 1H), 8.28 (d, J = 8.5 Hz, 1H), 7.68 (dd, J = 8.0, 1.4 Hz, 1H),
7.43 (m, 1H), 7.33−7.28 (m, 3H), 7.16−7.14 (m, 2H), 7.01−6.96 (m,
2H), 3.82 (m, 1H), 3.35 (s, 1H), 3.25 (s, 3H), 3.09 (m, 1H), 2.03 (br
d, J = 12.0 Hz, 2H), 1.81 (br d, J = 12.0 Hz, 2H), 1.48 (m, 2H), 1.20
(m, 2H). 13C NMR (DMSO-d6) δ (ppm) 164.84, 162.97, 144.57,
141.62, 132.81, 129.33, 128.04, 122.32, 122.00, 120.01, 119.63, 119.26,
118.30, 116.49, 77.74, 55.06, 46.95, 30.33, 29.73. LRMS (ES+): m/z
434 [M + H]+. HRMS (ES+): calcd for C24H28N5O3 [M + H]
+
434.2187, found 434.2165.
4-(2-((2,3-Dimethylphenyl)amino)benzamido)-N-(4-methoxycy-
clohexyl)-1H-pyrazole-3-carboxamide (4l). Yield: 53 mg (solid),
55%. 1H NMR (DMSO-d6) δ (ppm) 13.35 (br s, 1H), 10.89 (s, 1H),
9.53 (s, 1H), 8.33 (s, 1H), 7.63 (dd, J = 8.1, 1.4 Hz, 1H), 7.34 (m,
1H), 7.11−7.09 (m, 2H), 6.99−6.97 (m, 1H), 6.87 (m, 1H), 6.82 (dd,
J = 8.4, 1.0 Hz, 1H), 3.84 (m, 1H), 3.35 (s, 1H), 3.25 (s, 3H), 3.09 (m,
1H), 2.29 (s, 3H), 2.14 (s, 3H), 2.03 (br d, J = 12.0 Hz, 2H), 1.82 (br
d, J = 12.0 Hz, 2H), 1.49 (m, 2H), 1.21 (m, 2H). 13C NMR (DMSO-
d6) δ (ppm) 165.36, 163.08, 147.05, 138.87, 137.74, 132.95, 132.72,
130.25, 127.52, 125.96, 125.74, 122.41, 120.79, 119.98, 117.44, 115.36,
114.63, 77.74, 55.06, 46.95, 30.33, 29.75, 20.25, 13.64. LRMS (ES+):
m/z 462 [M + H]+. HRMS (ES+): calcd for C26H32N5O3 [M + H]
+
462.2500, found 462.2503.
4-(2,6-Dimethoxybenzamido)-N-(4-methoxycyclohexyl)-1H-pyra-
zole-3-carboxamide (4m). Yield: 73 mg, 43% (solid). 1H NMR
(DMSO-d6) δ (ppm) 13.28 (s, 1H), 9.75 (s, 1H), 8.29 (s, 1H), 8.20
(d, J = 8.4 Hz, 1H), 7.39 (t, J = 8.5 Hz, 1H), 6.75 (d, J = 8.5 Hz, 2H),
3.76 (s, 6H), 3.70 (m, 1H), 3.22 (s, 3H), 3.06 (m, 1H), 2.00 (m, 2H),
1.76 (m, 2H), 1.45 (m, 2H), 1.13 (m, 2H). 13C NMR (DMSO-d6) δ
(ppm) 162.79, 161.21, 156.88, 132.21, 131.08, 122.52, 119.81, 115.03,
104.28, 77.66, 55.81, 55.08, 46.93, 30.29, 29.66. LRMS (ES+): m/z 403
[M + H]+. HRMS (ES+): calcd for C20H27N4O5 [M + H]
+ 403.1976,
found 403.1960.
N-(4-Methoxycyclohexyl)-4-(2,4,6-trimethoxybenzamido)-1H-
pyrazole-3-carboxamide (4n). Yield: 76 mg (solid), 84%. 1H NMR
(CD3OD) δ (ppm) 8.36 (s, 1H), 6.17 (s, 2H), 3.84 (s, 3H), 3.82 (s,
6H), 3.35 (s, 3H), 3.22 (m, 1H), 2.08 (m, 4H), 1.36 (m, 4H). 13C
NMR (CD3OD) δ (ppm) 164.90, 164.72, 164.35, 160.74, 134.07,
124.36, 122.58, 108.39, 92.09, 79.74, 57.05, 56.89, 56.62, 48.71, 31.61,
31.40. LRMS (ES+): m/z 433 [M + H]+. HRMS (ES+): calcd for
C21H29N4O6 [M + H]
+ 433.2082, found 433.2065.
4-(2,4-Diﬂuorobenzamido)-N-(4-methoxycyclohexyl)-1H-pyra-
zole-3-carboxamide (4o). Yield: 114 mg (solid), 72%. 1H NMR
(DMSO-d6) δ (ppm) 13.24 (s, 1H), 10.89 (d, J = 10.2 Hz, 1H), 8.33
(s, 1H), 8.09 (q, J = 8.7 Hz, 1H), 8.05 (d, J = 8.4 Hz, 1H), 7.39 (m,
1H), 7.24 (m, 1H), 3.82 (m, 1H), 3.25 (s, 3H), 3.10 (m, 1H), 2.02 (d,
J = 10.3 Hz, 2H), 1.84 (d, J = 11.6 Hz, 2H), 1.47 (q, J = 12.0 Hz, 2H),
1.22 (q, J = 12.5 Hz, 2H). 13C NMR (DMSO-d6) δ (ppm) 164.3 (q, J
= 250.6, 10.9 Hz), 162.71, 160.3 (q, J = 250.8, 14.5 Hz), 158.03,
133.26, 133.18, 132.82, 122.12, 120.50, 117.39, 117.31, 112.59, 112.42,
104.96, 104.75, 104.52, 79.12, 78.84, 78.58, 77.71, 55.07, 46.89, 30.09,
29.76;. LRMS (ES+): m/z 379 [M + H]+. HRMS (ES+): calcd for
C18H21F2N4O3 [M + H]
+ 379.1576, found 379.1567.
4-(3,5-Diﬂuorobenzamido)-N-(4-methoxycyclohexyl)-1H-pyra-
zole-3-carboxamide (4p). Yield: 157 mg (solid), 99%. 1H NMR
(DMSO-d6) δ (ppm) 13.39 (s, 1H), 10.77 (s, 1H), 8.34 (d, J = 8.5 Hz,
1H), 8.30 (s, 1H), 7.59 (m, 1H), 7.52 (m, 2H), 3.84 (m, 1H), 3.24 (s,
3H), 3.09 (m, 1H), 2.02 (d, J = 10.7 Hz, 2H), 1.81 (d, J = 10.7 Hz,
2H), 1.49 (q, J = 11.8 Hz, 2H), 1.20 (q, J = 11.8 Hz, 2H). 13C NMR
(DMSO-d6) δ (ppm) 162.8, 162.5(q, J = 250.7, 14.4 Hz), 160.3,
137.16 127.75, 126.59, 124.12, 122.13, 118.94, 110.2 (q, J = 22.0, 14.5
Hz), 107.5 (t, J = 27.0 Hz), 77.71, 55.06, 46.99, 30.29, 29.76. LRMS
(ES+): m/z 379 [M + H]+. HRMS (ES+): calcd for C18H21F2N4O3 [M
+ H]+ 379.1576, found 379.1568.
4-(3,5-Dichlorobenzamido)-N-(4-methoxycyclohexyl)-1H-pyra-
zole-3-carboxamide (4q). Yield: 147 mg (solid), 85%. 1H NMR
(CDCl3) δ (ppm) 10.34 (s, 1H), 8.23 (s, 1H), 7.60 (d, J = 1.9 Hz,
2H), 7.31 (t, J = 1.8 Hz, 1H), 7.05 (s, 1H), 6.58 (d, 1H), 3.77 (m,
1H), 3.15 (s, 3H), 2.98 (m, 1H), 1.91 (m, 4H), 1.18 (m, 4H). 13C
NMR (DMSO-d6) δ (ppm) 163.12, 161.74, 136.46, 135.73, 131.89,
128.34, 126.03, 125.79, 121.09, 78.10, 55.91, 47.48, 30.69, 30.08.
LRMS (ES+): m/z 411 [M + H]+. HRMS (ES+): calcd for
C18H21Cl2N4O3 [M + H]
+ 411.0985, found 411.0966.
4-(4-(Diﬂuoromethoxy)benzamido)-N-(4-methoxycyclohexyl)-
1H-pyrazole-3-carboxamide (4r). Yield: 96 mg (solid), 56%. 1H
NMR (CDCl3) δ (ppm) 10.65 (s, 1H), 8.48 (s, 1H), 8.02 (d, J = 8.6
Hz, 2H), 7.24 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 8.3 Hz, 1H), 6.62 (t, J =
73.2 Hz, 1H), 4.00 (m, 1H), 3.39 (s, 3H), 3.22 (m, 1H), 2.15 (m, 4H),
1.42 (m, 4H). 13C NMR (CDCl3) δ (ppm) 163.28, 163.20, 154.0 (t, J
= 2.9 Hz), 133.56, 130.28, 129.24, 123.64, 120.74, 119.22, 118.94,
115.47, 112.01, 78.11, 55.94, 47.53, 30.67, 30.12. LRMS (ES+): m/z
409 [M + H]+. HRMS (ES+): calcd for C19H23F2N4O4 [M + H]
+
409.1682, found 409.1649.
N-(4-Methoxycyclohexyl)-4-(4-(pyrrolidin-1-yl)benzamido)-1H-
pyrazole-3-carboxamide (4s). Yield: 73 mg (solid), 42%. 1H NMR
(CDCl3) δ (ppm) 10.44 (s, 1H), 8.49 (s, 1H), 7.89 (d, J = 8.8 Hz,
2H), 6.85 (d, J = 8.3 Hz, 1H), 6.62 (d, J = 8.8 Hz, 2H), 4.01 (m, 1H),
3.39 (m, 7H), 3.20 (m, 1H), 2.15 (m, 4H), 2.06 (m, 4H), 1.41 (m,
4H). 13C NMR (CDCl3) δ (ppm) 164.74, 163.48, 150.26, 133.26,
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128.99, 124.26, 120.52, 119.42, 111.20, 78.20, 55.92, 47.66, 47.39,
30.73, 30.18, 25.46. LRMS (ES+): m/z 412 [M + H]+. HRMS (ES+):
calcd for C22H30N5O3 [M + H]
+ 412.2343, found 412.2338.
N-(4-Methoxycyclohexyl)-4-(4-(4-methylpiperazin-1-yl)-
benzamido)-1H-pyrazole-3-carboxamide (4t). Yield: 37 mg (solid),
20%. 1H NMR (CDCl3) δ (ppm) 10.48 (s, 1H), 8.47 (s, 1H), 7.90 (d,
J = 8.8 Hz, 2H), 6.94 (d, J = 8.8 Hz, 2H), 6.83 (m, 1H), 4.00 (m, 1H),
3.39 (s, 3H), 3.37 (t, J = 5 Hz, 4H), 3.20 (m, 1H), 2.60 (t, J = 5 Hz,
4H), 2.38 (s, 3H), 2.14 (m, 4H), 1.41 (m, 4H). 13C NMR (CDCl3) δ
(ppm) 164.17, 163.44, 153.54, 133.33, 128.81, 124.05, 122.92, 120.61,
114.27, 78.17, 55.92, 54.79, 47.62, 47.41, 46.11, 30.72, 30.17. LRMS
(ES+): m/z 441 [M + H]+. HRMS (ES+): calcd for C23H33N6O3 [M +
H]+ 441.2609, found 441.2597.
4-(Benzofuran-2-carboxamido)-N-(4-methoxycyclohexyl)-1H-
pyrazole-3-carboxamide (4u). Yield: 134 mg (solid), 83%. 1H NMR
(CDCl3) δ (ppm) 10.76 (s, 1H), 8.53 (s, 1H), 7.70 (d, J = 7.5 Hz,
1H), 7.66 (d, J = 8.4 Hz, 1H), 7.59 (d, J = 0.9 Hz, 1H), 7.46 (t, J = 7.8
Hz, 1H), 7.33 (t, J = 7.5 Hz, 1H), 6.85 (d, J = 8.4 Hz, 1H), 4.07 (m,
1H), 3.40 (s, 3H), 3.22 (m, 1H), 2.16 (m, 4H), 1.43 (m, 4H). 13C
NMR (CDCl3) δ (ppm) 163.03, 156.21, 155.22, 148.18, 133.76,
129.23, 127.56, 127.24, 123.77, 122.59, 121.20, 112.41, 111.23, 78.15,
55.91, 47.41, 30.74, 30.14. LRMS (ES+): m/z 383 [M + H]+. HRMS
(ES+): calcd for C20H23N4O4 [M + H]
+ 383.1714, found 383.1703.
N-(3-((4-Methoxycyclohexyl)carbamoyl)-1H-pyrazol-4-yl)-
pyrazolo[1,5-a]pyridine-2-carboxamide (4v). Yield: 115 mg (solid),
72%. 1H NMR (DMSO-d6) δ (ppm) 13.30 (s, 1H), 11.01 (s, 1H),
8.83 (d, J = 7.0 Hz, 1H), 8.37 (s, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.82
(d, J = 8.9 Hz, 1H), 7.34 (t, J = 7.7 Hz, 1H), 7.09 (t, J = 6.9 Hz, 1H),
3.85 (m, 1H), 3.26 (s, 3H), 3.11 (m, 1H), 2.04 (d, J = 10.3 Hz, 2H),
1.84 (d, J = 10.7 Hz, 2H), 1.49 (m, 2H), 1.23 (m, 2H). 13C NMR
(DMSO-d6) δ (ppm) 162.70, 158.15, 146.85, 141.15, 132.80, 128.99,
124.60, 122.00, 120.08, 119.14, 114.53, 97.79, 77.74, 55.06, 46.95,
30.33, 29.79. LRMS (ES+): m/z 383 [M + H]+. HRMS (ES+): calcd
for C19H23N6O3 [M + H]
+ 383.1826, found 383.1812.
N-(3-((4-Methoxycyclohexyl)carbamoyl)-1H-pyrazol-4-yl)-
imidazo[1,2-a]pyridine-3-carboxamide (4w). Yield: 11 mg (solid),
7%. 1H NMR (MeOD-d4) δ (ppm) 9.57 (d, J = 6.9 Hz, 1H), 8.31 (d, J
= 8.3 Hz, 2H), 7.74 (d, J = 9.0 Hz, 1H), 7.57 (td, J = 6.9, 1.2 Hz, 1H),
7.19 (t, J = 6.9, 1.2 Hz, 1H), 3.94 (m, 1H), 3.39 (s, 3H), 3.27 (m, 1H),
2.12 (m, 4H), 1.50 (m, 2H), 1.39 (m, 2H). 13C NMR (DMSO-d6) δ
(ppm) 162.89, 156.52, 147.37, 136.35, 127.61, 127.41, 122.12, 119.89,
117.57, 117.46, 114.43, 77.71, 55.07, 46.90, 30.30, 29.76. LRMS (ES+):
m/z 383 [M + H]+. HRMS (ES+): calcd for C19H23N6O3 [M + H]
+
383.1826, found 383.1811.
N-(3-((4-Methoxycyclohexyl)carbamoyl)-1H-pyrazol-4-yl)-2-
methylimidazo[1,2-a]pyridine-3-carboxamide (4x). Yield: 47 mg
(solid), 28%. 1H NMR (CDCl3) δ (ppm) 10.88 (s, 1H), 10.24 (s, 1H),
9.58 (d, J = 6.9 Hz, 1H), 8.51 (s, 1H), 7.67 (d, J = 9.0 Hz, 1H), 7.41 (t,
J = 7.9 Hz, 1H), 6.99 (t, J = 6.9 Hz, 1H), 6.80 (d, J = 7.9 Hz, 1H), 4.01
(m, 1H), 3.39 (s, 3H), 3.21 (m, 1H), 3.02 (s, 3H), 2.14 (m, 4H), 1.41
(m, 4H). 13C NMR (DMSO-d6) δ (ppm) 162.73, 157.27, 146.18,
145.49, 127.61, 127.42, 122.35, 120.04, 116.31, 114.46, 113.62, 77.74,
55.06, 46.77, 30.24, 29.81, 16.52. LRMS (ES+): m/z 397 [M + H]+.
HRMS (ES+): calcd for C20H25N6O3 [M + H]
+ 397.1983, found
397.1972.
N-(4-Methoxycyclohexyl)-4-(5-phenylfuran-2-carboxamido)-1H-
pyrazole-3-carboxamide (4y). Yield: 107 mg (solid), 62%. 1H NMR
(CDCl3): δ (ppm) 10.61 (s, 1H), 8.49 (s, 1H), 7.84 (m, 2H), 7.48 (t, J
= 7.5 Hz, 2H), 7.38 (t, J = 7.4 Hz, 1H), 7.31 (t, J = 3.6 Hz, 1H), 6.85
(d, J = 8.5 Hz, 1H), 6.80 (d, J = 3.6 Hz, 1H), 4.07 (m, 1H), 3.40 (s,
3H), 3.22 (m, 1H), 2.16 (m, 4H), 1.42 (m, 4H). 13C NMR (CDCl3) δ
(ppm) 163.03, 156.39, 155.72, 146.33, 133.74, 129.49, 128.94, 128.80,
124.72, 122.85, 120.91, 117.13, 107.30, 78.18, 55.88, 47.25, 30.78,
30.14. LRMS (ES+): m/z 409 [M + H]+. HRMS (ES+): calcd for
C22H25N4O4 [M + H]
+ 409.1870, found 409.1832.
N-(3-((4-Methoxycyclohexyl)carbamoyl)-1H-pyrazol-4-yl)-5-phe-
nyloxazole-4-carboxamide (4z). Yield: 71 mg (solid), 41%. 1H NMR
(DMSO-d6) δ (ppm) 13.30 (s, 1H), 11.20 (s, 1H), 8.68 (s, 1H), 8.38
(s, 1H), 8.30 (m, 2H), 8.14 (d, J = 8.4 Hz, 1H), 7.58−7.51 (m, 3H),
3.83 (m, 1H), 3.26 (s, 3H), 3.11 (m, 1H), 2.04 (d, J = 10.5 Hz, 2H),
1.84 (d, J = 11.0 Hz, 2H), 1.49 (q, J = 12.5 Hz, 2H), 1.23 (q, J = 11.5
Hz, 2H). 13C NMR (DMSO-d6) δ (ppm) 162.64, 157.34, 151.99,
150.43, 132.90, 130.23, 128.50, 128.07, 127.92, 126.62, 121.89, 120.02,
77.74, 55.06, 47.00, 30.33, 29.76. LRMS (ES+): m/z 410 [M + H]+.
HRMS (ES+): calcd for C21H24N5O4 [M + H]
+ 410.1823, found
410.1807.
Methyl 4-Nitro-1H-pyrazole-3-carboxylate (5). A 100 mL three-
necked round-bottomed ﬂask equipped with a magnetic stirring bar
and ﬁtted with a dropping funnel was charged with 4-nitro-1H-
pyrazole-3-carboxylic acid (4.0 g, 25.5 mmol) and methanol (40 mL).
The ﬂask was cooled to 0 °C, and thionyl chloride (2.1 mL, 28.9
mmol) was added to the vigorously stirred solution over a period of 10
min. The mixture was stirred for an additional 12 h at room
temperature, after which time TLC indicated complete consumption
of the starting acid. The reaction mixture was concentrated under
reduced pressure at 40 °C and the residue treated with toluene and
reconcentrated (3 × 20 mL) under reduced pressure at 40 °C to give
methyl ester 5 as an oﬀ-white solid. Yield: 4.42 g, 99%. 1H NMR
(DMSO-d6) δ (ppm) 14.39 (br s, 1H), 9.98 (s, 1H), 3.90 (s, 3H).
13C
NMR (DMSO-d6) δ (ppm) 161.15, 138.13, 133.20, 130.90, 52.84.
LRMS (ES+): m/z 172 [M + H]+.
Methyl-4-amino-1H-pyrazole-3-carboxylate (6). A 100 mL round-
bottomed ﬂask equipped with digital thermometer and stirrer was
charged with 10% palladium on carbon (0.621 g) under argon. In a
separate vessel, a slurry of methyl ester 5 (4.42 g, 25.8 mmol) in
ethanol (45 mL) was warmed to 35 °C to eﬀect dissolution and the
solution added to the catalyst under argon. Following a nitrogen−
hydrogen purge sequence, an atmosphere of hydrogen was introduced
and the reaction mixture maintained at 30 °C until the reaction
completion (6 h) was noted by 1H NMR analysis. Following a purge
cycle, the reaction mixture under argon was ﬁltered and the liquors
concentrated under reduced pressure to give amine 6 as a solid. Yield:
3.57 g, 98%. 1H NMR (DMSO-d6) δ (ppm) 12.83 (br s, 1H), 7.10 (s,
1H), 4.83 (br s, 2H), 3.78 (s, 3H). 13C NMR (DMSO-d6) δ (ppm)
160.39, 136.94, 128.43, 115.59, 50.88. LRMS (ES+): m/z 142 [M +
H]+.
Methyl-4-(2,6-dimethoxybenzamido)-1H-pyrazole-3-carboxylate
(7). A solution of amine 6 (3.57 g, 25.3 mmol) in 1,4-dioxane (50 mL)
under argon was treated with triethylamine (4.3 mL, 31 mmol)
followed by 2,6-dimethoxybenzoyl chloride (6.13 g, 30.6 mmol) such
that the internal temperature was maintained in the range 20−25 °C.
The reaction mixture was stirred at 25 °C until the reaction was
complete (12 h) by TLC analysis. The reaction mixture was ﬁltered,
the ﬁlter-cake washed with 1,4-dioxane, and the combined ﬁltrates
progressed to next stage without further isolation.
To obtain analytical data for compound 7 and also to determine the
yield of this reaction, a 2 g sample was taken out of the homogeneous
ﬁltrate solution (total weight of this solution is 91g). The 2 g sample
was then concentrated under reduced pressure until dryness. The
crude product (∼192 mg) was puriﬁed by column chromatography
(DCM/MeOH). Evaporation of the appropriate fractions yielded
ﬁnally the desired compound 7 as an amorphous solid (161 mg).
Therefore, in the whole ﬁltrate contained 7.33 g of compound 7. A 5
mg sample was used for to obtain analytical data; the rest was
redissolved for use in the next reaction. Yield: 7.33 g, 95%. 1H NMR
(DMSO-d6) 13.68 (br s, 1H), 9.16 (s, 1H), 8.31 (s, 1H), 7.41 (t, J =
8.4 Hz, 1H), 6.76 (d, J = 8.4 Hz, 2H), 3.83 (s, 3H), 3.77 (s, 6H). 13C
NMR (DMSO-d6) δ (ppm) 163.86, 161.55, 157.07, 131.27, 129.97,
123.61, 120.41, 114.66, 104.35, 55.84, 51.63. LRMS (ES+): m/z 306
[M + H]+. HRMS (ES+): calcd for C14H16N3O5 [M + H]
+ 306.1084,
found 306.1081.
4-(2,6-Dimethoxybenzamido)-1H-pyrazole-3-carboxylic Acid (8).
To a solution of sodium hydroxide (3.32 g, 83 mmol) in water (20
mL) was charged a solution of ester 7 in one portion (7.33 g, 24.0
mmol; the solution of crude 7 from the previous reaction, plus 156 mg
of redissolved pure 7). The reaction mixture was stirred at 25 °C until
completion as determined by TLC analysis. The reaction mixture was
concentrated under reduced pressure at 45 °C, the oily residue diluted
with water and acidiﬁed to pH 1 with concentrated hydrochloric acid,
such that the temperature was maintained below 30 °C. The resulting
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precipitate was collected by ﬁltration, washed with water, pulled dry on
the ﬁlter, and subsequently washed with heptanes. The ﬁlter cake was
charged to a 200 mL rotary evaporator ﬂask and drying completed
azeotropically with toluene. Yield: 6.22 g, 89%. 1H NMR (DMSO-d6)
13.44 (br s, 2H), 9.17 (br s, 1H), 8.29 (s, 1H), 7.40 (t, J = 8.4 Hz, 1H),
6.76 (d, J = 8.4 Hz, 2H), 3.77 (s, 6H). LRMS (ES+): m/z 292 [M +
H]+. HRMS (ES+): calcd for C13H14N3O5 [M + H]
+ 292.0928, found
292.0920.
General Method for Variation of Substituent R2: Example N-
Cyclohexyl-4-(2,6-dimethoxybenzamido)-1H-pyrazole-3-carboxa-
mide (9c). A mixture of carboxylic acid (50 mg, 0.17 mmol, 1.2 equiv),
amine (14 mg, 0.14 mmol, 1.0 equiv), hydroxybenzotriazole (19 mg,
0.14 mmol, 1.0 equiv), polymer supported-carbodiimide (105 mg, 0.14
mmol, 1.0 equiv), and acetonitrile was heated by microwave irradiation
for 10 min at 100 °C. The ﬁnal product (9c) was isolated from the
reaction mixture by ﬁltering through a short column of Si-carbonate
under gravity, which scavenged the excess carboxylic acid and
hydroxybenzotriazole. No further puriﬁcation was required. Removal
of the solvent under reduced pressure yielded the required compounds
as amorphous solids. Yield: 49 mg (solid), 67%. 1H NMR (CD3OD) δ
(ppm) 8.33 (s, 1H), 7.42 (t, J = 8.5 Hz, 1H), 6.75 (d, J = 8.4 Hz, 2H),
3.86 (s, 6H), 3.82 (m, 1H), 1.88 (m, 4H), 1.68 (d, J = 12.8 Hz, 1H),
1.40 (m, 4H), 1.27 (m, 1H). 13C NMR (CD3OD) δ (ppm) 165.02,
164.71, 159.24, 134.17, 132.97, 123.89, 121.82, 115.64, 105.24, 56.50,
49.36, 33.77, 26.58, 26.19. LRMS (ES+): m/z 373 [M + H]+. HRMS
(ES+): calcd for C19H25N4O4 [M + H]
+ 373.1870, found 373.1850.
N-Cyclopropyl-4-(2,6-dimethoxybenzamido)-1H-pyrazole-3-car-
boxamide (9a). Yield: 42 mg (solid), 64%. 1H NMR (CD3OD) δ
(ppm) 8.32 (s, 1H), 7.42 (t, J = 8.4 Hz, 1H), 6.76 (d, J = 8.4 Hz, 2H),
3.86 (s, 6H), 2.79 (m, 1H), 0.80 (m, 2H), 0.65 (m, 2H). 13C NMR
(DMSO-d6) δ (ppm) 161.32, 161.20, 131.10, 122.44, 122.30, 115.01,
104.28, 55.82, 22.13, and 22.02 (d, rotamers), 5.55. LRMS (ES+): m/z
331 [M + H]+. HRMS (ES+): calcd for C16H19N4O4 [M + H]
+
331.1401, found 331.1385.
N-Cyclobutyl-4-(2,6-dimethoxybenzamido)-1H-pyrazole-3-car-
boxamide (9b). Yield: 56 mg (solid), 94%. 1H NMR (DMSO-d6) δ
(ppm) 13.28 (s, 1H), 9.71 (s, 1H), 8.60 (d, J = 8.1 Hz, 1H), 8.30 (s,
1H), 7.40 (t, J = 8.4 Hz, 1H), 6.74 (d, J = 8.4 Hz, 2H), 4.37 (sex, J =
8.3, 1H), 3.76 (s, 6H), 2.13 (m, 4H), 1.63 (m, 2H). 13C NMR
(DMSO-d6) δ (ppm) 162.53, 161.23, 156.93, 132.14, 131.07, 122.61,
119.84, 115.07, 104.32, 55.82, 54.86, 43.39, 29.81, 14.62. LRMS (ES+):
m/z 345 [M + H]+. HRMS (ES+): calcd for C17H21N4O4 [M + H]
+
345.1557, found 345.1548.
N-Cycloheptyl-4-(2,6-dimethoxybenzamido)-1H-pyrazole-3-car-
boxamide (9d). Yield: 60 mg (solid), 90%. 1H NMR (CDCl3) δ
(ppm) 12.19 (br s, 1H), 9.94 (s, 1H), 8.41 (s, 1H), 7.29 (t, J = 8.5 Hz,
1H), 6.98 (d, J = 8.1 Hz, 1H), 6.57 (d, J = 8.5 Hz, 2H), 4.05 (m, 1H),
3.80 (s, 6H), 2.00−1.94 (m, 2H), 1.66−1.45 (m, 10H). 13C NMR
(CDCl3) δ (ppm) 161.75, 160.98, 155.95, 131.18, 129.57, 121.16,
119.75, 112.84, 102.24, 54.19, 48.30, 33.28, 26.12, 22.39. LRMS (ES+):
m/z 387 [M + H]+. HRMS (ES+): calcd for C20H27N4O4 [M + H]
+
387.2027, found 387.2043.
N-(Bicyclo[2.2.1]heptan-2-yl)-4-(2,6-dimethoxybenzamido)-1H-
pyrazole-3-carboxamide (9e). Yield: 49 mg (solid), 52%. 1H NMR
(DMSO-d6) δ (ppm) 11.80 (br s, 1H), 9.72 (s, 1H), 8.28 (s, 1H), 8.00
(br d, J = 6.9 Hz, 1H), 7.40 (t, J = 8.4 Hz, 1H), 6.75 (d, J = 8.4 Hz,
2H), 3.76 (s, 6H), 3.66 (m, 1H), 2.21 (br s, 1H), 2.15 (br s, 1H),
1.63−1.37 (m, 5H), 1.16−0.99 (m, 3H). 13C NMR (CD3OD) δ
(ppm) 165.11, 164.82, 159.28, 133.97, 133.00, 124.01, 122.33, 115.79,
105.34, 56.59, 53.91, 43.80, 40.38, 37.06, 36.28, 29.28, 27.54. LRMS
(ES+): m/z 385 [M + H]+. HRMS (ES+): calcd for C20H25N4O4 [M +
H]+ 385.1870, found 385.1857.
4-(2,6-Dimethoxybenzamido)-N-morpholino-1H-pyrazole-3-car-
boxamide (9f). Yield: 34 mg (solid), 53%. 1H NMR (DMSO-d6) δ
(ppm) 13.30 (s, 1H), 9.66 (s, 1H), 9.55 (s, 1H), 8.31 (s, 1H), 7.39 (t, J
= 8.4 Hz, 1H), 6.75 (d, J = 8.6 Hz, 2H), 3.76 (s, 6H), 3.62 (m, 4H),
2.84 (m, 4H). 13C NMR (DMSO-d6) δ (ppm) 161.26, 161.18, 156.93,
131.41, 131.10, 122.90, 119.80, 115.01, 104.32, 65.98, 55.82, 54.31.
LRMS (ES+): m/z 376 [M + H]+. HRMS (ES+): calcd for
C17H22N5O5 [M + H]
+ 376.1615, found 376.1620.
4-(2,6-Dimethoxybenzamido)-N-(3-(dimethylamino)propyl)-1H-
pyrazole-3-carboxamide (9g). Yield: 41 mg (solid), 63%. 1H NMR
(DMSO-d6) δ (ppm) 13.15 (brs, 1H), 9.70 (s, 1H), 8.99 (t, J = 6.3 Hz,
1H), 8.32 (s, 1H), 7.38 (t, J = 8.4 Hz, 1H), 7.31−7.29 (m, 4H), 7.22
(m, 1H), 6.74 (d, J = 8.4 Hz, 2H), 4.41 (d, J = 6.4 Hz, 2H), 3.75 (s,
6H). 13C NMR (DMSO-d6) δ (ppm) 163.46, 161.29, 156.93, 139.45,
131.95, 131.10, 128.21, 127.26, 126.71, 122.58, 120.18, 115.01, 104.32,
55.82, 41.66. LRMS (ES+): m/z 381 [M + H]+. HRMS (ES+): calcd
for C20H21N4O4 [M + H]
+ 381.1557, found 381.1543.
4-(2,6-Dimethoxybenzamido)-N-(pyridin-2-ylmethyl)-1H-pyra-
zole-3-carboxamide (9h). Yield: 28 mg (solid), 42%. 1H NMR
(DMSO-d6) δ (ppm) 13.33 (br s, 1H), 9.66 (s, 1H), 8.96 (t, J = 5.9,
1H), 8.50 (m, 1H), 8.34 (s, 1H), 7.74 (td, J = 7.7, 1.9 Hz, 1H), 7.39 (t,
J = 8.4 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 7.25 (m, 1H), 6.73 (d, J =
8.4 Hz, 2H), 4.53 (d, J = 5.6 Hz, 2H), 3.75 (s, 6H). 13C NMR
(DMSO-d6) δ (ppm) 163.65, 161.32, 158.14, 156.93, 148.75, 136.68,
131.89, 131.10, 122.61, 122.06, 120.84, 120.18, 114.98, 104.32, 55.82,
43.54. LRMS (ES+): m/z 382 [M + H]+.
4-(2,6-Dimethoxybenzamido)-N-((3-methylpyridin-2-yl)methyl)-
1H-pyrazole-3-carboxamide (9i). Yield: 30 mg (solid), 44%. 1H
NMR (DMSO-d6) δ (ppm) 13.30 (br s, 1H), 9.68 (s, 1H), 8.72 (t, J =
5.0 Hz, 1H), 8.39 (d, J = 5.0 Hz, 1H), 8.34 (s, 1H), 7.60 (d, J = 7.6 Hz,
1H), 7.39 (t, J = 8.4 Hz, 1H), 7.23 (dd, J = 7.6, 5.0 Hz, 1H), 6.75 (d, J
= 8.4 Hz, 2H), 4.54 (d, J = 5.0 Hz, 2H), 3.76 (s, 6H), 2.29 (s, 3H). 13C
NMR (DMSO-d6) δ (ppm) 163.28, 161.29, 156.96, 153.98, 145.81,
137.64, 132.10, 131.13, 130.64, 122.47, 122.24, 120.04, 114.98, 104.32,
55.84, 40.96, 17, 13. LRMS (ES+): m/z 396 [M + H]+. HRMS (ES+):
calcd for C20H22N5O4 [M + H]
+ 396.1666, found 396.1656.
N-(Cyclohexylmethyl)-4-(2,6-dimethoxybenzamido)-1H-pyra-
zole-3-carboxamide (9j). Yield: 56 mg (solid), 84%. 1H NMR
(CD3OD) δ (ppm) 8.35 (s. 1H), 7.37 (t, J = 8.4 Hz, 1H), 6.71 (d, J =
8.4 Hz, 2H), 3.82 (s, 6H), 3.17 (d, J = 7.0 Hz, 2H), 1.77−1.64 (m,
5H), 1.55 (m, 1H), 1.28−1.13 (m, 3H), 1.00−0.89 (m, 2H). 13C
NMR (CD3OD) δ (ppm) 165.64, 165.00, 159.22, 134.15, 132.99,
123.89, 122.10, 115.69, 105.31, 56.58, 46.09, 39.42, 32.00, 27.57,
27.03. LRMS (ES+): m/z 386 [M + H]+. HRMS (ES+): calcd for
C20H27N4O4 [M + H]
+ 387.2027, found 387.2008.
4-(2,6-Dimethoxybenzamido)-N-phenyl-1H-pyrazole-3-carboxa-
mide (9k). Yield: 48 mg (solid), 76%. 1H NMR (DMSO-d6) δ (ppm)
13.51 (s, 1H), 10.31 (s, 1H), 9.65 (s, 1H), 8.40 (s, 1H), 7.78 (d, J =
7.7 Hz, 2H), 7.41 (t, J = 8.5 Hz, 1H), 7.31 (t, J = 7.8 Hz, 2H), 7.09 (t,
J = 7.3 Hz, 1H), 6.76 (d, J = 8.5 Hz, 2H), 3.77 (s, 6H). 13C NMR
(DMSO-d6) δ (ppm) 162.29, 161.40, 157.02, 138.10, 132.32, 131.19,
128.49, 123.81, 123.02, 120.69, 120.37, 114.98, 104.40, 55.88. LRMS
(ES+): m/z 367 [M + H]+. HRMS (ES+): calcd for C19H19N4O4 [M +
H]+ 367.1401, found 367.1402.
4-(2,6-Dimethoxybenzamido)-N-(pyridin-4-yl)-1H-pyrazole-3-
carboxamide (9l). Yield: 10 mg (solid), 16%. 1H NMR (DMSO-d6) δ
(ppm) 13.63 (s, 1H), 10.73 (s, 1H), 9.55 (s, 1H), 8.43 (d, J = 6.4 Hz,
3H), 7.83 (d, J = 5.5 Hz, 2H), 7.42 (t, J = 8.3 Hz, 1H), 6.77 (d, J = 8.4
Hz, 2H), 3.78 (s, 6H). LRMS (ES+): m/z 368 [M + H]+. HRMS
(ES+): calcd for C18H18N5O4 [M + H]
+ 368.1353, found 368.1347.
4-(2,6-Dimethoxybenzamido)-N-(pyridin-2-yl)-1H-pyrazole-3-
carboxamide (9m). Yield: 10 mg (solid), 16%. 1H NMR (DMSO-d6)
δ (ppm) 13.61 (s, 1H), 9.63 (s, 1H), 9.49 (s, 1H), 8.42 (s, 1H), 8.38
(br d, J = 4.6 Hz, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.83 (m, 1H), 7.42 (t,
J = 8.4 Hz, 1H), 7.18 (m, 1H), 6.77 (d, J = 8.5 Hz, 2H), 3.78 (s, 6H).
13C NMR (DMSO-d6) δ (ppm) 161.87, 161.55, 157.01, 150.45,
148.29, 138.41, 131.62, 131.30, 123.04, 120.90, 120.15, 114.66, 113.86,
104.35, 55.84. LRMS (ES+): m/z 368 [M + H]+. HRMS (ES+): calcd
for C18H18N5O4 [M + H]
+ 368.1353, found 368.1335.
4-(2,6-Dimethoxybenzamido)-N-((1r,4r)-4-hydroxycyclohexyl)-
1H-pyrazole-3-carboxamide (9n). Yield: 51 mg (solid), 77%. 1H
NMR (DMSO-d6) δ (ppm) 13.21 (br s, 1H), 9.75 (s, 1H), 8.28 (s,
1H), 8.09 (d, J = 8.4 Hz, 1H), 7.39 (t, J = 8.4 Hz, 1H), 6.75 (d, J = 8.4
Hz, 2H), 4.53 (br d, J = 3.8 Hz, 1H), 3.76 (s, 6H), 3.66 (m, 1H),
3.40−3.33 (m, 1H), 1.82 (m, 2H), 1.73 (m, 2H), 1.44 (m, 2H), 1.19
(m, 2H). 13C NMR (DMSO-d6) 162.67, 161.25, 156.91, 131.07,
122.56, 115.10, 104.32, 68.11, 55.82, 47.00, 34.19, 30.00. LRMS (ES+):
m/z 389 [M + H]+. HRMS (ES+): calcd for C19H25N4O5 [M + H]
+
389.1819, found 389.1800.
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cis-/trans-(4-(2,6-Dimethoxybenzamido)-N-(4-methylcyclohexyl)-
1H-pyrazole-3-carboxamide) (9o). Yield: 49 mg (solid), 74%. 1H
NMR (CD3OD) δ (ppm) 8.36 (s, 0.5H), 8.33 (s, 0.5H), 7.39 (t, J =
8.5 Hz, 1H), 6.73 (d, J = 8.5 Hz, 2H), 4.05 (m, 0.5H), 3.84 (s, 6H),
3.76 (m, 0.5H), 1.96−1.32 (m, 8H), 1.06 (m, 1H), 0.98 (d, J = 6.5 Hz,
1.5 H), 0.92 (d, J = 6.6 Hz, 1.5H). 13C NMR (CD3OD) δ (ppm)
165.06, 165.02, 164.76, 164.64, 159.25, 134.07, 134.01, 132.97, 123.99,
123.91, 122.30, 122.12, 115.70, 115.66, 105.39, 105.29, 56.54, 49.52,
46.86, 35.15, 33.67, 33.12, 31.53, 31.01, 30.09, 22.63, 21.25. LRMS
(ES+): m/z 387 [M + H]+. HRMS (ES+): calcd for C20H27N4O4 [M +
H]+ 387.2027, found 387.2007.
tert-Butyl 4-(4-(2,6-Dimethoxybenzamido)-1H-pyrazole-3-
carboxamido)piperidine-1-carboxylate (9p). Yield: 50 mg (solid),
41%. 1H NMR (CD3OD) δ (ppm) 8.35 (s, 1H), 7.37 (t, J = 8.4 Hz,
1H), 6.71 (d, J = 8.4 Hz, 2H), 4.08−3.99 (m, 3H), 3.82 (s, 6H), 2.90
(m, 2H), 1.89 (m, 2H), 1.51 (m, 2H), 1.46 (s, 9H). 13C NMR
(CD3OD) δ (ppm) 165.00, 164.89, 159.22, 156.39, 134.00, 132.99,
124.03, 122.16, 115.72, 105.35, 81.17, 56.61, 47.67, 44.39, and 43.61
(br d, rotamers), 32.69, 28.79. LRMS (ES+): m/z 474 [M + H]+.
HRMS (ES+): calcd for C23H32N5O6 [M + H]
+ 474.2347, found
474.2324.
N-(1-Benzylpyrrolidin-3-yl)-4-(2,6-dimethoxybenzamido)-1H-pyr-
azole-3-carboxamide (9q). Yield: 69 mg (solid), 89%. 1H NMR
(CD3OD) δ (ppm) 8.32 (s, 1H), 7.36 (t, J = 8.4 Hz, 1H), 7.32−7.22
(m, 5H), 6.68 (d, J = 8.4 Hz, 2H), 4.52 (m, 1H), 3.78 (s, 6H), 3.58 (d,
J = 2.5 Hz, 2H), 2.76 (m, 2H), 2.58 (dd, J = 10.0, 4.3, 1H), 2.43 (q, J =
8.1 Hz, 1H), 2.27 (m, 1H), 1.75 (m, 1H). 13C NMR (CD3OD) δ
(ppm) 165.06, 165.00, 159.22, 139.26, 133.92, 132.99, 130.33, 129.50,
128.49, 124.01, 122.16, 115.67, 105.32, 61.26, 61.17, 56.58, 53.83,
49.19, 32.54. LRMS (ES+): m/z 450 [M + H]+. HRMS (ES+): calcd
for C24H28N5O4 [M + H]
+ 450.2136, found 450.2113.
4-(2,6-Dimethoxybenzamido)-N-(2-methoxyethyl)-1H-pyrazole-
3-carboxamide (9r). Yield: 39 mg (solid), 65%. 1H NMR (CD3OD) δ
(ppm) 8.35 (s. 1H), 7.38 (t, J = 8.4 Hz, 1H), 6.72 (d, 8.4 J = 8.4 Hz,
2H), 3.83 (s, 6H), 3.53 (s, 4H), 3.37 (s, 3H). 13C NMR (CD3OD) δ
(ppm) 165.76, 165.05, 159.26, 134.10, 132.99, 115.71, 105.32, 72.07,
59.03, 56.56, 39.52. LRMS (ES+): m/z 349 [M + H]+. HRMS (ES+):
calcd for C16H21N4O5 [M + H]
+ 349.1506, found 349.1504.
4-(2,6-Dimethoxybenzamido)-N-pentyl-1H-pyrazole-3-carboxa-
mide (9s). Yield: 52 mg (solid), 84%. 1H NMR (DMSO-d6) δ (ppm)
13.23 (br s, 1H), 9.74 (s, 1H), 8.38 (br s, 1H), 8.29 (s, 1H), 7.39 (t, J
= 8.5 Hz, 1H), 6.75 (d, J = 8.5 Hz, 2H), 3.76 (s, 6H), 3.19 (m, 2H),
1.49 (quint, J = 7.2 Hz, 2H), 1.31−1.22 (m, 4H), 0.85 (t, J = 7.0 Hz,
3H). 13C NMR (DMSO-d6) δ (ppm) 163.39, 161.20, 156.93, 132.25,
131.07, 122.35, 119.79, 115.05, 104.32, 55.82, 37.95, 28.77, 28.57,
21.78, 13.87. LRMS (ES+): m/z 361 [M + H]+. HRMS (ES+): calcd
for C18H25N4O4 [M + H]
+ 361.1870, found 361.1868.
4-(2,6-Dimethoxybenzamido)-N-(3-isopropoxypropyl)-1H-pyra-
zole-3-carboxamide (9t). Yield: 64 mg (solid), 95%. 1H NMR
(CD3OD) δ (ppm) 8.35 (s, 1H), 7.38 (t, J = 8.5 Hz, 1H), 6.71 (d, J =
8.5 Hz, 2H), 3.83 (s, 6H), 3.58 (sept, J = 6.1 Hz, 1H), 3.53 (t, J = 6.1
Hz, 2H), 3.45 (t, J = 6.6 Hz, 2H), 1.83 (quin, J = 6.4 Hz, 2H), 1.15 (d,
J = 6.1 Hz, 6H). 13C NMR (CD3OD) δ (ppm) 165.58, 165.00, 159.22,
134.17, 132.99, 123.82, 121.99, 115.69, 105.32, 73.08, 67.50, 56.61,
38.06, 30.72, 22.49. LRMS (ES+): m/z 391 [M + H]+. HRMS (ES+):
calcd for C19H27N4O5 [M + H]
+ 391.1976, found 391.1961.
4-(2,6-Dimethoxybenzamido)-N-(3-(dimethylamino)propyl)-1H-
pyrazole-3-carboxamide (9u). Yield: 49 mg (solid), 76%. 1H NMR
(CD3OD) δ (ppm) 8.23 (s, 1H), 7.26 (t, J = 8.4 Hz, 1H), 6.59 (d, J =
8.4 Hz, 2H), 3.71 (s, 6H), 3.26 (t, J = 7.5 Hz, 2H), 2.26 (t, J = 7.5 Hz,
2H), 2.11 (s, 6H), 1.65 (q, J = 7.5 Hz, 2H). 13C NMR (CD3OD) δ
(ppm) 165.70, 164.94, 159.22, 134.15, 132.99, 123.92, 122.05, 115.75,
105.35, 58.25, 56.61, 45.52, 38.23, 28.32. LRMS (ES+): m/z 376 [M +
H]+. HRMS (ES+): calcd for C18H26N5O4 [M + H]
+ 376.1979, found
376.1965.
4-(2,6-Dimethoxybenzamido)-N-(2-(pyrrolidin-1-yl)ethyl)-1H-pyr-
azole-3-carboxamide (9v). Yield: 57 mg (solid), 86%. 1H NMR
(CD3OD) δ (ppm) 8.34 (s, 1H), 7.38 (t, J = 8.4 Hz, 1H), 6.71 (d, J =
8.4 Hz, 2H), 3.83 (s, 6H), 3.51 (t, J = 6.9 Hz, 2H), 2.69 (t, J = 6.9 Hz,
2H), 2.59 (m, 4H), 1.80 (m, 4H). 13C NMR (CD3OD) δ (ppm)
165.69, 164.97, 159.22, 134.09, 132.99, 123.89, 122.01, 115.72, 105.32,
56.58, 56.32, 55.08, 38.64, 24.31. LRMS (ES+): m/z 388 [M + H]+.
HRMS (ES+): calcd for C19H26N5O4 [M + H]
+ 388.1979, found
388.1965.
4-(2,6-Dimethoxybenzamido)-N-(2-morpholinoethyl)-1H-pyra-
zole-3-carboxamide (9w). Yield: 37 mg (solid), 53%. 1H NMR
(CD3OD) δ (ppm) 8.34 (s, 1H), 7.40 (t, J = 8.4 Hz, 1H), 6.73 (d, J =
8.4 Hz, 2H), 3.84 (s, 6H), 3.70 (t, J = 4.5 Hz, 4H), 3.5 (t, J = 6.6, 2H),
2.57 (t, J = 6.6 Hz, 2H), 2.52 (br t, J = 4.5 Hz, 4 Hz). 13C NMR
(CD3OD) δ (ppm) 165.67, 165.00, 159.23, 134.06, 132.96, 123.86,
122.02, 115.72, 105.32, 67.80, 58.60, 56.55, 54.67, 36.50. LRMS (ES+):
m/z 404 [M + H]+. HRMS (ES+): calcd for C19H26N5O5 [M + H]
+
404.1928, found 404.1929.
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From On-Target to Off-Target Activity: Identification and
Optimisation of Trypanosoma brucei GSK3 Inhibitors and
Their Characterisation as Anti-Trypanosoma brucei Drug
Discovery Lead Molecules
Andrew Woodland,[a] Raffaella Grimaldi,[a] Torsten Luksch,[a] Laura A. T. Cleghorn,[a]
Kayode K. Ojo,[b] Wesley C. Van Voorhis,[b] Ruth Brenk,[a] Julie A. Frearson,[a] Ian H. Gilbert,*[a]
and Paul G. Wyatt*[a]
Introduction
Human African trypanosomiasis (HAT), also known as African
sleeping sickness, is a parasitic disease caused by protozoan
parasites of the species Trypanosoma brucei and is fatal if un-
treated. HAT is endemic in certain regions of sub-Saharan
Africa, with around 50 million people at risk of infection across
25 countries. The number of reported cases of HAT has fallen
recently and is now at about 10000 reported new cases per
year; however, the actual number of cases is estimated to be
much higher (30000–40000 new cases per year).[1–3]
Following infection by the bite of a tsetse fly, patients initial-
ly suffer from phase 1 disease, in which they experience epi-
sodes of fever, headache, sweating, and swelling of the lymph
nodes. Phase 2 disease results from the spread of infection
into the central nervous system (CNS). Patients begin to experi-
ence a disturbance in their circadian rhythm, resulting in bouts
of fatigue alternating with manic periods, which progress to
daytime slumber and nighttime insomnia, with progressive
mental deterioration leading to coma and death. Generally the
disease is diagnosed only when it has already progressed to
the phase 2 CNS stage.
HAT is a neglected disease, because despite millions of
people being under the threat of infection, there is no com-
mercial market to justify funding drug development. There are
only two stand-alone drugs available for the treatment of late-
stage sleeping sickness: melarsoprol and eflornithine. However,
both drugs have serious limitations such as toxicity, complex
parenteral administration, which is poorly suited to a rural Afri-
can setting, low and variable brain penetration, the develop-
ment of resistant parasites,[4] and patient compliance.[5] A com-
bination therapy of nifurtimox and eflornithine was recently
approved for the treatment of stage 2 HAT primarily due to
a cost benefit and improved convenience of the new treat-
ment over eflornithine alone. Unfortunately, resistance to nifur-
timox develops rapidly in the laboratory.[6–8]
In recent years a number of drug development initiatives
funded by foundations and/or governments have begun to ad-
dress the need for improved drugs to treat stage 2 HAT.[9] Two
new oral clinical candidates were recently developed: fexinida-
zole,[10] a nitroimidazole derivative that is currently in clinical
development, and SCYX-7158,[11] a benzoxaborole derivative
that has been selected for entry into clinical development.
However, owing to the high rates of attrition in drug discovery
and the requirement for multiple drugs to combat the devel-
opment of resistant parasites, the pipeline must be further en-
hanced.
There is a lack of validated drug discovery targets and lead
compounds for HAT and other neglected diseases.[12] Protein
kinases have been explored as possible targets for HAT, as they
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Human African trypanosomiasis (HAT) is a life-threatening dis-
ease with approximately 30000–40000 new cases each year.
Trypanosoma brucei protein kinase GSK3 short (TbGSK3) is re-
quired for parasite growth and survival. Herein we report
a screen of a focused kinase library against T. brucei GSK3.
From this we identified a series of several highly ligand-effi-
cient TbGSK3 inhibitors. Following the hit validation process,
we optimised a series of diaminothiazoles, identifying low-
nanomolar inhibitors of TbGSK3 that are potent in vitro inhibi-
tors of T. brucei proliferation. We show that the TbGSK3 phar-
macophore overlaps with that of one or more additional mo-
lecular targets.
 2013 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2013, 8, 1127 – 1137 1127
CHEMMEDCHEM
FULL PAPERS
play important roles in virtually every cellular event from cell
division to stress response.[13] Kinases are druggable targets,
and crystal structures have been published for many of
them.[14] Bioinformatics searches of the T. brucei genome identi-
fied 176 parasite protein kinases,[15,16] making this family an at-
tractive source of novel drug discovery targets for the treat-
ment of HAT and other parasitic diseases.[17–19]
Human GSK3b (HsGSK3b) is involved in the regulation of
a vast array of cellular processes in eukaryotes: insulin signal-
ling, growth factors, nutrient levels, cell fates during embryonic
development, cell division, apoptosis, and microtubule func-
tion.[20] HsGSK3b has been investigated as a drug target for
many diseases, from diabetes to neurodegenerative diseases.
To aid development, the crystal structure of HsGSK3b has been
solved, and high-affinity small-molecule inhibitors of HsGSK3b
have been developed.[14,21–24] Whilst the precise role of the try-
panosome orthologue GSK3 short kinase (TbGSK3) in the
bloodstream form of T. brucei has yet to be determined in
terms of parasite biology, the importance of this enzyme has
been demonstrated by RNA interference experiments that
showed decreased growth rates for parasites in in vitro cul-
ture.[25,26]
Herein we report our studies on the identification and opti-
misation of TbGSK3 inhibitors with potent antiparasitic activity
and highlight their potential for the development of new
therapies for the treatment of HAT.
Results and Discussion
Homology modelling
Crystal structures of Leishmania major[27] and human GSK3
have been published. The tertiary structure of LmGSK3 (PDB
code 3E3P) is very similar to that of HsGSK3b (PDB code 1R0E),
but several binding pocket residues are missing in the Leish-
mania crystal structure, as no clearly defined electron density
was present. In addition, no ligand is bound in the LmGSK3
crystal structure. Therefore, we selected the crystal structure of
HsGSK3b as the template to build a homology model for
TbGSK3. The TbGSK3 sequence is 52% identical and 71% simi-
lar to the sequence in the HsGSK3b structure (PDB code 1R0E).
Hence HsGSK3b provides a template for 91% of the TbGSK3
sequence (amino acids 20–348) which allowed a reliable model
to be built (Figure 1). Analysis of the ATP binding pockets re-
vealed amino acid differences that could be exploited to
design selective inhibitors (Table 1).
Hit discovery
Recombinant TbGSK3 was produced as previously described.[25]
The kinetic parameters were determined by measuring initial
reaction velocities in a matrix experiment of varied ATP and
peptide substrate concentrations. The KM value of TbGSK3 for
the substrate with sequence YRRAAVPPSPSLSAHSSPHQ[pS]E-
DEEE (GSP2) and ATP were 8.41.3 and 11.01.8 mm, respec-
tively, with no evidence of cooperativity (Figure 2). The deter-
mined KM values for GSP2 and ATP are similar to those previ-
ously reported of 2.4 and 4.5 mm, respectively.[25]
For the primary screen, a 384-well KinaseGlo (Promega) lumi-
nescence-based assay was used as previously described.[25] In
this assay, luminescence is inversely related to kinase activity
and directly related to ATP depletion (Figure 3A). GW8510 was
used as a standard inhibitor[6] (figure S1, Supporting Informa-
tion). The DDU kinase set of 4110 compounds[29] was screened
in single point at 25 mm providing robust data (Z’=0.610.06;
Table 2). From this, 567 compounds with a percentage of in-
hibition >30% were retested in a duplicate-point screen, to
give 517 reconfirmed compounds with inhibition values
30% (12.8% of the library; Figure 3B,C).
For hit validation and all subsequent compound potency de-
terminations, a radiometric 96-well Flashplate assay (PerkinElm-
Figure 1. Superposition of the HsGSK3b crystal structure (PDB code 1R0E)
with the homology model of TbGSK3. The human structure is shown in pink,
the TbGSK3 homology model in blue; both structures are shown in ribbon
representation. Binding pocket residues of TbGSK3 that differ from those of
HsGSK3b are represented as sticks. Regions of the kinase site are labelled ac-
cording to previously published conventions.[28]
Table 1. Residue differences in the ATP binding sites of HsGSK3b and
TbGSK3.
Kinase pocket region HsGSK3b[a] TbGSK3[b]
Hinge region D133 E
Y134 F
Gatekeeper L132 M
E1 Y140 H
Q185 H
Adenine pocket I62 A
Q72 L
G-loop N64 Q
S66 T
[a] PDB code 1R0E. [b] Homology model.
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er) was adopted (Figure 4A). Although the KinaseGlo format
has many advantages for screening of chemical libraries, its re-
liance upon ATP consumption means it requires a level of sub-
strate consumption >10% to achieve an acceptable signal
window; it is therefore unsuitable for accurate IC50 determina-
tions. The Flashplate assay was performed at an ATP concen-
tration below the enzyme’s KM value for ATP, so that the Ki
app
approximated the measured IC50 value, aiding the assessment
of selectivity. Potency evaluation (10-point curves) was carried
out in duplicate for the 100 most potent compounds. As in
the primary assay, the potency assay format yielded highly
robust data (Z’=0.800.08; Table 2). The compounds exhibit-
ed a range of potencies for TbGSK3 which were highly repro-
ducible, with an r2 value of 0.99 for two replicates (Figure 4B),
with 15 compounds having IC50 values <1 mm. The identity
and purity of hits taken into potency determination were con-
firmed by LC–MS.
Prioritisation of hits and series definition
To prioritise the hits, hit compounds were rank ordered by
their ligand efficiencies against TbGSK3, in which ligand effi-
ciency= [RT ln(IC50)]/Nnon-H atoms.[30] Subsequently, the highest-
priority compounds were grouped into series based on struc-
tural similarity (Figure 5), resulting in a number of different
compound series. Several of the TbGSK3 inhibitors identified
have ligand efficiencies
>0.4 kcalmol1 per heavy atom,
beyond the commonly used
guideline of 0.3 kcalmol1 per
heavy atom, which relates to an
optimised lead with an IC50 value
of 10 nm and 38 non-hydrogen
atoms (Mr~500 Da).[30] In particu-
lar, diaminothiazole 1 is a highly
ligand-efficient starting point,
with a TbGSK3 ligand efficiency
of 0.52 kcalmol1 per heavy
atom.
Hit validation
Five promising hit series contain-
ing ligands with ligand efficien-
cies >0.3 kcalmol1 per heavy
atom were progressed into hit
series validation. Series 2 was
based around a diaryl urea and
exemplified by compound 2.
Compounds of this series were
also identified as broad-spec-
trum kinase inhibitors with toxic-
Figure 2. Determination of kinetic parameters for TbGSK3. KM values for the
ATP and GSP2 substrates were determined in a time-course matrix experi-
ment in which the initial velocities (v) were determined as product formed
(P, nm) per minute. The grid represents the best fit obtained by globally fit-
ting the data to the equation for the random-order rapid equilibrium model
with cooperation parameter (a) equal to 1.
Figure 3. Format and results of the primary screen. A) A KinaseGlo assay format was adopted for the primary
screen based on luminescence detection. B) Distribution of the percent inhibition of the focused kinase set. Hits
were selected by setting 3 standard deviation units from the average of high controls as threshold (30% inhibi-
tion). C) 567 selected hits were retested in duplicate, and the two replicate values showed high correlation.
Table 2. Assay conditions and screening statistics.
KinaseGlo Flashplate
TbGSK3 7.5 nm 2.5 nm
GSP2 3.2 mm 1 mm
ATP 1 mm (<KM) 1 mm (<KM)
Z’ 0.610.06 0.800.08
GW8510 IC50 100.2 nm 64 nm
 2013 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2013, 8, 1127 – 1137 1129
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ity toward mammalian cell lines during our previous-
ly published investigations of the CRK3 kinase, so no
further work was conducted with this compound
series.[31]
Series 3 was based around 2-amino-1,3,5-triazines;
36 examples of this series were contained in the
screening library with compound 3 being the only
active example (Figure 5). Due to the limited com-
mercial availability for representatives of this series
and the apparent requirement for specific substitu-
ents, this series was not pursued further.
The 8-aminoimidazo[1,2-a]pyrazines (series 4) were
also identified in a previous DDU project and were
found to be broad-spectrum kinase inhibitors that
are toxic to human cell lines (MRC5 cells). In addition,
the lead compound 4 has an unfavourable calculated
logP value of 4.8 (Figure 5). Therefore, no further
work was carried out on this series.
Eleven oxazole-4-carboxamides (series 5) were
identified in the high-throughput screen (HTS), with
compound 5 inhibiting TbGSK3 at a sub-micromolar
IC50 value (Figure 5). Over 900 examples of this com-
pound series were commercially available at the time of our
study, and more than 100 compounds were selected for pur-
chasing and testing. However, none of these compounds dem-
onstrated activity in the T. brucei cell assay. This, combined
with the relatively poor TbGSK3 IC50 value of 0.1 mm observed
within the series after testing more than 140 examples, as well
as the flat SAR, it was decided that this series would not be
pursued any further.
Compound 1 (series 1) was the only 2,4-diaminothiazol-5-
carbaldehyde present in the DDU kinase screening set at the
time of screening (Figure 5). Although 1 was a singleton, it has
good predicted physical properties (Mr=288 Da, logP=2.1,
TPSA=68 2), a ligand efficiency of 0.52 kcalmol1 per heavy
atom for TbGSK3, and demonstrated promising activity in
a T. brucei proliferation assay (EC50 2 mm). Of slight concern is
the presence of a ketone functionality, which has the potential
to interact with nucleophiles within the cell ; this would have
to be monitored during compound development. Based on
these considerations, it was decided to progress this com-
pound to hit validation. As a side note, compound 1 is also
a very effective HsGSK3 inhibitor, with an IC50 value of 5 nm
(n=2) and an outstanding ligand efficiency of 0.67 kcalmol1
per heavy atom. Thus, 1 may also be an excellent starting
point for a human GSK3 drug discovery programme.
Structure-guided design
A potential binding mode for compound 1 in the homology
model of TbGSK3 was generated using Moloc (Gerber Molecu-
lar Design, Switzerland; Figure 6). In the proposed binding
mode the 2,4-diaminothiazole moiety forms three hydrogen
bonds with the protein backbone of the TbGSK3 hinge
(Glu102, Phe103, and Val104). Furthermore, the thiazole group
Figure 4. Format and results of the potency test. A) A flashplate radiometric
assay format was adopted for the potency determination based on selective
capture of the biotinylated phosphorylated product by the streptavidin-
coated plates. B) The 100 most potent hits were tested in 10-data point
curves in two independent determinations; the correlation plot between the
log IC50 values of the replicates is reported.
Figure 5. Series classification. Common features representative of each series are high-
lighted in red. Ligand efficiencies are given as kcalmol1 per heavy atom.
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is sandwiched between Leu159 and Ala47 and undergoes hy-
drophobic interactions with both amino acids. In addition, the
ligand carbonyl group is proposed to be in plane with the
core thiazole and forms an intramolecular hydrogen bond with
the primary amino group. A water molecule, observed in many
HsGSK3b structures, was kept for the binding mode generation
and is predicted to mediate a hydrogen bond between the in-
hibitor carbonyl lone pair and the backbone amide NH group
of Asp171. The presence of an
analogous water molecule in the
recently solved X-ray crystal
structure of LmGSK3 (PDB code
3E3P) gives further evidence that
the water molecule is conserved
and plays an important role in
GSK3–ligand binding. The 2-
chlorothiophene moiety is pre-
dicted to form lipophilic interac-
tions with Phe31 and Cys170,
while the ethyl group points
toward Leu159, and the hydro-
phobic part of Thr107 potentially
contributes van der Waals inter-
actions to the binding affinity.
Docking was carried out in
order to guide the hit expansion,
with the aim of confirming the
aminothiazoles as a series of
TbGSK3 inhibitors, improving in
vitro potency, and to build SAR.
A series of 112 commercially available 2,4-diaminothiazoles
with various substituents were docked into the homology
model of TbGSK3 using FlexX.[32] The docking solutions were
visually inspected, and 21 compounds were selected for pur-
chase (Table 3).
Biological results and structure–activity relationships
The biological data for early hit optimisation are summarised
in Table 3. The hit compound 1 has an ethyl group at R1 which
may form hydrophobic interactions with Leu159 and the hy-
drophobic part of Thr107 (Figure 6, Table 1). Although no
direct analogues were available, the closely related methyl ana-
logue 6 is around 50-fold less active than 1, suggesting that
lipophilic bulk in the R1 region is beneficial. Introducing an aro-
matic group into R1 and truncating R2 to methyl was tolerated,
with an IC50 value of 1 mm for 7. Increasing the size of R
1 while
maintaining a lipophilic group at R2 gave a 10-fold improve-
ment in activity, with several examples demonstrating IC50
values of <100 nm for TbGSK3, such as compounds 8, 9, and
10.
In general the 2,4-diaminothiazol-5-carbaldehydes tested
were found to be more potent inhibitors of HsGSK3b than
they are of TbGSK3, confirming that selectivity between Hs and
TbGSK3 can be achieved, albeit initially in the undesired direc-
tion. In contrast, in cellular assays, the lead molecules are selec-
tive antiparasitic agents as exemplified by 9, which has an EC50
value of 0.13 mm against T. brucei, but no activity against MRC5
cells (EC50>50 mm).
A correlation plot of cell efficacy (bloodstream form (BSF)
T. brucei logEC50) against enzyme potency (TbGSK3 log IC50)
gave a strong correlation for the early members of this series
(correlation coefficient: 0.90) with a 5-fold drop off between
the TbGSK3 and T. brucei activities (Figure 7 and Supporting In-
formation table S1). Considering that the physiological level of
Figure 6. Proposed binding mode for 1 in the homology model of TbGSK3.
Both, ligand and protein are represented in sticks and colour-coded by atom
type. Ligand carbon atoms are shown in salmon, and protein carbon atoms
in light blue. Putative hydrogen bonds to the ligand are shown as yellow
dotted lines (other hydrogen bonds within the active are not shown for
clarity).
Table 3. Activity of key compounds from series 1.
IC50 [mm] EC50 [mm]
Compd R1 R2 TbGSK3 HsGSK3b T. brucei MRC5
1 0.4 0.005 2 >15
6 25 ND[a] 7 >50
7 1 ND[a] 13 25
8 0.03 0.007 0.2 13
9 0.05 0.003 0.1 >50
10 0.1 0.007 0.7 4
[a] Not determined.
 2013 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2013, 8, 1127 – 1137 1131
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ATP in T. brucei is in the millimolar range, whilst in our TbGSK3
potency assay, the concentration was 1 mm, we expected the
IC50 value for TbGSK3 in cells to drop off by at least 100-fold
according to the Cheng–Prusoff equation [Eq. (1)] .[33] In addi-
tion, other factors such as protein binding or the requirement
for a high level of enzyme inhibition to achieve a phenotypic
effect, as observed previously for other T. brucei targets, could
even result in a >100-fold drop off.[34] The much lower ob-
served difference between IC50 and EC50 suggested that the
mode of action of series 1 may not be just through inhibition
of TbGSK3.
IC50 ¼ K i

1þ ½ATP
KMATP

ð1Þ
The small difference between potency against the enzyme
and the cell activity for this series led us to consider that there
may be more than one mechanism of action driving the cell
activity. Substituted 2,4-diaminothiazoles have been described,
and examples are known to be potent inhibitors of
HsGSK3b,[35] several CDKs,[36,37] p25,[37] and PDE4B.[38] Interest-
ingly, there are also reports of a 2,4-diaminothiazole (DAT1)
which binds to and disrupts microtubules.[39] Homologues of
these targets are present in T. brucei and could therefore be
modulated by compounds of this series. Additionally, prolific
kinase inhibitors often show toxicity toward cells in culture.
Compound 8 was profiled at 10 mm against the mammalian
protein kinase panel at the University of Dundee, which at the
time of testing consisted of 76 mammalian kinases. In agree-
ment with our biochemical assays, compound 8 potently inhib-
ited HsGSK3b ; it also inhibited CDK2, MKK1, ERK8, and HIPK2
by >90% at this concentration (Supporting Information
table S2). The human protein kinase profile was sufficiently
clean for an early-stage kinase inhibitor project, and we decid-
ed to monitor the kinase profile as the series was developed.
Hit-to-lead development
Based on the promising data obtained for the series we decid-
ed to progress the project into hit-to-lead development. A
stepwise solid-supported two-step synthetic route to diamino-
thiazoles has been published, starting from the non-commer-
cial reagent, benzyl carbamimidothioate hydrobromide 11.[40]
We modified the synthesis so that both steps are carried out in
a one-pot, solution-phase reaction (Scheme 1). Benzyl bromide
12 was treated with thiourea to give benzyl carbamimido-
thioate hydrobromide 11 in 89% yield. Benzyl carbamimido-
thioate 11 was allowed to react with an isothiocyanate in the
presence of Hnig’s base, 2-bromoketones were then added
along with an additional equivalent of Hnig’s base to give
the desired 2,4-diaminothiazoles 13 in a three-component
one-pot synthesis with yields ranging from 3 to 69%.
The most potent compounds identified in the early work
were 2,4-diamino-5-ketothiazoles 13 bearing aromatic groups
in both the R1 and R2 position, such as compound 8 (IC50=
0.03 mm, Table 3). Although we had identified several TbGSK3
inhibitors with IC50 values less than 1 mm, we wished to im-
prove the selectivity over HsGSK3b. Our design explored R1
and R2 groups of varying size, shape, and polarity to probe the
limits of the ATP binding pockets of the TbGSK3 and HsGSK3b
enzymes to identify regions where selectivity could be ach-
ieved (Table 4).
Initial work focused on the R2 group. Introduction of ortho
substituents, which would be expected to twist the R2 group
out of plane with the ketothiazole core, was well tolerated for
small groups such the fluorine-substituted analogue 14 (IC50=
0.02 mm). The larger and more electron-rich 2,6-dimethoxy-
phenyl 15 (IC50=0.4 mm) was over 10-fold less active than 14
against TbGSK3. Lipophilic bulk in the meta position of the R2
substituent was tolerated, but provided no significant potency
gains, with 3-bromo analogue 16 (IC50=0.1 mm) showing simi-
lar activity to the phenyl analogue 8 (IC50=0.03 mm).
The R1 substituent was then investigated. The 2,6-dimethyl-
phenyl derivative 17 (IC50=0.2 mm) is approximately 10-fold
less active against TbGSK3 than 8 (IC50=0.03 mm). Increasing
the meta and para lipophilic bulk at R1 had no benefit, with
3,4-dimethylphenyl 18 similar to 8. Replacing the R1 phenyl
ring with cyclohexyl 19 (IC50=0.19 mm) caused a small (sixfold)
decrease in potency against the enzyme. Insertion of one or
two methylene units between the amine and the cyclohexyl
and aromatic groups gave small decreases in activity against
TbGSK (20, IC50=0.7 mm ; 21, IC50=0.5 mm). As part of our strat-
Figure 7. Correlation between inhibition of TbGSK3 and inhibition of
T. brucei cell growth for the initial set of compounds. Supporting Information
table S1 lists the compounds used to derive the correlation plots along with
the TbGSK3 log IC50 and T. brucei logEC50 values.
Scheme 1. Reagents and conditions : a) thiourea (1 equiv), EtOAc, 120 8C,
5 min, b) isothiocyanate (1.1 equiv), DIPEA (1.2 equiv), DMF, RT, 24 h, then 2-
bromoketone (1.2 equiv), DIPEA (2.1 equiv), RT, 1 h.
 2013 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2013, 8, 1127 – 1137 1132
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egy to test the limits of the TbGSK3 and HsGSK3b pockets, the
tetrahedral lipophilic tert-butyl ketone 22 was synthesised. This
compound is ~300-fold less active than 8 toward TbGSK3;
however, it is a potent inhibitor of T. brucei growth in vitro,
with an EC50 value of 0.3 mm, and is also highly selective (>
150-fold) over the human MRC5 cell line.
Biological characterisation of 2,4-diaminothiazol-5-carbalde-
hydes
Studies of the mechanism of inhibition by compounds from
the diaminothiazole series (19 and 14) confirmed that they are
ATP-competitive inhibitors of TbGSK3, as evident from the
Lineweaver–Burk plots (Figure 8). The calculated Ki
app values
(0.250.03 and 0.050.01 mm for 19 and 14, respectively) cor-
related very well with the determined IC50 values in the bio-
chemical assay (Table 4) as expected, considering that the level
of ATP in the assay was below the KM value for ATP.
During analysis of the SAR it
became apparent that the inhibi-
tion of cellular (T. brucei) growth
was no longer tracking with in-
hibition of the enzyme, TbGSK3.
This was particularly apparent
when a correlation plot of
T. brucei logEC50 values against
TbGSK3 log IC50 values was pro-
duced for all of the compounds
generated by this stage in the
programme (Figure 9 and Sup-
porting Information table S1). At
the extremes of this plot, the
ratio of T. brucei EC50 values/
TbGSK3 IC50 values for 23 is 115,
whilst for 22 it is 0.017, a differ-
ence of ~6700-fold (Table 4). We
believe that the reason for this
variation is that an essential mo-
lecular target or targets is pres-
ent in the T. brucei parasite
which can be modulated by
compounds with a similar phar-
macophore to that required for
TbGSK3 inhibition.
Earlier in the project we had
demonstrated that 8 was not
a prolific kinase inhibitor (Table 3
and Supporting Information
table S2). To determine whether
22 is a broad-spectrum inhibitor
of protein kinases we tested 22
along with 14 and 19 in the Uni-
versity of Dundee kinase panel
at a concentration of 10 mm
(Supporting Information
table S2). Most members of
series 1 showed >90% inhibition against several of the kinases
tested. Interestingly, 22 was the least broad-spectrum kinase
inhibitor tested and it did not inhibit any kinase at the >90%
level; it only inhibited CDK2 and GSK3 at >70%. These en-
couraging data demonstrate that 22 selectively modulates the
activity of the unknown parasitic target(s) over a broad range
of mammalian kinases, and that these targets can be modulat-
ed by drug-like molecules. However, owing to the complex
pharmacology of these compounds, and as it is not clear what
the off-targets are, the only option will be to optimise these
compounds phenotypically, rather than through protein
screening.
Conclusions
In summary, we have shown that a screen of a focused kinase
library led to the identification of ligand-efficient inhibitors of
TbGSK3 with sub-micromolar potency. The chemotypes we
identified have physicochemical properties consistent with the
Table 4. Activity of key compounds from series 1.
IC50 [mm] EC50 [mm]
Compd R1 R2 TbGSK3 HsGSK3b T. brucei MRC5
8 0.03 0.007 0.2 13
14 0.02 0.005 0.2 1.6
15 0.4 2 0.4 20
16 0.1 0.005 0.2 >50
17 0.2 0.2 9 35
18 0.06 0.002 0.2 14
19 0.2 0.002 0.1 11
20 0.7 0.02 0.4 41
21 0.5 0.003 6 38
22 12 ND[a] 0.3 >50
23 0.04 0.007 4.1 0.3
[a] Not determined.
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development of orally bioavailable compounds. For the most
active series based on 2,4-diaminothiazoles, the compounds
were also active against the parasite T. brucei. Some of the ex-
amples had potencies in the order of 100 nm against the para-
site, which represents a very good starting point for a drug dis-
covery programme against HAT. However, it quickly became
apparent that this series has one or more molecular targets in
addition to TbGSK3, which contributes strongly to the trypano-
cidal activity of the compounds. Interestingly, although based
on a kinase scaffold, this series had a reasonably clean profile
against the 79 mammalian kinases investigated. In the absence
of a clear understanding of
which molecular target(s) are re-
sponsible for anti-trypanosomal
activity, the only way to optimise
this compound is phenotypically.
We shall report results for this in
due course.
Experimental Section
Homology modelling : Sequence
alignments between TbGSK3b
(Tb927.10.13780 in GeneDB) and
HsGSK3b were generated with
ClustalW.[41] Subsequently, Model-
ler 9.2[42] was used to build homol-
ogy models of TbGSK3 short,
whereas the human GSK3b crystal
structure (PDB code 1R0E) served
as template.[43] Modeller was run
with default settings, and only the
highest-scoring structure was used
for further analysis and modelling.
The quality of the model was as-
sessed with QMEAN.[44,45] A total
QMEAN score of 0.726 and Z-score
of 0.50 were calculated, indicat-
ing that the model is of good qual-
ity.
Generation of putative binding modes : An initial binding mode
for compound 1 was generated by manually docking the ligand
into the ATP binding pocket of the TbGSK3 homology model with
the requirement to establish hydrogen bonds to the hinge resi-
dues using Moloc. Its position was subsequently optimised with
the MAB force field as implemented in Moloc.[46] To allow for uncer-
tainties in the homology model, the amino acid side chains facing
the binding site were kept flexible during minimisation. For the hit
expansion, ligands were docked into the active site of the homolo-
gy model using FlexX.[32] A highly conserved water molecule (H20
82 in 1R0E) was kept in the structure used for docking. For the
active site determination, a radius of 13  around the ligand
bound in 1R0E was selected, always using complete amino acids.
Ligand conformations were calculated using CORINA.[47] Com-
pounds were docked using default settings.
TbGSK3 biochemical characterisation : TbGSK3 short protein with
an N-terminal maltose binding protein fusion was cloned, ex-
pressed, and purified as previously reported.[25] For biochemical
characterisation of TbGSK3, the kinase assay buffer (25 mm Tris·HCl
pH 7.5, 10 mm MgCl2, 5 mm DTT, 0.02% CHAPS, 2 UmL
1 heparin)
and mix of ATP/[g-33P]ATP and GSP2 substrate (YRRAAVPPSPSL-
SAHSSPHQ[pS]EDEEE; Pepceuticals) were used in a radiometric
format (filterplate assay). The KM values for the two substrates (ATP
and GSP2) were determined by varying the concentrations of both
substrates in a time-course matrix experiment.
Compound library selection was described previously.[29]
Primary screen assays : For the primary screening of the focused
kinase inhibitor library, a 384-well KinaseGlo (Promega) lumines-
cence-based assay was used as previously described.[25] The reac-
tions contained 7.5 nm TbGSK3, 3.2 mm substrate peptide (Pepceut-
icals), 1 mm ATP, and 25 mm test inhibitor compound in optimised
Figure 8. Mechanism of inhibition was determined for A) 19 and B) 14. Rates (CPM) were determined at the re-
ported inhibitor concentrations (mm) with four varied concentrations of ATP at saturating concentration of the
other substrate. The resulting Lineweaver–Burk plots were examined for diagnostic patterns for competitive inhib-
ition and globally fitted to the equation for competitive inhibition.
Figure 9. Correlation between inhibition of TbGSK3 and inhibition of
T. brucei cell growth for the initial set of compounds. The later compounds
show weaker correlation. Supporting Information table S1 lists the com-
pounds used to derive the correlation plots along with the TbGSK3 log IC50
and T. brucei logEC50 values. Figure 9 was generated using both the early
and later examples of series 1.
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kinase assay buffer. DMSO and an eight-point titration of GW8510
(Sigma) from 1 mm to 50 pm were included as negative and posi-
tive controls. Reactions were incubated at room temperature for
1 h and stopped by the addition of KinaseGlo reagent. Plates were
then sealed, and the signal was left to stabilise for 1 h in the dark
before luminescence was determined using a TopCount NXT HTS
counter (PerkinElmer).
Potency screen assays : For hit validation and all subsequent com-
pound potency determinations, a radiometric 96-well Flashplate
assay (PerkinElmer) was adopted. Compounds were solubilised in
DMSO at a top concentration of 3 mm and serially diluted to ach-
ieve 10-point titration of final assay concentrations from 30 mm to
0.3 nm with a final DMSO concentration of 1% (v/v). The reaction
mixtures contained 1 mm biotinylated GSP2 substrate, 1 mm ATP,
3.7 KBq [g-33P]ATP per well, and 2.5 nm TbGSK3 in the TbGSK3
kinase assay buffer. GSK3 inhibitors were screened for selectivity
assessment against HsGSK3b as well. For the HsGSK3b assay the re-
action mixes contained 1 mm biotinylated GSP2 substrate, 2 mm
ATP, 7.4 KBq [g-33P]ATP per well, and 15 nm HsGSK3b in the TbGSK3
kinase assay buffer (25 mm Tris·HCl pH 7.5, 10 mm MgCl2, 5 mm
DTT, 0.02% CHAPS, 2 UmL1 heparin).
Mammalian kinase profiling : Selected compounds were screened
against a panel of mammalian kinases routinely run by the Division
of Signal Transduction Therapy (DSTT) at the University of Dundee
in duplicate at 10 mm. Enzymes included in the panel and assay
conditions are reported.[48] All biochemical assays were carried out
below the KM
app value for ATP for each enzyme, allowing compari-
son of inhibition across the panel.
Trypanosome and MRC5 proliferation assay : Measurement of in-
hibition of the proliferation of MRC5 (human lung fibroblast) cells
and T. brucei bloodstream-stage cells was performed using a modifi-
cation of a cell viability assay previously described.[49] Compounds
(50 mm to 0.5 nm) were incubated with 2103 cells per well in
0.2 mL of the appropriate culture medium (MEM with 10% foetal
bovine serum for MRC-5 cells) in clear 96-well plates. Plates were
incubated at 37 8C in the presence of 5% CO2 for 69 h. Resazurin
was then added to a final concentration of 50 mm, and plates were
incubated as above for a further 4 h before being read on a BioTek
flx800 fluorescent plate reader.
Data analysis : Determination of the TbGSK3 kinetic parameters
was carried out as described previously.[50] IC50 values were deter-
mined using a four-parameter equation in XLFit 4.2. To establish
mode of inhibition, rates were determined at 10 inhibitor concen-
trations with four varied concentrations of ATP in saturating con-
centration of GSP2. The resulting Lineweaver–Burk plots were ex-
amined for diagnostic patterns for competitive, mixed, or uncom-
petitive inhibition. Graphs and analyses were carried out using
Grafit 6.0. The correlation between in vitro IC50 against TbGSK3 in
T. brucei cells and inhibitor potency (Ki) for ATP-competitive inhibi-
tors was determined according to the Cheng–Prusoff equation
[Eq. (1)] .
Chemistry
1H NMR spectra were recorded on a Bruker Avance DPX 500 instru-
ment unless otherwise stated. Chemical shifts (d) are expressed in
ppm. Signal splitting patterns are described as singlet (s), broad
singlet (br s), doublet (d), triplet (t), quartet (q), multiplet (m), or
combination thereof. Low-resolution electrospray (ES) mass spectra
were recorded on a Bruker MicroTof mass spectrometer, run in pos-
itive ion mode, using either MeOH, MeOH/H2O (95:5), or H2O/
CH3CN (1:1)+0.1% formic acid as the mobile phase. High-resolu-
tion electrospray MS measurements were performed on a Bruker
MicroTof mass spectrometer. LC–MS analyses were performed with
an Agilent HPLC 1100 (Phenomenex Gemini Column 5 m C18 110A
503.0 mm, eluting with 20% MeOH/H2O, 0–3 min) and a diode
array detector in series with a Bruker MicroTof mass spectrometer.
Column chromatography was performed using RediSep 4 or 12 g
silica pre-packed columns.
The following compounds were purchased from commercial sup-
pliers and their purity and identity confirmed by LC–MS analysis
(all compounds were >85% pure based on a diode array detec-
tor). Compounds 1 and 2 were purchased from ChemBridge Cor-
poration; 3 was purchased from Maybridge; 4 was purchased from
BioFocus; 5 was purchased from ChemDiv Inc. ; 6, 9, and 23 were
purchased from TimTec; 7 and 10 were purchased from Specs.
Benzyl carbamimidothioate hydrobromide (11): Benzyl bromide
(16.0 mL, 135 mmol), thiourea (10.0 g, 131 mmol), and EtOAc
(75 mL) were combined, and then heated at 120 8C in a microwave
reactor for 5 min. The reaction was allowed to cool to room tem-
perature, and the resulting solid was collected by filtration to give
benzyl carbamimidothioate hydrobromide 11 as a white solid
(29.3 g, 118.6 mmol, 89% yield); 1H NMR (500 MHz, [D6]DMSO): d=
9.07 (br s, 4H), 7.44–7.32 (m, 5H), 4.49 ppm (s, 2H).
4-Amino-2-(phenylamino)thiazol-5-yl)(phenyl)methanone (8):
General procedure A (used for the synthesis of compounds 8, 14–
22): Benzyl carbamimidothioate hydrobromide (100 mg, 0.4 mmol),
phenyl isothiocyanate (52 mL, 0.43 mmol), and N,N-diisopropylethyl-
amine (DIPEA; 76 mL, 0.43 mmol) were added to DMF (5 mL), and
the resulting mixture was stirred at room temperature for 24 h. 2-
Bromoacetophenone (96 mg, 0.48 mmol), DIPEA (139 mL,
0.80 mmol), and DMF (2 mL) were then added, and the mixture
was stirred at room temperature for 1 h, after which the reaction
was quenched by the addition of aqueous HCl (1m, 4 mL). The
product was extracted with EtOAc (33 mL), and the combined
extracts were back washed with LiCl (23 mL of a 5% w/w solu-
tion in H2O), brine (3 mL), and then dried with MgSO4, and the sol-
vent was removed under reduced pressure. Purification by column
chromatography on silica eluting with petroleum ether (PE) 40–
60 8C and EtOAc gave 8 as a yellow solid (47 mg, 0.15 mmol, 39%
yield); 1H NMR (500 MHz, [D6]DMSO): d=10.80 (br s, 1H), 8.22 (br s,
2H), 7.69–7.67 (m, 2H), 7.62 (d, J=7.7 Hz, 2H), 7.51–7.46 (m, 3H),
7.39–7.36 (m, 2H), 7.09 ppm (tt, J=7.4 and 1 Hz, 1H); 13C NMR
(125 MHz, DMSO): d=182.7, 167.2, 165.6, 141.9, 139.5, 130.4, 129.1,
128.4, 126.7, 123.4, 119.0, and 92.2 ppm; LC–MS m/z=296 [M+H]+
, tR=4.28 min, purity 88% (Agilent, 20–90% CH3CN, ES+ on an
acidic method).
(4-Amino-2-(phenylamino)thiazol-5-yl)(2,6-difluorophenyl)me-
thanone (14): General procedure A gave 14 as a yellow solid
(32 mg, 0.10 mmol, 10% yield); 1H NMR (500 MHz, [D6]DMSO): d=
10.89 (br s, 1H), 8.31 (br s, 2H), 8.08 (br s, 1H), 7.57–7.50 (m, 3H),
7.39–7.35 (m, 2H), 7.23–7.19 (m, 2H), 7.13–7.10 ppm (m, 1H); LC–
MS m/z=332 [M+H]+ , tR=4.25 min, purity 90% (Agilent, 20–90%
CH3CN, ES+ on an acidic method).
(4-Amino-2-(phenylamino)thiazol-5-yl)(2,6-dimethoxyphenyl)me-
thanone (15): General procedure A gave 16 as a yellow solid
(9 mg, 0.03 mmol, 3% yield); 1H NMR (500 MHz, [D6]DMSO): d=
10.58 (br s, 1H), 7.79 (s, 2H), 7.54 (d, J=8.0 Hz, 2H), 7.54–7.52 (m,
3H), 7.06 (t, J=7.3 Hz, 1H), 6.69 (d, J=8.4, 2H), 3.71 ppm (6H, s) ;
LC–MS m/z=356 [M+H]+ , tR=4.10 min, purity 100% (Agilent, 20–
90% CH3CN, ES+ on an acidic method).
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(4-Amino-2-(phenylamino)thiazol-5-yl)(3-bromophenyl)metha-
none (16): General procedure A gave 16 as a yellow solid (211 mg,
0.56 mmol, 69% yield); 1H NMR (500 MHz, [D6]DMSO): d=10.85
(br s, 1H), 8.29 (br s, 2H), 7.81 (t, J=1.7 Hz, 1H), 7.71 (ddd, J=1.0,
2.0, 8.0 Hz, 1H), 7.69–7.67 (m, 1H), 7.63 (d, J=7.8 Hz, 2H), 7.46 (t,
J=7.8 Hz, 1H), 7.39–7.36 (m, 2H), 7.12–7.08 ppm (m, 1H); LC–MS
m/z=376 [M+H]+ , tR=4.58 min, purity 100% (Agilent, 20–90%
CH3CN, ES+ on an acidic method).
(4-Amino-2-((2,6-dimethylphenyl)amino)thiazol-5-yl)-
(phenyl)methanone (17): General procedure A gave 17 as a yellow
solid (35 mg, 0.11 mmol, 11% yield); 1H NMR (500 MHz, [D6]DMSO):
d=10.11 (br s, 1H), 8.40 (br s, 1H), 7.97 (br s, 1H), 7.54–7.16 (m,
8H), 2.20 ppm (s, 6H); LC–MS m/z=324 [M+H]+ , tR=4.39 min,
purity 95.6% (Agilent, 20–90% CH3CN, ES+ on an acidic method).
(4-Amino-2-((3,4-dimethylphenyl)amino)thiazol-5-yl)-
(phenyl)methanone (18): General procedure A gave 18 as a yellow
solid (100 mg, 0.30 mmol, 30% yield); 1H NMR (500 MHz,
[D6]DMSO): d=10.60 (br s, 1H), 8.31 (br s, 1H), 8.11 (br s, 1H), 7.67–
7.65 (m, 2H), 7.51–7.45 (m, 3H), 7.34 (d, J=8.3 Hz, 1H), 7.31 (s,
1H), 7.12 (d, J=8.2 Hz, 1H), 2.21 (s, 3H), 2.19 ppm (s, 3H); LC–MS
m/z=324 [M+H]+ , tR=4.55 min, purity 88% (Agilent, 20–90%
CH3CN, ES+ on an acidic method); HRMS m/z [M+H]
+ calcd for
C18H18N3OS: 324.1165, found: 324.1158.
(4-Amino-2-(cyclohexylamino)thiazol-5-yl)(phenyl)methanone
(19): General procedure A gave 19 as a yellow solid (59 mg,
0.19 mmol, 19% yield); 1H NMR (500 MHz, [D6]DMSO): d=8.57 (br s,
1H), 8.49 (br s, 1H), 7.89 (br s, 1H), 7.63–7.61 (m, 2H), 7.47–7.42 (m,
3H), 3.70 (br s, 1H), 1.91 (d, J=10.7 Hz, 2H), 1.76–1.70 (m, 2H), 1.57
(d, J=12.9 Hz, 1H), 1.32–1.13 ppm (m, 5H); LC–MS m/z=302 [M+
H]+ , tR=4.42 min, purity 88% (Agilent, 20–90% CH3CN, ES+ on an
acidic method); HRMS m/z [M+H]+ calcd for C16H20N3OS:
302.1322, found: 302.1321.
(4-Amino-2-((cyclohexylmethyl)amino)thiazol-5-yl)-
(phenyl)methanone (20): General procedure A gave 20 as a yellow
solid (136 mg, 0.43 mmol, 43% yield); 1H NMR (500 MHz,
[D6]DMSO): d=8.63 (br s, 1H), 8.43 (br s, 1H), 7.84 (br s, 1H), 7.63–
7.61 (m, 2H), 7.48–7.43 (m, 3H), 3.17–3.03 (m, 2H), 1.17–1.52 (m,
6H), 1.23–1.11 (m, 3H), 0.94–0.87 ppm (m, 2H); LC–MS m/z=316
[M+H]+ , tR=4.63 min, purity 97% (Agilent, 20–90% CH3CN, ES+
on an acidic method); HRMS m/z [M+H]+ calcd for C17H22N3OS:
316.1478, found: 316.1472.
(4-Amino-2-(phenethylamino)thiazol-5-yl)(phenyl)methanone
(21): General procedure A gave 21 as a yellow solid (77 mg,
0.24 mmol, 24% yield); 1H NMR (500 MHz, [D6]DMSO): d=8.73 (br s,
1H), 8.47 (br s, 1H), 7.87 (br s, 1H), 7.63–7.61 (m, 2H), 7.48–7.43 (m,
3H), 7.32–7.29 (m, 2H), 7.26–7.21 (m, 3H), 2.90 (s, 1H), 2.87 (t, J=
7.2 Hz, 2H), 2.74 ppm (d, J=0.5 Hz, 1H); HRMS m/z [M+H]+ calcd
for C14H18N3OS: 324.1165, found: 324.1153.
1-(4-Amino-2-(cyclohexylamino)thiazol-5-yl)-2,2-dimethylpro-
pan-1-one (22): General procedure A gave 22 as a yellow powder
(171 mg, 0.61 mmol, 61% yield); 1H NMR (500 MHz, CDCl3) d=5.34
(d, J=7.1 Hz, 1H), 3.30–3.28 (m, 1H), 2.00 (dd, J=13.6, 3.3 Hz, 1H),
1.70 (dt, J=13.6, 4.0 Hz, 2H), 1.57 (dt, J=13.2, 4.0 Hz, 1H), 1.38–
1.33 (m, 2H), 1.20 (s, 9H, tBu-H), 1.19–1.17 (m, 1H), 0.81 (t, J=
7.1 Hz, 1H), 0.79–0.76 ppm (m, 1H); 13C NMR (DMSO, 125 MHz) d=
128.6, 128.4, 119.5, 53.4, 53.3, 32.0, 27.0, 24.9, 24.3, 17.9, 16.6,
12.2 ppm; LC–MS m/z=282 [M+H]+ , tR=4.60 min, purity 96%
(Agilent, 20–90% CH3CN, ES+ on an acidic method); HRMS m/z
[M+H]+ calcd for C14H24N3OS: 282.1635, found: 282.1641.
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